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ABSTRACT	  	  	  Connective	  tissue	  growth	  factor	  (CTGF)	  has	  been	  implicated	  in	  the	  pathogenesis	  of	  diabetic	  nephropathy	  and	  has	  been	  proposed	  as	  a	  possible	  specific	  biomarker	  for	  the	  early	  detection	  of	  fibrosis.	   	  CTGF	  is	  reported	  to	  be	  a	  349-­‐amino	  acid	  cysteine-­‐rich,	   heparin	   binding	   monomeric	   polypeptide	   that	   is	   secreted	   as	   a	   36-­‐38	   kDa	  protein.	  	  To	  date,	  the	  natural	  form	  of	  CTGF	  has	  not	  been	  successfully	  purified	  from	  clinical	   samples.	   	   Commercial	   test	   kits	   for	   detecting	   CTGF	   by	   ELISA	   utilize	  antibodies	  raised	  against	  recombinant	  human	  (rh)	  CTGF.	  	  	  	  In	   the	   present	   study,	   assessment	   of	   specific	   analytical	   methods	   for	   the	   reliable	  detection	  of	  naturally	  occurring	  CTGF	  has	  been	  deployed.	  	  In	  order	  to	  achieve	  this,	  a	  peptide	  sequence	   to	  CTGF	  was	  synthesized	  and	  an	  antibody	  raised	  against	   this	  peptide.	   	   This	   antibody	  was	   characterized	   using	   novel	   chemistry	   to	   improve	   the	  specificity	   of	   the	   final	   assay.	   	   The	   antibody	   raised	   against	   a	   unique	   peptide	  sequence	   in	   CTGF,	   and	   another	   to	   rhCTGF,	  were	   used,	   alongside	   a	   commercially	  available	   anti-­‐rhCTGF	   antibody	   to	   detect	   this	   protein	   in	   diabetic	   urine	   and	  peritoneal	   dialysis	   fluid.	   	   The	   synthetic	   peptide	   antibody	   was	   also	   coupled	   to	  Sepharose	  4B	  for	  the	  purification	  of	  CTGF	  from	  clinical	  samples.	  	  	  	  ELISA	  performed	  on	   the	  diabetic	   urine	   and	  peritoneal	   dialysis	   fluid	   showed	   that	  the	  response	  of	   the	  antibody	  against	   the	  synthetic	  peptide	  was	   the	  highest	  when	  compared	  to	  the	  rhCTGF	  and	  commercial	  antibodies.	  	  	  	  Five	   peritoneal	   dialysis	   fluid	   and	   five	   diabetic	   urine	   samples	   were	   assayed	   for	  CTGF.	   	   Diabetic	   urine	  was	   found	   to	   be	   a	   richer	   source	   of	   CTGF.	   	   2-­‐dimemsional	  electrophoresis	  and	  Western	  blot	  analyses	  on	  the	  peritoneal	  dialysis	  fluid	  showed	  various	   immunoreactive	   species	   to	   the	   synthetic	   peptide	   antibody	   at	   isoelectric	  point	   8.0.	   	   It	   can	   be	   concluded	   that	   these	   immunoreactive	   species	  may	   be	   CTGF	  bound	   to	   other	   proteins	   or	   CTGF	   complexes	   that	   have	   been	   formed	   from	   the	  oxidation	  of	  the	  cysteine	  residues.	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In	  conclusion,	  this	  study	  demonstrates	  that	  CTGF	  can	  be	  detected	  in	  diabetic	  urine	  and	  peritoneal	  dialysis	   fluid	  using	   the	  procedures	  described.	   	  Diabetic	  urine	  was	  found	   to	   be	   a	   rich	   source	   of	   CTGF.	   	   The	   ELISA	   procedure	   described,	   with	   some	  improvements	   has	   potential	   as	   a	   screening	   tool	   for	   the	   development	   of	   fibrosis.	  The	   antibody	   prepared	   against	   the	   synthetic	   peptide	   was	   far	   superior	   to	   the	  rhCTGF	  antibodies	  currently	  available.	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Fibrosis	  and	  the	  TGF-­‐β/Smad	  pathway	  	  
Fibrosis	  	  Fibrosis	  is	  a	  complex	  biological	  process	  involving	  an	  acute	  inflammatory	  response.	  	  Its	   predominant	   characteristics	   are	   the	   excessive	   and	   abonormal	   deposition	   of	  extracellular	  matrix	  (ECM)	  components,	  including	  collagen	  that	  may	  affect	  various	  organs.	   	   Fibrotic	   diseases	   include	   idiopathic	   pulmonary	   fibrosis,	   liver	   cirrhosis,	  systemic	   sclerosis,	   progressive	   kidney	   disease	   and	   cardiovascular	   fibrosis.	   	   A	  persistent	   antagonist	   sustains	   the	   production	   of	   growth	   factors,	   proteolytic	  enzymes,	  angiogenic	  factors	  and	  fibrogenic	  cytokines.	   	  This	  in	  turn	  stimulates	  the	  deposition	   of	   connective	   tissue	   elements	   that	   progressively	   remodel	   and	  ultimately	   destroy	   normal	   tissue	   (Wynn	   2008;	   Wynn	   2007;	   Rosenbloom	   et	   al.	  2010;	   Friedman	   2004).	   	   Damage	   to	   tissues	   such	   as	   infections,	   autoimmune	  reactions,	   toxins,	   radiation	  and	  mechanical	   injury,	   illicit	   the	   repair	  process.	   	  This	  generally	  involves	  the	  regenerative	  phase	  where	  the	  injured	  cells	  are	  replaced	  by	  cells	  of	  the	  same	  type,	  leaving	  no	  lasting	  evidence	  of	  damage.	  	  Fibrosis	  occurs	  when	  connective	  tissues	  replace	  normal	  parenchymal	  tissue.	   	  This	   is	   initially	  beneficial,	  but	  when	   not	   controlled	   accordingly,	   substantial	   deposition	   of	   ECM	   components	  result	  in	  normal	  tissue	  being	  replaced	  by	  permanent	  scar	  tissue	  (Wynn	  2008)	  	  
TGF-­‐β 	  	  Transforming	  growth	  factor-­‐β	  (TGF-­‐β)	  is	  widely	  regarded	  as	  one	  of	  the	  key	  growth	  factors	  involved	  in	  fibrosis.	  TGF-­‐β	  is	  a	  25	  kDa	  homodimeric	  polypeptide	  belonging	  to	  the	  TGF-­‐β	  superfamily	  of	  growth	  and	  differentiation	  factors.	   	  TGF-­‐β	  is	  involved	  in	   various	   biological	   functions	   such	   as	   normal	   development,	   wound	   repair	   and	  pathological	   processes.	   	   It	   also	   regulates	   a	   range	   of	   cellular	   functions	   including	  inhibition	   and	   stimulation	   of	   cell	   growth,	   apoptosis	   and	   cellular	   differentiation.	  	  Because	  TGF-­‐β	  induces	  ECM	  protein	  synthesis,	  it	  has	  been	  implicated	  as	  the	  main	  mediator	  of	  fibrogenesis	  in	  various	  tissues	  (McCartney-­‐Francis	  et	  al.	  1998;	  Border	  &	  Noble	  1994;	  Hironobu	  2002).	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TGF-­‐β 	  superfamily	  	  The	   TGF-­‐β	   superfamily	   include	   various	   forms	   of	   TGF-­‐β,	   bone	   morphogenic	  proteins	   (BMPs),	   nodal,	   activins,	   inhibins,	   growth/differentiation	   factors	   (GDF)s	  and	  anti-­‐Müllerian	  hormone	  (AMH).	   	  The	  cytokines	  of	  the	  TGF-­‐β	   	  superfamily	  are	  dimeric	  proteins	  with	  conserved	  structures	  (McCartney-­‐Francis	  et	  al.	  1998;	  Leask	  &	  Abraham	  2004).	  	  	  	  The	   members	   of	   the	   TGF-­‐β	   superfamily	   signal	   through	   the	   serine/threonine	  (ser/thr)	   kinase	   receptors.	   	   These	   receptors	   consist	   of	   a	   short,	   cysteine	   rich	  extracellular	   domail,	   a	   single	   transmembrane	   domain	   with	   specificity	   towards	  serine	  and	  threonine	  residues.	  	  There	  are	  two	  classes	  of	  receptors;	  type	  I	  and	  type	  II	   receptors.	   	   Type	   I	   receptors	   contain	   distantly	   related	   kinase	   domains	   and	   a	  ser/thr	   rich	   tail.	   	   Type	   II	   receptors	   lack	   the	   ser/thr	   rich	   tail	   but	   contain	   ser/thr	  kinase	   domains	   that	   are	   closely	   related	   and	   contain	   the	   ‘GS	   domain’,	   which	   is	   a	  highly	  conserved	  and	  functionally	  important	  sequence	  motif	  at	  the	  amino-­‐terminal	  of	  the	  kinase	  (Attisano	  &	  Wrana	  1996;	  Lin	  &	  Lodish	  1993).	  	  A	  schematic	  of	  the	  type	  I	  and	  type	  II	  receptors	  are	  represented	  in	  figure	  1.1.	  	  	  	  There	  are	  three	  secreted	  latent	  precursor	  molecules	  of	  TGF-­‐β;	  TGF-­‐β1,	  TGF-­‐β	  2	  and	  TGF-­‐β3.	   	   While	   they	   inhibit	   proliferation	   in	   most	   types	   of	   cells	   and	   induce	  apoptosis	  in	  epithelial	  cells,	  they	  stimulate	  the	  proliferation	  of	  mesenchymal	  cells	  and	   production	   of	   extracellular	   matrix,	   and	   induce	   fibrosis	   in	   various	   tissues.	  	  These	   latent	   precursors	   are	   synthesised	   complexed	   with	   latent	   TGF-­‐β	   binding	  proteins	   (LTBP-­‐1,	   3	   and	   4).	   	   TGF-­‐β	   is	   activated	   when	   LTPB	   is	   removed	  extracellularly	   by	   proteolytic	   cleavage	   (Leask	   &	   Abraham	   2004;	   Verrecchia	   &	  Mauviel	   2007).	   	   The	   binding	   of	   TGF-­‐β	   to	   TGF-­‐β	   receptor	   type	   II	   results	   in	   the	  phosphorylation	  of	  TGF-­‐β	   receptor	  type	  I	   to	  produce	  a	  heteromeric	  complex	  that	  activates	  signalling	  pathways	  that	  are	  downstream	  of	   it	  (figure	  1.1)	  (Wrana	  et	  al.	  1994).	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Figure 1.1 A schematic of a model for signalling by heterodimeric complexes of the type I and 
type II receptors.  Ligand-induced heteromeric complex formation allows the phosporylation of 
the type II receptor, which activates the type I receptor to signal to downstream targets.   	  
TGF-­‐β 	  signalling	  	  TGF-­‐β	   signalling	   from	   the	   TGF-­‐β	   receptor	   type	   I	   to	   the	   nucleus	   occurs	   by	   the	  phosphorylation	   of	   the	   receptor-­‐associated	   Smads	   (R-­‐Smads);	   Smad	   1,	   5	   and	   8	  downstream	  of	  BMP,	  and	  2	  and	  3	  downstream	  of	  TGF-­‐β	  and	  activin).	  	  The	  activated	  R-­‐Smads	   form	  heterodimeric	   complexes	  with	  Smad	  4	   (Co-­‐Smad),	  where	   they	  are	  translocated	  into	  the	  nucleus,	  and	  may	  function	  as	  transcription	  factors	  by	  directly	  binding	   to	   DNA	   or	   associating	   with	   other	   DNA	   binding	   transcription	   factors.	  	  Inhibitory	   Smads	   (Smad	   6	   or	   Smad	   7)	   prevent	   R-­‐Smad	   phosphorylation	   and	   the	  following	   nuclear	   translocation	   of	   R-­‐Smad/Smad	   4	   heterocomplexes.	   	   Smad	   7	  competes	  for	  the	  binding	  of	  Smad	  2	  and	  Smad	  3	  to	  TGF-­‐β	  receptor	  type	  I.	   	  TGF-­‐β	  also	   induces	   a	   negative	   feedback	   mechanism	   on	   itself	   by	   suppressing	   its	   own	  action	  through	  the	  induction	  of	  Smad	  7	  through	  a	  Smad	  3	  and	  Smad	  4-­‐dependent	  mechanism	  (Verrecchia	  &	  Mauviel	  2007;	  Leask	  &	  Abraham	  2004;	  Hironobu	  2002;	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Von	  Gersdorff	  et	  al.	  2000).	  	  A	  schematic	  of	  this	  signalling	  cascade	  is	  shown	  in	  figure	  1.2.	  	  	  	  
	  
Figure 1.2 A schematic showing the signalling cascade of TGF-β through the TGF-β receptors.  
The phosphorylation of Smad 2/3 results in the formation of heterodimeric complexes with 
Smad 4, and the nuclear translocation of this complex.  Smad 7 inhibits this by competing with 
Smad 2/3 to the binding of TGF-β receptor type I.   
 TGF-­‐β	   causes	   ECM	   deposition	   through	   the	   promotion	   of	   ECM	   genes,	   and	   the	  suppression	   of	   the	   genes	   that	   express	   matrix	   metalloproteinase	   genes,	   which	  degrade	  ECM.	  	  Type	  I	  collagen	  is	  the	  major	  component	  of	  ECM.	  	  It	  is	  composed	  of	  two	  α1	  chains	  and	  one	  α2	  chain.	  	  These	  are	  the	  product	  of	  two	  genes,	  COL1A1	  and	  COL1A2.	  	  Elevated	  levels	  of	  TGF-­‐β	  increase	  the	  expression	  of	  these	  genes,	  thereby	  increasing	   the	   production	   and	   deposition	   of	   collagen	   (Leask	   &	   Abraham	   2004;	  Verrecchia	  &	  Mauviel	  2007).	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Connective	  tissue	  growth	  factor	  (CTGF)	  	  
The	   Connective	   Tissue	   Growth	   Factor/Cysteine-­‐Rich	  
61/Nephroblastoma	  Overexpressed	  (CCN)	  gene	  family	  	  The	   Connective	   Tissue	   Growth	   Factor/Cysteine-­‐Rich	   61/Nephroblastoma	  Overexpressed	   (CCN)	  gene	   family	   is	  a	  group	  of	  proteins	   that	   includes	  connective	  tissue	   growth	   factor	   (CTGF;	   also	   termed	   fisp-­‐12),	   cysteine-­‐rich	   61	   (cyr61),	  nephroblastoma	  overexpressed	   (nov),	   expressed	   low	   in	  metastasis	   1	   (elm1;	   also	  termed	   WISP-­‐1),	   heparin-­‐inducible	   CTGF/cyr61/nov	   (CCN)-­‐like	   protein	   (HICP;	  also	  termed	  rCop-­‐1,	  CTGF-­‐3	  or	  WISP-­‐2)	  and	  WISP-­‐3.	  	  The	  various	  proteins	  have	  so	  far	  been	  characterized	   from	  human,	  mouse,	   rat,	  pig,	   cow,	   chicken,	  quail	   and	   frog	  and	  it	  is	  thought	  to	  be	  originated	  from	  a	  common	  ancestral	  gene	  (Brigstock	  1999).	  	  The	  term	  CCN	  refers	  to	  the	  fact	  that	  the	   initial	   three	  characterized	  proteins	  were	  CTGF,	  cyr61	  and	  nov	  (Bork	  1993).	   	  The	  primary	  translational	  products	  of	  almost	  all	   of	   the	   family	   members	   have	   between	   343	   –	   381	   amino	   acid	   residues	   that	  generate	   35	   –	   40	   kDa	   secreted	   proteins	   each	   containing	   38	   conserved	   cysteine	  residues	   that	   are	   organised	   into	   four	   individual	   structural	   modules	   (Brigstock	  1999).	   	   The	   biological	   properties	   of	   CTGF	   and	   cyr61	   in	   particular,	   include	   the	  stimulation	   of	   cell	   proliferation,	   chemotaxis,	   adhesion	   and	   extracellular	   matrix	  formation.	   	   CTGF	   and	   cyr61	   are	   encoded	   by	   growth	   factor-­‐inducible	   immediate	  early	   genes,	   whereas	   nov,	   elm1	   and	   HICP/rCop-­‐1	   are	   expressed	   in	   cells	  demonstrating	   growth	   arrest	   or	   quiescence	   (Brigstock	   1999).	   	   The	   CCN	   family	  have	   roles	   to	   play	   in	   normal	   physiological	   processes	   such	   as	   implantation,	  placentation,	  embryogenesis,	  differentiation	  and	  development	  as	  well	  as	  processes	  related	   to	   tissue	   pathology	   including	   wound	   healing	   and	   fibrotic	   disorders	  (Brigstock	  1999).	  	  
The	  CTGF	  gene	  	  The	  gene	  for	  CTGF	  is	  present	  on	  chromosome	  6q23.1	  and	  comprises	  five	  exons	  and	  four	  introns	  (Bradham	  et	  al.	  1991).	  The	  first	  discovery	  of	  an	  ortholog	  of	  CTGF	  first	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came	  in	  1988	  when	  cDNA	  encoding	  ‘fibroblast-­‐inducible	  secreted	  protein-­‐12’	  (fisp-­‐12)	  was	  isolated	  by	  differential	  screening	  of	  a	  cDNA	  library	  from	  serum	  stimulated	  NIH	   3T3	   cells	   (mouse	   embryonic	   fibroblast	   cells)	   (Brigstock	   1999).	   	   The	   gene	  structure	   and	  predicted	  protein	   sequence	  of	   fisp-­‐12	  was	   consequently	  described	  (Ryseck	  et	  al.	  1991).	  At	  the	  same	  time	  a	  protein	  termed	  βIG-­‐M2	  was	  characterized	  by	   isolating	   the	   same	   cDNA	   from	  TGF-­‐β2-­‐stimulated	  mice	   (Brunner	   et	   al.	   1991).	  	  Both	   fisp-­‐12	   and	   βIG-­‐M2	   comprise	   348	   amino	   acid	   residues	   of	   which	   39	   are	  cysteine	  (Brigstock	  1999).	   	  Human	  CTGF	  (hCTGF)	  was	  discovered	  in	  1991	  due	  to	  the	  cross-­‐reactivity	  of	  polyclonal	  antibodies	  against	  platelet-­‐derived	  growth	  factor	  (PDGF)	  with	  38	  kDa	  hCTGF	  secreted	  by	  cultured	  human	  umbilical	  vein	  endothelial	  cells	   (HUVECs).	   	   The	   corresponding	   cDNA	   was	   isolated	   by	   screening	   a	   HUVEC	  cDNA	   library	   with	   anti-­‐PDGF	   antibody	   and	   shown	   to	   encode	   a	   349	   amino	   acid	  protein	  that	  was	  91	  %	  homologous	  to	  fisp-­‐12.	  	  The	  protein	  was	  then	  termed	  ‘CTGF’	  due	   to	   both	   its	   mitogenic	   and	   chemotactic	   properties	   on	   fibroblast-­‐like	   cells	   in	  vitro	  (Bradham	  et	  al.	  1991).	  	  The	  fisp-­‐12	  gene	  spans	  3.1	  kilobases	  and	  comprises	  of	  five	  exons	  and	  four	  introns.	  	  Its	   organisation	   and	   structure	   are	   very	   similar	   to	   that	   of	   the	   hCTGF	   gene	   apart	  from	  the	  fact	  that	  exon	  1	  encodes	  one	  less	  amino	  acid	  in	  the	  signal	  peptide.	  	  There	  is	  also	  80	  %	  sequence	   identity	  between	  CTGF	  and	   fisp-­‐12	   in	   the	  300	  nucleotides	  directly	  before	  the	  mRNA	  cap	  site	  (Grotendorst	  et	  al.	  1996).	  	  Cell	   types	   that	   have	   been	   shown	   to	   produce	   CTGF	   mRNA	   include	   fibroblasts,	  endothelial	   cells,	   vascular	   smooth	  muscle	   cells,	   epithelial	   cells,	   chondrocytes	  and	  glioblastoma	  cells	  (Brigstock	  1999).	  	  The	   CTGF	   primary	   translational	   product	   comprises	   349	   (human,	   pig,	   cow),	   348	  (mouse)	   or	   343	   (xenopus	   (frog))	   amino	   acid	   residues	   and	   is	   more	   than	   90	   %	  conserved	  in	  mammals.	  	  Most	  of	  the	  non-­‐homology	  that	  exist	  between	  species	  are	  over	   the	   first	   43	   amino	   acid	   residues	   where	   the	   similarity	   is	   only	   60-­‐65	   %	  (Brigstock	   1999).	   	   The	   secreted	   proteins	   from	   all	   five	   of	   the	   above	   mentioned	  species	   are	   predicted	   to	   comprise	   of	   323	   amino	   acid	   residues	   and	   to	   contain	   38	  conserved	  cysteine	  residues,	  uniformly	  spread	  throughout	  the	  molecule	  apart	  from	  a	  region	  devoid	  of	  cysteines	  between	  Asp167	  and	  Asn198	  in	  the	  hCTGF	  (Steffen	  et	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al.	   1998).	   	   The	   heterogeneity	   between	   the	   molecular	   weight	   of	   native	   and	  recombinant	   forms	   of	   hCTGF	   is	   mainly	   due	   to	   the	   variations	   in	   its	   degree	   of	  glycosylation.	   	  The	  predicted	  sites	  for	  the	  N-­‐linked	  glycosylation	  of	  hCTGF	  are	  on	  aspartic	   acid	  28	   and	   aspartic	   acid	  225,	   and	   it	   is	   also	   known	   to	  be	   susceptible	   to	  Endoglycosidase	  F	  which	  decreases	  its	  Mr	  by	  2-­‐8	  kDa	  (Yang	  et	  al.	  1998).	  	  
CTGF	  Structure	  	  CTGF	  was	  first	  discovered	  in	  1991	  where	  it	  was	  shown	  that	  it	  is	  the	  major	  platelet-­‐derived	  growth	  factor	  (PDGF)	  immunorelated	  molecule	  secreted	  by	  human	  umbilical	  vein	  endothelial	  cells	  (HUVEC)	  (Bradham	  et	  al.	  1991).	  	  It	  is	  a	  36	  kDa	  (non-­‐reduced)	  to	  38	  kDa	  (reduced)	  cysteine-­‐rich	  polypeptide	  containing	  349	  amino	  acids.	  	  	  	  CTGF	  shares	  a	  multi-­‐modular	  structure	  with	  other	  members	  of	  the	  CCN	  family,	  but	  demonstrate	  distinctive	  functional	  features	  (Gupta	  et	  al.	  2000).	  	  CCN	  family	  members	  are	  cysteine	  rich	  proteins	  that	  possess	  a	  secretory	  signal	  peptide	  at	  the	  N-­‐terminus.	  	  All	  family	  members	  have	  four	  domains	  (figure	  1.3):	  an	  insulin-­‐like	  growth	  factor	  (IGFBP)-­‐binding	  domain,	  a	  von	  Willebrand	  factor	  (VWF)	  type	  C	  repeat	  domain,	  a	  thrombospondin	  (TSP)	  type	  1	  repeat	  domain	  and	  the	  C-­‐terminal	  (CT)	  domain.	  	  Connecting	  the	  VWF	  type	  C	  repeat	  domain	  to	  the	  TSP	  type	  1	  repeat	  domain	  is	  a	  region	  that	  is	  highly	  charged,	  variable	  and	  devoid	  of	  cysteines,	  which	  acts	  as	  a	  hinge	  region	  connecting	  both	  the	  N-­‐	  and	  C-­‐terminal	  halves	  of	  the	  protein	  (Gupta	  et	  al.	  2000).	  	  A	  fragment	  of	  10-­‐12	  kDa	  containing	  the	  cysteine	  knot	  domain	  from	  the	  cleavage	  of	  the	  C-­‐terminal	  half	  of	  the	  molecule	  has	  also	  been	  reported	  (Brigstock	  et	  al.	  1997;	  Ball	  et	  al.	  2003).	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Figure 1.3 The modular structure of CTGF with the insulin-like growth factor (IGF)-binding 
domain (domain1), a von Willebrand factor (VWF) type C repeat domain (domain 2), a 
thrombospondin (TSP) type 1 repeat domain (domain 3) and the C-terminal (CT) domain 
(domain 4).  The hinge region, which is susceptible to proteolytic cleavage separates the N-
terminal (domain 1 and 2) from the C-terminal (domain 3 and 4).   
 Each	   domain	   of	   the	   CTGF	   molecule	   interacts	   with	   different	   ligands	   shown	   in	  figures	  1.4,	  1.5.1.6	  and	  1.7.	  	  	  	  
	  	  
Figure 1.4 The insulin-like growth factor binding domain interacts with insulin-like growth factor 
and fibronectin.  	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Figure 1.5 The von Willebrand factor type C repeat domain interacts with bone morphogenic 
protein (BMP) 2/4/7, aggrecan, integrin and TGF-β.	  	  
	  	  
Figure 1.6 The thrombospondin repeat type 1 domain interacts with lipoprotein receptor-related 
protein1, vascular endothelial growth factor and integrin. 	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Figure 1.7 The C-terminal cysteine knot-like domain binds to lipoprotein receptor-related protein 
2, perlecan, fibronectin, integrin, heparan sulphate proteoglycan, bone morphogenic protein 2 
and vascular endothelial growth factor.  	  	  
CTGF	  function	  	  CTGF	  effects	  cells	  through	  the	  interaction	  with	  other	  bioactive	  proteins	  via	  one	  of	  its	  domains,	  thereby	  modifying	  the	  protein’s	  action,	   interaction	  with	  one	  or	  more	  cell	   surface	   tyrosine	   kinase	   receptors	   and	   integrins	   to	   trigger	   intracellular	  signalling	   and	   downstream	   actions,	   inducing	   the	   expression	   of	   other	   secreted	  molecules	  such	  as	  chemokines	  (Mason	  2009).	  	  	  	  CTGF	  stimulates	  the	  production	  of	  collagen,	  fibronectin,	  and	  laminin,	  which	  are	  key	  components	  of	  the	  extracellular	  matrix	  and	  critical	  to	  scar	  formation	  as	  part	  of	  the	  normal	   wound	   healing	   response	   and	   tissue	   repair.	   	   However,	   when	   these	  particular	   processes	   go	   wrong,	   CTGF	   is	   overexpressed.	   	   This	   leads	   to	   the	  differentiation	   of	   fibroblasts	   into	   myofibroblasts,	   which	   in	   turn	   causes	   the	  production	  of	  more	  CTGF.	  	  Elevated	  levels	  of	  CTGF	  cause	  excessive	  production	  and	  accumulation	   of	   collagen,	   from	   which	   chronic	   fibrosis	   subsequently	   develops	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(Hironobu	  2002;	  Wynn	  2008).	  	  CTGF	  has	  been	  implicated	  in	  diseases	  such	  as	  liver	  fibrosis,	  systemic	  sclerosis,	  diabetic	  nephropathy	  and	  non-­‐diabetic	  chronic	  kidney	  disease,	   idiopathic	   interstitial	   pneumonias,	   cardiomyopathy,	   atherosclerotic	  plaques,	   nephrogenic	   systemic	   fibrosis,	   peritoneal	   fibrosis	   in	   peritoneal	   dialysis	  patients	   and	   urethral	   stricture	   (Igarashi	   et	   al.	   1996;	   Ito	   et	   al.	   1998;	   Allen	   et	   al.	  1999;	  Paradis	  et	  al.	  1999;	  Sato	  et	  al.	  2000;	  Yoshisue	  et	  al.	  2002;	  Cicha	  et	  al.	  2005;	  Zhang	  et	  al.	  2008;	  Mizutani	  et	  al.	  2010;	  Schieren	  et	  al.	  2010).	  	  	  CTGF	  is	  a	  downstream	  mediator	  of	  TGF-­‐β.	   	  TGF-­‐β	  induces	  the	  expression	  of	  CTGF	  via	  a	  functional	  Smad	  3	  binding	  site	  in	  the	  CTGF	  promoter	  region	  (Hironobu	  2002).	  	  CTGF	  enhances	  the	  TGF-­‐β/Smad	  signalling	  cascade	  by	  binding	  directly	  to	  TGF-­‐β	  to	  facilitate	  its	  interaction	  with	  the	  TGF-­‐β	  receptors	  (Abreu	  et	  al.	  2002).	  	  CTGF	  binds	  to	   the	   tyrosine	   receptor	   kinase	   complex	   TrkA.p75	   NTR	   in	   mesangial	   cells.	   	   This	  causes	   the	   expression	   of	   the	  TGF-­‐β	   immediate	   early	   gene-­‐1	   (TIEG-­‐1),	  which	   is	   a	  known	  suppressor	  of	   the	   inhibitory	  Smad,	  Smad	  7	   (Wahab	  et	  al.	  2005).	   	  CTGF	   is	  also	   shown	   to	   bind	   to	   BMP-­‐7,	   which	   is	   a	   negative	   regulator	   of	   TGF-­‐β-­‐related	  fibrosis.	   	   Increase	   levels	   of	   CTGF	   was	   shown	   to	   inhibit	   the	   BMP-­‐7	   signalling	  cascade	  via	  the	  Smad	  1/5	  pathway.	  	  Smad	  5	  upregulates	  Smad	  6,	  which	  blocks	  the	  nuclear	  translocation	  of	  the	  Smad	  2/3	  and	  Smad	  4	  heterodimeric	  complex,	  thereby	  inhibiting	  TGF-­‐β	  signalling.	  	  Increased	  CTGF	  would	  promote	  this	  mechanism	  (Patel	  &	  Dressler	  2005;	  Nguyen	  et	   al.	   2008).	   	  A	   schematic	   representing	   these	  effects	  of	  CTGF	  on	  the	  TGF-­‐β	  signalling	  cascade	  is	  shown	  in	  figure	  1.8.	  	  	  
CTGF	  detection	  	  A	  sandwich	  ELISA	  is	  the	  method	  of	  choice	  for	  the	  detection	  of	  CTGF.	   	  This	  allows	  the	  accurate	  and	  sensitive	  detection	  of	  CTGF.	  	  This	  method	  has	  been	  applied	  with	  different	   antibodies	   raised	   against	   different	   fragments	   of	   CTGF.	   	   This	   allows	   the	  detection	  of	   its	  various	   fragments.	   	  The	  most	  common	  assays	  are	  those	  detecting	  either	   the	   full-­‐length	   and	  N-­‐terminal	   fragment,	   or	   the	   full-­‐length	   and	   C-­‐terminal	  fragment	  of	  CTGF	  (Dendooven	  et	  al.	  2011).	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Figure 1.8 A flow diagram summarising the actions of CTGF leading to the enhancement of 
TGF-β signalling, which ultimately leads to fibrosis. 	  Full-­‐length	   CTGF	   and	   its	   fragments	   have	   been	   identified	   in	   various	   body	   fluids.	  	  Plasma,	   serum,	   urine,	   vitreous	   fluid,	   dermal	   interstitial	   fluid	   and	   peritoneal	  dialysate	   were	   found	   to	   contain	   full-­‐length	   CTGF	   as	   well	   as	   the	   N-­‐terminal	  fragment	  (Hinton	  et	  al.	  2004;	  Kuiper	  et	  al.	  2006;	  Dziadzio	  et	  al.	  2005;	  Zarrinkalam	  et	   al.	   2003).	   	  The	  N-­‐terminal	   fragment	  was	   found	   to	  be	  more	  abundant	   than	   the	  full-­‐length	  CTGF	  (Cicha	  et	  al.	  2004;	  Roestenberg	  et	  al.	  2004;	  Miyazaki	  et	  al.	  2010).	  	  The	  C-­‐terminal	   fragment	  was	   found	  to	  be	  present	   in	  serum	  and	  urine.	   	  A	  23	  kDa	  heparin-­‐binding	  was	   identified	   in	   peritoneal	   dialysis	   fluid,	  which	   corresponds	   to	  the	  C-­‐terminal	  heparin-­‐binding	  domain.	  	  A	  12	  kDa	  fragment	  was	  also	  identified	  in	  the	  urine	  of	  diabetic	  patients	  (Zarrinkalam	  et	  al.	  2003;	  Riser	  et	  al.	  2003).	  	  	  	  Large	  amounts	  of	  full-­‐length	  CTGF	  are	  present	  in	  platelets,	  which	  are	  released	  into	  serum	  when	  blood	  coagulates.	  	  This	  may	  affect	  the	  measurement	  of	  CTGF	  in	  serum	  therefore;	  plasma	  is	  the	  medium	  of	  choice	  when	  detecting	  CTGF	  in	  blood	  (Cicha	  et	  al.	  2004;	  Miyazaki	  et	  al.	  2010).	  	  The	  presence	  of	  anticoagulants	  such	  as	  heparin	  will	  affect	  CTGF	  detection.	  	  This	  is	  because	  CTGF	  has	  a	  heparin-­‐binding	  domain,	  which	  may	   prevent	   antibody	   recognition	   through	   steric	   hindrance	   (Dendooven	   et	   al.	  2011).	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  Bao	   et	   al	   developed	   a	   competitive	   indirect	   ELISA	   using	   a	   rabbit	   polyclonal	   anti-­‐CTGF	  antibody	  from	  Santa	  Cruz	  Biotechnology.	   	  This	  assay	  was	  performed	  on	  rat	  urine	   samples	   and	   had	   the	   advantage	   of	   being	   a	   rapid	   test	   due	   to	   the	   one-­‐step	  addition	   of	   reagents,	   leading	   to	   the	   reduction	   of	   total	   test	   time	   to	   less	   than	   two	  hours.	  	  This	  assay	  has	  yet	  to	  be	  validated	  on	  human	  samples	  (Bao	  et	  al.	  2008).	  	  	  	  
Diabetes	  	  Diabetes	  is	  the	  lack	  of	  insulin	  or	  the	  presence	  of	  factors	  that	  oppose	  the	  action	  of	  insulin	  (Watkins	  2003).	  	  The	  main	  outcome	  of	  the	  insufficient	  action	  of	  insulin	  is	  an	  increase	   in	   the	   blood	   glucose	   levels	   known	   as	   hyperglycaemia.	   	   There	   are	   also	  many	  other	  metabolic	  abnormalities	   that	  arise	  as	  a	  consequence	  of	  diabetes.	   	  An	  example	  is	  an	  increase	  in	  the	  amount	  of	  ketone	  bodies	  within	  the	  blood	  when	  there	  is	   a	   severe	   lack	   of	   this	   hormone	   (Watkins	   2003).	   	   Diabetes	   is	   firstly	   diagnosed	  through	  a	  blood	  test	  that	  measures	  the	  patient’s	  blood	  glucose	  levels.	  	  
Type	  I	  Diabetes	  	  	  	  This	  is	  due	  to	  the	  destruction	  of	  B-­‐cells	  in	  the	  islets	  of	  Langerhans	  in	  the	  pancreas,	  which	  ultimately	  results	  in	  the	  loss	  of	  insulin	  production.	  	  Autoimmune	  attacks	  on	  the	  B-­‐cells	  is	  the	  main	  cause	  responsible	  for	  their	  destruction,	  and	  is	  triggered	  by	  a	  combination	   of	   environmental	   and	   genetic	   factors,	   especially	   in	   genetically	  susceptible	  individuals	  (Watkins	  2003).	  	  The	  process	  of	  islet	  destruction	  is	  thought	  to	   start	   very	   early	   in	   life,	   years	   before	   diabetes	   can	   be	   clinically	   diagnosed	  (Watkins	  2003).	  	  
Type	  II	  diabetes	  	  	  Type	   II	   diabetes	   is	   a	   slowly	   progressive	   disorder	   whereby	   insulin	   secretion	  declines	   over	   many	   decades,	   resulting	   in	   the	   deterioration	   of	   glycaemic	   control	  that	  consequently	  becomes	  more	  and	  more	  difficult	  to	  achieve	  (Watkins	  2003).	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This	   type	   of	   diabetes	   is	   now	   known	   to	   have	   several	   causes	   that	   include	   a	   wide	  range	   of	   disorders	  with	   differing	   progression	   and	   outlook	   (Watkins	   2003).	   	   The	  main	   mechanism	   involved	   in	   type	   II	   diabetes	   is	   due	   to	   either	   reduced	   insulin	  secretion	  or	  alternatively	  increased	  hepatic	  glucose	  output.	  	  The	  latter	  is	  typically	  due	   to	   pancreatic	   islet	   defects,	   which	   is	   consequently	   associated	  with	   increased	  peripheral	  resistance	  to	  the	  action	  of	  insulin.	  	  In	  turn,	  peripheral	  glucose	  uptake	  in	  decreased	   (Watkins	   2003).	   	   It	   is	   uncertain	   as	   to	   whether	   decreasing	   insulin	  secretion,	   or	   increasing	   insulin	   resistance	   occurs	   first.	   	   This	   sequence	   of	   events	  may	  well	  vary	  between	  individuals.	  	  The	  most	  common	  cause	  of	  insulin	  resistance	  is	  obesity	  (Watkins	  2003).	  	  
Other	  types	  of	  diabetes	  	  The	   other	   main	   type	   of	   diabetes	   is	   known	   as	   gestational	   diabetes.	   	   It	   is	  characterised	  as	  hyperglycaemia	  that	  is	  initially	  recognised	  during	  pregnancy.	  	  The	  symptoms	   of	   gestational	   diabetes	   are	   very	   similar	   to	   those	   of	   type	   II	   diabetes	  although	   it	   is	   most	   often	   diagnosed	   through	   prenatal	   screening	   rather	   than	  through	  reported	  symptoms	  (World	  Health	  Organisation	  2008).	  	  There	   are	   also	   intermediate	   conditions,	   in	   the	   transition	   between	  normality	   and	  diabetes,	   known	   as	   Impaired	   Glucose	   tolerance	   (IGT)	   and	   Impaired	   Fasting	  Glycaemia	  (IFG).	  	  People	  with	  IGT	  or	  IFG	  are	  at	  a	  high	  risk	  of	  progressing	  to	  type	  II	  diabetes,	  although	  this	  is	  not	  inevitable	  (World	  Health	  Organisation	  2008).	  	   	  
Incidences	  of	  diabetes	  	  Diabetes	   affects	   1-­‐2	   %	   of	   the	   population	   and	   unless	   it	   is	   treated	   early,	   it	   can	  progress	  to	  diabetic	  nephropathy,	  resulting	   in	  dialysis	  and	  even	  organ	  transplant	  (World	   Health	   Organisation	   2008).	   	   Therefore,	   an	   early	   monitoring/detection	  system	  of	  glomerular	  change	  will	  be	  an	   important	   innovation	   in	  this	   field.	   	  A	  key	  feature	   of	   diabetic	   nephropathy	   is	   the	   development	   of	   fibrosis	   along	  with	   other	  changes	   in	   the	   extracellular	  matrix.	   	   One	   of	   the	   key	  mediators	   in	   this	   process	   is	  connective	  tissue	  growth	  factor	  (CTGF).	  	  To	  date,	  there	  are	  no	  established	  methods	  of	  determining	  this	  molecule	  in	  patient	  samples.	  	  This	  thesis	  describes	  an	  approach	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to	  the	  development	  of	  a	  rapid,	  sensitive	  and	  specific	  procedure	  for	  the	  detection	  of	  CTGF.	   	   The	   key	   component	   of	   diabetic	   complication	   in	   the	   kidney	   is	   fibrosis.	  	  Although	   there	   are	   commercial	   kits	   available,	   the	   antibodies	   are	   against	  recombinant	  human	  CTGF	  (rhCTGF),	  with	  the	  competitor	  also	  being	  rhCTGF.	  	  The	  purpose	  of	  this	  study	  was	  the	  isolation	  and	  development	  of	  an	  assay	  against	  CTGF.	  	  	  	  
Complications	  of	  diabetes	  	  The	   principal	   consequence	   of	   uncontrolled	   diabetes	   is	   microangiopathy,	   which	  affects	   patients’	  micro	   blood	   vessels	   in	   the	   eyes,	   kidneys	   and	   nerves.	   	   There	   are	  also	  effects	  on	  the	  macrovascular	  system.	  	  	  	  Diabetic	   retinopathy,	  an	   important	  cause	  of	  blindness,	  occurs	  as	  a	   result	  of	   long-­‐term,	  accumulative,	  damage	  to	  the	  small	  blood	  vessels	  of	  the	  retina.	  	  About	  2	  %	  of	  patients	  will	  become	  blind	  after	  15	  years	  of	  suffering	  from	  diabetes,	  and	  10	  %	  will	  develop	  severe	  visual	  impairment	  (World	  Health	  Organisation	  2008).	  	  Diabetic	   neuropathy	   is	   seen	   as	   the	   nerve	   damage	   resulting	   from	   diabetes.	   	   This	  affects	   almost	   50	   %	   of	   patients.	   	   Many	   different	   problems	   are	   associated	   with	  diabetic	  neuropathy.	  The	  most	  common	  symptoms	  are	  tingling,	  pain,	  numbness,	  or	  even	   weakness	   in	   the	   feet	   and	   hands.	   	   Later	   consequences	   of	   suffering	   with	  diabetic	  neuropathy,	   in	  combination	  with	  reduced	  blood	  flow,	   lead	  to	  or	   increase	  the	  chance	  of	  foot	  ulcers	  and	  eventually	  limb	  amputation	  (Sheetz	  &	  King	  2002).	  	  Risk	   and	   incidence	   of	   heart	   disease	   and	   stoke	   is	   also	   markedly	   increased	   by	  diabetes.	  	  50	  %	  of	  diabetic	  patients	  will	  die	  as	  a	  result	  of	  a	  cardiovascular	  disease	  (World	  Health	  Organisation	  2008).	  	  
Consequences	  of	  diabetes	  on	  the	  kidney	  	  More	  importantly,	  diabetes	  is	  amongst	  the	  leading	  causes	  of	  kidney	  failure,	  with	  an	  estimated	   10	   to	   20	   %	   of	   people	   with	   diabetes	   dying	   as	   a	   result	   (World	   Health	  Organisation	  2008).	  	  The	  original	  link	  between	  diabetes	  and	  renal	  disease	  was	  first	  established	   in	   the	   early	   nineteenth	   century	   by	   Cotunnius	   and	   Bright	   (Shaw	   &	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Cummings	  2005).	   	  Renal	  disease	  caused	  by	  diabetes	  is	  primarily	  characterised	  by	  changes	   in	   both	   albuminuria	   (albumin	   excretion	   rate	   (AER))	   and	   the	   glomerular	  barrier	   fitration	  rate	  (GFR)	   in	  people	  predisposed	  to	  the	  development	  of	  diabetic	  renal	   disease	   (Shaw	   &	   Cummings	   2005).	   The	   normal	   sequence	   of	   events	   starts	  with	  an	  increase	  in	  GFR,	  also	  known	  as	  hyperfiltration,	  followed	  by	  an	  increase	  in	  AER	   that	   eventually	   leads	   to	  microalbuminuria.	   	   In	   addition	   to	   these	   changes	   in	  filtration,	  a	  rise	  in	  blood	  pressure	  can	  also	  be	  detected	  (Shaw	  &	  Cummings	  2005).	  	  
Diabetic	  nephropathy	  	  Although	   the	   introduction	   of	   insulin	   therapy	   in	   1924	   improved	   the	   immediate	  outlook	   for	   patients	  with	   diabetes	  mellitus,	   it	   also,	   as	   a	   consequence,	   uncovered	  the	   problem	   of	   the	   long	   term	   complications	   associated	   with	   the	   disease.	   	   As	  mentioned	   above,	   studies	   on	   diabetes	   subsequently	   showed	   the	   high	   incidence	  rate	  of	  occlusive	  vascular	  disease,	  retinopathy,	  neuropathy	  and	  nephropathy	  that	  are	   now	   collectively	   known	   as	   diabetic	   angiopathy	   due	   to	   specific	   degenerative	  lesions	  of	  blood	  vessels.	  	  	  	  As	   is	   publicised,	   the	   incidence	   of	   diabetes,	   in	   particular	   type	   II	   diabetes,	   is	  increasing	  worldwide	  (World	  Health	  Organisation	  2008).	   	  The	   impact	  of	   this	  rise	  on	  public	  health	  is	  huge	  for	  example,	  as	  diabetes	  is	  now	  the	  leading	  cause	  of	  end-­‐stage	  renal	  disease	  in	  Western	  countries.	  	  	  	  Diabetic	   nephropathy	   is	   defined	   as	   persistent	   clinically	   detectable	   proteinuria	   in	  association	   with	   an	   elevation	   in	   blood	   pressure	   and	   a	   decline	   in	   glomerular	  filtration	  rate	  has	  been	  reported	  to	  occur	  in	  25-­‐40	  %	  of	  people	  with	  either	  type	  I	  or	  type	  II	  diabetes	  (Riser	  et	  al.	  2000).	  	  It	  is	  also	  known	  that	  diabetics,	  especially	  those	  with	  renal	  involvement,	  have	  an	  increased	  cardiovascular	  morbidity	  and	  mortality.	  	  Therefore,	   the	   early	   identification	   of	   those	   at	   greatest	   risk	   and	   the	   subsequent	  initiation	   of	   renal	   and	   cardiovascular	   protective	   treatments	   are	   of	   utmost	  importance	  (Shaw	  &	  Cummings	  2005).	  	  Angiotensin-­‐converting	   enzyme	   (ACE)	   inhibitors,	   which	   block	   the	   conversion	   of	  angiotensin	  I	  to	  angiotensin	  II,	  are	  currently	  the	  first	  choice	  method	  for	  combating	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kidney	  failure	  by	  essentially	  slowing	  the	  progression	  of	  the	  disease.	  	  Unfortunately,	  this	  type	  of	  treatment	  is	  not	  suitable	  for	  all	  patients	  as	  approximately	  30-­‐40	  %	  will	  develop	  progressive	  renal	  disease	  (Parving	  &	  Hommel	  1989).	   	  Currently,	  the	  best	  method	   of	   monitoring	   patients	   with	   diabetes	   for	   signs	   of	   kidney	   damage	   and	  nephropathy	  is	  by	  measuring	  microalbuminuria	  (Riser	  et	  al.	  2003).	  	  	  
	  
Microalbuminuria	  	  Microalbuminuria	   is	   an	   early	   component	   in	   a	   range	   of	   progressive	   increases	   in	  albumin	  excretion	  rates.	  	  This	  is	  a	  typical	  characteristic	  in	  diabetic	  renal	  disease.	  	  It	  refers	   to	   a	   sub-­‐clinical	   increase	   in	   urinary	   albumin	   excretion,	   and	   by	   definition	  corresponds	  to	  an	  albumin	  excretion	  rate	  of	  20-­‐200	  μg	  min-­‐1	  (30-­‐300	  mg	  per	  day)	  or	  an	  albumin	  to	  creatinine	  ratio	  (ACR)	  of	  2.5-­‐35	  mg	  mmol-­‐1.	  	  The	  development	  of	  microalbuminuria	   is	   primarily	   equated	   to	   early	   nephropathy	   although;	   it	   is	   also	  seen	  as	  a	  risk	  factor	  for	  macrovascular	  disease	  in	  those	  with	  diabetes	  (Watts	  et	  al.	  1995).	   	   As	   a	   consequence,	   accurately	   measuring	   albumin	   excretions	   is	   still	   the	  easiest	  and	  best	  way	  of	  predicting	  diabetic	  kidney	  disease	  even	  though	  it	  has	  been	  demonstrated	   that	   a	   minority	   of	   diabetic	   patients	   with	   impaired	   renal	   function	  may	  not	  have	  an	  elevated	  albumin	  excretion	  rate	  (Caramori	  et	  al.	  2000).	  	  
Screening	  for	  diabetic	  renal	  disease	  	  Testing	   for	   the	   presence	   of	   persistent	   microalbuminuria	   is	   currently	   the	   most	  widely	   used	   screening	   method	   for	   patients	   with	   or	   at	   risk	   from	   diabetic	  nephropathy	  (Bojestig	  et	  al.	  1996).	  	  The	  testing	  can	  be	  accomplished	  in	  a	  number	  of	   ways.	   	   A	   24	   hr	   urine	   collection	   for	   the	   estimation	   of	   AER,	  which	   is	   currently	  accepted	  as	   the	   ‘gold	  standard’	   test	   that	  has	   the	  added	  advantage	  of	  allowing	   for	  the	   estimation	   of	   creatinine	   clearance	   values.	   	   A	   spot-­‐urine	   collection	   for	   the	  estimation	  of	  AER	  is	  more	  commonly	  used.	  	  (Shaw	  &	  Cummings	  2005).	  	  It	  is	  important	  to	  take	  care	  when	  analysing	  data,	  as	  increases	  in	  albuminuria	  into	  the	   microalbuminuric	   range	   may	   occur	   transiently	   with	   exercise,	   urinary	   tract	  infections,	   uncontrolled	   hyperglycaemia	   and	   cardiac	   failure	   to	   name	   but	   a	   few	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(Shaw	  &	  Cummings	  2005).	  	  It	  has	  also	  been	  shown	  in	  many	  cases,	  that	  by	  the	  time	  microalbinuria	   is	   identified,	   structural	   renal	   lesions	   of	   the	   kidney	   are	   found	  (Mogensen	  1995).	   	   It	   can	  also	  be	   the	   case	   that	   the	   actual	   level	   of	  microalbinuria	  does	   not	   directly	   correlate	   to	   and	   subsequently	   predict	   the	   development	   of	  nephropathy	  (Bojestig	  et	  al.	  1996).	  	  	  	  Considering	   these	  points,	   it	   can	   concluded	   that	   finding	   and	  utilising	   a	  marker	   to	  detect	   signs	   of	   disease	   earlier,	   and	  with	  more	   specificity	   than	  what	   is	   currently	  used	  is	  an	  important	  consideration.	  	  	  
Glomerulosclerosis	  and	  tubulointerstitial	  fibrosis	  	  Hyperglycaemia	   seems	   to	   be	   the	   main	   factor	   in	   initiating	   the	   development	   of	  diabetic	  nephropathy	   in	  humans	   and	   in	   animal	  models	   of	   diabetes	  mellitus	   (The	  Diabetes	   Control	   and	   Complications	   Trial	   Research	   Group	   1993).	   	   The	  characteristics	   of	   diabetic	   nephropathy	   include	   the	   accumulation	   of	   mesangial	  extracellular	   matrix,	   manifest	   as	   glomerulosclerosis	   and	   by	   the	   development	   of	  tubulointerstitial	  fibrosis	  (Wahab	  et	  al.	  2001).	  	  
 
Figure 1.9 Histology of a normal kidney (left panel) and of a diseased kidney showing 
glomerulosclerosis, tubular atrophy and interstitial fibrosis and arterial intimal hyalinosis. Image 
modified from (http://cmgm.stanford.edu/~kimlab/aging_kidney/figures.html)	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  Regardless	   of	   the	   initiating	   result,	   progression	   to	   end-­‐stage	   renal	   failure	   in	  (proteinuric)	   kidney	   disease	   appears	   to	   involve	   this	   final	   common	   pathway	   of	   a	  culmination	   in	   glomerulosclerosis	   and	   tubulointerstitial	   fibrosis.	   	   In	   the	   United	  States	  of	  America,	  diabetes	  is	  the	  seventh	  leading	  cause	  of	  death	  in	  2007	  (National	  Diabetes	   Information	   Clearinghouse	   (NDIC)	   2011).	   	   Despite	   many	   preventative	  measures	   such	   as	   blocking	   the	   rennin-­‐angiotensin	   system	   or	   the	   control	   of	  systemic	  hypertension,	  this	  loss	  of	  residual	  renal	  function	  will	  continue	  (Gupta	  et	  al.	   2000).	   	   Therefore,	   targeting	   initiators	   and	   promoters	   of	   tissue	   fibrosis	   at	   a	  molecular	  level	  would	  be	  the	  next	  logical	  step.	  	  Currently,	  patients	  are	  screened	  for	  diabetic	  renal	  disease	  by	  monitoring	  levels	  of	  microalbuminuria.	  	  Persistent	  microalbuminuria	  is	  a	  also	  a	  marker	  for	  widespread	  vascular	   damage	   as	   well	   as	   being	   regarded	   as	   an	   indicator	   of	   incipient	  nephropathy	  in	  type	  I	  and	  type	  II	  diabetes.	  	  Another	  problem	  is	  that	  the	  actual	  level	  of	   microalbuminuria	   may	   not	   necessarily	   predict	   the	   development	   of	   clinical	  nephropathy,	  particularly	  with	   long	  standing	  diabetes	  (Bojestig	  et	  al.	  1996).	   	   It	   is	  more	   often	   than	   not	   that	   by	   the	   time	   microalbuminuria	   has	   been	   detected,	  structural	   renal	   lesions	   are	   already	   present.	   	   Therefore	   an	   early	   marker	   to	  diagnose	  and	  monitor	  diabetic	  nephropathy	  is	  essential.	  	  
CTGF	  and	  TGF-­‐β	  in	  diabetic	  nephropathy	  
	  CTGF	   plays	   an	   important	   role	   in	   the	   pathogenesis	   of	   diabetic	   nephropathy	   and	  diabetic	  retinopathy,	  which	  are	  microvascular	  complications	  of	  diabetes	  mellitus.	  	  In	  diabetic	  nephropathy,	  CTGF	  mRNA	  was	  shown	  to	  be	  upregulated	   in	  mesangial	  cells,	   podocytes	   and	   tubulointerstitial	   fibroblasts	   (Ito	   et	   al.	   1998;	   Kuiper	   et	   al.	  2008;	   Nguyen	   et	   al.	   2008).	   	   CTGF	   is	   also	   implicated	   in	   the	   macrovascular	  complications	  (renal	  and	  vascular	  disease)	  of	  type	  I	  diabetes	  (Jaffa	  et	  al.	  2008).	  	  	  	  Elevated	   concentrations	   of	   TGF-­‐β	   are	   linked	   to	   the	   pathogenesis	   of	  glomerulosclerosis	  and	   interstitial	   fibrosis	   in	  diabetic	  nephropathy	   (Wahab	  et	   al.	  2005).	   	   Rats	   administered	   with	   streptozotocin,	   a	   drug	   that	   leads	   to	   insulin	  deficiency,	  were	  found	  to	  have	  progressively	  increasing	  amounts	  of	  TGF-­‐β1	  mRNA	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and	   protein	   in	   their	   glomeruli.	   	   (Yamamoto	   et	   al.	   1993).	   	   In	   the	   glomeruli	   of	  humans	   with	   diabetic	   nephropathy,	   TGF-­‐β	   levels	   as	   well	   as	   matrix	   proteins	  induced	   by	   TGF-­‐β	   were	   also	   seen	   to	   be	   elevated.	   	   The	   stimulus	   triggering	   the	  expression	  of	  TGF-­‐β	  in	  diabetes	  is	  thought	  to	  be	  hyperglycaemia	  or	  an	  increase	  in	  the	  activity	  of	  the	  renin-­‐angiotensin	  system	  in	  renal	  tissue.	  	  In	  humans,	  controlling	  blood	   glucose	   levels	   with	   insulin	   and	   the	   administering	   of	   an	   angiotensin-­‐converting-­‐enzyme	   inhibitor	  (ACE	   inhibitor)	  will	  help	   to	  hinder	   the	  development	  of	  diabetic	  nephropathy	  (Yamamoto	  et	  al.	  1993).	  	  Although	   targeting	   TGF-­‐β	   would	   seem	   to	   be	   a	   feasible	   and	   productive	   way	   of	  monitoring	  and	  interfering	  with	  the	  disease,	  there	  would	  be	  other	  manifestations	  in	  the	   long	  term.	  For	  example,	   in	  addition	  to	   its	  pro-­‐fibrotic	  activities,	  TGF-­‐β	  also	  has	  anti-­‐proliferative	  and	  anti-­‐inflammatory	  effects.	  	  Because	  of	  this,	  investigations	  have	  now	  also	  focused	  on	  downstream	  or	  even	  parallel	  mediators	  of	  tissue	  fibrosis	  that	   ideally	   will	   yield	   a	   pharmaceutical	   intervention	   and	   at	   the	   same	   time	   not	  influence	  cell	  cycle	  control	  (Franklin	  1997).	  	  	  	  One	   of	   these	   mediators	   is	   connective	   tissue	   growth	   factor	   (CTGF).	   	   CTGF	   is	   a	  downstream	   mediator	   of	   TGF-­‐β	   action	   on	   connective	   tissue	   cells	   (Grotendorst	  1997).	  	  It	  is	  induced	  by	  TGF-­‐β	  and	  modulates	  fibroblast	  cell	  growth,	  and	  fibroblast	  and	  mesangial	  cell	  extracellular	  matrix	  excretion.	  	  CTGF	  is	  responsible	  for	  the	  final	  common	  pathology	  in	  chronic	  fibrosis	  from	  both	  TGF-­‐β	  -­‐	  dependent	  pathways	  and	  independent	  pathways	  (Gupta	  et	  al.	  2000).	  	  This	  makes	  CTGF	  an	  ideal	  and	  valuable	  biomarker	  for	  the	  detection	  of	  the	  onset	  of	  chronic	  fibrotic	  disorders.	   	  Because	  of	  the	   presence	   of	   different	   CTGF	   fragments	   as	   well	   as	   the	   full-­‐length	   molecule	   in	  body	   fluids,	   detection	   of	   this	   protein	   has	   proven	   to	   be	   difficult.	   	   An	   assay	   may	  detect	   either	   the	   full-­‐length	   and	   N-­‐terminal,	   or	   the	   full-­‐length	   and	   C-­‐terminal	  fragment.	   	  Therefore,	  both	  assays	  may	  not	  reflect	  the	  true	  amount	  of	  CTGF	  in	  the	  sample.	   	   The	   clinical	   significance	   of	   the	   molecular	   form	   of	   CTGF	   detected	   and	  measured	  is	  dependant	  on	  the	  technique	  used.	  	  	  	  Ngyuyen	  et	  al.	   (2006)	  detected	  the	  N-­‐terminal	   fragment	  whilst	  Tam	  et	  al.	   (2009)	  detected	   the	   C-­‐terminal	   fragment	   in	   the	   urine	   of	   patients	   with	   diabetic	   kidney	  disease	  Tam	  et	  al	  measured	  significantly	  higher	  CTGF	  levels	  in	  patients	  with	  micro-­‐	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and	  macroalbuminuria	  compared	  to	  those	  with	  normoalbuminuria.	  	  Urinary	  CTGF	  was	   higher	   in	   microalbuminuric	   than	   in	   macroalbuminuric	   patients.	   	   Therefore,	  they	  suggested	  that	  urinary	  CTGF	  might	  be	  a	  biomarker	  for	  the	  early	  progression	  of	  diabetic	  nephropathy.	   	  Nguyen	  et	  al.	  proved	   that	   the	  N-­‐terminal	   fragment	  was	  higher	   in	   macroalbuminuric	   patients,	   but	   there	   was	   no	   significant	   difference	  between	  normoalbuminuric	  and	  microalbuminuric	  patients.	  	  They	  showed	  that	  the	  levels	   of	   the	   N-­‐terminal	   fragment	   of	   CTGF	   correlated	   to	   the	   urinary	   albumin	  excretion	  rate	  and	  glomerular	  filtration	  rate.	   	  These	  two	  studies	  showed	  differing	  data	   due	   to	   the	   different	   CTGF	   fragment	   that	  was	   detected	   (Nguyen	   et	   al.	   2006;	  Tam	  et	  al.	  2009).	  	  	  	  Whilst	   these	   studies	   are	   of	   significance,	   standardization	   of	   the	   CTGF	   assay	   is	   of	  utmost	   importance.	   	   Dendooven	   et	   al.	   (2011)	   state	   that	   the	   validation	   and	  comparison	   of	   the	   different	   assay	   formats	   is	   highly	   warranted	   before	   clinical	  implementation	  (Dendooven	  et	  al.	  2011).	  	  To	  date,	  naturally	  occurring	  CTGF	  or	  its	  fragments	  have	  not	  been	   isolated	   from	  body	   fluids.	   	   The	  published	  CTGF	  ELISAs	  rely	  solely	  on	  recombinant	  full-­‐length	  CTGF	  and	  its	  fragments,	  as	  well	  as	  synthetic	  CTGF	   peptides	   for	   antibody	   generation.	   	   An	   ideal	   assay	  would	   utilise	   antibodies	  that	  are	   raised	  against	   the	  native	  molecule.	   	  Urine	  has	  also	   shown	   to	  be	  a	  better	  medium	  for	  the	  detection	  of	  CTGF	  compared	  to	  plasma	  or	  serum,	  largely	  due	  to	  the	  complications	   arising	   from	   using	   heparin	   as	   an	   anticoagulant	   and	   platelet	  activation	  of	  CTGF.	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Aim:	  	  To	   isolate	   and	   characterise	   CTGF	   in	   diabetic	   urine	   and	   peritoneal	   dialysis	   fluid	  with	  a	  view	  to	  its	  assay	  and	  evaluation	  in	  renal	  fibrosis.	  	  
Objectives:	  	   1. To	   determine	   whether	   diabetic	   urine	   or	   peritoneal	   dialysis	   fluid	   is	   a	  potential	  source	  of	  CTGF.	  2. To	   assay	   the	   efficacy	   of	   the	   antibody	   against	   the	   developed	   recombinant	  human	  (rh)	  CTGF.	  3. To	  raise	  antibodies	  against	  a	  peptide	  fragment	  of	  CTGF.	  4. To	  assay	  whether	  antibodies	  against	  the	  isolated	  natural	  molecule	  are	  more	  advantageous	  over	  those	  against	  the	  developed	  and	  commercial	  rhCTGF.	  5. To	  isolate	  the	  natural	  CTGF	  molecule	  for	  biochemical	  characterization.	  6. To	  determine	  whether	  the	  assay	  against	  the	  natural	  molecule	  is	  superior	  to	  that	  against	  the	  rhCTGF	  antibody.	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Chapter	  2	  
Materials	  and	  Methods





    1,4-­‐Dioxane	  	   Sigma-­‐Aldrich	  2-­‐Mercaptoethanol	  	   Sigma-­‐Aldrich	  3-­‐(Maleimido)propionic	  acid	  N-­‐hydroxysuccinimide	  ester	  	   Sigma-­‐Aldrich	  ABTS	  liquid	  substrate	  system	  	   Sigma-­‐Aldrich	  Acetone	   Sigma-­‐Aldrich	  Acetonitrile	   Sigma-­‐Aldrich	  Acrylamide/Bis-­‐acrylamide,	  30%	  solution	   Sigma-­‐Aldrich	  Activated	  charcoal	  	   Sigma-­‐Aldrich	  Ammonium	  bicarbonate	   Sigma-­‐Aldrich	  Ammonium	  persulfate	   Sigma-­‐Aldrich	  Ammonium	  sulphate	  	   Sigma-­‐Aldrich	  Anti-­‐Mouse	  IgG	  (whole	  molecule)–Peroxidase	  	   Sigma-­‐Aldrich	  Boric	  acid	  	   Sigma-­‐Aldrich	  Bromophenol	  Blue	  	   Sigma-­‐Aldrich	  Cyanuric	  chloride	  (CC)	   Sigma-­‐Aldrich	  Dithiothreitol	  (DTT)	   Sigma-­‐Aldrich	  Donkey	  anti-­‐sheep	  IgG-­‐peroxidase	  conjugate	  	   Sigma-­‐Aldrich	  Ethylenediaminetetraacetic	  acid	  (EDTA)	  	   Sigma-­‐Aldrich	  Gelatin	  from	  porcine	  skin	  	   Sigma-­‐Aldrich	  Glycerol	   Sigma-­‐Aldrich	  Glycine	  	   Sigma-­‐Aldrich	  Isobutyl	  chloroformate	   Sigma-­‐Aldrich	  Methyl	  6-­‐aminohexanoate	  	   Sigma-­‐Aldrich	  N-­‐Hydroxysuccinimide	  	   Sigma-­‐Aldrich	  
N,N-­Diisopropylethylamine	  	   Sigma-­‐Aldrich	  
N,N-­‐Dimethylformamide	  (DMF)	   Sigma-­‐Aldrich	  
N,N′-­‐Dicyclohexylcarbodiimide	  (DCC)	   Sigma-­‐Aldrich	  Protein	  G	  Sepharose®	  Fast	  Flow	   Sigma-­‐Aldrich	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Equipment   
    2-­‐D	  Quant	  Kit	   G	  E	  Healthcare	  Blotting	  Paper	   G	  E	  Healthcare	  ECL	  detection	  kit	   G	  E	  Healthcare	  Hybond-­‐C	  Extra	  (20	  ×	  20	  cm)	   G	  E	  Healthcare	  PD-­‐10	  Sephadex	  G-­‐25	  columns	   G	  E	  Healthcare	  TE	  77	  PWR	  Semi-­‐Dry	  Transfer	  Unit	   G	  E	  Healthcare	  XK	  16/20	  column	   G	  E	  Healthcare	  XCell	  SureLock	  Mini-­‐Cell	  	   Invitrogen	  NuPAGE	  Novex	  10%	  Bis-­‐Tris	  Gel	  1.0	  mm,	  15	  well	  	   Invitrogen	  NuPAGE	  MOPS	  SDS	  Running	  Buffer	  (20X)	   Invitrogen	  Novex	  Tris-­‐Glycine	  SDS	  Sample	  Buffer	  (2X)	  	   Invitrogen	  NuPAGE	  Transfer	  Buffer	  (20X)	  	   Invitrogen	  Snap	  i.d.	  Protein	  Detection	  System	   Millipore	  Amicon	  Ultra-­‐4	  10	  kDa	  Centrifuga	  filter	  unit	  	   Millipore	  Amicon	  Stirred	  cell	  8400	  	   Millipore	  	  Table	  2.2	  List	  of	  instruments	  	  
2.2	  List	  of	  buffers	  	  
Sodium	   Phosphate	   Buffer	   50	   mM	   sodium	   phosphate,	   pH	   7.0	   with	   potassium	  dihydrogen	  orthophosphate	  
	  
Sodium	  Carbonate	  Buffer	  0.1	  M	  and	  0.5	  M	  sodium	  carbonate,	  pH	  9.0	  (HCl)	  
	  
Sodium	  Bicarbonate/Carbonate	  Buffer	  0.1	  M	  sodium	  bicarbonate,	  pH	  9.0	  with	  solid	  sodium	  carbonate	  	  
Gel	  running	  buffer	  25	  mM	  Tris,	  200	  mM	  glycine,	  0.1%	  SDS	  (w/v),	  pH	  8.3	  (HCl)	  
	  
TBS	  Buffer	  20	  mM	  Tris,	  500	  mM	  sodium	  chloride,	  pH	  7.5	  (HCl)	  
	  
TBST	  0.1%	  (v/v)	  Tween	  20,	  TBS	  buffer	  
	  
Protein	   Sample	   Buffer	   (non-­‐reducing)	   (0.0625	   M	   Tris,	   2%	   SDS,	   10%	   Glycerol,	  0.001%	  bromophenol-­‐blue)	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Staining	  Solution	  (0.2%	  coomassie	  blue	  (brilliant	  blue	  250R),	  10	  parts	  de-­‐ionised	  water,	  10	  parts	  methanol,	  1	  part	  glacial	  acetic	  acid)	  –	  dissolve	  coomassie	  blue	   in	  methanol	   first	   then	  add	  acetic	   acid	   and	  de-­‐ionised	  water	   and	   filter	   through	  with	  Whatman	  No.1	  filter	  paper	  	  
Destain	  Solution	  150	  ml	  glacial	  acetic	  acid,	  100	  ml	  methanol,	  1750	  ml	  de-­‐ionised	  water	  
	  
Coating	  Buffer	   20	  mM	  Tris	  and	  100	  mM	  sodium	  chloride,	  pH	  7.8	   (HCl),	  0.1	  mM	  EDTA	  and	  0.01	  %	  thimerosal	  added	  after	  
	  
Plate	   Washing	   Buffer	   100	   mM	   sodium	   bicarbonate	   solution,	   100	   mM	   sodium	  chloride,	  10%	  Tween	  20	  .	  	  	  
	  
Plate	  Blocking	  and	  Antibody	  Buffer	   20	  mM	  Tris	   and	  100	  mM	  sodium	  chloride	  pH	  7.8	  (HCl).	  	  0.1	  mM	  EDTA,	  0.01	  %	  thimerosal	  and	  0.05	  %	  Tween	  20	  added	  after).	  	  1	  %	  milk	  powder	  added	  just	  before	  each	  use.	  	  
Solution	   A	   20	   ml	   acetonitrile	   (v/v)	   and	   10	   ml	   propionic	   acid	   (v/v)	   per	   litre	  deionised	  water	  	  
Solution	   B	   20	   ml	   acetonitrile	   (v/v)	   and	   20	   ml	   propionic	   acid	   (v/v)	   per	   litre	  deionised	  water	  	  
Solution	   C:	   20	   ml	   acetonitrile	   (v/v)	   and	   30	   ml	   propionic	   acid	   (v/v)	   per	   litre	  deionised	  water	  	  
Solution	   D:	   20	   ml	   acetonitrile	   (v/v)	   and	   50	   ml	   propionic	   acid	   (v/v)	   per	   litre	  deionised	  water	  	  
Neutralizing	   solution:	   1	   %	   N.N-­‐bis(3-­‐aminopropyl)ethylenediamine	   (v/v)	   in	  sodium	  phosphate	  buffer.	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2.3	  General	  Methods	  	  
Ammonium	  sulphate	  precipitation	  	  Ammonium	   sulphate	   precipitation,	   also	   known	   as	   ‘salting	   out’	   is	   a	   widely	   used	  technique	   based	   on	   differences	   in	   solubility.	   	   It	   is	   a	   very	   useful	  method,	   in	   that	  most	  precipitated	  proteins	  are	  not	  permanently	  denatured,	  and	  can	  also	  be	  readily	  re-­‐dissolved	  (Reed	  et.	  al.,	  2003).	   	  The	  precipitation	  taking	  place	   in	  this	   technique	  depends	   on	   the	   existence	   of	   hydrophobic	   regions	   on	   the	   surfaces	   of	   proteins,	  immunoglobulins	  in	  the	  case	  of	  this	  project,	  that	  will	  encourage	  a	  reorganisation	  of	  water	  molecules	  in	  their	  area	  (Reed	  et.	  al.,	  2003).	  	  With	  the	  addition	  of	  ammonium	  sulphate	   to	   the	   sample,	   fewer	   water	   molecules	   are	   left	   in	   association	   with	   the	  protein	   because	   the	   ammonium	   sulphate	   dissolves	   to	   produce	   ions	   that	   can	  become	  hydrated.	   	  This	   leads	  to	  the	  hydrophobic	  patches	  becoming	  exposed,	  and	  subsequent	   hydrophobic	   interactions	   between	   neighbouring	   protein	   molecules	  therefore	   leads	   to	   their	   aggregation	   and	   ensuing	   precipitation.	   	   The	   basis	   of	  fractionation	   in	   this	  method	   is	   that	  as	  salt	  concentration	  of	   the	  extract	   increases,	  proteins	   with	   more	   hydrophobic	   regions	   will	   precipitate	   out	   before	   those	   with	  smaller	  or	  less	  hydrophobic	  regions	  (Reed	  et.	  al.,	  2003).	  
	  An	   equal	   volume	   of	   phosphate	   buffer	   (0.1	   M	   sodium	   chloride,	   50	   mM	   sodium	  phosphate	  pH	  7.4)	  was	  added	  to	  the	  serum	  from	  sheep	  that	  have	  been	  immunised	  with	   an	   immunogen.	   An	   equal	   volume	   of	   45	   %	   saturated	   ammonium	   sulphate	  solution	  was	  added	  drop	  wise	   to	   the	  serum-­‐buffer	   solution	  and	   the	  solution	  was	  gently	  stirred	  on	   ice	   to	  allow	  precipitation.	   	  The	  mixture	  was	   then	  centrifuged	  at	  3000	  rpm	  for	  one	  hour	  at	  4	  °C.	  	  The	  pellet	  was	  further	  washed	  with	  45	  %	  saturated	  ammonium	  sulphate	  and	  centrifuged	  again	  before	  being	  stored	  at	  4	  °C	  until	  further	  use.	  	  	  
Enzyme-­‐linked	  immunoassay	  (ELISA)	  	  Enzyme	   linked	   immunoassays	   combine	   the	   specificity	   of	   an	   antibody-­‐antigen	  interaction	   with	   the	   sensitivity	   of	   enzyme	   assays	   and	   can	   be	   performed	   using	  either	  an	  antibody	  or	  an	  antigen	  conjugated	  to	  an	  enzyme	  so	  as	  not	  to	  disturb	  the	  
	   41	  
biological	   function	   of	   either	   molecule	   (Reed	   et.	   al.,	   2003).	   	   The	   presence	   of	   the	  enzyme	  is	   then	  determined	  by	  adding	  an	  appropriate	  substrate	  usually	  causing	  a	  change	   in	   colour	  of	   the	   solution.	   	   Indirect	  Enzyme	  Linked	   Immunosorbant	  Assay	  (ELISA)	   is	   a	   method	   used	   to	   detect	   antibody.	   	   In	   this	   assay,	   an	   antigen	   of	   the	  antibody	   of	   interest	   is	   bound	   to	   the	   solid	   support	   matrix,	   therefore,	   when	   the	  antibody	   is	  added	   it	  will	  bind,	  with	  all	  else	  being	  washed	  away.	   	  The	  presence	  of	  this	   bound	   antibody	   can	   then	   be	   measured	   by	   adding	   a	   second	   antibody	   with	  enzyme	  conjugated.	   	  This	   secondary	  antibody	  will	   also	  have	   to	  have	  been	   raised	  against	  the	  primary	  antibody:	  for	  example	  a	  secondary	  anti-­‐sheep	  IgG	  peroxidase	  antibody	  will	  detect	  a	  primary	  sheep	  anti	  L-­‐thyroxine	  antibody.	   	  An	  advantage	  of	  this	   technique	   is	   that	   the	  enzyme	  conjugated	  anti	   immunoglobuin	  can	  be	  used	  to	  detect	  several	  different	  antibodies,	   since	   the	  specificity	   is	  provided	  by	   the	  bound	  antigen	  (Reed	  et.	  al.,	  2003).	  	  Initially	  150	  µl	  coating	  buffer	  was	  added	  to	  one	  half	  of	  an	  ELISA	  plate.	  	  Antigen	  (50	  µl)	  was	   added	   to	   column	   1	   and	   serially	   diluted	   1:4	   across	   the	   ELISA	   plate.	   	   The	  plate	  was	  left	  to	  incubate	  for	  1	  hr	  at	  21	  °C.	  	  The	  microtitre	  plate	  was	  washed	  three	  times	   with	   250	   µl	   of	   washing	   buffer	   in	   each	   well.	   	   The	   plate	   was	   subsequently	  ‘blocked’	  by	  the	  addition	  of	  blocking	  buffer	  (250	  µl)	  for	  1	  hr	  at	  21	  °C.	  	  The	  plate	  was	  washed	  and	  150	  µl	  of	  antibody	  buffer	  was	  added	  to	  all	  the	  wells.	  	  Next,	  50	  µl	  each	  of	  an	  antibody	  solution	  were	  added	   to	   the	  wells	  A1-­‐A6	  and	  serially	  diluted	   (1:4)	  down	  the	  microtitre	  plate.	  	  Incubation	  was	  for	  16	  hr	  at	  4	  °C,	  after	  which	  the	  wells	  were	  washed	  with	  washing	  buffer.	   	  A	  secondary	  antibody	  was	  used	  at	  a	  working	  dilution	  of	  1:2000,	  diluted	  in	  secondary	  antibody	  buffer	  and	  150	  µl	  of	  the	  solution	  was	  added	  to	  each	  well	  and	   left	   to	   incubate	   for	  1	  hr	  at	  37	   °C.	   	  Following	  this,	   the	  wells	  are	  once	  again	  washed	  and	  ABTS	   liquid	  substrate	  system	  (150	  µl	  per	  well)	  was	   immediately	  added	  to	  the	  microtitre	  plate.	   	  The	  absorbance	  was	  read	  at	  205	  nm	  using	  an	  ELISA	  plate	  reader.	  	  	  	  
SDS-­‐PAGE	  	  A	  Mini-­‐Protean	  II	  –cell	  ®	  (Bio-­‐Rad)	  was	  used	  to	  for	  electrophoresis	  unless	  stated	  otherwise.	   	  The	  gel	  cassette	  was	  placed	  in	  the	  electrophoresis	  tank,	  and	  the	  inner	  chamber	   was	   filled	   with	   gel	   running	   buffer.	   	   The	   samples	   were	   loaded	   into	   the	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wells	  and	  the	  gels	  were	  then	  run	  at	  100	  V	  until	  the	  samples	  reached	  the	  resolving	  gel,	   at	  which	   time	   the	  voltage	  was	  raised	   to	  160	  V.	   	  The	  power	  was	  switched	  off	  once	   the	   bromophenol	   blue	   front	   had	   reached	   the	   bottom	   of	   the	   gel.	   	   The	   gel	  cassette	   was	   then	   removed	   and	   the	   gel	   was	   either	   stained	   or	   used	   for	  Western	  blotting.	  	  	  
More	  specialist	  methods	  are	  described	  in	  the	  appropriate	  chapters.	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Chapter	  3	  	  
Development	  of	  an	  immunoassay	  
procedure	  to	  assess	  CTGF	  in	  diabetic	  urine	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3.1	  Introduction	  	  Connective	  tissue	  growth	  factor	  (CTGF)	  has	  been	  implicated	  fibrotic	  diseases	  such	  as	   in	   diabetic	   nephropathy	   (Mason	   2009;	   Riser	   et	   al.	   2003;	   Riser	   et	   al.	   2003).	  	  Therefore,	   in	   order	   to	   help	   determine	   the	   stage,	   progression	   and	   severity	   of	  fibrosis	   non-­‐invasively,	   it	   is	   very	   important	   to	   be	   able	   to	   efficiently	   detect	   this	  protein	  in	  patient	  samples.	   	  CTGF	  has	  been	  detected	  in	  the	  urine	  of	  patients	  with	  diabetic	  nephropathy	  (Gilbert	  et	  al.	  2003;	  Riser	  et	  al.	  2003).	   	  The	  availability	  of	  a	  simple,	   robust	   and	   rapid	   method	   to	   detect	   CTGF	   is	   required.	   	   The	   screening	   of	  CTGF	   in	   urine	   has	   the	   advantage	   of	   being	   non-­‐invasive	   and	   easier	   to	   obtain	  compared	  to	  plasma.	  	  	  	  The	   published	   method	   of	   choice	   for	   detecting	   urinary	   and	   plasma	   CTGF	   is	   a	  sandwich	   ELISA	   represented	   in	   figure	   3.1	   (Gressner	   et	   al.	   2006;	   Nguyen	   et	   al.	  2006;	   Riser	   et	   al.	   2003).	   	   This	   utilises	   an	   antibody	   to	   recombinant	   human	  CTGF	  (either	   the	   full	   length	  protein	  or	  a	   fragment	  of	   the	  whole	  protein)	  as	   the	  capture	  antibody,	   and	   another	   antibody	   to	   recombinant	   human	   CTGF	   (different	   to	   the	  capture	   antibody)	   is	   used	   to	   detect	   the	   CTGF	   that	   has	   been	   ‘captured’	   by	   the	  previous	  antibody.	  
	  
Figure 3.1.  A schematic of an example of a sandwich ELISA.  Horseradish peroxidase (HRP) is 
coupled to the detecting antibody.   
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 A	   recent	   publication	   by	   Bao	   et	   al	   used	   a	   recombinant	   human	   CTGF,	  which	   is	   an	  11.2	  kDa	  protein	  of	   98	   amino	  acid	   residues	   containing	   the	  C-­‐terminal	  portion	  of	  the	   full-­‐length	  CTGF	  protein	  as	   the	  coating	  antigen.	   	  They	   then	  assayed	  rat	  urine	  samples	   using	   the	   antibody	   against	   the	   CTGF	   C-­‐terminal	   portion	   followed	   by	   a	  secondary	  antibody	  conjugated	  with	  horseradish	  peroxidase	   (HRP)	   in	  a	  one-­‐step	  competitive	   indirect	   ELISA	   (Bao	   et	   al.	   2008).	   	   The	   results	   observed	   would	   be	  inversely	   proportional	   to	   that	   of	   an	   assay	   that	   does	   not	   contain	   CTGF.	   	  Meaning	  that	  the	  absorbance	  values	  on	  the	  dilution	  response	  curve	  that	  contain	  CTGF	  will	  be	   less	   than	   that	   of	   the	   control,	  which	   does	   not	   contain	   CTGF.	   	   CTGF	   fragments	  from	  both	  the	  C	  and	  N-­‐terminal	  are	  shown	  to	  be	  present	  in	  diabetic	  urine	  (Riser	  et	  al.	  2003;	  Tam	  et	  al.	  2009;	  Nguyen	  et	  al.	  2006),	  therefore	  this	  assay	  does	  not	  reflect	  the	  true	  amount	  of	  CTGF	  that	  is	  present.	  	  A	  more	  accurate	  assay	  of	  CTGF	  would	  be	  to	  utilise	  an	  antibody	  or	  antibodies	  that	  are	  raised	  against	  the	  naturally	  occurring	  CTGF	  molecule.	  	  	  	  Aim:	  	  In	   this	   chapter,	   a	   number	   of	   immunoassay	   procedures	   were	   assessed	   for	   their	  suitability	  for	  the	  determination	  of	  CTGF	  in	  urine.	  	  They	  were	  modified	  in	  order	  to	  develop	   a	   rapid,	   accurate	   and	   sensitive	   assay	   for	   the	   identification	   of	   CTGF	   in	  urine.	  	  Two	  antibodies	  were	  deployed	  to	  develop	  a	  sandwich	  ELISA	  for	  CTGF.	  	  	  	  Objective:	  	  The	   objective	   of	   this	   chapter	  was	   to	   characterize	   these	   antibodies	   by	   ELISA	   and	  Western	  blot.	  	  
3.2	  Methods	  	  
Samples	  	  	  Urine	  samples	  from	  diabetic	  patients	  were	  obtained	  as	  a	  kind	  gift	  from	  Dr	  Frederic	  Tam	  of	  the	  Renal	  Division,	  Hammersmith	  Hospital.	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  Number	  of	  urine	  samples	  	  Urine	   samples	   (39)	   from	   diabetic	   patients	   and	   healthy	   volunteers	   (2)	   were	  screened.	   	   Urine	   samples	   were	   collected	   by	   the	   clinicians	   in	   Hammersmith	  Hospital,	  centrifuged,	  and	  the	  supernatant	  stored	  at	  	  –	  86	  °C.	  	  
CTGF	  antibodies	  	  Antibodies	   to	   recombinant	   human	  CTGF	   (full	   length	   –	  NWA	  and	  partial	   length	   –	  NWB)	   were	   already	   available	   from	   the	   Chemical	   Biology	   Group,	   King’s	   College	  London.	   	  Both	  full	  and	  partial	   length	  rhCTGF	  were	  previously	  coupled	  to	  keyhole	  limpet	   hemocyanin	   (KLH)	   using	   gluteraldehyde	   to	   cross-­‐link	   KLH	   to	   the	  recombinant	   proteins	   (Avrameas	   and	   Ternynck,	   1969).	   	   In	   summary,	   equal	  amounts	   of	   KLH	  was	  mixed	  with	   gluteraldehyde	   in	   a	   50	  mM	   sodium	  phosphate,	  100	  mM	  sodium	  chloride,	  pH	  7.4	  buffer.	  	  The	  solution	  was	  dialysed	  against	  1	  litre	  50	   mM	   sodium	   phosphate,	   100	   mM	   sodium	   chloride,	   pH	   7.4	   buffer	   to	   remove	  excess	   KLH.	   	   The	   resulting	   KLH-­‐gluteraldehyde-­‐CHO	   (50	   µg)	   was	   added	   to	   the	  rhCTGF	  (10	  µg)	  to	  form	  the	  rhCTGF-­‐gluteraldehyde-­‐KLH	  conjugate.	  	  The	  resulting	  immunogen	   was	   sent	   to	   MicroPharm	   (Wales)	   to	   raise	   polyclonal	   antibodies	   in	  sheep.	   	   The	   antibodies	  were	   then	   purified	   using	   a	   Protein	  G	   resin.	   	   The	   purified	  NWA	   and	  NWB	   antibodies	  were	   then	   coupled	   to	   horseradish	   peroxidase	   (NWA-­‐HRP	  and	  NWB-­‐HRP)	  and	  stored	  at	  –	  20	  °C	  until	  further	  use.	  	  	  	  
3.2.1	  Detection	  of	  CTGF	  in	  diabetic	  urine	  samples	  by	  ELISA	  	  Urine	   samples	   from	   patients	   were	   screened	   using	   the	   following	   direct	   ELISA	  method.	  	  To	  a	  96-­‐well	  microtitre	  plate,	  150	  µl	  of	  coating	  buffer	  was	  added	  to	  all	  the	  wells.	  	  Urine	  samples	  (50	  µl)	  were	  added	  to	  the	  top	  row	  (A1-­‐A12)	  of	  the	  microtitre	  plate.	   	   Duplicates	   were	   carried	   out	   for	   each	   patient	   sample.	   	   The	   samples	   were	  serially	  diluted	  downwards	  (1:4)	  and	  allowed	  to	  coat	  the	  wells	  for	  16	  hrs	  at	  4	  °C.	  	  The	   plate	  was	   then	  washed	   4	   times	  with	  washing	   buffer	   and	   250	  µl	   of	   blocking	  solution	  was	  added	  to	  all	  the	  wells	  of	  the	  plate.	  	  The	  plate	  was	  allowed	  to	  block	  for	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1	  hr	  and	  was	  washed	  again	  (4	  times)	  with	  washing	  buffer.	  	  Antibody	  solution	  (150	  
µl)	  was	  added	  to	  all	  the	  wells	  of	  the	  plate	  and	  allowed	  to	  react	  for	  16	  hrs	  at	  4	  °C.	  	  The	  plate	  was	  washed	  with	  washing	  buffer	  (4	  times),	  and	  then	  developed	  using	  the	  ABTS	  liquid	  substrate	  system.	  	  The	  plate	  was	  read	  at	  405	  nm	  using	  an	  ELISA	  plate	  reader.	  	  	  	  
	  
Figure 3.2. Direct ELISA procedure for the detection of CTGF in urine using the NWA-HRP and 
NWB-HRP antibodies.  
 
3.2.2	  Detection	  of	  CTGF	  in	  urine	  samples	  by	  SDS-­‐PAGE	  and	  
Western	  blot	  analysis	  	  The	  NWA	  and	  NWB	  antibodies	  were	  used	  to	  detect	  CTGF	  in	  urine	  samples	  by	  SDS-­‐PAGE	  and	  Western	  blot	  analysis.	  	  Diabetic	  urine	  samples	  were	  loaded	  onto	  a	  10	  %	  acylamide	  gel	  and	  run	  according	  to	  the	  protocol	  described	  in	  chapter	  2	  (Laemmli	  1970).	   	   The	   proteins	   in	   the	   gel	   were	   then	   transferred	   onto	   a	   nitrocellulose	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membrane	  using	  the	  Amersham	  semi-­‐dry	  blotter	  (GE	  Healthcare)	  according	  to	  the	  manufacturer’s	   instructions	   (Renart	   et	   al.	   1979;	   Towbin	   et	   al.	   1979).	   	   The	  membrane	  was	  then	  probed	  with	  NWA	  and	  NWB	  antibodies,	  and	  an	  anti-­‐sheep	  IgG	  peroxidase	  second	  antibody.	   	  A	   third	  membrane,	  acting	  as	  a	   control,	  was	  probed	  with	   only	   the	   second	   antibody.	   	   The	   blots	  were	   developed	   using	   the	   Amersham	  ECL	   Western	   blotting	   detection	   kit	   (GE	   Healthcare)	   in	   accordance	   to	   the	  manufacturer’s	   protocol.	   	   A	   schematic	   of	   the	  Western	   blot	   analysis	   is	   shown	   in	  figure	  3.3.	  	  	  	  
	  
 
Figure 3.3. A schematic of the Western blotting steps performed.  
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3.3	  Results	  	  
3.3.1	  Detection	  of	  CTGF	  from	  patient	  urine	  samples	  by	  ELISA	  	  Preliminary	   tests	   on	   patient	   urine	   samples	   were	   carried	   out	   using	   the	   ELISA	  procedure	   described	   (3.2.1).	   	   The	   procedure	   was	   carried	   out	   using	   the	   two	  different	  antibodies,	  NWA	  and	  NWB.	  	  	  	  
	  
Figure 3.3.  Dilution response by ELISA using urine from patient R53.  The urine sample was 
assayed with NWA-HRP (anti-full length CTGF-peroxidase conjugate) and NWB-HRP (anti-
partial length CTGF-peroxidase conjugate).  Error bars represent standard error and sample 
was assayed three times.   	  A	  comparison	  of	  the	  results	  with	  the	  two	  antibodies	  is	  shown	  in	  figures	  3.3	  and	  3.4.	  	  They	   show	   the	   dilution	   responses	   of	   diabetic	   patient	   R53	   and	   healthy	   volunteer	  N19	  respectively	  when	  titrated	  against	  NWA-­‐HRP	  and	  NWB-­‐HRP.	  	  In	  figure	  3.3,	  the	  absorbance	  values	  of	  the	  response	  against	  NWA-­‐HRP	  are	  slightly	  higher	  than	  that	  against	  NWB-­‐HRP.	  	  This	  is	  broadly	  true	  for	  all	  the	  urine	  sampled.	  	  The	  response	  in	  figure	  3.3	  is	  indicative	  of	  the	  presence	  of	  CTGF.	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Figure 3.4.  Dilution response by ELISA using urine from healthy volunteer N19.  The urine 
sample was assayed with NWA-HRP (anti-full length CTGF-peroxidase conjugate) and NWB-
HRP (anti-partial length CTGF-peroxidase conjugate).  Error bars represent standard error and 
sample was assayed three times.  	  Figure	  3.4	  shows	   the	  dilution	  response	  of	  N19	  (healthy	  volunteer)	  when	   titrated	  against	  both	  NWA-­‐HRP	  and	  NWB-­‐HRP.	  	  The	  response	  from	  this	  sample	  is	  relatively	  low	  compared	  to	  that	  of	  patient	  R53.	   	  This	  will	  be	   indicative	  of	   the	   low	  levels,	  or	  even	  absence	  of	  CTGF	  in	  the	  urine.	   	  Again,	  titration	  against	  NWA-­‐HRP	  resulted	  in	  higher	  absorbance	  values	  (except	  at	  dilution	  1:40).	  	  	  	  For	  better	  comparison,	  figures	  3.5,	  3.6,	  3.7	  and	  3.8	  show	  the	  absorbance	  values	  of	  the	  urine	  samples	   from	  the	  35	  diabetic	  patients	  and	  2	  healthy	  volunteers	  at	  1:40	  dilution.	   	  There	   is	  a	   large	  variation	   in	  absorbance	  values	   (ranging	   from	  0.2	   to	  3)	  between	  the	  patient	  samples.	   	  This	  suggests	  that	  there	  are	  varying	  levels	  of	  CTGF	  present	  in	  the	  different	  urine	  samples.	  	  It	  can	  be	  better	  observed	  that	  the	  response	  from	  NWA-­‐HRP	  resulted	  in	  higher	  absorbance	  values	  (bar	  N19)	  than	  NWB-­‐HRP	  in	  all	   the	   samples.	   	   The	   differences	   between	   the	   values	   can	   be	   quite	   large	   e.g.	   R13	  (figure	  3.5)	  and	  R34	  (figure	  3.6),	  where	  the	  variation	   is	  a	  great	  as	  approximately	  1.7	  absorbance	  units.	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Figure 3.5. Variation in absorbance values (at 405 nm) of the different patient urine samples 
(R10 – R28) at a 1:40 dilution.  A direct ELISA was performed using NWA-HRP (anti-full length 
CTGF-peroxidase conjugate) and NWB-HRP (anti-partial length CTGF-peroxidase conjugate).  
Each bar represents a single antibody dilution factor. 
 
	  
Figure 3.6. Refer to details in figure 3.5 
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Figure 3.7. Refer to details in figure 3.5 
 
	  
Figure 3.8. Refer to details in figure 3.5 
 
3.3.2	  Detection	  of	  CTGF	  in	  urine	  samples	  by	  Western	  blot	  
analysis	  	  	  In	  order	   to	   assess	   the	  value	  of	   the	  ELISA	  procedures,	   the	  diabetic	  urine	   samples	  that	  showed	  a	  high	  response	  were	   further	   investigated	  by	  Western	  blot	  analysis.	  	  The	  diabetic	  urine	  samples	  were	  subjected	  to	  further	  analysis	  by	  Western	  blot	  so	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as	  to	  determine	  and	  compare	  the	  molecular	  weight	  of	  CTGF	  identified	  on	  the	  blots	  with	  those	  that	  have	  been	  reported.	   	  It	  was	  also	  suspected	  that	  human	  IgG	  would	  be	   present	   in	   the	   urine	   samples,	   therefore	   a	   third	   blot	  was	   developed	  with	   only	  anti-­‐sheep	  IgG	  peroxidase.	  	  	  
 
 
Figure 3.9.  Western blots of diabetic urine samples run under reducing condition.  Lane 1: 
carbonic anhydrase (25 kDa).  Lane 2: human serum albumin (62 kDa).  Lane 3: sheep IgG.  
Lane 4, 5 and 6: diabetic urine sample.  a: Developed with NWB (anti-partial length CTGF) and 
anti-sheep IgG peroxidase.  b: Developed with anti-sheep IgG peroxidase only.  c: Developed 
with NWA (anti-full length CTGF) and anti-sheep IgG peroxidase.  A, B and C indicate 
immunoreactive species detected by the antibodies at 55 kDa.  Experiments were repeated (3 
times).   	  Figure	   3.9	   (c),	   was	   developed	   with	   NWA	   and	   anti-­‐sheep	   IgG	   peroxidase.	   	   The	  antibody	   is	   shown	   to	   detect	   carbonic	   anhydrase	   (lane	   1)	   and	   human	   serum	  albumin	  (lane	  2),	  along	  with	  various	  other	  proteins	  present	   in	   the	  urine	  samples	  (lanes	  4,	  5	  and6).	  	  It	  was	  observed	  in	  lanes	  4,	  5	  and	  6	  that	  there	  are	  three	  distinct	  bands	  present,	  with	  the	  centre	  band	  (55	  kDa)	  giving	  the	  strongest	  signal.	  	  There	  is	  a	   possibility	   that	   this	   centre	   band	   could	   be	   a	   56	   kDa	   form	   of	   CTGF	   previously	  reported	  (Wahab	  et	  al.,	  2001).	   	  The	  band	  above	  (~62	  kDa)	  and	  below	  (~50	  kDa)	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could	  also	  be	  unreported	  forms	  of	  CTGF.	  	  Lane	  3,	  containing	  sheep	  IgG,	  is	  detected	  in	  all	  three	  blots.	  	  This	  is	  due	  to	  the	  recognition	  by	  the	  anti-­‐sheep	  IgG	  peroxidase.	  	  The	  fact	  that	  the	  NWA-­‐HRP	  has	  also	  detected	  carbonic	  anhydrase	  as	  well	  as	  human	  serum	  albumin	  suggests	  non-­‐specific	  binding	  by	  the	  antibody	  preparation.	   	  There	  are	  only	   three	  distinct	  bands	  present	   in	   lanes	  4,	  5	  and	  6	  of	  blot	   (a).	   	  This	   shows	  very	   little	  non-­‐specific	  binding	  by	   the	  NWB	  antibody	  when	  compared	   to	  blot	   (c).	  	  Blot	   (b),	   which	   was	   developed	   with	   only	   anti-­‐sheep-­‐IgG	   peroxidase,	   shows	   a	  similar	  binding	  pattern	  to	  blot	  (a).	  	  This	  confirms	  that	  there	  is	  an	  immunoreactive	  species	  to	  anti-­‐sheep	  IgG	  peroxidase	  present	   in	  the	  diabetic	  urine	  sample.	   	  There	  may	  be	  a	  possibility	  that	  this	  species	  is	  human	  IgG.	  	  The	  bands	  in	  blot	  (a)	  are	  more	  distinct	   than	   in	   blot	   (b).	   	   This	   suggests	   that	   NWB	   antibody,	   being	  more	   specfic,	  could	  be	  detecting	  CTGF	  at	  about	  56	  kDa.	  	  But	  because	  of	  the	  suspected	  presence	  of	  IgG	  in	  the	  urine	  (as	  seen	  in	  blot	  a),	  there	  could	  be	  problems	  arising	  from	  the	  use	  of	  anti-­‐sheep	  IgG	  peroxidase	  as	  a	  secondary	  antibody	  in	  further	  experiments.	  	  	  	  
Discussion	  	  Several	  studies	  have	  reported	  the	  potential	  use	  of	  CTGF	  as	  a	  potential	  biomarker,	  not	  only	  for	  diabetic	  nephropathy,	  but	  also	  for	  the	  progression	  of	  fibrosis	  due	  to	  it	  being	  a	  downstream	  mediator	  of	  TGF-­‐β	  (Riser	  et	  al.	  2003;	  Nguyen	  et	  al.	  2008;	  Tam	  et	  al.	  2009).	  	  The	  assessment	  of	  urine	  samples	  from	  diabetic	  patients	  for	  CTGF	  by	  ELISA	   is	   an	   important	   step	   to	   determine	   urine	   samples	   that	   generate	   a	   high	  response	   to	   the	   antibodies,	   and	   therefore	   contain	   the	   highest	   amount	   of	   CTGF.	  	  This	   in	   turn	   would	   lead	   to	   a	   larger	   volume	   of	   the	   sample	   obtained	   from	  Hammersmith	  Hospital	  to	  be	  used	  in	  further	  experiments.	  	  	  	  As	   expected,	   all	   the	   patient	   urine	   samples	   gave	   very	   varied	   responses	   to	   both	  NWA-­‐HRP	  (against	  full-­‐length	  recombinant	  human	  CTGF,	  and	  coupled	  to	  HRP)	  and	  NWB-­‐HRP	  (against	  partial-­‐length	  recombinant	  human	  CTGF,	  and	  coupled	  to	  HRP)	  antibodies.	   	   This	   is	   in	   line	   with	   the	   fact	   that	   the	   patients	   would	   have	   varying	  degrees	  of	  diabetic	  nephropathy	  resulting	  from	  kidney	  fibrosis.	  	  	  	  The	   ELISA	   results	   for	   the	   patient	   urine	   samples	   indicate	   that	   CTGF	   is	   present,	  albeit	   in	   varying	   levels.	   	   This	   is	   because	   the	   antibodies	   are	   raised	   specifically	   to	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recombinant	   human	   CTGF	   (full	   or	   partial	   length),	   which	   in	   theory	   would	   be	  identical	   to	   that	  of	   the	  native	  or	  naturally	  occurring	  protein.	   	  As	   expected,	  when	  both	  antibodies	  were	  applied	  to	  the	  urine	  from	  healthy	  volunteers,	  a	  low	  response	  was	   observed.	   	   This	   is	   because	   there	   would	   be	   no	   fibrotic	   kidney	   damage,	   and	  therefore	  very	  little	  or	  no	  CTGF	  present.	  	  	  	  The	  responses	  of	  all	  patient	  and	  healthy	  volunteer	  urine	  samples	  (bar	  N19	  at	  1:40	  dilution)	  are	  higher	  when	  probed	  with	  NWA-­‐HRP	  than	  NWB-­‐HRP.	   	  This	  could	  be	  because	   the	   NWA	   antibody	   is	   against	   the	   full-­‐length	   recombinant	   human	   CTGF	  protein	   whereas	   the	   NWB	   antibody	   is	   against	   the	   partial-­‐length	   protein.	  	  Therefore,	  the	  NWB-­‐HRP	  antibody	  would	  recognise	  only	  the	  partial-­‐length	  protein	  that	   is	   present	   in	   the	   urine.	   	   The	   NWB-­‐HRP	   antibody	   will	   not	   identify	   CTGF	  fragments	   in	   the	   urine	   with	   that	   specific	   partial-­‐length	   protein	   absent.	   	   This	  probably	  accounts	  for	  the	  lower	  absorbance	  values	  that	  are	  observed	  in	  the	  ELISA	  results.	  	  	  	  It	   is	   also	   observed	   that	   the	   differences	   between	   absorbance	   values	   in	   individual	  patients,	   derived	   from	   the	   NWA-­‐HRP	   and	   NWB-­‐HRP	   antibodies,	   are	   quite	   large.	  	  Another	   possibility	   is	   that	   there	   are	   significantly	   smaller	   amounts	   of	   the	   partial	  fragment	  of	  CTGF	  present	  in	  these	  patients,	  which	  might	  result	  in	  the	  difference	  in	  sensitivity	  of	  the	  antibodies.	  	  	  The	  Western	  blot	  of	  the	  patient	  urine	  samples	  indicates	  that	  the	  NWA	  antibody	  is	  not	  as	  specific	  as	  desired.	  	  In	  addition	  to	  the	  protein	  bands	  present	  observed	  in	  the	  urine	  samples,	  bands	  in	  the	  carbonic	  anhydrase	  and	  human	  serum	  albumin	  lanes	  are	   also	   observed.	   	   This	   could	   mean	   that	   the	   antibody	   preparation	   is	   not	   pure	  enough,	   which	   resulted	   in	   the	   non-­‐specific	   binding	   of	   other	   proteins	   observed.	  	  This	   could	   also	   indicate	   that	   at	   the	   initial	   stage	   of	   immunogen	   preparation	  (recombinant	   human	   CTGF	   coupled	   to	   keyhole	   limpet	   hemocyanin)	   to	   raise	  antibodies,	   either	   the	   recombinant	   protein	   or	   the	   immunogen	   itself	  was	   impure,	  which	  led	  to	  the	  presence	  of	  antibodies	  that	  are	  not	  CTGF	  specific.	  	  	  	  When	  comparing	  the	  Western	  blots	  that	  were	  developed	  with	  the	  NWA	  and	  NWB	  antibodies,	   the	   NWB	   antibody	   would	   seem	   to	   be	   more	   specific	   than	   the	   NWA	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antibody.	   	  This	  is	  because	  only	  one	  distinct	  band	  corresponding	  to	  approximately	  50	  kDa	  is	  present	  in	  all	  three	  urine	  samples.	  	  But	  upon	  applying	  only	  the	  secondary	  anti-­‐sheep	  IgG	  peroxidase	  to	  the	  blot,	  the	  same	  band	  (although	  not	  as	  distinct)	  that	  was	   observed	   when	   developed	   with	   NWB	   antibody	   was	   also	   observed.	   	   This	  confirms	   that	   IgG	   is	  present	   in	  patient	  urine	   samples	   (Fomsgaard	  et	  al.	  1987)	  as	  the	  heavy	  chain	  of	  IgG	  has	  a	  molecular	  weight	  of	  55	  kDa.	   	  This	  could	  also	  suggest	  that	   the	   NWB	   antibody	   could	   be	   detecting	   CTGF	   at	   55	   kDa,	   but	   the	   protein	   is	  masked	   by	   the	   presence	   of	   the	   IgG	   heavy	   chain.	   	   Only	   one	   paper	   has	   been	  published	   where	   CTGF	   was	   reported	   at	   56	   kDa	   (Riser	   et	   al.	   2003),	   whilst	   the	  generally	  reported	  molecular	  weight	  for	  CTGF	  is	  36-­‐38	  kDa.	  	  	  	  By	   looking	  at	   the	  results	   from	  the	  ELISA,	   the	  NWA	  antibody	  was	  be	  the	  better	  of	  the	  two	  antibodies	  because	  of	  the	  higher	  absorbance	  readings	  that	  was	  produced.	  	  But	   when	   this	   result	   is	   compared	   to	   the	  Western	   blots,	   the	   NWA	   antibody	   was	  found	  to	  be	  non-­‐specific,	  whilst	  the	  NWB	  antibody	  showed	  to	  specifically	  bind	  to	  a	  protein	   at	   55	   kDa.	   	   This	   result	   in	   itself	   demonstrates	   in	   a	   very	   straightforward	  manner	   that	   the	   NWB	   antibody	   was	   the	   better	   antibody.	   	   But,	   in	   the	   onset	   of	  diabetic	  nephropathy,	  the	  presence	  of	  human	  IgG	  would	  be	  expected	  in	  the	  patient	  urine	  samples	  assayed.	  	  This	  was	  observed	  quite	  distinctly	  in	  figure	  3.9	  (b),	  where	  the	   secondary	   antibody	   also	   detected	   a	   protein	   at	   55	   kDa.	   	   Because	   the	   protein	  samples	   were	   assayed	   under	   reducing	   conditions,	   it	   was	   concluded	   that	   this	  protein	  was	  the	  heavy	  chain	  of	  the	  IgG	  molecule.	  	  	  	  Another	   concern	   was	   the	   non-­‐specific	   binding	   of	   the	   NWA	   antibody	   to	   other	  proteins.	  	  It	  is	  almost	  impossible	  to	  ascertain	  the	  purity	  of	  the	  initial	  recombinant	  proteins	  or	  the	  immunogens	  derived	  from	  them.	   	  A	  reduction	  in	  the	  purity	  of	  the	  immunogen	  would	  lead	  to	  antibodies	  whose	  specificity	  is	  compromised.	  	  The	  best	  way	   to	   overcome	   this	   problem	  would	   be	   to	   produce	  more	   recombinant	   protein,	  and	  then	  take	  sufficient	  purification	  steps	  to	  ensure	  that	  the	  immunogen	  is	  highly	  purified.	  	  Conclusion:	  The	  NWA	  and	  NWB	  antibodies	  were	  shown	  to	  be	  not	  as	  specific	  as	  desired.	  	  It	  was	  observed	   that	   the	   commercial	   anti-­‐IgG	   peroxidase	   antibody	   cross-­‐reacted	   with	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human	   IgG	   that	  was	   present	   in	   urine.	   	   In	   conclusion,	   these	   antibodies	  were	   not	  suitable	  for	  the	  intended	  purpose.	  	  Therefore,	  in	  chapter	  4,	  a	  different	  approach	  will	  be	  used	  to	  tackle	  the	  issue	  of	  the	  suspected	  presence	  of	  human	   IgG.	   	  The	  approach	  used	  will	   be	   the	   synthesis	  of	   a	  unique	   peptide	   sequence	   from	   CTGF,	   and	   the	   generation	   of	   an	   antibody	   to	   this	  synthetic	  peptide.	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Chapter	  4	  
Synthesis	  of	  a	  peptide	  sequence	  in	  CTGF	  
and	  the	  production	  of	  an	  antibody	  to	  this	  
sequence	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4.1	  Introduction	  	  The	  antibodies	  used	  in	  the	  previous	  chapter	  (NWA	  and	  NWB)	  were	  not	  as	  specific	  as	  desired	  for	  the	  identification	  and	  isolation	  of	  CTGF	  from	  human	  biological	  fluids.	  	  Neither	   purified	   native	   CTGF	   nor	   its	   antibodies	  were	   available	   commercially.	   	   It	  was	  decided	  to	  synthesise	  a	  peptide	  whose	  sequence	  is	  contained	  within	  CTGF	  and	  to	  raise	  sheep	  polyclonal	  antibodies.	  	  	  	  Natural	   or	   synthetic	   small	   peptides	   of	   3	   to	   15	   amino	   acids	   may	   be	   active	  biomolecules	   (Severini	   et	   al.	   2002;	   Lord	   et	   al.	   1977)	   and	  may	   represent	   specific	  sequences	  in	  the	  chains	  of	  much	  larger	  proteins.	  	  The	  sequences	  can	  then	  be	  used	  to	   generate	   antibodies	   (Riser	   et	   al.	   2000).	   	   Most	   processes	   involving	   the	   use	   of	  small	  peptides	  require	  the	  covalent	  linking	  of	  the	  peptides	  to	  macromolecules	  or	  to	  solid	  phase	  matrices.	  	  Peptides	  are	  used	  that	  are	  known	  to	  contain	  reactive	  groups	  including	   one	   or	   more	   free	   amino	   groups	   and	   carboxylic	   acid	   functions.	   These	  groups	  may	  be	  used	  to	  form	  covalent	  bonds	  to	  other	  proteins,	  but	  use	  of	  functional	  groups	   within	   the	   peptide	   for	   attachment	   is	   unadvisable	   as	   this	   may	   block	  biological	  functions	  or	  unique	  features	  important	  for	  subsequent	  processes.	  	  	  In	  order	  to	  direct	  the	  attachment	  of	  peptides	  via	  pre-­‐determined	  sites	  other	  than	  the	   functionally	   important	  groups,	   cysteine	  residues	  are	  added	   to	  one	  end	  of	   the	  peptide	   chain	   to	   provide	   a	   highly	   reactive	   thiol	   group	   through	   which	   specific	  linkages	  can	  be	  carried	  out.	  	  This	  is	  chemically	  feasible	  due	  to	  the	  specific	  reactivity	  of	   thiols	   toward	   a	   number	   of	   functional	   groups	   including	   second	   thiols	   and	  maleimides	   (Brinkley	   1992).	   	  With	   careful	   control	   of	   conditions,	   thiols	  may	   also	  preferentially	  react	  with	  halo-­‐alkanes,	  trichloro	  and	  dichloro-­‐triazines.	  	  	  Seven	   types	   of	   linker	   arms	   are	   used	   in	   this	   chapter.	   	   The	   first	   linker	   arm,	   3-­‐(Maleimido)propionic	   acid	   N-­‐succinimidyl	   ester	   (MPSE)	   was	   used	   to	   couple	   the	  synthetic	   peptide	   to	   keyhole	   limpet	   hemocyanin	   (KLH).	   	   This	   peptide-­‐KLH	  conjugate	  was	  used	  as	  an	  immunogen	  to	  generate	  polyclonal	  antibodies	  in	  sheep.	  	  KLH	  is	  commonly	  used	  as	  a	  carrier	  protein	  because	  of	  its	  size	  (4.5	  ×	  105	  –	  8	  ×	  105)	  and	  large	  amounts	  of	  lysine	  residues.	  	  The	  same	  linker	  arm	  was	  also	  used	  to	  couple	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the	   synthetic	   peptide	   to	   gelatine	   to	   make	   the	   homologous	   conjugate.	   	   The	  conjugate	  is	  deemed	  homologous	  because	  it	  contains	  the	  same	  linker	  arm	  as	  that	  used	   in	   the	   immunogen.	   	   Maleimide	   is	   an	   important	   building	   block	   in	   organic	  synthesis.	   	   It	   is	   an	   unsaturated	   imide	   with	   the	   formula	   H2C2(CO)2NH.	   	   3-­‐(Maleimido)propionic	   acid	   N-­‐succinimidyl	   ester	   (MPSE)	   	   reacts	   in	   two	   ways:	  acylation	  of	  the	  amino	  groups	  by	  the	  active	  ester	  and	  formation	  of	  thioether	  bonds	  by	  the	  addition	  of	  a	   thiol	  group	  to	   the	  double	  bond	  of	   the	  maleimide	  moiety	   in	  a	  neutral,	  aqueous	  solution	  (Kitagawa	  &	  Aikawa	  1976).	  	  	  	  The	   further	   six	   linker	   arms	   generated	   were	   synthesised	   using	   novel	   chemistry.	  	  They	   were	   used	   to	   prepare	   the	   heterologous	   conjugates	   for	   the	   coupling	   of	   the	  synthetic	  peptide	  to	  gelatine	  to	  be	  deployed	  as	  the	  plate	  coating	  antigen	  in	  ELISA.	  	  These	  conjugates	  are	  deemed	  heterologous	  because	  they	  contain	  a	  different	  linker	  arm	  to	  that	  of	  the	  immunogen.	  	  Porcine	  gelatine	  was	  used	  as	  a	  carrier	  protein	  for	  the	  synthetic	  peptide	  because	  it	  contains	  amino	  groups	  that	  can	  be	  easily	  coupled	  to	   various	   peptides	   and	   haptens.	   	   Linker	   arms	   are	   used	   to	   present	   the	   peptide	  efficiently	   to	   the	   anti-­‐peptide	   antibody.	   	   Three	   haloalkanes	   are	   used.	   	   The	  haloalkanes	  are	  a	  group	  of	  chemical	  compounds	  that	  are	  derived	  from	  alkanes	  that	  contain	  one	  or	  more	  halogens	  (elements	  from	  group	  17	  of	  the	  periodic	  table).	  	  The	  haloalkanes	   undergo	   substitution	   reactions	   that	   involve	   the	   replacement	   of	   the	  halogen	  with	  another	  molecule	  (Nesmeyanov	  et	  al.	  1956).	  	  Three	  triazines	  are	  used	  to	   couple	   the	   synthesised	   peptide	   to	   gelatine.	   	   Triazines	   are	   a	   group	   of	   three	  compounds	   containing	   three	  nitrogen	  and	   three	   carbon	  atoms	  arranged	   in	  a	   six-­‐membered	   ring	   and	   having	   the	   formula	   C3	   H3	   N3.	   	   Cyanuric	   chloride	   (CC)	   is	   an	  example	   of	   a	   triazine.	   	   Its	   IUPAC	   name	   is	   2,4,6-­‐trichloro-­‐1,3,5-­‐triazine.	   	   An	  advantage	  of	  using	  CC	  as	  a	  linking	  agent	  is	  that	  it	  can	  react	  with	  hydroxyl	  as	  well	  as	  amino	   compounds	   through	   the	   chlorine	   atoms	   (Yacynych	   &	   Kuwana	   1978).	  	  Through	  the	  preparation	  of	  six	  heterologous	  conjugates,	  it	  was	  demonstrated	  that	  peptide-­‐gelatine	   conjugates	   with	   different	   linker	   arms	   would	   elicit	   different	  responses	  from	  the	  same	  antibody.	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  Aims:	  To	  obtain	   a	  more	   specific	   antibody	   to	  CTGF	   for	   the	  detection	  of	   this	  molecule	   in	  body	  fluid.	  	  	  	  Objective:	  To	  establish	  which	  peptide	  and	  antigen	  is	  best	  suited	  for	  antibody	  generation.	  	  	  	  
4.2	  Results	  	  
Section	  A	  
4.2.1	   Synthesis	   of	   the	   selected	   peptide	   sequence	   using	   the	  
Fmoc	  solid-­‐phase	  synthesis	  method	  	  The	  sequence	  of	  the	  peptide	  to	  be	  synthesised	  was	  confirmed	  after	  bioinformatic	  analysis	  using	  RASMOL,	  EMBL	  and	  BLAST.	  	  This	  was	  used	  to	  determine	  the	  criteria	  for	  selection.	  	  The	  sequence	  was	  selected	  because	  it	  lies	  on	  the	  surface	  of	  the	  whole	  molecule	  and	  does	  not	  contain	  any	  cysteine	  residues.	  	  Bioinformatics	  analysis	  was	  kindly	  conducted	  by	  Mr	  Phil	  Cunningham.	  	  The	  peptide	  sequence	  is	  as	  follows:	  	  Phe-­‐Glu-­‐Ser-­‐Leu-­‐Tyr-­‐Tyr-­‐Arg-­‐Lys-­‐Met-­‐Tyr-­‐Gly-­‐Asp-­‐Met-­‐Ala-­‐Cys	  	  An	   additional	   cysteine	   (in	   red)	  was	   attached	   to	   the	   C-­‐terminus	   of	   the	   sequence.	  	  This	  is	  for	  the	  conjugation	  to	  the	  amino	  groups	  of	  carrier	  proteins	  later.	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MTAASMGPVR VAFVVLLALC SRPAVGQNCS GPCRYPDEPA PRCPAGVSLV 50 
LDGCGCCRVC AKQLGELCTE RDPCDPHKGL FCDFGSPANR KIGVCTAKDG 100 
APCIFGGTVY RSGESFQSSC KYQCTCLDGA VGCMPLCSMD VRLPSPDCPF 150 
PRRVKLPGKC CEEWVCDEPK DQTVVGPALA AYRLEDTFGP DPTMIRANCL 200 
VQTTEWSACS KTCGMGISTR VTNDNASCRL EKQSRLCMVR PCEADLEENI 250 
KKGKKCIRTP KISKPIKFEL SGCTSMKTYR AKFCGVCTDG RCCTPHRTTT 300 
LPVEFKCPDG EVMKKNMMFI KTCACHYNCP GDNDIFESLY YRKMYGDMA  349 
 
Figure 4.1.  The complete amino acid sequence of CTGF.  Highlighted in red are the cysteine 
residues present in this protein.  Highlighted in green is the amino acid sequence of the peptide 
that was chosen for synthesis.  	  The	  Fmoc	  solid-­‐phase	  synthesis	  method	  was	  first	  described	  by	  Merrifield	  (1963).	  	  This	  involved	  the	  stepwise	  addition	  of	  protected	  amino	  acids	  to	  a	  growing	  peptide	  chain	   that	   was	   covalently	   attached	   to	   a	   solid	   resin	   particle.	   	   The	   synthesised	  peptide	   was	   cleaved	   with	   a	   solution	   of	   phenol,	   thioanisole,	   ethanedithiol,	  trifluoroacetic	   acid	   and	   silane.	   	   Trifluoroacetic	   acid	   breaks	   the	   covalent	   bond	  between	  the	  peptide	  and	  the	  resin	  while	  the	  other	  compounds	  pick	  up	  the	  cations	  that	   would	   otherwise	   react	   with	   the	   peptide.	   	   The	   peptide-­‐resin	   solution	   was	  filtered	  through	  a	  sintered	  glass	  funnel.	  	  A	  rotor-­‐evaporator	  was	  used	  to	  evaporate	  off	  the	  trifluoroacetic	  acid.	  	  Any	  remaining	  trifluoroacetic	  acid	  was	  extracted	  with	  ether.	  	  This	  method	  was	  adapted	  in	  accordance	  from	  Bansal	  et	  al.	  (2009).	  	  A	   sample	   of	   the	   synthesised	   peptide	   used	   for	   HPLC	   analysis	   and	   the	   remaining	  peptide	   solution	  was	   freeze-­‐dried.	   	   A	   crude	   purification	   of	   the	   peptide	  was	   also	  carried	  out	   by	  HPLC	   and	   the	   volumes	  were	   reduced	  by	   a	   rotor-­‐evaporator.	   	   The	  resultant	  eluate	  was	  then	  freeze-­‐dried	  and	  then	  stored	  at	  -­‐20	  °C.	   	  This	  procedure	  was	   carried	   out	   with	   the	   assistance	   of	   Drs	   Sukhi	   Bansal	   and	   Dirk	   Wildeboer	  (Pharmaceutical	  Sciences	  Research	  Division,	  King’s	  College	  London).	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4.2.2	  Three-­‐stage	  preparation	  of	  immunogen	  	  
	  	  
Figure 4.2.  A schematic diagram showing the conjugation steps for the synthesised peptide to 
the homologous and heterologous linker arms for the preparation of the immunogen and plate 
coating antigens for ELISA. 
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Stage	  1:	  Preparation	  of	  3-­‐(Maleimido)propionic	  acid	  N-­‐succinimidyl	  ester	  	  
(MPSE)	  	  An	   active	   ester	   of	   3-­‐(Maleimido)propionic	   acid	   was	   prepared	   using	   N-­‐hydroxysuccinimide	  as	  an	  activating	  reagent.	  	  The	  active	  ester	  can	  then	  react	  with	  an	   amine	   group	   such	   as	   keyhole	   limpet	   hemocyanin	   (KLH).	   	   3-­‐(Maleimido)propionic	  acid	   (125	  mg)	  of	  was	  dissolved	   in	  6	  ml	  of	  1,4-­‐dioxane	   (20	  mg	  ml-­‐1).	  	  N-­‐hydroxysuccinimide	  (115	  mg)	  was	  added	  to	  the	  solution	  and	  allowed	  to	  dissolve	  completely.	  	  N,N′-­‐Dicyclohexylcarbodiimide	  (DCC)	  (210	  mg)	  was	  added	  to	   the	  solution,	  and	   left	  on	   the	  bench	   to	  precipitate	   for	  1	  h.	   	  The	  MPSE	  was	   then	  diluted	  to	  a	  concentration	  of	  10	  mg	  ml-­‐1,	  ready	  to	  be	  used	  in	  the	  activation	  of	  KLH	  in	  the	  following	  stage.	  (Kitagawa	  &	  Aikawa	  1976;	  Anderson	  et	  al.	  1964).	  	  	  
Stage	   2:	   Activation	   of	   keyhole	   limpet	   hemocyanin	   (KLH)	   with	   3-­‐
(Maleimido)propionic	  acid	  N-­‐succinimidyl	  ester	  (MPSE)	  	  KLH	  was	   used	   as	   a	   carrier	   protein	   in	   the	   preparation	   of	   the	   immunogen	   for	   the	  generation	   of	   the	   CTGF	   peptide	   antibody.	   	   As	   this	   protein	   is	   non-­‐reactive	   on	   its	  own,	   it	  has	   to	  be	  activated	  by	  MPSE	  before	   it	   can	  be	   conjugated	   to	   the	   synthetic	  peptide.	  	  KLH	  (20	  mg)	  was	  dissolved	  in	  1.5	  ml	  of	  50	  mM	  sodium	  phosphate	  buffer,	  pH	  7.0,	   followed	  by	  75	  µl	  of	  DMF.	   	  The	  protein	   solution	  was	   cooled	  on	   ice	  while	  stirring	  gently.	  	  The	  MPSE	  solution	  was	  dissolved	  in	  DMF	  to	  provide	  a	  10	  mg	  ml-­‐1	  solution.	  	  This	  solution	  was	  stored	  under	  a	  desiccating	  agent	  at	  4	  oC.	  	  200	  µl	  of	  the	  MPSE	  reagent	  was	  added	  to	  the	  stirred	  KLH	  solution	  in	  50	  μl	  aliquots	  over	  a	  period	  of	  10	  min	  (a	  ratio	  of	  1	  mg	  of	  MPSE	  to	  10	  mg	  of	  protein).	  	  	  	  While	   the	   above	   reaction	  was	   being	   carried	   out,	   a	   PD-­‐10	   Sephadex	   column	  was	  prepared	  by	   flushing	   the	   column	  with	   ice-­‐cold	  50	  mM	  sodium	  phosphate	   buffer,	  pH	   7.0	   (1	  ml	   at	   a	   time).	   	   0.8	  ml	   of	   the	   reaction	  mixture	   (approximately	   half	   the	  original	  volume)	  was	  transferred	   into	  the	  PD-­‐10	  column.	   	  Fractions	  of	  1	  ml	  were	  collected	  and	  kept	  on	  ice.	  	  The	  absorbencies	  of	  the	  fractions	  were	  measured	  at	  280	  nm.	  	  The	  first	  sharp	  peak	  contained	  the	  required	  activated	  KLH	  fractions	  (usually	  fractions	  3-­‐5).	  	  A	  fresh	  PD-­‐10	  column	  was	  used	  for	  the	  chromatography	  of	  the	  rest	  of	   the	   reaction	  mixture.	   	   The	   fractions	   from	   both	   columns	  were	   pooled	   and	   the	  volume	   was	   reduced	   to	   about	   1	   ml	   using	   a	   Millipore	   centrifugal	   filter	   unit	   by	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centrifugation	   at	   7000	   r.p.m.	   for	   approximately	   30	   min	   in	   a	   pre-­‐cooled	   (4	   °C)	  centrifuge.	   	  This	   is	   the	  maleimide-­‐KLH	  preparation,	  which	  was	  used	   immediately	  in	  the	  following	  reaction	  (Lateef	  et	  al.	  2007).	  	  	  
Stage	  3:	  Coupling	  of	  the	  peptide	  to	  the	  maleimide-­‐KLH	  preparation	  	  Before	   any	   of	   the	   following	   reactions	   were	   carried	   out,	   nitrogen	   was	   bubbled	  through	  all	  solutions.	  	  	  	  The	   peptide	   prepared	   in	   4.2.1	   was	   dissolved	   in	   nitrogen-­‐saturated	   DMF-­‐H2O	  mixture	   (80:20,	  v/v)	   to	  provide	  a	  10	  mg	  ml-­‐1	   solution.	   	  The	  peptide	  solution	  (0.5	  ml)	  was	   transferred	   to	   the	  maleimide-­‐KLH	  preparation.	   	   0.5	  ml	   of	   0.5	  M	   sodium	  carbonate	  buffer,	   pH	  9.0	  was	   added	   immediately	   to	   the	   solution	   to	   raise	   the	  pH.	  	  Approximately	  7	  ml	  of	  0.1	  M	  sodium	  carbonate,	  pH	  9.0	  was	  added	  to	  the	  Amicon	  Ultra	   Filter	   unit	   so	   that	   the	   actual	   filter	   unit	   (containing	   the	   insert	   with	   the	  conjugate	  reaction	  mixture)	   is	  partially	  submerged.	   	  The	  addition	  of	  buffer	  to	  the	  filter	  unit	  ensures	   that	   the	   temperature	  of	   the	  sample	   is	  at	  37	   ˚C.	   	  The	  conjugate	  reaction	  mixture	  was	  incubated	  in	  a	  water	  bath	  at	  37	  °C	  for	  16	  h.	   	  The	  conjugate	  mixture	  was	  then	  dialysed	  against	  2	  litre	  of	  0.01	  M	  sodium	  phosphate,	  pH	  7.0,	  and	  1g	   litre-­‐1	   of	   activated	   charcoal	   for	  16	  h	   at	   4	   °C.	   	   The	  KLH-­‐peptide	   conjugate	  was	  recovered	  and	  adjusted	  to	  7	  ml	  with	  50	  mM	  sodium	  phosphate	  buffer,	  pH	  7.0.	  	  The	  peptide-­‐KLH	   conjugate	  was	   recovered	   and	   freeze-­‐dried	   in	   aliquots	   of	   1	  ml.	   	   The	  conjugate	  (immunogen)	  was	  then	  used	  to	  generate	  sheep	  polyclonal	  antiserum	  to	  the	  synthesised	  CTGF	  peptide	  (Lateef	  et	  al.	  2007).	  	  	  	  
4.2.3	  Generation	  of	  a	  polyclonal	  sheep	  antisera	  to	  CTGF	  peptide	  	  
Immunization	  	  Immunization	   was	   carried	   out	   by	   MicroPharm	   Ltd.	   	   In	   summary,	   2.7	   mg	   of	   the	  immunogen	   (peptide-­‐KLH)	   in	   Freund’s	   Complete	   Adjuvant	   was	   injected	  subcutaneously	  at	  multiple	  sites	  in	  the	  sheep.	  	  Subsequently,	  1.7	  mg	  of	  immunogen	  in	   Freund’s	   Incomplete	   Adjuvant	  was	   injected	   subcutaneously	   every	   four	  weeks	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(booster	  shots).	   	  Antisera	  was	  collected	  and	  screened	  in	  an	  ELISA	  described	  later	  (4.2.14).	  	  
4.2.4	  Preparation	  of	  the	  homologous	  plate	  coating	  antigen	  	  	  
Activation	  of	  porcine	  gelatine	   (bloom	  150)	  with	  3-­‐(Maleimido)propionic	  
acid	  N-­‐succinimidyl	  ester	  (MPSE)	  	  	  	  
	  	  
Figure 4.3.  The chemical structure of the homologous gelatine conjugate, peptide-MPSE-
gelatine. 	  As	  with	  KLH,	  porcine	  gelatine	  is	  an	  inert	  protein	  and	  therefore	  cannot	  be	  coupled	  directly	  to	  the	  peptide.	  	  Gelatine	  has	  to	  first	  be	  activated	  by	  the	  attachment	  of	  the	  MPSE	   via	   an	   amino	   group	   on	   the	   gelatine	  molecule.	   	   This	   activated	   gelatine	   can	  then	  be	  coupled	  to	  the	  peptide	  via	  the	  thiol	  group	  present	  on	  the	  terminal	  cysteine.	  	  Porcine	  gelatine,	  bloom	  150	  (1	  g),	  was	  dissolved	  in	  80	  ml	  of	  de-­‐ionised	  water	  along	  with	  20	  ml	  of	  DMF	  and	  1	  ml	  of	  TEA	  (triethylamine)	  to	  provide	  a	  10	  mg	  ml-­‐1.	   	  The	  solution	  was	  heated	  gently	   in	  a	  water	  bath	  held	  at	  60	  °C	   to	  dissolve	   the	  gelatine	  and	   allowed	   to	   cool	   to	   room	   temperature.	   	   The	  MPSE	   (as	   described	   above)	  was	  dissolved	  in	  DMF	  to	  provide	  a	  10	  mg	  ml-­‐1	  solution,	  which	  may	  be	  stored	  dry	  at	  4	  °C.	  	  The	  equivalent	  of	  10	  mg	  of	  MPSE	  (1	  ml)	  was	  added	  to	  50	  mg	  of	  gelatine	  solution	  (5	  ml),	  50	  µl	  at	  a	  time.	  	  The	  reaction	  was	  carried	  out	  whilst	  the	  solution	  was	  stirring.	  	  Care	   was	   taken	   to	   ensure	   that	   the	   gelatine	   solution	   did	   not	   turn	   cloudy.	   	   The	  addition	   of	   the	   active	   ester	  was	   stopped	   once	   cloudiness	  was	   observed,	   and	   the	  solution	  was	   left	   to	  stand	  on	   ice	   for	  30	  min.	   	  The	  MPSE-­‐gelatine	  preparation	  was	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dialysed	   against	   3	   litre	   of	   0.1	  %	   sodium	   acetate	   (w/v),	   pH	   5.5	   and	   1	   g	   litre-­‐1	   of	  activated	  charcoal	  at	  4	  °C	  for	  16	  h.	   	  The	  sample	  was	  recovered	  and	  10	  %	  (v/v)	  of	  DMF	  was	  added	  to	  the	  solution,	  which	  was	  stored	  in	  8	  mg	  aliquots	  at	  4	  °C.	  	  	  
	  
Coupling	  of	  thiolated	  peptide	  to	  MPSE-­‐activated	  gelatine	  	  
	  Nitrogen	  was	   bubbled	   through	   all	   solutions	   prior	   to	   the	   reactions.	   	   The	   peptide	  solution	  (200	  µl)	  was	  added	  to	  2	  ml	  of	  MPSE-­‐	  activated	  gelatine	  solution.	  	  A	  0.1	  M	  sodium	  bicarbonate/carbonate	  buffer,	  pH	  9.0	  (200	  µl),	  was	  added	  to	  the	  solution	  and	  incubated	  at	  37	  °C	  for	  16	  h.	   	  The	  solution	  was	  carefully	  mixed	  so	  as	  to	  avoid	  the	  introduction	  of	  oxygen.	  	  The	  conjugate	  was	  dialysed	  against	  2	  litre	  0.4%	  (w/v)	  sodium	   bicarbonate	   solution	   and	   1	   g	   litre-­‐1	   activated	   charcoal	   for	   16	   h	   at	   room	  temperature.	  	  The	  sample	  was	  recovered	  and	  stored	  at	  -­‐20	  °C	  in	  1	  ml	  aliquots.	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4.2.5	  Preparation	  of	  the	  heterologous	  plate	  coating	  antigens	  	  The	  six	  heterologous	  linker	  arms	  prepared	  to	  couple	  the	  CTGF	  peptide	  to	  gelatine	  are	   all	   novel.	   	   By	   preparing	   several	   linker	   arms,	   optimum	   presentation	   of	   the	  peptide	  to	  the	  antibody	  can	  be	  established.	  	  	  	  
 
Table 4.1.  Linker arms used for the conjugation of the synthesised peptide to gelatine. 	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Table 4.2.  Linker arms used for the conjugation of the synthesised peptide to gelatine. 
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Figure 4.4.  An example of the chemical structure of the heterologous peptide conjugate, 
peptide-CC-gelatine where the peptide was coupled to gelatine using cyanuric chloride. 
 
4.2.5.1	  Addition	  of	   linker	  arm	  using	  haloalkane	  active	  esters	   to	  porcine	  
gelatine	  (bloom	  150).	  	  Three	   types	   of	   linker	   arms	  were	   prepared	   by	   the	   activation	   of	   three	   haloalkane	  acids.	  	  	  
Preparation	   of	   5-­‐bromovaleric	   acid	   N-­‐hydroxysuccinimide	   ester,	   3-­‐
bromopropionic	   acid	   N-­‐hydroxysuccinimide	   ester	   and	   5-­‐chlorovaleric	   acid	   N-­‐
hydroxysuccinimide	  ester	  	  5-­‐bromovaleric	  acid	  (181	  mg),	  3-­‐bromopropionic	  acid	  (153	  mg)	  or	  5-­‐chlorovaleric	  acid	  (137	  mg)	  was	  dissolved	  in	  18	  ml	  of	  1,4-­‐dioxane.	  	  N-­‐hydroxysuccinimide	  (120	  mg)	  was	  added	   to	   the	  solution	  and	  allowed	   to	  dissolve.	   	  DCC	  (220	  mg)	  was	   then	  added	  and	  the	  solution	  was	  mixed	  immediately.	  	  The	  reaction	  was	  left	  to	  stand	  at	  room	   temperature	   for	   16	   h	   (a	   heavy	   precipitate	  was	   observed)	   (Anderson	   et	   al.	  1964).	  	  
Activation	  of	  gelatine	  with	  haloalkane	  active	  ester	  linker	  arms	  	  Porcine	  gelatine,	  bloom	  150	  (200	  mg),	  was	  dissolved	  in	  20	  ml	  of	  de-­‐ionised	  water	  and	  2	  ml	  of	  DMF.	  	  The	  solution	  was	  heated	  gently	  in	  a	  water	  bath	  held	  at	  60	  °C	  to	  dissolve	   the	   gelatine	   and	   allowed	   to	   cool	   to	   room	   temperature.	   	   The	   following	  reaction	  was	  carried	  out	  whilst	  the	  solution	  is	  stirring.	  	  TEA	  (400	  µl)	  was	  added	  to	  the	   solution.	   	   The	   active	   ester	   preparation	   (clear	   solution)	   was	   added	   to	   the	  gelatine	   solution,	   50	   µl	   at	   a	   time.	   	   Care	   was	   taken	   to	   ensure	   that	   the	   gelatine	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solution	  did	  not	   turn	   cloudy.	   	   The	   addition	  of	   the	   active	   ester	  was	   stopped	  once	  cloudiness	  was	  observed.	  	  The	  activated	  gelatine	  preparation	  was	  dialysed	  against	  2	   litre	  of	  de-­‐ionised	  water	  and	  1	  g	   litre-­‐1	  activated	  charcoal	  at	  room	  temperature	  for	   16	   h.	   	   The	   sample	   was	   recovered	   and	   30	   %	   (v/v)	   DMF	   was	   added	   to	   the	  solution,	  which	  was	  stored	  at	  4	  °C.	  	  	  
	  
Coupling	   of	   thiolated	   peptide	   to	   gelatine	   modified	   with	   haloalkane	   active	  
esters	  	  	  Nitrogen	  was	   bubbled	   through	   all	   solutions	   prior	   to	   the	   reactions.	   	   The	   peptide	  solution	  (100	  µl)	  (stored	  at	  10	  mg	  ml-­‐1	  in	  80:20	  (v/v)	  DMF-­‐H2O)	  was	  added	  to	  2	  ml	  of	  modified	  gelatine	   solution.	   	  A	  0.1	  M	  sodium	  bicarbonate/carbonate	  buffer,	  pH	  9.0	  (200	  µl)	  was	  added	  to	  the	  solution	  and	  incubated	  at	  37	  °C	  for	  3	  h.	  	  The	  solution	  was	  carefully	  mixed	  so	  as	  to	  not	  introduce	  air.	  	  2-­‐mercaptoethanol	  (10	  µl)	  was	  then	  added	  and	   reaction	  mixture	  was	   further	   incubated	  at	  37	   °C	   for	  30	  min	   (to	  block	  excess	   halogen	   groups).	   	   The	   conjugate	  was	  dialysed	   against	   2	   litre	   0.4	  %	   (w/v)	  sodium	   bicarbonate	   solution	   and	   1	   g	   litre-­‐1	   activated	   charcoal	   for	   16	   h	   at	   room	  temperature.	  	  The	  sample	  was	  recovered	  and	  stored	  at	  -­‐20	  °C	  in	  1	  ml	  aliquots.	  	  
4.2.5.2	  Procedure	  for	  the	  preparation	  of	  linker	  arms	  using	  triazines	  	  
Crystallisation	  of	  cyanuric	  chloride	  	  Cyanuric	  chloride	  (20	  g)	  was	  dissolved	  in	  approximately	  70	  ml	  of	  boiling	  benzene	  for	  30	  min	  until	  solution	  was	  saturated.	   	  The	  solution	  was	  filtered	  whilst	  hot	  and	  left	  to	  crystallize	  at	  room	  temperature.	  	  The	  crystals	  were	  filtered	  and	  washed	  with	  approximately	  20	  ml	  of	   ice-­‐cold	  benzene	  and	  dried	  under	  vacuum.	   	  The	  cyanuric	  chloride	  crystals	  were	  stored	  dry	  at	  4	  °C	  until	  required	  (Kaiser	  et	  al.	  1951).	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Activation	  of	  gelatine	  with	  cyanuric	  chloride	  
	  Porcine	  gelatine,	  bloom	  150	  (800	  mg),	  was	  dissolved	  in	  80	  ml	  of	  de-­‐ionised	  water	  and	  20	  ml	  of	  DMF.	  	  The	  solution	  was	  heated	  gently	  in	  a	  water	  bath	  held	  at	  60	  °C	  to	  dissolve	   the	   gelatine	   and	   allowed	   to	   cool	   to	   room	   temperature.	   	   The	   following	  reaction	  was	  carried	  out	  whilst	  the	  solution	  is	  stirring.	   	  Solid	  sodium	  bicarbonate	  (3	  g)	  was	  added	  to	   the	  solution.	   	  Crystallised	  CC	  (160	  mg)	  was	  dissolved	   in	  2	  ml	  ice-­‐cold	  acetone.	   	  The	  CC	  solution	  was	  added	  to	   the	  dissolved	  gelatine,	  50	  µl	  at	  a	  time.	  	  Care	  was	  taken	  to	  ensure	  that	  the	  gelatine	  solution	  did	  not	  turn	  cloudy.	  	  The	  addition	   of	   the	   CC	   solution	   was	   stopped	   once	   cloudiness	   was	   observed.	   	   The	  modified	   gelatine	   solution	  was	   dialysed	   against	   4	   litre	   de-­‐ionised	  water	   and	   1	   g	  litre-­‐1	  activated	  charcoal	  at	  room	  temperature	  for	  16	  h.	  	  The	  sample	  was	  recovered	  and	   30	   %	   (v/v)	   DMF	   was	   added	   to	   the	   solution,	   which	   was	   stored	   at	   4	   °C	  (Abuknesha	  &	  Luk	  2005).	  	  
Coupling	  of	  thiolated	  peptide	  to	  CC-­‐gelatine	  	  	  Nitrogen	  was	   bubbled	   through	   all	   solutions	   prior	   to	   the	   reactions.	   	   The	   peptide	  solution	   (150	   µl)	   was	   added	   to	   2	   ml	   of	   CC-­‐gelatine.	   	   A	   0.1	   M	   sodium	  bicarbonate/carbonate	   buffer,	   pH	   9.0	   (200	   µl)	   was	   added	   to	   the	   solution	   and	  incubated	  at	  37	  °C	  for	  3	  h.	  	  The	  solution	  was	  carefully	  mixed	  so	  as	  to	  not	  introduce	  air.	   	   The	   conjugate	   was	   dialysed	   against	   2	   litre	   0.4%	   (w/v)	   sodium	   bicarbonate	  solution	   and	   1	   g	   litre-­‐1	   activated	   charcoal	   for	   16	   h	   at	   room	   temperature.	   	   The	  sample	  was	  recovered	  and	  stored	  at	  -­‐20	  °C	  in	  1	  ml	  aliquots.	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Modification	   of	   gelatine	   with	   CC-­‐6-­‐aminocaproic	   acid	   N-­‐hydroxysuccinimide	  
ester	  and	  CC-­‐benzoic	  acid	  N-­‐hydroxysuccinimide	  ester	  	  	  In	  order	  to	  prepare	  the	  above	  conjugates,	  it	  was	  necessary	  to	  firstly	  synthesise	  the	  active	  ester,	  which	  is	  described	  below.	  	  	  
Preparation	  of	  cyanuric	  chloride-­‐6-­‐aminocaproic	  acid	  	  Methyl	   6-­‐aminohexanoate	   (1.8	   g)	   was	   suspended	   in	   60	   ml	   of	   3	   %	   sodium	  bicarbonate	  solution.	  	  	  Acetone	  (10	  %	  v/v)	  was	  added	  and	  the	  solution	  was	  cooled	  on	  ice	  whilst	  stirring.	   	  N,N-­‐diisopropylethylamine	  (1.8	  ml)	  was	  then	  added	  to	  the	  solution.	   	   CC	   crystals	   (2	   g)	   was	   dissolved	   in	   50	  ml	   of	   ice-­‐cold	   acetone.	   	   The	   CC	  solution	  was	  added	  to	  the	  methyl	  6-­‐aminohexanoate	  solution	  in	  5	  ml	  volumes	  over	  a	   period	   of	   30	   min.	   	   The	   reaction	   mixture	   was	   left	   to	   stir	   for	   16	   h	   at	   room	  temperature.	  	  The	  acetone	  was	  removed	  by	  rotary	  evaporation	  and	  under	  reduced	  pressure.	   	   A	   heavy	   precipitate	   was	   observed.	   	   The	   suspension	   was	   acidified	   by	  adding	   5	  M	   cold	   hydrochloric	   acid	   and	   left	   on	   ice	   for	   about	   1h.	   	   The	   precipitate	  (crude	  methyl	  6-­‐CC-­‐aminohexanoate)	  was	  collected	  by	  filtration	  and	  washed	  with	  cold	  0.1	  M	  hydrochloric	  acid.	  	  The	  solid	  was	  dissolved	  in	  minimum	  volume	  of	  warm	  acetonitrile,	   filtered	   and	   left	   to	   crystallize.	   	   The	   solid	   (pure	   methyl	   6-­‐CC-­‐aminohexanoate)	   was	   collected	   by	   filtration,	   washed	   with	   cold	   acetonitrile	   and	  stored	  dry	  at	  4	  °C.	  	  	  	  Methyl	   6-­‐CC-­‐aminohexanoate	   (0.67	   g)	   was	   dissolved	   in	   5	   ml	   of	   0.1	   M	   sodium	  hydroxide.	   	   It	   was	   heated	   at	   60	   °C	   for	   10	   min	   and	   the	   heated	   preparation	   was	  transferred	  onto	  ice	  and	  diluted	  with	  20	  ml	  of	  de-­‐ionised.	  	  Hydrochloric	  acid	  (1	  M)	  was	  added	  drop-­‐wise	  to	  precipitate	  the	  free	  acid	  (6-­‐CC-­‐aminohexanoic	  acid).	  	  The	  pH	  was	  monitored	  until	   it	  reached	  pH	  3	  –	  4,	  and	  then	   left	  on	   ice	  to	  complete	  the	  precipitation	  process.	  	  The	  suspension	  was	  poured	  into	  200	  ml	  of	  ethyl	  acetate	  and	  the	  organic	  layer	  was	  washed	  with	  dilute	  hydrochloric	  acid,	  then	  with	  water.	  	  The	  ethyl	   acetate	   layer	   was	   dried	   over	   sodium	   sulphate.	   	   The	   ethyl	   acetate	   was	  removed	  by	  rotary	  evaporation	  under	  reduced	  pressure.	   	  The	  solid	  was	  collected	  and	  left	  to	  dry	  under	  vacuum.	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Preparation	   of	   cyanuric	   chloride-­‐6-­‐aminocaproic	   acid	   N-­‐hydroxysuccinimide	  
active	   ester	   and	   cyanuric	   chloride-­‐benzoic	   acid	   N-­‐hydroxysuccinimide	   active	  
ester	  	  CC-­‐6-­‐aminocaproic	  acid	  (189	  mg)	  or	  CC-­‐benzoic	  acid	  (1	  mM)	  was	  dissolved	  in	  19	  ml	   of	   1,4-­‐dioxane.	   	   5N-­‐hydroxysuccinimide	   (6	   mg)	   was	   added	   and	   allowed	   to	  dissolve.	  	  DCC	  (110	  mg)	  was	  added	  and	  mixed	  immediately.	  	  The	  reaction	  was	  left	  to	   stand	  at	   room	   temperature	   for	  16	  h	   (a	  heavy	  precipitate	  was	  observed).	   	  The	  solution	   contains	   CC-­‐6-­‐aminohexanoic	   acid	  N-­‐hydroxysuccinimide	   ester	   and	  was	  stored	  dry	  at	  4	  °C	  and	  used	  without	  further	  processing.	  	  The	  method	  was	  adapted	  from	  Anderson	  et	  al.	  (1964).	  	  	  	  
Activation	  of	  gelatine	  with	  CC-­‐6-­‐aminocaproic	  acid	  N-­‐hydroxysuccinimide	  ester	  
and	  CC-­‐benzoic	  acid	  N-­‐hydroxysuccinimide	  ester	  	  Bloom	  150	  porcine	  gelatine	   (200mg)	  was	  dissolved	   in	  40	  ml	  of	  DMF-­‐H2O	  (20:80	  
v/v).	  	  The	  solution	  was	  heated	  gently	  in	  a	  water	  bath	  held	  at	  60	  °C	  to	  dissolve	  the	  gelatine	   and	   allowed	   to	   cool	   to	   room	   temperature.	   	   The	   following	   reaction	   was	  carried	  out	  whilst	  the	  solution	  is	  stirring.	   	  Solid	  sodium	  bicarbonate	  (0.16	  g)	  was	  added	  to	  the	  solution,	   followed	  by	  40	  µl	  of	  TEA.	   	  The	  active	  ester	  solution	  (CC-­‐6-­‐aminohexanoic	   acid	   N-­‐hydroxysuccinimide	   ester	   or	   CC-­‐benzoic	   acid	   N-­‐hydroxysuccinimide	  ester)	  (1.5	  ml)	  was	  added	  to	  the	  gelatine	  solution,	  50	  µl	  at	  a	  time	  while	  mixing.	  	  Care	  was	  taken	  to	  ensure	  that	  the	  gelatine	  solution	  did	  not	  turn	  cloudy.	  	  The	  addition	  of	  the	  active	  ester	  solution	  was	  stopped	  once	  cloudiness	  was	  observed.	   	  The	  modified	  gelatine	   solution	  was	  dialysed	  against	  4	   litre	  de-­‐ionised	  water	  and	  1	  g	  litre-­‐1	  activated	  charcoal	  at	  room	  temperature	  for	  16	  h.	  	  The	  sample	  was	  recovered	  and	  30	  %	  (v/v)	  DMF	  was	  added	  to	  the	  solution,	  which	  was	  stored	  at	  4	  °C.	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Coupling	  of	  thiolated	  peptide	  to	  CC-­‐caproic	  acid-­‐gelatine	  and	  CC-­‐benzoic	  acid-­‐
gelatine	  	  	  Nitrogen	  was	   bubbled	   through	   all	   solutions	   prior	   to	   the	   reactions.	   	   The	   peptide	  solution	  (150	  µl)	  was	  added	  to	  2	  ml	  of	  CC-­‐caproic	  acid-­‐gelatine	  or	  CC-­‐benzoic	  acid-­‐gelatine.	  	  A	  0.1	  M	  sodium	  bicarbonate/carbonate	  buffer,	  pH	  9.0	  (200	  µl)	  was	  added	  to	  the	  solution	  and	  incubated	  at	  37	  °C	  for	  3	  h.	  	  The	  solution	  was	  mixed	  carefully	  to	  not	   introduce	  air.	   	  The	  conjugate	  was	  dialysed	  against	  2	   litre	  0.4%	  (w/v)	  sodium	  bicarbonate	   solution	   and	   1	   g	   litre-­‐1	   activated	   charcoal	   for	   16	   h	   at	   room	  temperature.	  	  The	  sample	  was	  recovered	  and	  stored	  at	  -­‐20	  °C	  in	  1	  ml	  aliquots.	  
	  
	  4.2.6	   Coupling	   of	   cysteine	   to	   activated	   gelatines	   (control	  
conjugates)	  	  Nitrogen	  was	  bubbled	   through	  all	   solutions	  prior	   to	   the	   reactions.	   	  Cysteine	  was	  dissolved	   carefully	   (so	   as	   to	   not	   introduce	   oxygen)	   in	   0.1	   M	   sodium	  bicarbonate/carbonate	  buffer,	  pH	  9.0,	  to	  form	  a	  2	  mg	  ml-­‐1	  solution.	  	  Approximately	  1	  –	  2	  mg	  of	  cysteine	  was	  added	  to	  8	  –	  10	  mg	  of	  activated	  gelatine	  solution	  and	  2	  ml	  of	  0.1	  M	  sodium	  bicarbonate/carbonate	  buffer,	  pH	  9.0.	  	  The	  solution	  was	  heated	  at	  60	  °C	  for	  10	  min	  and	  left	  to	  stand	  for	  2	  hours.	  	  The	  conjugates	  were	  then	  dialysed	  against	   4	   litre	   of	   0.1	   M	   sodium	   bicarbonate	   solution	   and	   1	   g	   litre-­‐1	   activated	  charcoal	  for	  16	  h	  at	  room	  temperature.	  	  The	  samples	  were	  recovered	  and	  stored	  at	  -­‐20	  °C	  in	  1	  ml	  aliquots.	  	  	  	  
Peptide	  conjugates	   Cysteine	  conjugates	  Peptide-­‐MPSE-­‐gelatine	  (homologous)	   Cysteine-­‐MPSE-­‐gelatine	  Peptide-­‐Br-­‐valeric	  acid-­‐gelatine	  (heterologous)	   Cysteine-­‐Br-­‐valeric	  acid-­‐gelatine	  Peptide-­‐Br-­‐propionic	  acid-­‐gelatine	  (heterologous)	   Cysteine-­‐Br-­‐propionic	  acid-­‐gelatine	  Peptide-­‐Cl-­‐valeric	  acid-­‐gelatine	  (heterologous)	   Cysteine-­‐Cl-­‐valeric	  acid-­‐gelatine	  Peptide-­‐CC	  (cyanuric	  chloride)-­‐gelatine	  	  (heterologous)	   Cysteine-­‐CC-­‐gelatine	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Peptide-­‐CC(cyanuric	  chloride)-­‐-­‐caproic	  acid-­‐gelatine	  (heterologous)	   Cysteine-­‐CC-­‐caproic	  acid-­‐gelatine	  Peptide-­‐CC	  (cyanuric	  chloride)-­‐benzoic	  acid-­‐gelatine	  (heterologous)	   Cysteine-­‐CC-­‐benzoic	  acid-­‐gelatine	  
	  
Table 4.3.  Summary of all the novel linker arms that were synthesised in this study. The 
homologous conjugate is peptide-MPSE-gelatine.  The heterologous conjugates are the rest of 
the peptide-gelatine conjugates that does not contain the MPSE linker arm.  The term 
homologous is used because the linker arm, MPSE, was also utilised in the preparation of the 
immunogen, peptide-MPSE-KLH.   
	  The	  peptide-­‐CC-­‐gelatine	  heterologous	  conjugate	  was	  selected	  to	  be	  used	  in	  further	  experiments.	  	  	  
	  
Section	  B	  
4.2.7	  Binding	  activity	  of	  the	  protein-­‐peptide	  conjugates.	  	  An	  ELISA	  procedure	  described	  in	  Chapter	  2	  was	  used	  to	  assess	  the	  peptide-­‐protein	  conjugates,	   the	   level	   of	   antibody	   binding	   activity	   and	   antigenic	   response	   of	   the	  peptide	   conjugates.	   	   The	   assessment	   method	   of	   choice	   was	   a	   checkerboard	  titration	  assay	  in	  which	  both	  the	  antibody	  and	  the	  peptide-­‐gelatine	  conjugates	  are	  assessed	  in	  series	  of	  dilutions.	  	  	  	  
Isolation	   of	   the	   immunoglobulin	   fraction	   from	   the	   antiserum	   using	  
ammonium	  sulphate	  precipitation	  	  Ammonium	   sulphate	   was	   initially	   used	   to	   ‘salt	   out’	   most	   of	   the	   albumin	   that	   is	  present	  in	  the	  sheep	  serum.	  	  It	  was	  found	  that	  at	  45	  %	  ammonium	  sulphate	  (v/v)	  in	  phospate	   buffer	   removed	   albumin	   from	   the	   serum	   most	   efficiently.	   	   Saturated	  ammonium	  sulphate	  was	  also	  used	  to	  store	  processed	  antibodies	  efficiently	  at	  4	  °C.	  	  All	  solutions	  used	  were	  ice-­‐cold	  and	  the	  addition	  of	  saturated	  ammonium	  sulphate	  was	  carried	  out	  on	  ice.	   	  A	  50	  mM	  sodium	  phosphate,	  100	  mM	  NaCl,	  pH	  7.4	  buffer	  (4.8	   ml)	   was	   added	   to	   4	   ml	   of	   antiserum	   while	   stirring	   on	   ice.	   	   Saturated	  ammonium	  sulphate	  (7.2	  ml)	  was	  added	  drop-­‐wise	  to	  obtain	  a	  final	  concentration	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of	  45	  %.	  	  The	  solution	  was	  left	  for	  on	  ice	  for	  1	  h.	  	  The	  suspension	  was	  centrifuged	  at	  6000	   rpm.	   for	   approximately	   30	   min	   in	   a	   pre-­‐cooled	   centrifuge	   (4	   °C).	   	   The	  supernatant	   was	   discarded	   and	   the	   pellet	   was	   re-­‐suspended	   in	   4	   ml	   of	   45	   %	  saturated	   ammonium	   sulphate	   (in	   50	  mM	   sodium	   phosphate,	   100	  mM	  NaCl,	   pH	  7.4),	  mixed	   and	  divided	   into	  1	  ml	   aliquots	   and	   stored	   at	   4	   °C.	   	   This	   process	  was	  repeated	  for	  all	  bleeds	  of	  antisera.	  	  	  	  
Comparison	   of	   the	   binding	   activity	   of	   homologous	   (peptide-­‐MPSE-­‐
gelatine)	   and	   heterologous	   peptide-­‐gelatine	   (peptide-­‐CC-­‐gelatine)	  
conjugates	  	  An	   ELISA	   was	   used	   to	   compare	   the	   binding	   activities	   of	   the	   homologous	   and	  heterologous	   conjugates.	   	   Theoretically,	   higher	   activity	  would	   be	   observed	   from	  the	   homologous	   conjugate.	   	   This	   is	   because	   there	   would	   inadvertently	   be	  antibodies	  that	  are	  raised	  against	  part	  or	  the	  whole	  linker	  arm	  (MPSE).	  	  	  Therefore,	  by	  using	  a	  linker	  arm	  that	  is	  different	  to	  that	  used	  in	  the	  immunogen,	  the	  readings	  that	   are	   observed	   in	   the	   ELISA	   would	   be	   more	   accurate.	   	   Plate	   coating	   buffer	  (equilibrated	  to	  37	  °C)	  was	  added	  (150	  µl)	  into	  a	  96-­‐well	  microtitre	  plate.	  	  A	  1:20	  solution	  of	  the	  peptide-­‐CC-­‐gelatine	  conjugate	  (equilibrated	  to	  37	  °C)	  was	  prepared	  in	  coating	  buffer	   (typically	  100	  µl	  of	   stock	  peptide-­‐gelatine	  conjugate	   into	  1.9	  ml	  coating	   buffer).	   	   The	   diluted	   peptide-­‐CC-­‐gelatine	   conjugate	   was	   added	   (100	  µl/well)	  to	  all	  wells	  in	  column	  1	  of	  the	  microtitre	  plate.	  	  The	  solution	  was	  serially	  diluted	  2:5	  from	  columns	  1	  to	  6.	  	  The	  plate	  was	  covered	  and	  left	  on	  the	  bench	  for	  2	  h,	   then	   overnight	   at	   4	   °C.	   	   The	   plate	  was	  washed	   five	   times	  with	   250	   µl/well	   of	  washing	  buffer	  and	  then	  patted	  dry.	   	  The	  plate	  was	  blocked	  at	  room	  temperature	  with	  250	  µl/well	  of	  blocking	  buffer	  for	  2	  h.	  	  The	  microtitre	  plate	  was	  washed	  again.	  	  The	  anti-­‐peptide	  antisera	  (1	  ml)	  stored	  in	  45	  %	  saturated	  ammonium	  sulphate	  was	  centrifuged	   at	   10,000	   rpm	   for	   approximately	   15	   min	   in	   a	   pre-­‐cooled	   (4	   °C)	  centrifuge.	  	  The	  supernatant	  was	  discarded	  and	  the	  pellet	  was	  re-­‐dissolved	  in	  200	  µl	  of	  glycerol	  solution	  (50	  %	  glycerol	   in	  0.05	  M	  sodium	  phosphate,	  0.1	  M	  sodium	  chloride	  buffer,	   pH	  7.4),	   and	   stored	   at	   -­‐	   20	   °C.	   	   150	  µl/well	   of	   primary	   antibody	  buffer	  was	  added	  into	  all	  wells	  of	  the	  peptide-­‐CC-­‐gelatine-­‐coated	  plate.	   	  The	  anti-­‐peptide	   antibody	   was	   prepared	   to	   a	   dilution	   of	   1:20	   by	   adding	   100	   µl	   of	   anti-­‐peptide	  antibody	  solution	  in	  1.99	  ml	  of	  antibody	  buffer.	  	  The	  anti-­‐peptide	  antibody	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was	  added	   (100	  µl/well)	   to	   all	  wells	   in	   row	  A	   (A1-­‐A6).	   	  The	   solution	  was	  mixed	  and	  100	  µl	  of	  the	  solution	  was	  transferred	  downward	  (rows	  A	  to	  H)	  discarding	  the	  final	  100	  µl.	   	  The	  plate	  was	   incubated	  at	  4	   °C	   for	  16	  h.	   	  The	  microtitre	  plate	  was	  washed	   again.	   	   The	   anti-­‐sheep	   IgG-­‐	   HRP	   solution	   (diluted	   to	   1:2000,	   and	  equilibrated	   to	   37	   °C)	   was	   added	   to	   all	   the	   wells	   of	   the	   microtitre	   plate	   (150	  µl/well).	   	   The	  plate	  was	   covered	  and	   incubated	   for	  1	  h	   at	   37	   °C.	   	   The	  microtitre	  plate	   was	   washed	   again.	   	   ABTS	   liquid	   substrate	   (150	   µl/well)	   was	   added	   to	   all	  wells	  of	  the	  plate.	  	  The	  plate	  was	  kept	  out	  of	  direct	  light	  at	  room	  temperature.	  	  The	  absorbance	  was	  read	  at	  405	  nm	  after	  15	  and	  30	  min	  using	  an	  ELISA	  plate	  reader.	  	  This	  was	  repeated	  for	  all	  bleeds	  of	  the	  anti-­‐peptide	  antisera.	  	  It	   is	   imperative	  when	   raising	   antibodies	   that	   they	   are	  monitored	   throughout	   the	  life	  of	  the	  animal,	  which	  in	  this	  case	  is	  sheep.	  	  This	  is	  so	  that	  any	  problems,	  such	  as	  a	   weak	   response	   or	   non-­‐specificity,	   can	   be	   identified	   early	   on	   and	   rectified.	  	  Figures	   4.5	   and	   4.6	   show	   the	   immune	   response	   of	   the	   peptide	   antiserum	  when	  titrated	  against	  the	  homologous	  and	  heterologous	  peptide-­‐gelatine	  conjugate.	  	  	  	  The	  immune	  response	  shown	  in	  figure	  4.5	  indicates	  that	  the	  response	  of	  the	  pre-­‐immune	   serum	   and	   6-­‐week	   bleed	   is	   very	   low	   when	   compared	   to	   the	   32-­‐week	  bleed.	   	   The	   immune	   response	   then	   gradually	   increases	   after	   the	   10-­‐week	   bleed,	  which	  is	  expected.	  	  This	  indicates	  that	  the	  immune	  system	  of	  the	  animal	  (sheep)	  is	  eliciting	  a	  response	  to	  the	   immunogen,	  peptide-­‐MPSE-­‐KLH.	   	  There	  are	  two	  major	  phases	   in	   the	   serum	   antibody	   response	   of	   an	   animal.	   	   The	   first	   is	   the	   low	   level	  primary	   response	   after	   the	   animal	   has	   been	   first	   exposed	   to	   the	   foreign	   protein	  antigen.	   	   This	   is	   followed	   by	   a	   much	   higher	   secondary	   response	   after	   second	  exposure	   (Hanly	   et	   al.	   1995).	   	   This	   is	   evident	   in	   both	   figure	   4.5	   and	   4.6.	   	   As	  observed	   with	   both	   heterologous	   (figure	   4.5)	   and	   homologous	   (figure	   4.6)	  conjugates,	  the	  immune	  responses	  increase	  sharply	  after	  week-­‐14.	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Figure 4.5.  The titration of the anti-peptide antibody was carried out using peptide-CC-gelatine 
(heterologous conjugate). The antibody dilution response curves of the peptide antiserum 
samples were obtained from the various bleeds during the maturation of the immune response.  
Anti-peptide antiserum was collected every four weeks.   	  
	  
Figure 4.6.  The titration of the anti-peptide antibody was carried out using peptide-MPSE-
gelatine (homologous conjugate). The antibody dilution response curves of the peptide 
antiserum samples were obtained from the various bleeds during the maturation of the immune 
response.  Anti-peptide antiserum was collected every four weeks.   
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Screening	   the	   peptide	   antiserum	   with	   both	   heterologous	   and	   homologous	  conjugates	   shows	   the	   difference	   in	   anti-­‐peptide	   antibody	   activity	   to	   both	  conjugates.	   	   The	   response	   of	   the	   anti-­‐peptide	   antibody	   to	   the	   homologous	  conjugate	  will	   always	  be	  higher	   than	   that	  of	   the	  heterologous	   conjugate.	   	  This	   is	  evident	  when	  the	  dilution	  response	  curves	  of	  both	  conjugates	  are	  compared	  side	  by	  side	  (figure	  4.7).	  	  
	  
Figure 4.7.  Comparison of the dilution response curves of the peptide antiserum sample 
obtained from the 32-week bleed.  The titration was carried out using peptide-MPSE-gelatine 
(homologous conjugate) and the peptide-CC-gelatine (heterologous) conjugate.  Error bars 
represent standard error and sample was assayed three times.  
 Comparisons	  of	   the	   immune	  responses	  of	   the	  32-­‐week	  bleed	   to	   the	  heterologous	  and	   the	  homologous	  conjugate	   (figure	  4.7)	   indicate	   that	   the	   immune	  response	  of	  the	  homologous	  conjugate	  is	  higher	  than	  the	  heterologous	  conjugate.	   	  This	  is	  due	  to	  the	  interference	  of	  the	  linker	  arm	  with	  the	  antibody,	  which	  gives	  a	  significantly	  higher	   response.	   	   The	   antiserum	   contains	   not	   only	   antibodies	   raised	   against	   the	  peptide,	   but	   also	   antibodies	   to	   different	   parts	   of	   the	   peptide-­‐MPSE-­‐KLH	  immunogen,	   as	   can	   be	   observed	   in	   figure	   4.7.	   	   The	   dilution	   response	   curves	   for	  both	  conjugates	  show	  a	  similar	  trend	  where	  the	  absorbance	  value	  decreases	  when	  the	  antibody	  dilution	  factor	  increases.	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The	   homologous	   peptide	   conjugate	   contain	   the	   same	   linker	   arm	   (MPSE)	   to	   the	  immunogen.	   	  The	  antisera	  generated	  contain	  not	  only	  antibodies	  that	  are	  specific	  to	  the	  peptide,	  but	  also	  antibodies	  to	  the	  linker	  arm	  as	  well	  as	  the	  carrier	  molecule,	  KLH.	  	  Therefore,	  in	  order	  to	  abolish	  the	  falsely	  high	  absorbance	  readings,	  different	  linker	  arms	  and	  carrier	  protein	   (gelatine)	  were	  used.	   	  This,	   in	  effect,	   isolates	   the	  antibodies	  specific	  only	  to	  the	  peptide.	  	  This	  is	  the	  reason	  why	  six	  peptide	  gelatine	  conjugates	   were	   prepared.	   	   These	   conjugates	   were	   previously	   assessed	   and	  peptide-­‐CC-­‐gelatine	  was	   used	   in	   subsequent	   immunoassays	   because	   it	   produced	  the	  highest	  response	  to	  the	  anti-­‐peptide	  antibody.	  	  	  	  
4.2.8	   Comparing	   the	   binding	   activity	   of	   a	   control	   antiserum	  
raised	   against	   a	   conjugate	   made	   with	   the	   same	   linker	   arm	  
(MPSE)	  	  A	   control	   experiment	   was	   conducted	   to	   assess	   the	   specificity	   of	   antiserum	   to	  different	   parts	   of	   the	   immunogen.	   	   A	   15	   amino	   acid	   control	   peptide	   was	  synthesized	  in-­‐house	  in	  the	  same	  way	  as	  the	  peptide	  to	  CTGF	  i.e.	  Fmoc	  solid-­‐phase	  synthesis	  method.	  	  The	  sequence	  of	  this	  control	  peptide	  is	  as	  follows:	  	  Cys-­‐Ala-­‐Asp-­‐Phe-­‐Tyr-­‐Pro-­‐Glu-­‐Val-­‐Lys-­‐Glu-­‐Lys-­‐Ala-­‐Asp-­‐Phe-­‐Iso-­‐Ala.	   	   The	   peptide	   was	   also	  conjugated	   to	  KLH	  using	  3-­‐(Maleimido)propionic	  acid	  N-­‐succinimidyl	  ester.	   	  This	  assay	  was	  performed	   to	   show	   that	   the	   antibodies	   present	   in	   the	  peptide	   (CTGF)	  antiserum	  recognize	  different	  parts	  of	  the	  immunogen,	  including	  the	  linker	  arm.	  	  	  	  The	  steps	  of	  the	  assay	  are	  described	  as	  above.	  	  In	  this	  assay,	  a	  double	  checkerboard	  titration	  method	  is	  used	  where	  the	  homologous	  peptide-­‐MPSE-­‐gelatine	  conjugate	  was	  added	  to	  the	  wells	   in	  column	  1	  and	  the	  heterologous	  conjugate	  (peptide-­‐CC-­‐gelatine)	   in	   column	   7.	   	   The	   control	   antibody	   was	   added	   to	   wells	   A1-­‐A12	   and	  serially	  diluted	  downwards.	  	  The	   objective	   of	   this	   key	   experiment	  was	   to	   demonstrate	   the	   cross	   reactivity	   of	  homologous	   (peptide-­‐MPSE-­‐gelatine)	   and	   heterologous	   (peptide-­‐CC-­‐gelatine)	  conjugates	  with	  a	  control	  antiserum.	   	  The	  control	  polyclonal	  antibody	  was	  raised	  in	  sheep	  against	  a	  control	  peptide,	  which	  was	  coupled	  to	  KLH	  via	  the	  MPSE	  linker	  arm	  using	  the	  same	  chemistry	  as	  mentioned	  in	  4.2.2.	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  In	  figure	  4.8,	  the	  homologous	  conjugate	  showed	  a	  higher	  response	  when	  compared	  to	  the	  heterologous	  conjugate	  after	  titration	  against	  the	  control	  antibody.	   	  This	  is	  because	  antibody	  was	  raised	  against	  the	  control	  immunogen,	  which	  contained	  the	  same	   linker	   arm	   as	   the	   homologous	   conjugate.	   	   As	   explained	   previously,	   the	  antisera	  generated	  contain	  not	  only	  antibodies	  that	  are	  specific	  to	  the	  peptide,	  but	  also	  antibodies	  to	  the	  linker	  arm	  as	  well	  as	  the	  carrier	  molecule.	  	  	  	  
	  	  
Figure 4.8.  The dilution response curves of the homologous (peptide-MPSE-gelatine) and 
heterologous (peptide-CC-gelatine) conjugates of the titration against a control antiserum, which 
contained the same MPSE linker arm to KLH.  Error bars represent standard error and sample 
was assayed three times.  	  It	  is	  evident	  from	  figure	  4.8	  that	  the	  control	  antibody	  displays	  considerable	  activity	  towards	  the	  linker	  arm	  as	  well	  as	  the	  carrier	  protein	  in	  the	  control	  antiserum.	  	  The	  same	  response	  was	  observed	  for	  the	  anti-­‐CTGF	  peptide	  serum	  shown	  in	  fig.	  4.7.	  	  It	  can	  be	  concluded	  that	  using	  the	  heterologous	  gelatine	  conjugate	  in	  further	  ELISA	  is	  essential.	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4.2.9	   Comparison	   of	   the	   binding	   activity	   of	   the	   anti-­‐peptide	  
antiserum	  against	  the	  peptide-­‐CC-­‐gelatine	  and	  control	  cysteine-­‐
CC-­‐gelatine	  	  The	   cysteine-­‐CC-­‐gelatine	   control	   was	   used	   to	   show	   that	   the	   antisera	   contained	  anti-­‐peptide	   antibodies	   that	   were	   specific	   peptide	   sequence	   synthesised.	   	   The	  steps	  of	  the	  assay	  are	  as	  described	  above.	  	  	  	  It	   is	   of	   utmost	   importance	   when	   raising	   a	   polyclonal	   antibody	   that	   it	   would	   be	  specific	   to	  only	   the	   target	  molecule.	   	   If	   specificity	   is	   compromised,	   such	  as	  when	  the	  immunogen	  is	  impure,	  then	  this	  will	  result	  in	  non-­‐specific	  binding,	  which	  will	  present	  itself	  as	  artificially	  high	  readings	  in	  immunoassays.	  	  	  	  A	   simple	   test	   to	   determine	   that	   the	   anti-­‐peptide	   antiserum	   contained	   antibodies	  that	  are	  specific	  to	  the	  peptide	  was	  to	  couple	  cysteine	  with	  CC-­‐gelatine,	  and	  titrate	  the	  conjugate	  against	  the	  anti-­‐peptide	  antibody.	  	  	  	  
	  
Figure 4.9.  The dilution response curves of the peptide-CC-gelatine and cysteine-CC-gelatine 
conjugate when titrated against the anti-peptide antibody.  The antibody sample was obtained 
from the 32-week bleed.  Error bars represent standard error and sample was assayed three 
times.  
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  Figure	  4.9	  shows	  that	  there	  is	  very	  little	  response	  of	  the	  anti-­‐peptide	  antibody	  to	  the	   cysteine-­‐CC-­‐gelatine	   conjugate	   compared	   to	   that	   of	   the	   peptide-­‐CC-­‐gelatine	  conjugate.	  	  	  	  The	  peptide-­‐CC-­‐gelatine	  conjugate	  consist	  of	  the	  same	  linker	  arm	  (CC)	  and	  carrier	  molecule	   (gelatine)	   as	   the	   peptide-­‐CC-­‐gelatine	   conjugate.	   	   The	   reason	   for	   using	  cysteine	  as	  a	  control	  is	  because	  the	  peptide	  fragment	  of	  CTGF	  that	  was	  synthesized	  contained	   a	   cysteine	   residue	   on	   the	   C-­‐terminal.	   	   Therefore,	   this	   shows	   that	   the	  anti-­‐peptide	  antibodies	  are	  specific	  to	  only	  the	  synthesised	  CTGF	  peptide.	  	  	  	  
Discussion	  	  The	  overall	  aim	  of	  this	  study	  was	  to	  develop	  a	  specific	  assay	  for	  the	  isolation	  and	  purification	   of	   CTGF	   from	   human	   fluids.	   	   This	   was	   to	   be	   achieved	   by	   isolating	  naturally	   occurring	   CTGF	   from	   human	   biological	   fluids,	   and	   raise	   a	   specific	  antibody	   to	   this	   protein.	   	   The	   key	   point	   is	   that	   to	   date,	   CTGF	   has	   not	   been	  successfully	  isolated	  or	  purified	  from	  clinical	  samples,	  and	  there	  are	  no	  antibodies	  to	   the	  native	   form	  of	   CTGF	   available	   commercially.	   	   To	  overcome	   this,	   a	   peptide	  sequence	   present	   in	   CTGF	   was	   synthesised	   and	   an	   antibody	   was	   raised	   to	   this	  peptide.	  	  	  	  CTGF	   contains	  349	  amino	  acids,	   of	  which	   there	  are	  38	   cysteine	   residues.	   	   It	  was	  imperative	  that	  there	  were	  no	  cysteine	  residues	  in	  the	  peptide	  sequence	  selected.	  	  This	   is	   because	   the	   cysteine	  may	   form	   disulphide	   bridges	  with	   other	  molecules.	  	  The	  only	  exception	  was	  that	  when	  the	  peptide	  was	  synthesised,	  a	  cysteine	  residue	  was	  added	  to	   the	  C-­‐terminus	  of	   the	  peptide	  sequence.	   	  This	  addition	  allowed	  the	  conjugation	  of	  the	  peptide	  to	  carrier	  proteins	  such	  as	  KLH	  and	  gelatine.	  	  	  	  When	  generating	   antibodies	   in	   the	  development	  of	   immunoassays,	   it	   is	   essential	  that	   the	   antibody	   is	   specific	   only	   to	   the	   antigen	   in	   question.	   	   The	   homologous	  conjugate	   (peptide-­‐MPSE-­‐gelatine)	   used	   in	   this	   set	   of	   experiments	   demonstrates	  the	  presence	  of	  antibodies	  that	  are	  specific	  to	  other	  parts	  of	  the	  conjugate.	  	  Falsely	  high	   readings	   will	   result	   if	   the	   homologous	   conjugate	   was	   then	   used	   in	   further	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immunoassays.	  	  This	  is	  further	  shown	  when	  a	  control	  antibody	  (anti-­‐PEVKEK)	  was	  titrated	   against	   the	   heterologous	   and	   homologous	   conjugates.	   	   The	   PEVKEK	  sequence	  was	   synthesised	  and	  coupled	   to	  KLH	  via	   the	  MPSE	   linker	  arm,	  and	   the	  anti-­‐PEVKEK	  antibody	  was	  raised	  in	  exactly	  the	  same	  way	  as	  the	  peptide	  antibody.	  	  The	  ELISA	  result	  of	  the	  homologous	  conjugate	  showed	  a	  typical	  dilution	  response	  curve	   even	   though	   the	   anti-­‐PEVKEK	   antibody	   is	   completely	   unrelated	   to	   the	  peptide.	   	  By	   comparison,	   the	  ELISA	   result	   of	   the	  heterologous	   conjugate	   showed	  very	   little	   response	   when	   titrated	   against	   the	   anti-­‐PEVKEK	   antibody.	   	   The	   only	  difference,	   chemically,	   between	   these	   two	   conjugates	   is	   the	   linker	   arm,	  which	   is	  shown	  to	  cause	  such	  a	  large	  and	  significant	  difference	  in	  the	  readings.	  	  This	  is	  the	  reason	   why	   peptide-­‐gelatine	   conjugates	   with	   different	   linker	   arms	   were	  synthesised	  so	  as	  to	  optimise	  the	  response	  obtained	  by	  the	  peptide	  antibody.	  	  	  	  The	   specificity	   of	   the	   anti-­‐peptide	   antibody	   was	   assessed	   by	   titrating	   the	   anti-­‐peptide	   antibody	   against	   the	   peptide-­‐CC	   conjugate	   and	   a	   cysteine-­‐CC-­‐gelatine	  conjugate.	   	   This	   determines	   whether	   the	   anti-­‐peptide	   antibody	   recognises	   the	  cysteine	   part	   of	   the	   peptide.	   	   The	   response	   of	   the	   peptide-­‐CC-­‐gelatine	   conjugate	  showed	  a	  typical	  antibody	  dilution	  response	  curve	  when	  titrated	  against	  the	  anti-­‐peptide	  antibody.	  	  There	  was	  no	  response	  when	  the	  cysteine-­‐CC-­‐gelatine	  conjugate	  was	  titrated	  against	  the	  anti-­‐peptide	  antibody.	  	  This	  indicates	  that	  the	  anti-­‐peptide	  antibody	   is	  specific	   to	  only	   the	  synthesised	  peptide,	  which	  will	   result	   in	  accurate	  and	  reliable	  assays.	  	  	  Conclusion:	  It	  was	  demonstrated	  using	  several	  different	  tests	  that	  the	  anti-­‐peptide	  antibody	  is	  specific	  to	  the	  synthesised	  peptide.	  	  	  	  The	   availability	   of	   this	   specific	   antibody	   enabled	   tools	   to	   be	   developed	   for	   the	  study	   of	   CTGF.	   	   These	   would	   include	   affinity	   purification	   and	   development	   of	  immunoassays.	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  5	  
Further	  development	  of	  a	  specific	  assay	  for	  CTGF	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5.1	  Introduction	  	  There	  are	  an	  abundance	  of	  commercial	  kits	  for	  the	  detection	  of	  CTGF	  in	  biological	  fluids.	   	  Unfortunately,	  these	  are	  extremely	  expensive	  and	  utilise	  antibodies	  raised	  against	   the	   recombinant	  CTGF.	   	   It	   should	  be	  noted	   that	   little	   is	  known	  about	   the	  background	  and	  origin	  of	  the	  antibodies	  in	  these	  kits.	  	  Antibodies	  to	  CTGF	  that	  are	  commercially	  available	  are	  raised	  against	  only	  a	  partial	  length	  of	  the	  recombinant	  CTGF	   protein,	   where	   the	   main	   use	   of	   the	   antibody	   is	   to	   detect	   the	   biologically	  active	  part	  of	  the	  protein.	  	  To	  date,	  there	  are	  no	  commercially	  available	  antibodies	  that	   are	   raised	   against	   native	   CTGF	   protein.	   	   In	   this	   chapter,	   several	   different	  technologies	  were	  investigated	  and	  adapted	  in	  order	  to	  develop	  a	  specific	  assay	  for	  CTGF	  from	  biological	  sources.	  	  	  	  Horseradish	   peroxidase	   (HRP),	   an	   enzyme	   of	   approximately	   44	   kDa	   found	   in	  horseradish,	   is	  used	  widely	  in	  biochemistry	  applications,	  such	  as	  in	  immuoassays	  (Veitch	  2004).	  	  It	  is	  usually	  coupled	  to	  an	  antibody	  and	  used	  as	  a	  detection	  method	  for	  in	  ELISAs	  and	  Western	  blots.	  	  HRP	  is	  a	  catalyst	  for	  the	  reaction	  of	  chromogenic	  substrates,	  such	  as	  TMB	  and	  ABTS,	  with	  an	  oxidising	  reagent	  (hydrogen	  peroxide)	  to	   produce	   a	   signal.	   	   The	   signal	   can	   then	   be	   detected	   and	   quantified	   by	  spectrophotometry	  (Childs	  &	  Bardsley	  1975;	  Josephy	  et	  al.	  1982).	  	  	  	  Biotin,	  also	  known	  as	  vitamin	  H,	  is	  a	  small	  molecule	  (244.31	  Da)	  that	  is	  present	  in	  small	   amounts	   in	   every	   living	   cell.	   	   Its	   function	   is	   to	   co-­‐factor	   carboxylating	  enzymes	   such	   as	   pyruvate	   carboxylase,	   which	   catalyses	   the	   formation	   of	  oxaloacetate	   through	   the	   condensation	   of	   pyruvate	   and	   CO2	   (Diamandis	   &	  Christopoulos	   1991).	   	   Avidin,	   an	   egg	   white	   protein,	   and	   streptavidin,	   a	   similar	  protein	   found	   in	   Streptomyces	   avidinii,	   have	   a	   very	   high	   affinity	   to	   biotin.	   	   The	  interaction	   between	   avidin	   and	   streptavidin	   to	   biotin	   is	   non-­‐covalent,	   and	   is	  characterised	  by	  a	   formation	  constant	  of	  1015L	  mol-­‐1,	  which	   is	  one	  of	   the	  highest	  formation	   constants	   reported	   (Green	   1975).	   	   Because	   of	   this,	   the	   biotin-­‐avidin/streptavidin	   system	   is	   widely	   used	   as	   a	   universal	   tool	   e.g.	   in	   isolation	  (affinity	   chromatography),	   localisation	   (affinity	   cytochemistry),	   assay	  amplification	  and	  diagnostics	  (immunoassays)	  (Meir	  et	  a.	  l	  1988).	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  A	   procedure	   can	   be	   developed	   where	   an	   antibody	   to	   CTGF	   is	   used	   for	   the	  recognition	  of	  this	  protein	  in	  human	  biological	  samples	  by	  utilising	  the	  principles	  of	   biotin-­‐avidin	   interaction,	   affinity	   chromatography	   and	   HRP	   as	   a	   detection	  system.	   	   This	   would	   eliminate	   the	   need	   to	   use	   anti-­‐sheep	   IgG	   peroxidase	   as	   a	  second	  antibody,	   therefore	  eradicate	   the	  detection	  of	   IgG	   that	   is	  present	   in	   these	  samples.	  	  	  	  Cuatrecasas	   et	   al.	   (1968)	   first	   described	   the	   procedure	   for	   affinity	  chromatography.	   	   The	   enzyme	   to	   be	   purified	  was	   passed	   through	   a	   column	   that	  contained	  a	  cross-­‐linked	  polymer	  or	  gel	  to	  which	  a	  specific	  competitive	  inhibitor	  of	  the	  enzyme	  has	  been	  covalently	  attached.	  	  Any	  protein	  without	  substantial	  affinity	  for	   the	   bound	   inhibitor	   would	   pass	   directly	   through	   the	   column.	   	   Proteins	   that	  recognise	   the	   inhibitor	   will	   be	   retained	   in	   proportion	   to	   its	   affinity	   constant.	  	  Elution	  of	  the	  bound	  enzyme	  would	  be	  achieved	  easily	  by	  changing	  conditions	  such	  as	  salt	  concentration	  or	  pH,	  or	  by	  the	  addition	  of	  another	  competitive	  inhibitor	  in	  solution.	  	  	  	  Another	   affinity	   procedure	   involves	   Protein	   G,	   which	   originates	   from	   group	   G	  streptococci	   and	   is	   a	   cell	   wall	   protein	   that	   binds	   to	   IgG.	   Agarose	   or	   sepharose	  beads	  that	  contain	  covalently	  bound	  protein	  G	  is	  widely	  used	  in	  the	  purification	  of	  IgG	  from	  serum	  samples	  (Akerström	  &	  Björck	  1986;	  Guss	  et	  al.	  1986;	  Akerstrom	  et	  al.	  1985).	  	  However,	  purification	  of	  antibodies	  by	  this	  method	  will	  only	  produce	  a	  structurally	  pure	  sample,	  meaning	  that	  the	  IgG	  purified	  using	  Protein	  G	  may	  not	  be	  specific	  to	  a	  particular	  hapten.	  	  	  Aim:	  To	  improve	  the	  ELISA	  system	  for	  CTGF	  in	  patient	  samples,	  eliminating	  the	  need	  for	  anti-­‐sheep	  IgG	  peroxidase	  as	  a	  second	  antibody.	  	  Objective:	  	  	  The	  sensitivity	  was	  enhanced	  through	  the	  development	  of	  biotin	  antibodies,	  which	  were	   affinity	   purified	   and	   coupled	   to	   horseradish	   peroxidase,	   and	   a	   biotinylated	  anti-­‐peptide	  antibody.	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5.2	  Results	  and	  discussion	  	  
5.2.1	   Preparation	   of	   gelatine-­‐biotin	   conjugate	   for	   the	   solid-­‐
phase	  ELISA	  	  Biotin	   is	   a	   small	   molecule,	   and	   does	   not	   readily	   adsorb	   onto	   microtitre	   plates.	  	  	  Biotin-­‐gelatine	   conjugate	   can	   be	   used	   as	   a	   plate	   coating	   antigen	   in	   ELISAs	   by	  coupling	  biotin	   to	  a	   larger	  carrier	  protein	  such	  as	  gelatine.	   	   In	   the	  present	  study,	  biotin	  was	  activated	  using	  the	  mixed	  anhydride	  method	  previously	  described	  (Lau	  et	  al.	  1980;	  Gendloff	  et	  al.	  1986).	  	  This	  was	  performed	  so	  as	  to	  enable	  biotin	  to	  be	  coupled	  to	  gelatine.	  	  A	  5	  mg	  ml-­‐1	  gelatine	  (bloom	  150)	  solution	  was	  prepared	  in	  50	  mM	  sodium	  bicarbonate	  and	  20	  %	  (v/v)	  DMF.	  	  The	  solution	  was	  heated	  up	  to	  50	  °C	  to	  ensure	  that	  the	  gelatine	  was	  completely	  dissolved.	  	  Biotin	  (10	  mg)	  was	  dissolved	  in	   0.5	  ml	   of	   DMF.	   	   Pyridine	   (0.5	  ml)	  was	   added	   to	   the	   solution,	   followed	   by	   the	  sequential	   addition	   of	   tributylamine	   (75	   µl)	   and	   isobutyl	   chloroformate	   (30	   µl),	  and	  allowed	  to	  react	  for	  7	  min.	  	  The	  activated	  biotin	  solution	  (50	  µl)	  was	  added	  to	  the	   gelatine	   solution	   (10	   ml)	   every	   3	   min	   while	   stirring	   rapidly	   on	   ice.	   	   The	  reaction	  solution	  was	  monitored	  for	  cloudiness	  and	  the	  addition	  of	  activated	  biotin	  was	   stopped	   when	   cloudiness	   was	   observed	   (~150	   µl).	   	   The	   solution	   was	   left	  mixing	  in	  the	  fume	  cupboard	  for	  2	  h.	   	  The	  conjugate	  was	  dialysed	  in	  2	   litre	  of	  50	  mM	   sodium	   bicarbonate,	   5	   g	   activated	   charcoal	   solution	   overnight	   at	   room	  temperature.	  	  The	  conjugates	  were	  then	  recovered	  and	  stored	  in	  1	  ml	  aliquots	  at	  -­‐20	   °C	   until	   further	   required.	   	   An	   important	   feature	   in	   the	   development	   of	   this	  research	  was	  that	  various	  linker	  arms	  were	  investigated	  and	  the	  mixed	  anhydride	  method	  was	  found	  to	  be	  the	  most	  successful.	  
 
5.2.2	  Preparation	  of	  the	  immunoaffinity	  gel	  	  
Coupling	   of	   biotin	   to	   dipropylenetriamine	   (DPTA)	   using	   the	   mixed	  
anhydride	  method	  	  Biotin	  was	  coupled	  Sepharose	  4B	  via	  diproplyenetriamine	  (DPTA)	  using	  the	  mixed	  anhydride	   method.	   	   DPTA	   was	   selected	   out	   of	   several	   other	   linker	   arms	   e.g.	  
	   90	  
diethyenetriamine	   (DETA)	   and	   cyanuric	   chloride	   (CC)	   as	   it	   most	   efficiently	  presented	  biotin	  to	  the	  anti-­‐biotin	  antibody	  during	  the	  affinity	  purification	  process.	  	  DPTA	  (42	  µl)	  and	  de-­‐ionised	  water	  (200	  µl)	  was	  added	  to	  THF	  (15	  ml)	  and	  left	  to	  stir	  on	  ice.	  	  	  	  The	  following	  reaction	  was	  carried	  out	  as	  described	  in	  the	  optimised	  protocol	  for	  the	  mixed	  anhydride	  method	  modified	  from	  5.2.1,	  except	  using	  70	  mg	  of	  biotin,	  2	  ml	  DMF,	  2	  ml	  pyridine,	  100	  µl	  tributylamine	  and	  40	  µl	  isobutyl	  chloroformate.	  	  	  
 
Coupling	  of	  biotin-­‐DPTA	  to	  CNBr-­‐activated	  Sepharose-­‐4B	  	  The	  prepared	  biotin-­‐DPTA	  was	  coupled	  to	  CNBr-­‐activated	  Sepharose	  4B	  beads	  as	  follows.	   	  The	  beads	  (5	  g)	  were	  allowed	  to	  swell	   in	  100	  ml	  of	   ice-­‐cold	  10	  mM	  HCl	  according	   to	   manufacturer’s	   instructions	   (Kohn	   et	   al.	   1982;	   March	   et	   al.	   1974;	  Axen	  et	  al.	  1967).	  	  The	  swollen	  beads	  were	  then	  washed	  (in	  a	  sintered	  glass	  funnel)	  with	  200	  ml	  cold	  de-­‐ionised	  water	  and	  10	  ml	  cold	  conjugation	  buffer.	  	  The	  gel	  was	  immediately	  transferred	  as	  a	  ‘wet	  cake’	  to	  the	  biotin-­‐DPTA	  solution	  and	  allowed	  to	  mix	  for	  16	  h	  at	  4	  °C.	  	  Following	  mixing,	  the	  gel	  was	  washed,	  sequentially,	  with	  50	  %	  (v/v)	  methanol	   in	   de-­‐ionised	  water,	   1	   litre	   de-­‐ionised	  water,	   1	   litre	   1	  %	   sodium	  bicarbonate	   buffer,	   1	   litre	   de-­‐ionised	   water,	   20	   ml	   1	   %	   elution	   solution	   (three	  times,	  mixing	  for	  5	  min	  each	  time)	  and	  1	  litre	  de-­‐ionised	  water.	  	  The	  gel	  was	  stored	  in	   50	  %	   (v/v)	   methanol	   in	   de-­‐ionised	   water	   until	   required.	   	   A	   schematic	   of	   the	  coupling	  steps	  is	  shown	  in	  figure	  5.1.	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Figure 5.1 Conjugation of biotin-DPTA to cyanogen bromide (CNBr)-activated Sepharose 4B for 
the immunoaffinity purification of biotin antibody.  
 
5.2.3	  Immunoaffinity	  purification	  of	  biotin	  antiserum	  	  Biotin	   antiserum,	   which	   was	   raised	   previously,	   was	   first	   treated	   with	   activated	  charcoal	  to	  remove	  impurities	  present	  in	  the	  serum.	  	  This	  step	  was	  carried	  out	  to	  facilitate	  and	  improve	  the	  efficiency	  of	  the	  actual	  affinity	  purification	  process.	  	  The	  biotin	  antiserum	  (25	  ml)	  was	  diluted	   in	  125	  ml	  of	  50	  mM	  sodium	  phosphate,	  pH	  7.4.	   	   This	   was	   followed	   by	   the	   addition	   of	   0.4	   %	   activated	   charcoal	   (Hanson	   &	  Ballard	   1968;	   Chen	   1967).	   	   The	   solution	  was	  mixed	   on	   ice	   for	   2	   h	   then	   filtered	  through	  a	  Buchner	  funnel	  containing	  three	  layers	  of	  Whatman	  Grade	  3	  filter	  paper.	  	  The	  resultant	  clear	  solution	  (1	  ml	  sample)	  was	  used	  for	  further	  analysis.	  	  	  	  The	  antibody	  binding	  and	  elution	  steps	  were	  modified	  from	  a	  method	  previously	  described	  (Griffith	  &	  Abuknesha	  2005).	  	  The	  treated	  biotin	  serum	  was	  added	  to	  the	  biotin-­‐Sepharose	   4B	   affinity	   gel	   and	   allowed	   to	   mix	   by	   rolling	   at	   a	   slow	   speed	  overnight	   at	   4	   °C	   on	   a	   roller.	   	   The	  mixture	  was	   filtered	   through	   a	   sintered	   glass	  funnel,	  under	  gentle	  vacuum,	  and	  the	  flow-­‐through	  solution	  was	  collected	  and	  kept	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on	  ice.	  	  Care	  was	  taken	  not	  to	  allow	  the	  gel	  to	  dry	  out	  or	  crack	  when	  filtering.	  	  The	  elution	  profile	  was	  monitored	  at	  280	  nm.	  	  The	  gel	  was	  washed	  with	  50	  ml	  column	  washing	   buffer	   (0.5	   M	   sodium	   chloride	   and	   50	   mM	   sodium	   bicarbonate).	   	   The	  washing	  step	  was	   repeated	  until	   the	  absorbance	  value	   reached	  0.2.	   	  The	  gel	  was	  then	  washed	   three	   times	  with	   ice-­‐cold	  de-­‐ionised	  water.	   	   Solution	  A	   (20ml)	  was	  added	   to	   the	   gel	   and	  allowed	   to	  mix	   for	  5	  min.	   	  The	   filtrate	  was	   collected	   into	   a	  flask	  containing	  2	  ml	  of	  collecting	  solution.	  	  This	  was	  repeated	  until	  the	  absorbance	  value	  reached	  0.2.	  	  The	  elution	  steps	  were	  repeated	  with	  solutions	  B,	  C	  and	  D	  and	  200	  µl	   of	  neutralising	   solution	   (1	  %	  v/v	  N.N-­‐bis(3-­‐aminopropyl)ethylenediamine	  in	   50	   mM	   sodium	   phosphate,	   pH	   7.4)	   was	   added	   to	   the	   eluted	   fractions.	   	   The	  collected	  fractions	  were	  then	  dialysed	  against	  4	   litre	  of	  pre-­‐cooled	  dialysis	  buffer	  (20	  mM	  sodium	  phosphate,	   20	  mM	  sodium	   chloride)	   containing	  5	   g	   of	   activated	  charcoal.	  	  The	  fractions	  were	  recovered	  and	  the	  volume	  reduced	  using	  an	  Amicon	  stirred	  cell	  (model	  8400).	  	  The	  concentrated	  antibody	  samples	  were	  then	  dialysed	  against	  2	  litre	  of	  ion-­‐exchange	  buffer	  (50	  mM	  sodium	  phosphate,	  100	  mM	  sodium	  chloride,	  pH	  6.9)	  overnight	  at	  4	  °C.	  	  	  	  DEAE	  ion-­‐exchange	  was	  performed	  on	  the	  affinity	  purified	  anti-­‐biotin	  antibody	  to	  further	  remove	  any	  impurities.	  	  As	  the	  Sephadex	  A-­‐50	  gel	  is	  a	  weak	  anion,	  it	  would	  attract	   positively	   charged	   impurities	   whilst	   allowing	   the	   anti-­‐biotin	   antibody	   to	  pass	   through	   the	   matrix.	   	   Sephadex	   A-­‐50	   gel	   was	   swollen	   according	   to	   the	  manufacturer’s	  instructions	  (G	  E	  Lifesciences).	  	  A	  column	  was	  prepared	  by	  packing	  3	   ml	   of	   the	   swollen	   gel	   into	   a	   10	   ml	   glass	   syringe.	   	   The	   column	   was	   then	  equilibrated	  with	  15	  ml	  of	  50	  mM	  sodium	  phosphate,	  100	  mM	  sodium	  chloride,	  pH	  6.9	  buffer.	   	  The	  affinity-­‐purified	  anti-­‐biotin	  antibody	  sample	  was	  passed	   through	  the	  column,	  collected	  and	  dialysed	  against	  2	  litre	  of	  50	  mM	  sodium	  phosphate,	  100	  mM	  sodium	  chloride	  pH	  7.4	  buffer	  overnight	  at	  4	  °C.	  	  	  	  As	   a	   final	   treatment,	   the	   purified	   anti-­‐biotin	   antibody	   was	   passed	   through	   a	  Protein	  G	  column.	  	  This	  step	  was	  carried	  out	  to	  ensure	  that	  the	  resulting	  anti-­‐biotin	  antibody	  was	  specific	  and	  contained	  purely	  the	  IgG	  fraction.	  	  Protein	  G	  beads	  were	  packed	   into	   a	   glass	   column	   and	   prepared	   according	   to	   the	   manufacturer’s	  instructions	  (Sigma-­‐Aldrich).	  	  The	  dialysed	  antibody	  samples	  were	  passed	  through	  the	   column	   and	   eluted	   according	   to	   the	  manufacturer’s	   protocol.	   	   The	   antibody	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sample	   (obtained	   from	   the	   second	  peak)	  was	  dialysed	   again	   in	  2	   litre	  of	   sodium	  phosphate	  buffer	  overnight	  at	  4	  °C.	  	  The	  dialysed	  antibody	  was	  then	  stored	  under	  an	  equal	  volume	  of	  saturated	  ammonium	  sulphate	  at	  4	  °C	  until	  further	  use.	  	  	  	  
5.2.4	  Monitoring	  the	  purification	  steps	  	  
Assessment	  of	  antibody	  uptake	  by	  the	  affinity	  gel	  by	  ELISA	  	  The	  binding	  of	  the	  antibody	  to	  the	  affinity	  gel	  was	  assessed	  by	  the	  measurement	  of	  the	  antibody	  activity	  in	  the	  starting	  antibody	  solution,	  and	  in	  the	  supernatant	  after	  mixing	  the	  serum	  with	  the	  gel.	  	  This	  ’before-­‐and-­‐after’	  titration	  of	  antibody	  activity	  provides	  a	  valuable	  indicator	  of	  the	  efficiency	  of	  the	  uptake	  of	  antibody	  by	  the	  gel.	  	  	  	  A	   microtitre	   plate	   was	   coated	   with	   gelatine-­‐biotin	   conjugate	   as	   described	  previously	  in	  chapter	  2	  for	  a	  double	  ‘checkerboard’	  titration	  assay.	  	  The	  plate	  was	  blocked	   and	   150	   µl	   of	   antibody	   buffer	   was	   added	   to	   each	   well.	   	   The	   charcoal-­‐treated	   serum	   and	   the	   supernatant	   were	   diluted	   in	   antibody	   buffer	   to	   1:250.	  	  Charcoal-­‐treated	   serum	   (50	   µl)	   was	   added	   to	   wells	   A1-­‐A6,	   and	   50	   µl	   of	   the	  supernatant	   was	   added	   to	   wells	   A7-­‐A12.	   	   The	   solutions	   were	   serially	   diluted	  downwards	   and	   the	   microtitre	   plate	   was	   developed	   as	   described	   previously	  chapter	  2.	  	  	  	  The	  solid	  phase	  ELISA	  was	  used	  to	  monitor	  the	  degree	  of	  antibody	  absorption	  onto	  the	  affinity	  gel.	   	  The	  test	  was	  carried	  out	  prior	  to	  embarking	  on	  the	  elution	  steps.	  	  This	  was	  to	  determine	  whether	  sufficient	  antibody	  had	  adsorbed	  onto	  the	  affinity	  gel.	  	  	  	  The	  level	  of	  uptake	  of	  the	  anti-­‐biotin	  antibody	  fraction	  from	  the	  antiserum	  is	  one	  of	  the	  critical	  factors	  in	  the	  purification	  process	  as	  it	  determines	  the	  efficiency	  of	  the	  overall	  process.	  	  The	  level	  of	  uptake	  is	  dependent	  on	  the	  capacity	  of	  the	  affinity	  gel.	  	  This	  is	  in	  turn	  dependent	  on	  the	  efficiency	  of	  the	  chemistry	  for	  the	  coupling	  steps	  described	  in	  5.2.2	  used	  to	  attach	  the	  ligand	  to	  the	  solid	  phase	  Sepharose	  4B	  beads.	  	  Different	  linker	  arms	  can	  be	  used	  to	  couple	  biotin	  to	  the	  Sepharose	  4B	  beads.	  	  The	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length	   of	   the	   linker	   arm	   will	   influence	   the	   efficiency	   by	   which	   the	   ligand	   is	  presented	  to	  the	  antibody.	  	  	  	  Two	  antibody	  dilution	  curves	  are	  shown	  in	  figure	  5.2	  a.	   	   	  The	  upper	  curve	  shows	  the	  results	  when	  the	  ELISA	  was	  carried	  out	  before	  the	  serum	  was	  treated	  with	  the	  affinity	  gel.	  	  The	  lower	  curve	  shows	  the	  ELISA	  results	  after	  the	  serum	  was	  treated	  with	  the	  affinity	  gel.	  	  Figure	  5.2	  b	  demonstrates	  that	  the	  level	  of	  absorption	  of	  the	  anti-­‐biotin	   antibodies	   onto	   the	   biotin-­‐DPTA-­‐Sepharose	   4B	   gel	   was	   substantial.	  	  Optimum	  antibody	  titre	   is	  defined	  by	   the	  antibody	  concentration	  or	  dilution	  that	  gives	  the	  strongest	  reaction	  for	  positive	  tests	  with	  minimum	  background	  reaction.	  	  The	   optimum	   antibody	   titre	   before	   mixing	   with	   the	   affinity	   gel	   was	   1:55,000	  (figure	   5.2	  a).	   	   The	   antibody	   titre	   after	  mixing	  with	   the	   affinity	   gel	  was	   1:5200.	  	  Comparison	   of	   these	   two	   values	   imply	   that	   approximately	   10	   %	   of	   antibody	  activity	  found	  in	  the	  starting	  solution	  was	  detected	  in	  the	  solution	  after	  treatment	  with	   the	  affinity	  gel.	   	  This	  demonstrates	   clearly	   that	   the	  chemistry	  used	   to	  make	  the	  gel	  worked.	  	  






Figure 5.2.  a:  An example of ELISA dilution response curves of anti-biotin antibody using 
antibody samples before and after mixing with the affinity gel.  b:  A photograph of the actual 
ELISA microtitre plate.  The left hand side of the microtitre plate showed titrations of antiserum 
before mixing with the affinity gel.  The right hand side of the microtitre plate showed titrations of 
antiserum after mixing with the affinity gel.   
 It	  should	  be	  noted	  that	  the	  choice	  of	  method	  of	  preparation	  of	  the	  affinity	  gel	  was	  a	  significant	  factor	  in	  achieving	  a	  high	  capacity	  affinity	  gel.	  	  In	  fact,	  the	  strategy	  taken	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in	  the	  methods	  described	  in	  5.2.2	  where	  the	  ligand	  was	  first	  coupled	  to	  the	  linker	  arm,	   and	   without	   laborious	   processing	   steps,	   the	   ligand-­‐arm	   preparation	   then	  coupled	  to	  the	  activated	  Sepharose,	  was	  a	  key	  factor	  in	  providing	  the	  high	  capacity	  affinity	  gel.	  	  	  Anti-­‐biotin	   antibodies	   had	   to	   be	   functionally	   pure	   before	   labelling	   with	   HRP	  (Oellerich	   1984;	   Porstmann	   &	   Kiessig	   1992).	   	   This	   required	   the	   anti-­‐biotin	  antibodies	   from	   the	   antiserum	   to	   be	   affinity	   purified.	   	   A	   large	   scale	   and	   highly	  efficient	  affinity	  purification	  system	  had	  to	  be	  set	  up	  in	  order	  to	  obtain	  preparative	  amounts	   of	   pure	   antibody.	   	   The	   method	   used	   for	   affinity	   purifying	   anti-­‐biotin	  antibodies	   was	   adapted	   from	   Griffith	   &	   Abuknesha	   (2005).	   	   The	   success	   of	   the	  purification	  process	  is	  infinitely	  dependant	  on	  the	  uptake	  of	  anti-­‐biotin	  antibodies	  by	   the	   biotin-­‐DPTA-­‐Sepharose	   4B	   gel.	   	   This	   is	   in	   turn	   dependant	   upon	   the	  chemistry	  used	  to	  couple	  biotin	  to	  Sepharose	  4B.	  	  Biotin	  was	  first	  coupled	  to	  DPTA	  using	   the	  mixed	   anhydride	  method	   (Gendloff	   et	   al.	   1986;	   Anderson	   et	   al.	   1967)	  before	  conjugation	  to	  Sepharose	  4B.	  	  The	  attachment	  of	  biotin	  to	  Sepharose	  4B	  was	  carried	   out	   using	   excess	   biotin-­‐DPTA.	   	   This	  will	   ensure	   the	   high	   capacity	   of	   the	  affinity	  gel	  to	  anti-­‐biotin	  antibodies.	  	  DPTA	  was	  selected	  and	  used	  as	  a	  linker	  arm	  because	   of	   its	   length,	   which	   allowed	   better	   accessibility	   of	   the	   anti-­‐biotin	  antibodies	  to	  biotin.	   	  By	  taking	  these	  factors	  into	  consideration,	  there	  is	  about	  90	  %	  uptake	  of	  anti-­‐biotin	  antibody	  by	  the	  biotin-­‐DPTA-­‐Sepharose	  4B	  gel	  as	  seen	  in	  figure	   5.1	   a.	   	   This	   makes	   the	   biotin-­‐DPTA-­‐Sepharose	   4B	   affinity	   gel	   extremely	  efficient	   for	   the	   purification	   of	   anti-­‐biotin	   antibodies.	   	   Furthermore,	   this	   means	  that	  preparative	  quantities	  of	  anti-­‐biotin	  antibody	  can	  be	  purified	  each	  time.	  	  	  	  
Monitoring	   of	   elution	   of	   bound	   anti-­‐biotin	   antibody	   by	   ELISA	   and	   SDS-­‐
PAGE	  	  The	   elution	   of	   the	   bound	   anti-­‐biotin	   antibody	   was	   closely	   monitored	   by	   ELISA.	  	  This	  gives	  a	  good	  indication	  of	  the	  purity	  of	  the	  eluted	  fractions	  as	  well	  as	  showing	  the	  points	  at	  which	   the	  anti-­‐biotin	  antibodies	  of	  different	  affinities	  are	  eluted.	   	  A	  microtitre	   plate	   was	   coated	   as	   described	   in	   chapter	   2	   with	   the	   gelatine-­‐biotin	  conjugate	  at	  a	  fixed	  dilution	  (1:2000	  in	  coating	  buffer)	   in	  all	  the	  wells.	   	  The	  plate	  was	  blocked	  and	  150	  µl	  of	  antibody	  buffer	  was	  added	  to	  all	  the	  wells	  of	  the	  plate.	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Fractions	  (pre-­‐diluted	  to	  1:40)	  from	  the	  affinity	  purification	  process	  were	  added	  to	  the	   top	   row	   of	   the	   microtitre	   plate	   (50	   µl	   per	   well).	   	   The	   fractions	   were	   then	  serially	  diluted	  (1:4)	  downwards.	   	  The	  plate	  was	  allowed	  to	  incubate	  for	  1	  h	  on	  a	  shaker	   at	   room	   temperature.	   	   The	   microtitre	   plate	   was	   then	   developed	   as	  described	  previously	  in	  chapter	  2.	  	  	  	  The	   eluted	   antibody	   samples	   were	   analyzed	   further	   by	   SDS-­‐PAGE.	   	   An	   8-­‐12	   %	  gradient	   gel	   (Invitrogen)	   was	   used.	   	   The	   samples	   were	   separated	   using	   a	  Invitrogen	   X-­‐Cell	   SureLock	   mini-­‐cell	   system	   according	   to	   the	   manufacturer’s	  instructions.	  	  	  Recovery	  of	  bound	  anti-­‐biotin	  antibodies	  from	  the	  affinity	  column	  is	  a	  critical	  step	  in	  the	  affinity	  purification	  process.	  	  Bound	  antibodies	  were	  exposed	  to	  the	  different	  denaturing	  solutions	  (figure	  5.3)	  for	  a	  minimum	  period	  of	  time.	  	  The	  elution	  profile	  was	  sharp	  to	  avoid	  excessive	  dilution	  of	  the	  recovered	  material	  (P	  Cuatrecasas	  et	  al.	  1968).	   	  A	  chromatogram	  of	   the	  elution	  profile	  of	  anti-­‐biotin	  antibodies	  (figure	  5.3)	  is	  shown	  where	  the	  absorbance	  at	  280	  nm	  indicates	  protein	  concentration	  and	  absorbance	   at	   405	   nm	   indicate	   antibody	   activity.	   	   The	   antibody	   activity	   was	  measured	  in	  eluted	  fractions	  diluted	  to	  1:160,000	  with	  50	  mM	  sodium	  phosphate,	  100	  mM	  sodium	  chloride,	  pH	  7.4.	  	  	  The	   propionic	   acid/acetonitrile	  mixture	   used	   in	   the	   study	   proved	   to	   be	   an	   ideal	  elution	   mixture	   for	   recovering	   the	   anti-­‐biotin	   antibodies.	   	   Antibodies	   began	   to	  appear	  in	  the	  fractions	  as	  soon	  as	  the	  elution	  solution	  was	  applied	  (figure	  5.3,	  E1)	  and	  the	  elution	  profile	  showed	  a	  distinct	  protein	  peak	  at	  E4	  where	  the	  majority	  of	  the	  recoverable	  antibody	  was	  present.	  	  The	  chromatogram	  shows	  the	  response	  to	  the	  application	  of	  the	  elution	  solution	  where	  immediate	  emergence	  of	  antibodies	  is	  seen	  in	  E1,	  and	  the	  rapid	  appearance	  of	  the	  main	  peak	  (E1	  to	  E8)	  where	  the	  elution	  was	   carried	  out	  using	   the	  milder	   solution	   (solution	  A	   -­‐	  20%	  acetonitrile	   and	  1%	  propionic	  acid).	  	  A	   second	   peak	   of	   eluted	   antibodies	   (E18	   –	   E26)	   can	   be	   observed	   upon	   the	  subsequent	  addition	  of	   solutions	  B,	  C	  and	  D.	   	  This	   is	  attributed	   to	   the	  anti-­‐biotin	  antibody,	  which	  has	  a	  higher	  affinity	  for	  the	  biotin-­‐DTPA-­‐Sepharose	  4B	  gel.	  	  	  
	   98	  
	  When	  comparing	  antibody	  activity,	  there	  is	  significantly	  higher	  activity	  from	  E1	  –	  E10	   compared	   to	   W1	   –	   DW3.	   	   This	   indicates	   that	   very	   little	   or	   no	   anti-­‐biotin	  antibodies	  are	  present	  in	  the	  wash	  fractions	  compared	  to	  the	  eluted	  fractions.	  	  The	  high	   absorbance	   (280	   nm)	   values	   shown	   in	   W1	   –	   W4	   is	   attributed	   to	   the	   high	  levels	  of	  serum	  proteins	  e.g.	  albumin	  that	  was	  washed	  from	  the	  affinity	  gel.	  	  	  	  
	  	  
Figure 5.3.  An example of a chromatogram showing the wash and elution profiles of the 
purification of anti-biotin antibodies.  The figure is indicative of protein concentration 
(absorbance at 280 nm) and antibody activity (absorbance at 405 nm).  A, B, C and D are the 
different elution solutions applied containing 1 %, 2 %, 3% and 5 % propionic acid respectively.  
Fractions W1 – W5 represent the washing steps with wash buffer.  Fractions DW1 – DW3 
represent the washing steps with de-ionised water.  Fractions E1-E32 represent the elution 
steps using the different elution solutions.   	  Upon	  the	  application	  of	  elution	  solution	  A	  (20	  %	  acetonitrile,	  1	  %	  propionic	  acid),	  the	   majority	   of	   the	   anti-­‐biotin	   antibodies	   readily	   dissociate	   from	   the	   attached	  biotin	   (E1	   –	   E10	   in	   figure	   5.3).	   	   This	   allows	   for	   the	   anti-­‐biotin	   antibodies	   to	   be	  quickly	   dialysed	   in	   dialysis	   buffer	   (5	   mM	   sodium	   phosphate,	   10	   mM	   sodium	  chloride,	   pH	  7.4,	   0.4	  %	  activated	   charcoal),	  which	   reduces	   the	   time	  at	  which	   the	  antibodies	  are	  exposed	  to	  the	  harsh	  elution	  solution.	  	  Incubation	  of	  the	  anti-­‐biotin	  antibodies	  with	  the	  elution	  solution	  for	  long	  periods	  of	  time	  might	  compromise	  the	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structural	   integrity	   of	   the	   immunoglobulin	   due	   to	   low	  pH	   and	   the	   presence	   of	   a	  solvent.	  	  Looking	  at	  fractions	  E1	  –	  E10	  of	  the	  chromatogram	  in	  figure	  5.3,	  antibody	  activity	  (absorbance	  at	  405	  nm)	  is	  relatively	  high	  throughout.	  This	   indicates	  high	  functional	  purity	  in	  the	  anti-­‐biotin	  antibody	  fractions.	  	  	  	  
a      b 
	  	  
Figure 5.4.  a: An example of SDS-PAGE analysis of the antiserum sample (M.S) and eluted 
anti-biotin antibody samples after pooling, dialysis and ion exchange chromatography.  Lane 1 
shows the bands obtained from sample of pooled fractions (E1-E9), lane 2: (E10-E13), lane 3: 
(E14-E16), lane 4: (E17-E19), lane 5: (E20-E23), lane 6: (E24-E30), lane 7: (E31-E32).  b:  
Reduced SDS-PAGE analysis of the biotin antiserum sample (M.S) and eluted antibody sample 
(1) after pooling, dialysis and ion exchange chromatography, and (2) after Protein G column 
treatment.  	  SDS-­‐PAGE	  analysis	  of	  purified	  anti-­‐biotin	  antibody	  samples	  shown	  in	  figure	  5.4	  a	  and	  b	  provided	  evidence	  for	  the	  structural	  purity	  of	  the	  recovered	  antibody.	   	  The	  test	  confirmed	  the	  IgG	  identity	  of	  the	  purified	  antibody	  and	  showed	  that	  the	  eluted	  fractions	  contained	  a	  similar	  protein	  pattern;	  except	  for	  the	  early	  fractions	  (lane	  1	  and	  2),	  where	  minor	  amounts	  of	  high	  molecular	  weight	  protein	  appeared.	  	  Further	  treatment	   of	   antigen	   affinity-­‐purified	   antibody	   sample	   with	   Protein	   G	   column	  showed	   that	   this	   step	  would	   enhance	   the	  purity	   of	   the	  preparation	  by	   removing	  minor	   protein	   bands	   that	   were	   apparent	   prior	   to	   the	   step	   (b).	   	   The	   Protein	   G	  column-­‐cleaning	  step	  is	  recommended	  when	  the	  purified	  antibody	  is	  intended	  for	  labelling	  with	  enzymes	  or	  similar	  detectable	  signalling	  agents.	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A	  highly	  purified	  sample	  of	  anti-­‐biotin	  antibody	  is	  required	  for	  the	  conjugation	  to	  HRP.	  	  To	  further	  purify	  the	  antibody	  sample,	  the	  purified	  anti-­‐biotin	  antibody	  was	  passed	  through	  a	  DEAE	  Sephadex	  A-­‐50	  weak	  anion	  exchange	  column,	  followed	  by	  a	  Protein	  G	   column.	   	  Lane	  1	  of	   figure	  5.4	  b	   shows	  an	  affinity	  purified	  anti-­‐biotin	  antibody	   sample	   that	   was	   passed	   though	   a	   DEAE	   column.	   	   Lane	   2	   shows	   the	  purified	  anti-­‐biotin	  antibody	  sample	  that	  was	  passed	  though	  a	  DEAE	  ion-­‐exchange	  column	   as	   well	   as	   Protein	   G	   column.	   	   DEAE	   Sephadex	   A-­‐50	   is	   a	   weak	   anion	  exchanger;	  therefore	  the	  anti-­‐biotin	  antibody	  sample	  will	  pass	  through	  the	  column	  and	   collected	  while	   impurities	  will	   be	   retained	   onto	   the	   column.	   	   This	   is	   a	   very	  effective	  way	   of	   cleaning	   up	   the	   sample,	   as	   there	   is	   no	   need	   to	   increase	   the	   salt	  content	  of	  the	  buffer	  used	  to	  elute	  bound	  proteins.	  	  Protein	  G	  is	  a	  bacterial	  cell	  wall	  protein	  found	  in	  group	  C	  and	  G	  streptococcal	  bacterial	  and	  has	  an	  affinity	  for	  IgG	  (Bjorck	  &	  Kronvall	  1984).	  	  Protein	  G	  coupled	  to	  agarose	  is	  widely	  available	  and	  is	  used	  to	  structurally	  purify	  immunoglobulin	  samples.	  	  By	  comparing	  lanes	  1	  and	  2	  of	   figure	   5.4	  b	   ,	   it	   can	   be	   observed	   that	   a	   cleaner	   preparation	   of	   the	   anti-­‐biotin	  antibody	   sample	   is	   obtained	   by	   passing	   it	   though	   a	   Protein	   G	   column.	   	   This	  preparation	  of	  the	  antibody	  has	  shown	  to	  be	  conjugated	  to	  HRP	  optimally.	  	  	  	  
5.2.5	   Conjugation	   of	   purified	   biotin	   antibody	   to	   horseradish	  
peroxidase	  	  	  It	  was	  essential	  that	  the	  biotin	  anti-­‐biotin	  antibody	  was	  pure	  before	  being	  coupled	  to	   horseradish	   peroxidase	   (HRP).	   	   This	   ensures	   that	   there	   would	   be	   a	   higher	  concentration	  of	  coupled	  antibody,	  which	  in	  turn	  would	  result	  in	  a	  higher	  antibody	  titre.	  	  Cyanuric	  chloride	  was	  used	  as	  the	  linker	  arm	  of	  choice	  because	  the	  molecule	  contains	  three	  chlorine	  atoms,	  of	  which	  two	  will	  be	  readily	  available	  for	  coupling.	  	  A	  schematic	  of	  the	  conjugation	  steps	  is	  shown	  in	  figure	  5.5.	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Figure 5.5  A schematic showing the conjugation of HRP to the anti-biotin antibody via cyanuric 
chloride. 
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The	   purified	   anti-­‐biotin	   antibody	   was	   prepared	   for	   conjugation	   to	   HRP-­‐CC	   by	  dialysing	  the	  antibody	  (~	  10	  mg)	  in	  2	  L	  of	  conjugation	  buffer	  for	  16	  h	  at	  4	  °C.	  	  This	  was	  kept	  on	  ice	  during	  the	  after	  conjugation	  steps.	  	  The	  methods	  described	  below	  were	  adapted	  from	  (Abuknesha	  et	  al.	  2005;	  2009).	  	  Cyanuric	   chloride	   crystals	   were	   prepared	   for	   conjugation	   to	   HRP	   by	   firstly	  dissolving	  cyanuric	  chloride	  (20	  g)	  in	  boiling	  benzene	  (~	  70	  ml).	  	  The	  solution	  was	  filtered	  over	  dry	  silica	  whilst	  still	  hot	  and	  left	  to	  re-­‐crystallize	  in	  a	  fume	  cupboard.	  	  The	  crystals	  were	  filtered	  and	  washed	  with	  ~	  20	  ml	  ice-­‐cold	  benzene,	  and	  allowed	  to	  dry	  under	  vacuum.	  	  The	  crystals	  were	  then	  stored	  at	  4	  °C	  until	  required.	  	  	  	  
Activation	  of	  horseradish	  peroxidase	  by	  cyanuric	  chloride	  	  Horseradish	  peroxidase	  was	  activated	  via	  coupling	  to	  cyanuric	  chloride.	  	  Cyanuric	  chloride	   crystals	  were	  dissolved	   in	   ice-­‐cold	   anhydrous	   acetone	   to	  make	  a	  20	  mg	  ml-­‐1	  solution.	  	  Acetone	  solution	  containing	  3.2	  mg	  of	  cyanuric	  chloride	  (160	  µl)	  was	  transferred	  into	  a	  glass	  vial	  and	  the	  solvent	  was	  allowed	  to	  evaporate	  off.	  	  HRP	  was	  dissolved	  in	  ice-­‐cold	  conjugation	  buffer	  (50	  mM	  sodium	  bicarbonate,	  pH	  9.4	  with	  sodium	  carbonate)	  to	  make	  up	  a	  6	  mg	  ml-­‐1	  solution.	  	  The	  HRP	  solution	  (1	  ml)	  was	  immediately	   added	   to	   the	   glass	   vial	   containing	   the	   dried	   cyanuric	   chloride.	   	   The	  solution	  was	  allowed	  to	  stir	  in	  the	  dark	  at	  4	  °C	  for	  4	  h.	  	  	  	  A	   PD-­‐10	   Sephadex	   G-­‐25	   column	   was	   prepared	   according	   to	   the	   manufacturer’s	  instructions.	  	  The	  HRP-­‐CC	  reaction	  mixture	  was	  transferred	  into	  the	  column	  and	  1	  ml	   fractions	   were	   collected	   on	   ice.	   	   PD-­‐10	   column	   equilibration	   buffer	   (10	   mM	  sodium	  phospate,	  pH	  5.5	  with	  citric	  acid)	  was	  added	  1	  ml	  at	  a	  time.	  	  The	  fractions	  containing	  HRP-­‐CC	   fractions	   (pale	   brown)	  were	   pooled	   together	   into	   an	  Amicon	  Ultra	  Filter	  unit.	  	  	  	  The	  prepared	  anti-­‐biotin	  solution	  was	  conjugated	  to	  HRP-­‐CC	  through	  the	  addition	  of	   the	   purified	   antibody	   (6	   mg)	   into	   the	   Amicon	   Ultra-­‐4	   Filter	   unit	   (Millipore)	  containing	  the	  HRP-­‐CC	  and	  1	  ml	  of	  conjugation	  buffer	  (50	  mM	  sodium	  bicarbonate,	  pH	  9.4	  with	  sodium	  carbonate)	  .	  	  The	  filter	  unit	  was	  then	  centrifuged	  for	  ~	  20	  min	  at	   4000	   g	   and	   4	   °C.	   	   The	   solution	   remaining	   in	   the	   unit	  was	  mixed	   and	   1	  ml	   of	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conjugation	   buffer	   (50	  mM	   sodium	   bicarbonate,	   pH	   9.4	  with	   sodium	   carbonate)	  added	   again.	   	   The	   centrifugation	   procedure	   was	   repeated,	   and	   the	   sample	  concentrated	  to	  a	  final	  volume	  of	  ~	  300	  µl.	  	  The	  HRP-­‐CC	  and	  antibody	  solution	  was	  then	   incubated	   overnight	   at	   37	   °C	   in	   a	  water	   bath.	   	   The	   resulting	   antibody-­‐HRP	  conjugate	  was	  equilibrated	  twice,	  with	  1	  ml	  conjugate	  equilibration	  buffer	  (50	  mM	  sodium	  phospate,	  pH	  5.5	  with	  citric	  acid)	  each	  time,	  by	  centrifugation	  of	  the	  filter	  unit.	  	  The	  final	  volume	  of	  the	  conjugate	  was	  reduced	  to	  ~	  500	  µl.	  	  An	  equal	  volume	  of	  glycerol	  was	  added	  and	  the	  antibody-­‐HRP	  conjugate	  was	  stored	  at	  –	  80	  °C	  until	  further	  use.	  	  	  	  The	  anti-­‐biotin-­‐HRP	  conjugate	  was	  assessed	  by	  ELISA	   to	  determine	   its	   efficiency	  for	  use	  in	  further	  experiments.	  	  A	  96-­‐well	  microtitre	  plate	  was	  coated	  with	  biotin-­‐gelatine	  conjugate	  according	  to	  the	  method	  described	  in	  chapter	  2.	  	  The	  plate	  was	  then	  washed	  and	  blocked,	  and	  the	  anti-­‐biotin-­‐HRP	  conjugate	  was	  titrated	  serially	  down	  the	  plate.	  	  The	  microtitre	  plate	  was	  incubated	  on	  the	  shaker	  for	  1	  h	  at	  room	  temperature,	  and	  developed	  as	  described	  in	  chapter	  2.	  	  Assay	  of	   the	  binding	  activity	  of	   the	  prepared	  anti-­‐biotin-­‐HRP	  conjugate	  by	  ELISA	  (figure	  5.6)	  showed	  a	  titre	  value	  greater	  than	  1:100,000.	  	  The	  value	  was	  calculated	  with	   respect	   to	   the	   conjugate	   dilution	   that	   showed	   a	   binding	   signal	   of	   1.7	  absorbance	  units.	  	  Titration	  of	  the	  conjugate	  (6	  mg	  ml-­‐1)	  	  was	  carried	  out	  using	  the	  resulting	  product	  recovered	  from	  the	  centrifugal	  units.	  	  The	  high	  antibody	  binding	  activity	   in	   the	   conjugate	   is	   evident	   from	   the	   dilution	   response	   curve	   of	   the	  conjugate.	  	  	  	  The	  amount	  of	  antibody	  (at	  a	  dilution	  of	  1:100,000)	  present	  in	  each	  well	  is	  ∼	  9	  ng.	  	  This	   can	   be	   calculated	   on	   the	   basis	   that	   the	   original	   conjugate	   solution	   had	   a	  concentration	  of	  6	  mg	  ml-­‐1.	   	   This	  was	  diluted	   to	  1:100,000,	   of	  which	  150	  µl	  was	  added	   to	  each	  assay	  well.	   	  This	  demonstrates	   the	  high	  purity	  of	   the	  antibody,	   its	  high	   affinity	   for	   the	   hapten	   and	   the	   high	   molar	   ratio	   of	   HRP:antibody	   in	   the	  conjugate.	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Figure 5.6.  An example of an ELISA of anti-biotin-HRP conjugate.  The antibody dilution 
response curve was obtained by a direct solid phase ELISA.  The figure indicates an optimum 
titre value in excess of 1:100,000. 
 
	  	  
Figure 5.7.  An example of a non-reducing SDS-PAGE gel analysis of the anti-biotin-HRP 
conjugate and samples of un-conjugated anti-biotin antibody and enzyme.  Lane 1: molecular 
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 Analysis	  of	  the	  anti-­‐biotin-­‐HRP	  conjugate	  and	  the	  original	  starting	  proteins	  by	  SDS-­‐PAGE	  under	  non-­‐reducing	  conditions	   in	   figure	  5.7	  showed	  the	  presence	  of	   IgG	   in	  lane	  2	   (150	  kDa),	  HRP	   in	   lane	  3	   (44	   kDa)	   and	   a	   range	   of	   high	  molecular	  weight	  complexes	  in	  lane	  4.	  	  A	  small	  amount	  of	  un-­‐conjugated	  peroxidase	  enzyme	  can	  also	  be	  seen	  in	  lane	  4.	  	  It	  should	  be	  noted	  that	  there	  is	  virtually	  no	  free	  antibody	  present	  in	  lane	  4,	  which	  indicate	  that	  all	  the	  IgG	  was	  used	  up	  in	  the	  conjugation	  process.	  	  	  	  Conjugation	  of	  the	  anti-­‐biotin	  antibody	  to	  HRP	  and	  the	  subsequent	  titration	  of	  the	  anti-­‐biotin-­‐HRP	  conjugate	  by	  ELISA	  (figure	  5.6)	  showed	  that	   the	  titre	  of	   the	  anti-­‐biotin	   antibody	   conjugate	   was	   high	   (1:100,000).	   	   This	   is	   indicative	   of	   the	   high	  purity	  of	  the	  anti-­‐biotin	  antibody,	  as	  well	  as	  the	  high	  molar	  ratio	  of	  the	  HRP	  to	  anti-­‐biotin	  antibody	  present,	  which	  confirms	  the	  success	  of	  the	  conjugation	  steps.	  	  The	  high	  antibody	  titre	  also	  shows	  the	  high	  affinity	  that	  the	  anti-­‐biotin-­‐HRP	  has	  for	  the	  biotin	   gelatine	   conjugate	   used	   in	   the	   assay.	   	   Further	   proof	   of	   the	   success	   of	   the	  conjugation	   can	   be	   seen	   in	   figure	   5.6,	   lane	   4,	   which	   contains	   very	   little	   un-­‐conjugated	  HRP	  and	  no	  un-­‐conjugated	  anti-­‐biotin	  antibody.	  	  	  	  
5.2.6	  Biotinylation	  of	  anti-­‐peptide	  antibody	  	  The	   anti-­‐peptide	   antiserum	   (from	  Chapter	  4)	  was	  processed	   in	   the	   same	  way	   as	  described	   in	   chapter	   2.	   	   After	   the	   first	   centrifugation	   step,	   the	   pellet	   was	   re-­‐suspended	  in	  25	  ml	  of	  a	  45	  %	  ammonium	  sulphate	  solution	  and	  spun	  down	  again.	  	  The	  supernatant	  was	  discarded	  and	  the	  pellet	  was	  re-­‐dissolved	  in	  a	  50	  mM	  sodium	  phosphate	  buffer,	  pH	  7.4	  and	  dialysed	  against	  a	  sodium	  bicarbonate	  buffer,	  pH	  8.6	  for	  16	  h	  at	  4	  °C.	  	  The	  absorbance	  was	  the	  solution	  was	  then	  taken	  at	  280	  nm.	  	  This	  was	  done	  to	  determine	  the	  protein	  content	  of	  the	  solution.	  	  	  	  Biotin	  was	   activated	   using	   the	  mixed	   anhydride	  method	   described	   previously	   in	  this	  chapter.	  	  Pyridine	  was	  omitted	  in	  this	  instance	  because	  (it	  was	  too	  severe	  to	  be	  used	  with	  IgG).	  	  Biotin	  (30	  mg)	  was	  dissolved	  in	  1.5	  ml	  of	  DMF.	  	  The	  solution	  was	  cooled	  on	  ice,	  and	  whilst	  stirring,	  60	  µl	  of	  tributylamine	  was	  added	  followed	  by	  30	  µl	  chloroformate.	   	  The	  mixture	  was	   left	   to	  react	   for	  10	  min	  while	  still	   stirring	  on	  ice.	  	  This	  method	  was	  based	  on	  the	  one	  described	  previously	  (Gendloff	  et	  al.	  1986).	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  While	   the	   above	   reaction	   was	   being	   carried	   out,	   the	   dialysed	   anti-­‐peptide	  antibodies	  (at	  4	  °C)	  were	  divided	  into	  five	  test	  tubes	  containing	  approximately	  100	  mg	   of	   protein	   each.	   	   The	   tubes	   were	   all	   placed	   on	   ice	   and	   the	   activated	   biotin	  solution	  was	  added,	  20	  µl	  at	  a	  time,	  to	  the	  antibody	  solutions	  in	  increasing	  volumes	  containing	  50	  µl,	  150	  µl,	  300	  µl,	  450	  µl	  and	  600	  µl	  of	  the	  total	  activated	  biotin.	  	  This	  was	   to	   used	   to	   determine	   the	   optimum	   amount	   of	   activated	   biotin	   that	   can	   be	  coupled	  to	  the	  anti-­‐peptide	  antibody.	  	  Care	  was	  taken	  when	  mixing	  the	  solutions	  so	  as	   to	   not	   denature	   the	   proteins.	   	   The	   biotinlylated	   antibodies	   were	   dialyzed	  immediately	  against	  sodium	  phosphate	  buffer,	  pH	  7.4,	  pre-­‐cooled	  to	  4	  °C,	  for	  16	  h	  at	   4	   °C.	   	   The	   biotinylated	   antibodies	   were	   recovered	   and	   stored	   under	   50	   %	  ammonium	   sulphate	   at	   4	   °C	   until	   further	   required	   (Diamandis	   &	   Christopoulos	  1991).	  	  	  	  
	  
Figure 5.8.  Schematic of the activation of biotin using the mixed anhydride method, followed by 
the coupling of the activated biotin to the anti-CTGF peptide antibody. 	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The	   binding	   activity	   of	   the	   biotinylated	   anti-­‐peptide	   antibody	   was	   assessed	   by	  ELISA	  and	   the	   assay	   compared	  against	   another	  using	   the	   commercially	   available	  anti-­‐sheep	  IgG	  peroxidase	  antibody.	  	  The	  steps	  of	  this	  assay	  are	  as	  in	  chapter	  2.	  	  A	  1:25	  dilution	  of	  the	  peptide-­‐gelatine	  conjugate	  was	  prepared	  and	  50	  µl/well	  of	  the	  peptide-­‐gelatine	   conjugate	   was	   added	   to	   all	   wells	   in	   column	   1	   of	   the	  microtitre	  plate.	  	  The	  solution	  was	  mixed	  and	  50	  µl	  was	  transferred	  across	  the	  columns	  from	  1	   to	   6,	   discarding	   the	   final	   50	   µl.	   	   1	  ml	   of	   biotinylated	   antibody	   stored	   in	   50	  %	  saturated	  ammonium	  sulphate	  was	   centrifuged	  at	  10,000	   rpm	   for	  approximately	  15	  min	  in	  the	  pre-­‐cooled	  (4	  °C)	  centrifuge.	  	  The	  supernatant	  was	  discarded	  and	  the	  pellet	  was	  re-­‐dissolved	  in	  1	  ml	  of	  glycerol	  solution	  (50	  %	  glycerol	  in	  0.05	  M	  sodium	  phosphate,	   0.1	  M	   sodium	   chloride	   buffer,	   pH	  7.4),	   and	   stored	   at	   -­‐	   20	   °C.	   	   150	   µl	  /well	  of	  primary	  antibody	  buffer	  was	  added	  into	  all	  wells	  of	  the	  PCA-­‐coated	  plate.	  	  A	  1:25	  dilution	  of	  the	  antibody	  was	  prepared	  in	  antibody	  buffer.	  	  50	  µl	  /well	  of	  the	  1:25	  antibody	  solution	  was	  added	  to	  all	  wells	  in	  row	  A	  (A1-­‐A6).	  	  The	  solution	  was	  mixed	   and	   50	   µl	   of	   the	   solution	   was	   transferred	   downward	   (rows	   A	   to	   H)	  discarding	  the	  final	  50	  µl.	  	  This	  was	  repeated	  for	  all	  the	  biotinylated	  antibodies.	  	  A	  control	   was	   used,	   where	   a	   non-­‐biotinylated	   antibody	   was	   used	   as	   primary	  antibody.	  	  The	  microtitre	  plates	  were	  developed	  as	  in	  chapter	  2.	  	  	  	  The	  commercial	  anti-­‐sheep	   IgG-­‐HRP	  was	   found	   to	  cross-­‐react	  with	  human	   IgG	   in	  the	   urine	   samples	   (Chapter	   3).	   	   Therefore,	   an	   assay	   that	   is	   independent	   of	   the	  commercial	  anti-­‐sheep	  IgG-­‐HRP	  had	  to	  be	  developed.	  	  	  	  The	   biotinylated	   anti-­‐peptide	   antibody-­‐anti-­‐biotin-­‐HRP	   system	   (1)	   showed	   a	  higher	   binding	   activity	   when	   compared	   to	   that	   developed	   with	   the	   commercial	  anti-­‐sheep	   IgG-­‐HRP	   (2)	   seen	   in	   figure	  5.9.	   	  A	   schematic	   of	   the	   assay	   is	   shown	   in	  figure	  5.10.	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Figure 5.9.  An example of an ELISA antibody dilution response curves of the peptide-CC-
gelatine conjugate titrated against (1) anti-peptide-biotin developed with anti-biotin-HRP and (2) 
anti-peptide antibody developed with a commercial anti-sheep IgG-peroxidase.  At an optimum 
absorbance value of 1.7, the titre for 1 is about 1:20,000.  The titre for 2 is about 1:2500.   	  There	   is	  nearly	  a	   ten-­‐fold	  difference	   in	  antibody	   titres	  between	   the	  anti-­‐peptide-­‐biotin	   developed	   with	   anti-­‐biotin-­‐HRP	   compared	   to	   the	   anti-­‐peptide	   antibody	  developed	  with	   the	   commercial	   anti-­‐sheep	   IgG-­‐HRP.	   	   This	   higher	   response	   from	  the	  biotinylated	  anti-­‐peptide	  antibody	  is	  most	  likely	  due	  to	  the	  high	  antibody	  titre	  as	  well	  as	  the	  greater	  specificity	  of	  the	  anti-­‐biotin-­‐HRP	  antibodies	  compared	  to	  the	  commercial	  anti-­‐sheep	  IgG-­‐HRP.	  	  	  	  Conjugation	  of	  the	  anti-­‐biotin	  antibody	  to	  HRP	  and	  the	  subsequent	  titration	  of	  the	  anti-­‐biotin-­‐HRP	  conjugate	  by	  ELISA	  (figure	  5.6)	  showed	  that	   the	  titre	  of	   the	  anti-­‐biotin	   antibody	   conjugate	   was	   high	   (1:100,000).	   	   This	   is	   indicative	   of	   the	   high	  purity	  of	  the	  anti-­‐biotin	  antibody,	  as	  well	  as	  the	  high	  molar	  ratio	  of	  the	  HRP	  to	  anti-­‐biotin	  antibody	  present,	  which	  confirms	  the	  success	  of	  the	  conjugation	  steps.	  	  The	  high	  antibody	  titre	  also	  shows	  the	  high	  affinity	  that	  the	  anti-­‐biotin-­‐HRP	  has	  for	  the	  biotin	   gelatine	   conjugate	   used	   in	   the	   assay.	   	   Further	   proof	   of	   the	   success	   of	   the	  conjugation	   can	   be	   seen	   in	   figure	   5.7,	   lane	   4,	   which	   contains	   very	   little	   un-­‐conjugated	  HRP	  and	  no	  un-­‐conjugated	  anti-­‐biotin	  antibody.	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Figure 5.10.  Schematic of an ELISA of the peptide-gelatine conjugate using biotinylated and 
non-biotinylated anti-peptide antibody.  a represents the ‘conventional’ method used for the 
colour development stage i.e. using a commercial second antibody (anti-sheep IgG-
peroxidase).  b represents the use of the biotinylated anti-peptide antibody, which is developed 
using anti-biotin-HRP. 	  It	  was	  mentioned	  previously	  in	  chapter	  3	  that	  the	  commercial	  anti-­‐sheep	  IgG-­‐HRP	  cross-­‐reacted	  with	   human	   IgG	   in	   patient	   urine	   samples.	   	   This	   led	   to	   the	   need	   to	  develop	  a	  specific	  CTGF	  assay	  that	  was	  independent	  of	  the	  commercial	  anti-­‐sheep	  IgG-­‐HRP.	  	  In	  chapter	  4,	  a	  peptide	  sequence	  that	  is	  present	  in	  CTGF	  was	  synthesised	  and	  a	  sheep	  polyclonal	  antibody	  was	  raised	  against	  this	  peptide.	  	  	  	  A	  relatively	  cheap	  and	  efficient	  way	  to	  overcome	  the	  use	  of	   the	  commercial	  anti-­‐sheep	   IgG-­‐HRP	   in	  assays	   is	   the	  use	  biotinylated	  anti-­‐peptide	  antibodies	   to	  detect	  CTGF	  and	  an	  anti-­‐biotin-­‐HRP	  as	  a	  ‘second	  antibody’.	  	  It	  is	  possible	  to	  couple	  HRP	  to	  the	   anti-­‐peptide	   antibody,	   thus	   resulting	   in	   a	   direct	   enzyme	   immunoassay.	  	  However,	   the	   advantages	   of	   using	   this	   indirect	   ELISA	   method	   will	   effectively	  increase	  the	  sensitivity	  as	  well	  as	  amplifying	  the	  signal.	  	  	  	  Conclusion:	  	  A	  biotin	  antibody	  was	  successfully	  prepared	  for	  the	  coupling	  to	  HRP.	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It	  was	  possible	  to	  successfully	  prepare	  biotin-­‐coupled	  primary	  antibody	  for	  CTGF.	  	  This	   anti-­‐CTGF	   peptide	   antibody	   improved	   detection	   of	   CTGF	  when	   used	  with	   a	  secondary	  anti-­‐biotin	  peroxidase	  antibody.	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Chapter	  6	  
Purification	  of	  CTGF	  using	  anti-­‐CTGF	  
peptide	  antibody	  coupled	  to	  Sepharose	  4B	  
and	  heparin	  column	  	  
	   112	  
	  
6.1	  Introduction	  	  The	   ability	   to	   detect	   and	   isolate	   native	   CTGF	   is	   a	   primary	   requirement	   in	   the	  development	  of	  robust,	  cheap	  and	  reliable	  immunoassays	  .	  	  Assay	  kits	  for	  CTGF	  are	  widely	   available	   but	   utilise	   recombinant	   human	   CTGF	   as	   an	   internal	   standard.	  	  While	   there	   are	   the	   advantages	   of	   using	   recombinant	   human	  CTGF,	   using	   native	  CTGF	  as	  a	  standard	  and	  in	  developing	  antibodies	  would	  result	  in	  a	  more	  accurate	  assay.	   	   However,	   CTGF	   has	   not	   been	   purified	   from	   actual	   human	   patient	   fluid	  samples,	  which	  is	  a	  necessary	  first	  step.	  Therefore,	  no	  antibodies	  to	  native	  human	  CTGF	  have	  so	  far	  been	  reported.	  	  Peritoneal	  dialysis	  fluid	  and	  diabetic	  urine,	  which	  are	  the	  subject	  of	  the	  current	  study,	  have	  been	  reported	  to	  contain	  CTGF	  (Riser	  et	  al.	  2003;	  Mizutani	  et	   al.	  2010)	  and	  can	   therefore	  be	  used	  as	  a	   source.	   	  CTGF	  has	  been	  reported	  bind	  to	  heparin,	  and	  was	  subsequently	  purified	  by	  heparin	  affinity	  purification	  (Ball	  et	  al.	  2003;	  Riser	  et	  al.	  2000;	  Steffen	  et	  al.	  2009).	  	  Purification	  of	  CTGF	  using	  other	  methods	  has	  not	  been	  reported.	  	  An	  immunoaffinity	  purification	  method	  was	  developed	  to	  purify	  CTGF	  with	  the	  hope	  of	  eventually	  scaling-­‐up	  the	  process.	   	   This	  method	   utilised	   the	   coupling	   of	   Sepharose	   4B	   to	   the	   anti-­‐peptide	  antibody	  via	  a	  novel	  linker	  arm.	  	  Theoretically,	  CTGF	  will	  bind	  to	  the	  immobilised	  anti-­‐peptide	  antibody,	  and	  then	  be	  eluted	  off.	  	  	  	  Liquid	  chromatography	  coupled	  with	   tandem	  mass	  spectrometry	  (LC-­‐MS/MS),	  2-­‐dimensional	  (2-­‐D)	  electrophoresis	  and	  Western	  blot	  analyses	  will	  be	  used	  for	  the	  confirmation	  of	  the	  presence	  of	  CTGF	  after	  the	  purification	  process.	  	  The	  use	  of	  LC-­‐MS/MS	  or	  2-­‐D	  electrophoresis	  for	  the	  identification	  of	  CTGF	  has	  yet	  to	  be	  reported.	  	  Digested	   peptides	   are	   passed	   through	   an	   HPLC	   (high	   performance	   liquid	  chromatography)	  column	  that	  is	  coupled	  to	  the	  mass-­‐spectrometer.	  	  The	  peptides	  are	   eluted	   in	   order	   of	   their	   hydrophobicity	   prior	   to	   ionization	   in	   a	   mass	  spectrometer	  (Steen	  &	  Matthias	  Mann	  2004).	  	  This	  method	  can	  be	  used	  to	  confirm	  the	  presence	  of	  CTGF	  and	  its	  fragments	  in	  SDS-­‐PAGE	  gels,	  and	  when	  used	  alongside	  2d-­‐electrophoresis,	   will	   accurately	   identify	   CTGF.	   	   It	   should	   be	   noted	   that	   the	  ‘Methods	  and	  results’	  are	  divided	  into	  two	  sections	  for	  better	  clarification.	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Aim:	  	  	  To	   develop	   an	   isolation	   procedure	   for	   CTGF	   using	   heparin	   (Section	  A)	   and	   anti-­‐peptide-­‐Sepharose	  columns	  (Section	  B).	  	  Objective:	  	  This	  chapter	  describes	  the	  incorporation	  of	  the	  anti-­‐peptide-­‐biotin	  and	  anti-­‐biotin-­‐HRP	   antibodies	   in	   the	   purification	   and	   detection	   of	   CTGF	   from	   clinical	   samples.	  	  Simultaneously,	  the	  data	  were	  compared	  with	  a	  commercially	  available	  anti-­‐CTGF	  antibody.	  	  	  	  
6.2	  Methods	  for	  heparin	  affinity	  purification	  	  
6.2.1	   Heparin	   affinity	   purification	   of	   CTGF	   from	   peritoneal	  
dialysis	  fluid	  sample	  	  	  Riser	   et.	   al	   (2000,	   2003)	  used	  heparin	   coupled	   to	   Sepharose	  4B	  beads	   to	   isolate	  CTGF	   from	   cell	   culture	   supernatants	   as	   well	   as	   diabetic	   patient	   urine	   samples.	  	  They	  eluted	  CTGF	  by	  boiling	  the	  beads	  in	  sodium	  dodecyl	  sulphate	  sample	  buffer.	  	  This	  method	  was	  adapted	  for	  the	  isolation	  of	  CTGF	  from	  peritoneal	  dialysis	  fluid.	  	  Peritoneal	  dialysis	  fluid	  was	  kindly	  provided	  by	  Dr	  Frederick	  Tam	  from	  the	  Renal	  Division,	  Hammersmith	  Hospital.	  	  	  	  Nitrogen	  was	  passed	  through	  all	  buffers	  to	  prevent	  polymerization	  of	  the	  cysteine-­‐rich	   CTGF.	   	   Peritoneal	   dialysis	   fluid	   (5	  ml)	   was	   diluted	   in	   ice-­‐cold	   5	  ml	   10	  mM	  sodium	  phosphate,	  pH	  7	  buffer.	   	  This	  diluted	   sample	  was	   then	  passed	   through	  a	  HiTrap	   Heparin	   HP	   5	   ml	   column	   (G	   E	   Healthcare)	   in	   accordance	   to	   the	  manufacturer’s	  instructions.	  	  A	  10	  mM	  sodium	  phosphate,	  2	  M	  sodium	  chloride,	  pH	  7	  buffer	  was	  used	  to	  elute	  any	  bound	  CTGF.	  	  Fractions	  of	  5	  ml	  were	  collected	  and	  the	  protein	  content	  of	  these	  fractions	  was	  monitored	  by	  a	  spectrophotmeter	  at	  280	  nm.	  	  The	  fractions	  were	  equilibrated	  three	  times	  against	  5	  mM	  sodium	  phosphate,	  10	  mM	  sodium	  chloride,	  pH	  7.4,	  and	   the	  volume	  of	  all	   the	   fractions	  was	  reduced	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using	   an	   Amicon	   Ultra-­‐4	   Filter	   unit	   (Millipore).	   	   The	   volume-­‐reduced	   fractions	  were	  kept	  at	  –	  68	  °C	  until	  further	  use.	  	  	  	  
6.2.2	  SDS-­‐PAGE	  and	  Western	  blot	  analysis	  of	  fractions	  obtained	  
from	  heparin	  affinity	  purification	  	  Laemmli	   sample	   buffer	   containing	   5	   %	   β-­‐mercaptoethanol	   was	   added	   in	   equal	  volumes	  to	  the	  volume-­‐reduced	  fractions	  and	  was	  heated	  at	  90	  °C	  for	  5	  min.	  	  The	  samples	  were	   then	   loaded	  onto	  a	  NuPAGE®	  Novex	  10	  %	  Bis-­‐Tris	  Gel	   and	   the	  gel	  was	   run	   in	   an	   XCell	   SureLock™	   Mini-­‐Cell	   (Invitrogen)	   in	   accordance	   to	   the	  manufacturer’s	   instructions.	   	  The	  separated	  proteins	  on	   the	  gel	  were	   transferred	  onto	  a	  nitrocellulose	  membrane	  using	  a	  TE	  77	  PWR	  Semi-­‐Dry	  Transfer	  Unit	   (G	  E	  Healthcare)	  according	  to	  the	  manufacturer’s	  instructions.	  	  	  	  
Identification	  of	  CTGF	  by	  Western	  blot	  using	  the	  following	  antibodies:	  	  
1. Anti-­‐peptide	  antibody	  and	  anti-­‐sheep	  IgG	  peroxidase	  
2.	   Anti-­‐sheep	  IgG	  peroxidase	  only	  
3.	   Anti-­‐peptide-­‐biotin	  and	  anti-­‐biotin-­‐HRP	  	  The	  Western	  blots	  were	  developed	  using	   the	  SNAP	   i.d.	  Protein	  Detection	  System	  (Millipore)	   in	   accordance	   to	   the	   manufacturer’s	   instructions.	   	   The	   blots	   were	  blocked	  with	  0.5	  %	  skimmed	  milk	  powder	  in	  TBST	  (20	  mm	  Tris,	  100	  mM	  sodium	  chloride,	  pH	  7.6,	  0.1	  %	  Tween	  20)	  15	  min.	   	  The	  blots	  were	  then	  probed	  with	  the	  primary	   and	   secondary	   antibodies	   respectively	   for	  1	  h	   each.	   	   TMB	  1-­‐Component	  Membrane	  Peroxidase	  Substrate	  (KPL)	  was	  used	  as	  a	  substrate	  for	  the	  colorimetric	  development	  of	  the	  blot.	  	  	  	  
6.2.3	   Sequencing	  of	   protein	  bands	   isolated	  by	  heparin	   affinity	  
purification	  by	  LC-­‐MS/MS	  	  	  Further	  confirmation	  of	  the	  identities	  of	  the	  protein	  bands	  detected	  from	  Western	  blot	   analysis	   was	   required.	   	   This	   is	   because	   even	   though	   the	   anti-­‐CTGF	   peptide	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identified	   immunologically	   reactive	   species	   in	   the	   bands,	   the	   identity	   of	   the	  proteins	  present	  can	  only	  be	  confirmed	  through	  mass	  spectrometry.	  	  	  Protein	  bands	  that	  were	  identified	  by	  the	  Western	  blot	  were	  excised	  from	  gels	  that	  have	  been	   stained	  and	  de-­‐stained	  using	   the	  protocol	   from	  Pierce	  Silver	   Stain	   for	  Mass	   Spectrometry	   (Pierce).	   	   These	   excised	   protein	   bands	   were	   then	   kindly	  sequenced	  by	  Dr	  Xiaoke	  Yin	  of	  the	  Cardiovascular	  Division,	  King’s	  College	  London,	  where	  all	  the	  mass	  spectrometry	  work	  was	  performed.	  	  Briefly,	  excised	  gel	  bands	  were	   digested	   with	   sequencing-­‐grade	   trypsin	   (Promega)	   using	   an	   Investigator	  ProGest	   Genomic	   Solutions)	   robotic	   digestion	   system	   (Shevchenko	   et	   al.	   1996;	  Wilm	   et	   al.	   1996).	  	   The	   tryptic	   peptides	  were	   separated	   by	   reverse	   phase	   nano-­‐flow	  liquid	  chromatography	  (Ultimate	  3000,	  C18	  PepMAp	  100,	  3	  μm,	  100A,	  25	  cm,	  Dionex)	  and	  subjected	  to	  online	  tandem	  mass	  spectrometry	  analysis	  (LTQ	  Orbitrap	  XL,	   Thermo	   Scientific)	   via	   a	   nano-­‐spray	   source	   (Picoview).	  	   The	   spectra	   were	  collected	  from	  the	  mass	  analyser	  using	  full	  ion	  scan	  mode	  over	  the	  m/z	  range	  450	  -­‐	  1600.	  	  
6.3	  Results	  for	  heparin	  affinity	  purification	  	  
Identification	  of	  CTGF	  by	  Western	  blot	  using	  anti-­‐peptide	  antibody	  and	  
anti-­‐sheep	  IgG	  peroxidase	  	  Fractions	   from	   the	   heparin	   affinity	   purification	   of	   CTGF	   from	  peritoneal	   dialysis	  fluid	  were	  assessed	  by	  Western	  blot	  analysis	  to	  identify	  and	  isolate	  any	  CTGF	  that	  is	  present.	  	  Peritoneal	  dialysis	  fluid	  was	  passed	  through	  a	  HiTrap	  Heparin	  column	  and	   the	   fractions	   collected	   were	   concentrated	   before	   analyses.	   	   Purification	   of	  CTGF	   by	   heparin	   affinity	   chromatography	   was	   used	   because	   CTGF	   binds	   to	  heparin,	   and	   purification	   of	   CTGF	   by	   heparin	   affinity	   chromatography	   has	   been	  reported	  (Brigstock	  et	  al.	  1997;	  Ball	  et	  al.	  2003;	  B	  L	  Riser	  et	  al.	  2000).	  	  	  	  In	  figure	  6.1,	  blot	  (a)	  shows	  the	  wash	  fractions	  where	  three	  distinct	  bands,	  A,	  B	  and	  C	   were	   observed.	   	   Their	   respective	   molecular	   weights	   are	   50,	   26	   and	   20	   kDa	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respectively.	  	  The	  bands	  are	  strongest	  at	  50	  and	  20	  kDa.	  	  The	  intensity	  of	  the	  bands	  increases	   significantly	   between	   lane	   1	   and	   lane	   2,	   and	   then	   decreases	   gradually	  from	  lane	  2	  to	  5.	   	  This	  indicates	  that	  the	  unbound	  proteins	  in	  the	  peritoneal	  fluid	  are	  being	  washed	  out	  of	  the	  column.	   	  The	  bands	  were	  identified	  by	  Western	  blot,	  which	   indicates	   that	   the	   column	  may	   have	   been	   overloaded	   and	   the	   antibodies	  (anti-­‐peptide	   and	   anti-­‐sheep	   IgG	   peroxidase)	   have	   detected	   their	   corresponding	  antigens.	  	  	  	  Blot	  (b)	  shows	  the	  eluted	  fractions	  from	  the	  Heparin	  HiTrap	  column.	  	  Six	  bands	  are	  observed,	  D,	  E,	  F,	  G,	  H	  and	  I	  with	  molecular	  weights	  of	  95	  kDa,	  55	  kDa,	  50	  kDa,	  40	  kDa	   30	   kDa	   and	   28	   kDa	   respectively.	   	   Lane	   8	   shows	   the	   most	   distinct	   bands	  compared	  to	  lanes	  7	  and	  9.	  	  One	  notable	  feature	  in	  lane	  blot	  (b)	  is	  that	  three	  more	  proteins	  are	  identified	  compared	  to	  blot	  (a).	  	  This	  can	  be	  attributed	  to	  the	  fact	  that	  the	  Heparin	  HiTrap	  column	  has	  enriched	  certain	  proteins	  that	  are	  otherwise	  in	  low	  abundance	   in	   the	   peritoneal	   fluid.	   	   CTGF	   is	   reported	   to	   be	   a	   36-­‐38	   kDa	   protein.	  	  Other	  molecular	  weights	  ranging	  from	  18-­‐55	  kDa	  have	  also	  been	  reported	  (Wahab	  et	  al.	  2001;	  Zarrinkalam	  et	  al.	  2003).	  	  These	  molecular	  weights	  correspond	  to	  those	  identified	   in	   the	   Western	   blots	   (a	   and	   b),	   although	   further	   identification	   is	  required.	  






Figure 6.1 Western blots of fractions obtained from heparin affinity purification of CTGF from 
peritoneal dialysis fluid developed with anti-peptide antibody and anti-sheep IgG peroxidase.  
(a): Lanes 1-5 indicate the wash fractions.  A, B and C indicate the protein bands observed at 
50 kDa, 26 kDa and 20 kDa respectively.  (b): Lanes 7-9 indicate the eluted fractions.  D, E, F, 
G, H and I indicate the protein bands observed at 95 kDa, 55 kDa, 50 kDa, 40 kDa 30 kDa and 
28 kDa respectively.   
 
Identification	  of	  CTGF	  by	  Western	  blot	  using	  anti-­‐sheep	   IgG	  peroxidase	  
only	  	  As	  described	  in	  chapter	  3,	  the	  anti-­‐sheep	  IgG	  peroxidase	  used	  as	  a	  second	  antibody	  in	  immunoassays	  was	  not	  as	  specific	  as	  desired.	  	  Therefore,	  only	  the	  anti-­‐sheep	  IgG	  peroxidase	   was	   used	   in	   this	   assay.	   	   Figure	   6.2	   confirms	   that	   the	   anti-­‐sheep	   IgG	  peroxidase	  antibody	  detects	  proteins	  found	  in	  the	  peritoneal	  dialysis	  fluid.	  	  Lane	  1	  represents	  a	  wash	  fraction	  and	  lanes	  2	  and	  4	  are	  eluted	  fractions	  from	  the	  Heparin	  HiTrap	  column.	  	  There	  are	  three	  distinct	  bands	  present	  in	  lane	  1	  (A,	  B	  and	  C	  at	  130	  kDa,	  95	  kDa	  and	  50	  kDa	  respectively).	  	  There	  is	  a	  very	  faint	  band	  at	  50	  kDa	  in	  lanes	  2	  and	  3.	   	  The	  band	  at	  50	  kDa	  could	   indicate	   the	  presence	  of	   the	  heavy	  chain	   IgG	  (the	   samples	   have	   been	   subjected	   to	   reducing	   conditions	   by	   DTT).	   	   The	   bands	  identified	  at	  130	  and	  95	  kDa	  could	  indicate	  non-­‐specific	  binding	  by	  the	  antibody,	  which	  indicates	  that	  the	  anti-­‐sheep	  IgG	  peroxidase	  is	  not	  an	  ideal	  second	  antibody	  when	  used	  specifically	  for	  these	  assays.	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Figure 6.2 Western blot of peritoneal dialysis fluid after heparin affinity purification that was 
developed with the anti-sheep IgG peroxidase antibody only.  Lane 1: Wash fraction.  Lanes 2-
3: Eluted fractions.  A, B and C are protein bands observed at 130 kDa, 95 kDa and 50 kDa 
respectively.   	  
Identification	  of	  CTGF	  by	  Western	  blot	  using	  anti-­‐peptide-­‐biotin	  and	  anti-­‐
biotin-­‐HRP	  	  Figures	  6.1	  and	  6.2	  all	  point	   to	   the	   fact	   that	   the	  anti	   sheep	   IgG	  peroxidase	   is	  not	  ideal	   to	   be	   used	   as	   a	   second	   antibody	   as	   it	   detects	   other	   proteins	   found	   in	   the	  peritoneal	  dialysis	   fluid,	  which	  may	  result	   in	  a	   falsely	  positive	  Western	  blots	  and	  ELISAs.	   	  Chapters	  4	  and	  5	  describe	   the	  production	  of	   the	  anti-­‐peptide-­‐biotin	  and	  anti-­‐biotin-­‐HRP	  antibodies,	  which	   can	  be	  used	  as	   an	  alternative	  method	  of	  CTGF	  detection.	  	  Figure	  6.3	  shows	  a	  Western	  blot	  that	  was	  developed	  using	  the	  anti-­‐peptide-­‐biotin	  and	   anti-­‐biotin-­‐HRP	   antibodies	   that	   were	   prepared	   previously	   as	   described	   in	  chapter	  5.	  	  Lane	  1	  represents	  a	  wash	  fraction	  and	  lanes	  2	  to	  4	  are	  eluted	  fractions	  from	   the	   Heparin	   HiTrap	   column.	   	   There	   are	   three	   distinct	   bands,	   A,	   B	   and	   C,	  observed	  in	  lanes	  1	  to	  3	  at	  >	  170	  kDa,	  170	  kDa	  and	  95	  kDa	  respectively.	  	  Bands	  B	  and	  C	  are	  present	  in	  lane	  1.	  	  Bands	  A,	  B	  and	  C	  are	  present	  in	  lane	  2	  and	  bands	  A	  and	  B	  are	  present	   in	   lane	  3.	   	  There	  are	  no	  bands	  observed	  at	  50	  kDa,	  which	   indicate	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that	   the	   anti-­‐peptide-­‐biotin	   and	   anti-­‐biotin-­‐HRP	   antibodies	   did	   not	   detect	   the	  heavy	  chain	  of	  IgG	  that	  was	  observed	  in	  figure	  6.2.	  	  	  	  
	  
Figure 6.3 Western blot of peritoneal dialysis fluid after heparin affinity purification developed 
with the anti-peptide-biotin and anti-biotin-HRP.  Lane 1: Wash fraction.  Lanes 2-3: Eluted 
fractions.  A, B and C are protein bands observed at >170 kDa, 170 kDA and 95 kDa 
respectively.   
 
6.3.2	  Analysis	  of	  results	  obtained	  from	  LC-­‐MS/MS	  	  	  	  LC-­‐MS/MS	  was	  used	   to	   sequence	   the	  protein	  bands	   (A,	  B	   and	  C	   from	   figure	  6.3)	  that	  were	  suspected	  to	  be	  CTGF	  or	  its	  fragments/polymers.	   	  The	  results	  obtained	  from	   the	   analysis	   and	   after	   input	   into	   the	   DAVID	   Functional	   Annotation	  Biotinformatics	   Microarray	   Analysis	   website,	   which	   was	   used	   to	   deduce	  interacting	   proteins	   and	   list	   gene-­‐disease	   association.	   	   The	   result	   showed	   that	  apolipoprotein	  B	  and	  coagulation	  factor	  XI	  present	  in	  the	  peritoneal	  dialysis	  fluid	  bind	  to	  heparin.	  	  The	  complete	  list	  of	  predicted	  proteins	  are	  in	  the	  appendix.	  	  This	  finding	  concludes	  that	  the	  Heparin	  HiTrap	  column	  is	  unsuitable	  for	  the	  isolation	  of	  CTGF	  from	  the	  peritoneal	  dialysis	  fluid	  as	  it	  is	  not	  specific	  enough.	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6.4	  Preparation	  of	  anti-­‐peptide-­‐Sepharose	  4B	  	  
Treatment	   of	   the	   anti-­‐CTGF	   peptide	   antibody	   by	   DEAE	   ion-­‐
exchange	  	  It	   was	   imperative	   that	   the	   anti-­‐CTGF	   peptide	   antibody	   was	   as	   pure	   as	   possible	  before	  being	  coupled	  to	  Sepharose	  4B.	   	  As	  mentioned	   in	  chapter	  5,	   the	  purer	  the	  antibody	  sample,	  the	  greater	  the	  capacity	  of	  the	  affinity	  gel	  prepared.	   	  As	  there	  is	  no	  commercially	  available	  native	  CTGF	  for	  the	  affinity	  purification,	  other	  methods	  of	  purifying	  the	  antibody	  from	  serum	  were	  used.	  	  Anti-­‐CTGF	  peptide	  antiserum	  was	  processed	  by	  ammonium	  sulphate	  precipitation	  in	  the	  same	  manner	  as	  described	  in	  5.2.7.1,	  with	  the	  exception	  that	  the	  pellet	  was	  dialysed	  against	  50	  mM	  sodium	  phosphate,	  100	  mM	  sodium	  chloride,	  pH	  6.9	  buffer	  instead.	   	   DEAE	   Sephadex	   A-­‐50	   gel	   was	   swollen	   according	   to	   the	  manufacturer’s	  instructions	   (G	   E	   Lifesciences).	   	   A	   column	  was	   prepared	   by	   packing	   3	  ml	   of	   the	  swollen	  gel	  into	  a	  10	  ml	  glass	  syringe.	  	  The	  column	  was	  then	  equilibrated	  with	  15	  ml	   of	   50	   mM	   sodium	   phosphate,	   100	   mM	   sodium	   chloride,	   pH	   6.9	   buffer.	   	   The	  antibody	  sample	  was	  passed	  through	  the	  column,	  collected	  and	  dialysed	  against	  2	  litre	  50	  mM	  sodium	  carbonate,	  pH	  8.6	  buffer	  overnight	  at	  4	  °C.	  	  	  	  
Coupling	  of	  the	  anti-­‐peptide	  antibody	  to	  Sepharose	  4B	  	  Diethylenetriamine	   (DETA)	   was	   previously	   attached	   to	   cyanogen	   bromide	  activated-­‐Sepharose	   4B,	   and	   20	  ml	   of	   the	   gel	  was	   first	  washed	  with	   200	  ml	   de-­‐ionised	  water	  followed	  by	  200	  ml	  of	  50	  mM	  sodium	  bicarbonate,	  pH	  8.6.	   	  The	  gel	  was	  then	  suspended	  in	  40	  ml	  of	  30	  %	  DMF/de-­‐ionised	  water	  and	  allowed	  to	  stir	  on	  ice.	   	   TEA	   (0.5	  ml)	  was	   added	   to	   the	   suspension	   followed	   by	   CC-­‐6-­‐amino	   caproic	  acid	  active	  ester	  (prepared	  in	  4.2.10)	  in	  100	  µl	  volumes	  (total	  1	  ml).	  	  The	  mixture	  was	   allowed	   to	   react	   for	  30	  min	   and	   the	   gel	  was	   then	  washed	  with	  1	  L	  of	   50	  %	  methanol/de-­‐ionised	  water	  using	  a	  sintered	  glass	  funnel.	  	  The	  DEAE	  ion	  exchange-­‐treated	   anti-­‐peptide	   antibody	   (250	   µl)	   was	   diluted	   in	   25	   ml	   of	   50	   mM	   sodium	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bicarbonate,	   pH	   8.6.	   	   The	   CC-­‐6-­‐amino	   caproic	   acid-­‐DETA-­‐Sepharose	   4B	   gel	   was	  then	  added	  to	  the	  antibody	  solution	  and	  allowed	  to	  stir	  for	  1	  min.	   	  The	  antibody-­‐gel	  mixture	  was	  then	  heated	  at	  37	  °C	  for	  30	  min	  and	  left	  to	  stand	  on	  the	  bench	  at	  room	   temperature	   overnight.	   	   The	   anti-­‐peptide-­‐CC-­‐6-­‐amino-­‐caproic	   acid-­‐Sepharose	  4B	  gel	  was	  washed	  with	  500	  ml	  of	  50	  mM	  sodium	  bicarbonate,	  pH	  8,	  500	  ml	  50	  mM	  glycine	  pH	  3.5,	  500	  ml	  de-­‐ionised	  water	  and	  500	  ml	  10	  mM	  sodium	  phosphate,	   pH	   7	   respectively.	   	   The	   gel	   was	   then	   stored	   in	   10	   mM	   sodium	  phosphate,	  pH	  7	  containing	  0.01	  %	  thimerosal	  at	  4	  °C	  until	  further	  use.	  	  	  
	  	  
Figure 6.4.  Schematic of the addition of cyanuric chloride-6-amino caproic acid active ester to 
DETA-Sepahrose 4B 	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Figure 6.5.  Schematic showing the coupling of the anti-CTGF peptide antibody to cyanuric 
chloride-6-amino caproic acid-DETA-Sepharose 4B. 
 
6.5	  Affinity	  purification	  of	  CTGF	  from	  peritoneal	  fluid	  by	  
anti-­‐peptide-­‐CC-­‐6-­‐amino-­‐caproic	  acid-­‐Sepharose	  4B	  	  Nitrogen	  was	  passed	  through	  all	  buffers	  to	  prevent	  polymerization	  of	  the	  cysteine-­‐rich	  CTGF.	  	  Peritoneal	  dialysis	  fluid	  (5	  ml)	  was	  diluted	  in	  ice-­‐cold	  150	  ml	  of	  10	  mM	  sodium	  phosphate,	  pH	  7.	   	  This	  diluted	  sample	  was	   then	  passed	  through	  the	  anti-­‐peptide-­‐CC-­‐6-­‐amino-­‐caproic	  acid-­‐Sepharose	  4B	  gel	  using	  an	  XK	  16/20	  column	  (GE	  Healthcare).	  	  The	  column	  was	  flushed	  with	  three	  10	  ml	  volumes	  of	  10	  mM	  sodium	  phosphate,	   pH	   7.	   	   A	   50	  mM	   glycine	   pH	   3.5	   buffer	  was	   used	   to	   elute	   any	   bound	  CTGF.	  	  Fractions	  (10	  ml)	  were	  collected	  and	  the	  protein	  content	  of	  these	  fractions	  was	  measured	   by	   a	   spectrophotmeter	   at	   280	   nm.	   	   The	   collected	   fractions	   were	  eluted	   with	   150	   µl	   of	   0.5	   M	   Tris.	   	   The	   fractions	   were	   equilibrated	   three	   times	  against	  10	  mM	  sodium	  phosphate,	   pH	  7,	   and	   the	  volume	  of	   all	   the	   fractions	  was	  reduced	   using	   an	   Amicon	   Ultra-­‐4	   Filter	   unit	   (Millipore).	   	   The	   volume-­‐reduced	  fractions	  were	  kept	  at	  –	  68	  °C	  until	  further	  use.	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SDS-­‐PAGE	  and	  Western	  blot	  analysis	  of	  fractions	  obtained	  from	  
the	  purification	  of	  CTGF	   from	  peritoneal	   fluid	  by	  anti-­‐peptide-­‐
CC-­‐6-­‐amino-­‐caproic	  acid-­‐Sepharose	  4B	  	  The	  SDS-­‐PAGE	  and	  Western	  blotting	  protocol	  was	  carried	  out	  in	  the	  same	  manner	  as	  in	  6.2.2.	  	  One	  blot	  was	  then	  probed	  with	  the	  anti-­‐peptide-­‐biotin	  and	  anti-­‐biotin-­‐HRP	  antibodies	  and	  another	  blot	  was	  probed	  with	  the	  anti-­‐CTGF	  (Santa	  Cruz)	  and	  anti-­‐mouse	  IgG	  peroxidase	  antibodies.	  	  	  
Assessment	   of	   fractions	   from	   the	   purification	   of	   CTGF	   from	  
peritoneal	   fluid	   by	   anti-­‐peptide-­‐CC-­‐6-­‐amino-­‐caproic	   acid-­‐
Sepharose	  4B	  by	  sandwich	  ELISA	  	  The	   fractions	   from	   the	  purification	   steps	  were	  monitored	  by	  ELISA.	   	   This	  would	  give	  a	  good	  indication	  of	  the	  content	  of	  the	  fractions	  as	  well	  as	  the	  capacity	  of	  the	  affinity	   gel.	   	   Using	   a	   sandwich	   ELISA	   rendered	   the	   assay	   more	   robust	   as	   there	  would	  be	  minimal	  non-­‐specific	  binding	  to	  the	  microtitre	  plate.	  	  	  	  A	   fixed	  dilution	   (1:100)	  of	  anti-­‐CTGF	   (Santa	  Cruz)	  antibody	   (50	  µl	  per	  well)	  was	  allowed	   to	   coat	   the	  wells	   of	   a	  microtitre	  plate	   overnight	   at	   4	   °C.	   	   The	  microtitre	  plate	  was	   then	  washed	   three	   times	  with	   plate	  washing	   buffer	   (100	  µl	   per	  well).	  	  The	  plate	  was	  blocked	  with	  1	  %	  skimmed	  milk	  powder	  in	  TBST	  for	  1	  h.	  	  Fractions	  from	  the	  affinity	  purification	  of	  CTGF	   from	  peritoneal	   fluid	  by	  anti-­‐peptide-­‐CC-­‐6-­‐amino-­‐caproic	  acid-­‐Sepharose	  4B	  were	  serially	  diluted	  (1:2)	  three	  times	  down	  the	  plate	   and	   allowed	   to	   incubate	   at	   37	   °C	   for	   1	   h.	   	   The	   microtitre	   plate	   was	   then	  washed	   three	   times	   with	   plate	   washing	   buffer	   (100	   µl	   per	   well).	   	   Anti-­‐peptide-­‐biotin	  antibody	  (1:350)	  was	  added	  to	   the	  wells	  of	   the	  microtitre	  plate	  (50	  µl	  per	  well)	  and	  allowed	  to	  incubate	  37	  °C	  for	  1	  h.	  	  The	  microtitre	  plate	  was	  then	  washed	  three	  times	  with	  plate	  washing	  buffer	  (100	  µl	  per	  well).	  	  Anti-­‐biotin-­‐HRP	  antibody	  (1:1000)	   was	   added	   to	   the	   wells	   of	   the	   microtitre	   plate	   (50	   µl	   per	   well)	   and	  allowed	   to	   incubate	   37	   °C	   for	   1	   h.	   	   The	  microtitre	   plate	  was	   then	  washed	   three	  times	   with	   plate	   washing	   buffer	   (100	   µl	   per	   well).	   	   The	   microtitre	   plate	   was	  developed	   using	   the	  ABTS	   liquid	   substrate.	   	   The	   plate	  was	   subsequently	   read	   at	  405	  nm	  using	  an	  ELISA	  plate	  reader.	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Sequencing	   of	   protein	   bands	   isolated	   by	   the	   purification	   of	  
CTGF	   from	  peritoneal	   fluid	  by	  anti-­‐peptide-­‐CC-­‐6-­‐amino-­‐caproic	  
acid-­‐Sepharose	  4B	  	  Protein	  bands	  that	  were	  identified	  by	  the	  Western	  blot	  were	  excised	  from	  gels	  that	  have	  been	   stained	  and	  de-­‐stained	  using	   the	  protocol	   from	  Pierce	  Silver	   Stain	   for	  Mass	   Spectrometry	   (Pierce).	   	   These	   excised	   protein	   bands	   were	   then	   kindly	  sequenced	  by	  Dr	  Xiaoke	  Yin	  of	  the	  Cardiovascular	  Division,	  King’s	  College,	  London.	  	  	  	  
6.6	  Depletion	  of	   albumin	   from	   concentrated	  peritoneal	  
dialysis	  fluid	  	  	  The	  depletion	  of	  albumin	  from	  peritoneal	  dialysis	  fluid	  was	  modified	  from	  (Chen	  et	  al.	  2005).	  	  Four	  volumes	  of	  ice-­‐cold	  10	  %	  trichloroacetic	  (TCA)	  acid	  in	  acetone	  was	  added	  to	  one	  volume	  of	  volume–reduced	  peritoneal	  dialysis	  fluid.	   	  The	  peritoneal	  dialysis	  fluid	  was	  concentrated	  using	  an	  Amicon	  Ultra	  Filter	  unit.	  	  The	  solution	  was	  mixed	  immediately	  by	  gentle	  vortexing,	  and	  then	  incubated	  at	  –	  20	  °C	  for	  90	  min.	  	  The	  sample	  was	  then	  centrifuged	  at	  13500	  ×	  g,	  4	  °C	  for	  30	  min.	   	  The	  supernatant	  was	  removed	  and	  collected	  and	  five	  volumes	  of	  ice-­‐cold	  acetone	  were	  used	  to	  wash	  the	   precipitate.	   	   The	   sample	   was	   allowed	   to	   stand	   on	   ice	   for	   15	   min	   and	   was	  centrifuged	   again.	   	   Ten	   volumes	   of	   ice-­‐cold	   acetone	  were	   added	   to	   the	   collected	  supernatant	  to	  precipitate	  any	  proteins	  and	  the	  sample	  was	  also	  centrifuged.	  	  The	  pellets	  obtained	  from	  both	  the	  pellet	  and	  the	  supernatant	  was	  dried	  overnight	  by	  a	  continuous	  flow	  of	  air.	  	  The	  dried	  samples	  were	  stored	  at	  –	  20	  °C	  until	  further	  use.	  	  	  	  
Western	   blot	   analysis	   of	   albumin-­‐depleted	   peritoneal	   dialysis	  
fluid	  	  The	  SDS-­‐PAGE	  and	  Western	  blotting	  protocol	  was	  carried	  out	  in	  the	  same	  manner	  as	  in	  6.2.2.	  	  One	  blot	  was	  then	  probed	  with	  the	  anti-­‐peptide-­‐biotin	  and	  anti-­‐biotin-­‐HRP	  antibodies	  and	  another	  blot	  was	  probed	  with	  the	  anti-­‐CTGF	  (Santa	  Cruz)	  and	  anti-­‐mouse	  IgG	  peroxidase	  antibodies.	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Sequencing	   of	   protein	   bands	   isolated	   by	   the	   Western	   blot	  
analysis	   of	   albumin-­‐depleted	   peritoneal	   dialysis	   fluid	   by	   LC-­‐
MS/MS	  	  Protein	  bands	  that	  were	  identified	  by	  the	  Western	  blot	  were	  excised	  from	  gels	  that	  have	  been	   stained	  and	  de-­‐stained	  using	   the	  protocol	   from	  Pierce	  Silver	   Stain	   for	  Mass	   Spectrometry	   (Pierce).	   	   These	   excised	   protein	   bands	   were	   then	   kindly	  sequenced	  by	  Dr	  Xiaoke	  Yin	  of	  the	  Cardiovascular	  Division,	  King’s	  College,	  London	  by	  LC-­‐MS/MS.	  	  
6.7	  Results	  for	  the	  affinity	  purification	  of	  CTGF	  using	  the	  
anti-­‐peptide	  Sepharose	  4B	  	  
Western	   blot	   analysis	   of	   fractions	   obtained	   from	   the	  
purification	   of	   CTGF	   from	   peritoneal	   dialysis	   fluid	   by	   anti-­‐
peptide-­‐CC-­‐6-­‐amino-­‐caproic	  acid-­‐Sepharose	  4B	  	  Section	  6.3.2	   showed	   that	  apoliproprotein	  B	  and	  coagulation	   factor	  XI	  present	   in	  the	   peritoneal	   dialysis	   fluid	   also	   bound	   to	   the	   Heparin	   HiTrap	   column.	   	   This	  renders	  the	  Heparin	  HiTrap	  column	  unsuitable	  to	  be	  used	  in	  the	  isolation	  of	  CTGF	  from	  peritoneal	  dialysis	  fluid.	  	  An	  alternative	  method	  was	  required,	  which	  resulted	  in	   the	   coupling	   of	   the	   anti-­‐peptide	   antibody	   to	   Sepharose	   4B.	   	   This,	   in	   theory,	  would	   bind	   only	   to	   the	   C-­‐terminus	   of	   CTGF	   or	   its	   fragments	   that	   contain	   the	  peptide	   sequence	   (Phe-­‐Glu-­‐Ser-­‐Leu-­‐Tyr-­‐Tyr-­‐Arg-­‐Lys-­‐Met-­‐Tyr-­‐Gly-­‐Asp-­‐Met-­‐Ala).	  	  Blots	  (a)	  and	  (b)	  of	  figure	  6.6	  show	  the	  washes	  and	  eluted	  fractions	  obtained	  from	  the	   purification	   of	   CTGF	   by	   the	   anti-­‐peptide-­‐CC-­‐6-­‐amino-­‐caproic	   acid-­‐Sepharose	  4B	  column.	  	  The	  blots	  were	  developed	  with	  the	  anti-­‐peptide-­‐biotin	  and	  anti-­‐biotin-­‐HRP.	  	  Blot	  (a),	  which	  contains	  the	  washes,	  shows	  a	  band	  present	  in	  lanes	  2,	  3	  and	  4	  at	  around	  72	  kDa.	  	  The	  intensity	  of	  the	  band	  increases	  in	  lane	  3,	  and	  then	  decreases	  in	  lane	  4.	  	  Blot	  (b)	  contains	  a	  single	  band	  in	  lane	  1,	  also	  at	  72	  kDa.	  	  The	  presence	  of	  bands	  of	   the	   same	  molecular	  weights	   in	   the	  wash	  as	  well	   as	   the	  eluted	   fractions	  imply	   that	   the	   column	  may	  have	  been	  overloaded	  due	   to	   the	   low	  capacity	  of	   the	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Figure 6.6 Western blot of the fractions obtained from the purification of CTGF from peritoneal 
dialysis fluid by the anti-peptide-CC-6-amino-caproic acid-Sepharose 4B.  Lanes 1-4 in (a): 
wash fractions.  Lanes 1-2 in (b): Eluted fractions.  Protein bands (A) and (B) observed at 72 
kDa.   	  
Assessment	   of	   fractions	   from	   the	   purification	   of	   CTGF	   from	  
peritoneal	   dialysis	   fluid	   by	   anti-­‐peptide-­‐CC-­‐6-­‐amino-­‐caproic	  
acid-­‐Sepharose	  4B	  by	  sandwich	  ELISA	  	  To	   show	   the	   elution	   profile	   of	   the	   purification	   process,	   a	   sandwich	   ELISA	   was	  carried	  out	  on	  the	  fractions	  obtained.	  	  By	  performing	  an	  ELISA,	  the	  competence	  of	  the	   anti-­‐peptide-­‐CC-­‐6-­‐amino-­‐caproic	   acid-­‐Sepharose	   4B	   can	   be	   ascertained.	   	   The	  ELISA	   results	   can	   be	   compared	   with	   the	   Western	   blots	   to	   obtain	   further	  confirmation	   of	   the	   protein	   of	   interest,	   in	   this	   case	   CTGF.	   	   Figure	   6.7	   shows	   the	  elution	   profile	   of	   the	   purification	   of	   CTGF	   from	   peritoneal	   dialysis	   fluid	   by	   anti-­‐
	   127	  
peptide-­‐CC-­‐6-­‐amino-­‐caproic	   acid-­‐Sepharose	   4B.	   	   The	   absorbance	   is	   shown	   to	  decrease	   from	   the	   supernatant	   (S)	   right	   down	   to	   the	   last	   eluted	   fraction	   (E2).	  	  There	   are	   no	   distinct	   peaks	   of	   washed	   and	   eluted	   fractions,	   where	   a	   first	   peak	  would	  indicate	  the	  proteins	  not	  bound	  to	  the	  column,	  and	  the	  second	  peak	  would	  be	  observed	  once	  the	  elution	  solution	  was	  applied	  to	  the	  column.	  	  This	  may	  imply	  that	   the	   coupling	   process	   between	   the	   anti-­‐peptide	   antibody	   and	   Sepharose	   4B	  may	  be	  flawed.	  	  This	  will	  result	  in	  a	  low	  capacity	  gel,	  where	  very	  little	  anti-­‐peptide	  antibody	  has	  bound	  to	  Sepharose	  4B,	  which	  in	  turn	  leads	  to	  very	  little	  CTGF	  being	  isolated.	   	   Another	   consequence	   of	   a	   flawed	   coupling	   procedure	   is	   that	   no	   anti-­‐peptide	  antibody	  was	  coupled	  to	  Sepharose	  4B,	  causing	  all	  the	  proteins,	  including	  CTGF,	  to	  be	  washed	  through	  the	  column.	  	  	  	  
	  
Figure. 6.7 ELISA of the fractions obtained from the purification of CTGF from peritoneal 
dialysis fluid by anti-peptide-CC-6-amino-caproic acid-Sepharose 4B.  S: supernatant, W1-W3: 
washes, E1-E2: eluted fractions.   	  
6.5.3	  Analysis	  of	  results	  obtained	  from	  LC-­‐MS/MS	  	  	  	  LC-­‐MS/MS	   was	   used	   to	   sequence	   the	   protein	   bands	   that	   were	   suspected	   to	   be	  CTGF	  or	   its	   fragments/polymers.	   	  The	  result	  obtained	  from	  the	  analysis	  confirms	  that	   the	   band	   at	   72	   kDa	   was	   albumin	   (table	   6.2.1),	   which	   leads	   to	   several	  conclusions.	   	  The	  immunogens	  used	  to	  raise	  both	  the	  anti-­‐peptide	  and	  anti-­‐biotin	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antibodies	  were	  not	  pure.	   	  The	  anti-­‐peptide-­‐biotin	  antibody	  was	  not	  pure	  enough	  because	  it	  was	  not	  affinity-­‐purified,	  which	  resulted	  in	  the	  presence	  of	  anti-­‐albumin	  antibodies.	   	  The	  result	  obtained	  from	  the	  analysis	  shows	  that	  the	  band	  at	  72	  kDa	  was	   likely	   albumin,	   which	   leads	   to	   the	   conclusion	   that	   the	   anti-­‐peptide-­‐biotin	  serum	  may	   not	   have	   been	   sufficiently	   pure	   for	   the	   purpose	   because	   it	   was	   not	  affinity-­‐purified,	  resulting	  in	  the	  presence	  of	  anti-­‐albumin	  antibodies.	  	  
Molecular	  
weight	   Protein	  name	   Mw	  (Da)	  




72	  kDa	   Serum	  albumin	   69,349	   34	   55.00%	  	   Keratin,	   type	   II	  cytoskeletal	  1	   66,022	   10	   17.20%	  	   Serotransferrin	   77,032	   8	   11.90%	  
 
Table 6.1 Table showing data obtained from LC-MS/MS of the excised gel bands.  A gel band 
was cut at 72 kDa.  The protein highlighted in bold is the most likely protein that have been 
identified.  The number of its unique peptides and its percentage sequence coverage 
determined the probability of the presence of a protein.   
 
6.8	  Results	  for	  the	  depletion	  of	  albumin	  from	  peritoneal	  
dialysis	  fluid	  	  
Western	   blot	   analysis	   of	   concentrated	   albumin-­‐depleted	  
peritoneal	  dialysis	  fluid	  	  	  A	   cheap	   and	   efficient	  method	   of	   depleting	   albumin	  was	   required	   to	   remove	   this	  protein	  from	  peritoneal	  dialysis	  fluid.	  	  The	  commercial	  kits	  available	  are	  too	  costly,	  and	  cannot	  handle	  larger	  volumes	  (10	  ml	  and	  up).	  	  Chen	  et	  al.	  (2005)	  described	  a	  method	   of	   efficiently	   depleting	   albumin	   from	   serum	   using	   acetone	   and	  trichloroacetic	  acid	  as	  trichloroacetic	  acid-­‐albumin	  complex	   is	  soluble	   in	  solvents	  such	  as	  acetone.	  	  This	  method	  was	  applied	  to	  concentrated	  peritoneal	  dialysis	  fluid	  and	   figure	   6.8	   shows	   the	  Western	   blots	   of	   the	   pellet	   and	   supernatant	   from	   the	  precipitation	   of	   proteins	   from	   peritoneal	   dialysis	   fluid.	   	   Blot	   (a)	   was	   developed	  with	  the	  anti-­‐peptide-­‐biotin	  antibodies	  and	  blot	  (b)	  was	  developed	  with	  the	  anti-­‐CTGF	   (Santa	   Cruz)	   and	   anti-­‐mouse	   IgG	  peroxidase	   antibodies.	   	   The	  precipitation	  process	  was	  done	  in	  duplicates	  and	  the	  pellets	  are	  represented	  in	  lanes	  2	  and	  4	  of	  blots	   (a)	  and	   (b),	   and	   the	  supernatants	  are	   represented	   in	   lanes	  1	  and	  3	  of	  both	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blots.	   	   Lane	   5	   in	   both	   blots	   represents	   the	   concentrated	   peritoneal	   dialysis	   fluid	  before	   precipitation.	   	   It	   is	   shown	   on	   blots	   (a)	   and	   (b)	   that	   albumin	   has	   been	  efficiently	  removed	  through	  this	  process.	   	  Lanes	  1	  and	  3	  of	  both	  blots	  show	  only	  one	  band	  at	  72	  kDa,	  which	   from	  LC-­‐MS/MS	  analysis	   is	   confirmed	   to	  be	  albumin.	  	  This	  confirms	  that	  albumin	  did	  not	  precipitate	  when	  the	  10	  %	  trichloroacetic	  acid	  in	   acetone	   was	   added	   to	   the	   concentrated	   peritoneal	   dialysis	   fluid.	   	   Looking	   at	  lanes	  2	  and	  4	  of	  both	  blots,	  a	  range	  of	  proteins	  of	  varying	  molecular	  weights	  have	  been	   detected	   by	   both	   the	   anti-­‐peptide-­‐biotin	   and	   anti-­‐CTGF	   (Santa	   Cruz)	  antibodies.	  	  A	  band	  at	  72	  kDa	  is	  noticeably	  absent,	  which	  further	  confirms	  that	  the	  depletion	  of	  albumin	  from	  the	  concentrated	  peritoneal	  dialysis	  fluid	  was	  a	  success.	  	  Lane	  5	  of	  both	  blots	  shows	  a	  very	  heavy	  band	  at	  72	  kDa,	  which	  is	  now	  known	  to	  be	  albumin.	   	  With	   the	   removal	  of	  albumin,	   it	   is	  now	  possible	   to	   locate	  CTGF	  and	   its	  fragments	  from	  the	  Western	  blots	  for	  mass	  spectrometry	  analysis.	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Figure 6.8 Western blots of concentrated albumin-depleted peritoneal dialysis fluid.  Lanes 1 
and 3: Supernatant collected from the precipitation of the peritoneal dialysis fluid.  Lanes 2 and 
4: Precipitated pellet.  Lane 5 Concentrated peritoneal dialysis fluid prior to precipitation. (a): 
Blot developed with anti-peptide-biotin and anti-biotin-HRP.   (b): Blot developed with anti-CTGF 
(Santa Cruz) and anti-mouse IgG peroxidase.   
 
Analysis	  of	  results	  obtained	  from	  LC-­‐MS/MS	  	  	  The	   excised	   gel	   bands	   from	   the	   SDS-­‐PAGE	  of	   the	   albumin-­‐depleted	   concentrated	  peritoneal	  dialysis	   fluid	  were	  predicted	  sequencing	  data	   to	  be	  apolipoprotein	  A1	  (30	  kDa),	  immunoglobulin	  gamma-­‐1	  chain	  C	  region	  (50	  kDa)	  and	  antithrombin	  III	  (55	  kDa).	  	  Table	  6.2	  shows	  the	  proteins	  that	  are	  most	  likely	  to	  be	  present.	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Molecular	  
weight	   Protein	  name	   Mw	  (Da)	  
Number	   of	   unique	  
peptides	  
%	   sequence	  
coverage	  
30	  kDa	   Apolipoprotein	  A-­I	   30,760.50	   11	   42.70%	  	   Ig	   lambda	   chain	   C	  regions	   11,218.10	   5	   62.90%	  
50	  kDa	   Ig	   gamma-­1	   chain	   C	  
region	   36,087.00	   11	   34.20%	  	   Alpha-­‐1-­‐antitrypsin	   46,719.90	   7	   20.30%	  	   Beta-­‐2-­‐glycoprotein	  1	   38,280.50	   9	   35.90%	  
55	  kDa	   Alpha-­1-­antitrypsin	   46,719.90	   17	   41.60%	  
	   Antithrombin-­III	   52,586.00	   17	   39.00%	  	   Alpha-­‐1-­‐antichymotrypsin	   47,634.90	   10	   24.10%	  
 
Table 6.2 Table showing data obtained from LC-MS/MS of the excised gel bands.  Gel bands 
were cut at 30, 50 and 55 kDa.  The proteins highlighted in bold are the most likely proteins that 
have been identified.  The number of its unique peptides and its percentage sequence coverage 
determined the probability of the presence of a protein.   	  
6.6	  Discussion	  	  It	   is	  of	  utmost	   importance	  to	  be	  able	  to	  detect	  and	   isolate	  CTGF	  in	  diabetic	  urine	  and	  peritoneal	  dialysis	  fluid	  samples	  because	  of	  the	  involvement	  of	  this	  protein	  in	  fibrosis.	   	   To	   date,	   CTGF	   has	   not	   been	   purified	   from	   any	   human	   fluid	   samples.	  	  Published	   data	   have	   only	   shown	   the	   purification	   of	   recombinant	   human	   CTGF.	  	  Expressing	  CTGF	  from	  cells,	  be	  it	  viral	  or	  bacterial,	  will	  produce	  a	  protein	  molecule	  with	   the	   identical	   amino	   acids	   contained	   in	   CTGF,	   but	   this	   does	   not	   mimic	  conditions	  in	  vivo.	  	  Two	  groups	  (Ball	  et	  al.	  2003;	  Riser	  et	  al.	  2000)	  have	  shown	  that	  CTGF	  binds	  to	  heparin,	  and	  that	  it	  was	  possible	  to	  purify	  recombinant	  human	  CTGF	  from	  in	  vitro	  conditioned	  media,	  whose	  contents	  is	  highly	  controlled	  compared	  to	  clinical	   samples.	   	   It	  was	   found	   to	  be	  not	   as	   straightforward	  when	   this	   technique	  was	   applied	   to	   peritoneal	   dialysis	   fluid.	   	   LC-­‐MS/MS	   showed	   that	   other	   proteins	  present	  in	  the	  peritoneal	  dialysis	  fluid	  (apolipoprotein	  B	  and	  coagulation	  factor	  XI)	  also	   bind	   to	   heparin.	   	   Therefore,	   it	   was	   not	   possible	   to	   continue	   using	   this	  technique	  to	  isolate	  CTGF,	  as	  it	  was	  not	  specific	  enough.	  	  Western	  blot	  analysis	  of	  the	  peritoneal	  dialysis	   fluid	   showed	   that	   the	  anti-­‐sheep	   IgG	  peroxidase	  antibody,	  by	   itself,	  detects	  proteins	  present	   in	  the	  peritoneal	  dialysis	   fluid.	   	  This	  makes	  the	  anti-­‐sheep	   IgG	   peroxidase	   antibody	   unsuitable	   for	   use	   in	   further	   immunoassays.	  	  Biotin	  is	  not	  known	  to	  be	  present	  in	  peritoneal	  dialysis	  fluid	  or	  urine,	  therefore	  the	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anti-­‐peptide-­‐biotin	   and	   anti-­‐biotin-­‐HRP	   antibodies	   were	   deemed	   to	   be	   an	   ideal	  detection	  system	  for	  CTGF.	  	  Comparison	  of	  Western	  blots	  of	  the	  peritoneal	  dialysis	  fluid	  developed	  with	  the	  anti-­‐peptide-­‐biotin	  and	  the	  commercial	  anti-­‐CTGF	  (Santa	  Cruz)	  antibodies	  showed	  that	  both	  antibodies	  detected	  the	  similar	  sized	  proteins.	  	  This	   result	   in	   itself	   encouraging	   because	   it	   was	   the	   first	   time	   the	   anti-­‐peptide-­‐biotin	  antibody	  was	  compared	  with	  a	  commercial	  antibody.	  	  Another	   method	   was	   required	   to	   isolate	   CTGF	   from	   peritoneal	   dialysis	   fluid,	  therefore	   the	   anti-­‐peptide	   antibody	   was	   conjugated	   to	   Sepharose	   4B	   with	   the	  intention	  of	  affinity	  purifying	  CTGF.	  	  It	  was	  found,	  from	  Western	  blot	  analysis	  and	  ELISA,	   that	   the	   anti-­‐peptide-­‐CC-­‐6-­‐amino-­‐caproic	   acid-­‐Sepharose	   4B	   could	   be	  flawed.	   	   This	   resulted	   in	   the	   identification,	   by	   LC-­‐MS/MS,	   of	   albumin	   present	   in	  peritoneal	  dialysis	   fluid.	   	  The	   identification	  of	  albumin	   led	   to	   the	  conclusion	   that	  the	   presence	   of	   this	   protein,	   being	   one	   of	   the	   most	   abundant	   proteins,	   in	   the	  peritoneal	   dialysis	   fluid	   could	   be	   preventing	   CTGF	   from	   being	   identified	   by	   LC-­‐MS/MS.	   	  Albumin	  was	  depleted	   from	  the	  peritoneal	  dialysis	   fluid	  using	  a	  method	  adapted	   from	  Chen	  et	  al.	   (2005).	   	  Commercially	  available	  kits	  are	  expensive,	  and	  can	  only	  handle	  microlitre	  quantities	  of	  fluid.	  	  This	  method	  allowed	  albumin	  to	  be	  depleted	  from	  large	  volumes	  of	  peritoneal	  dialysis	  fluid.	   	  ELISA	  performed	  on	  the	  albumin-­‐depleted	  peritoneal	  dialysis	   fluid	  did	  not	  show	  any	  response	  against	   the	  anti-­‐peptide	  biotin	  and	  the	  anti-­‐CTGF	  (Santa	  Cruz)	  antibodies.	  	  The	  response	  of	  the	  peritoneal	  dialysis	  fluid	  to	  the	  NWA	  antibody	  was	  not	  expected,	  and	  may	  be	  falsely	  high.	  	  One	  of	  the	  reasons	  to	  expect	  an	  exaggerated	  signal	  is	  that	  the	  anti-­‐sheep	  IgG	  peroxidase	   antibody	   used	   as	   the	   secondary	   antibody	   was	   found	   to	   bind	   other	  proteins	  than	  sheep	  IgG,	  including	  human	  IgG	  (chapter	  3).	  	  The	  antibody	  could	  also	  be	  detecting	  human	  IgG,	  which	  would	  be	  structurally	  similar	  to	  sheep	  IgG.	  Because	  the	  peritoneal	  dialysis	  fluid	  was	  obtained	  from	  only	  one	  patient,	  the	  most	  sensible	  thing	  to	  do	  was	  to	  obtain	  more	  patient	  samples	  so	  that	  analyses	  could	  be	  carried	  out	  and	  compared	  between	  patients.	  	  	  	  The	  method	  of	   assessing	   proteins	   identified	   through	  Western	   blot	   by	   LC-­‐MS/MS	  proved	  to	  be	  crucial	  in	  the	  identification	  of	  the	  presence	  (or	  absence)	  of	  CTGF	  from	  diabetic	  urine	  and	  peritoneal	  dialysis	  fluid.	  	  This	  chapter	  has	  shown	  that	  it	  is	  better	  to	  err	  on	  the	  side	  of	  caution	  by	  not	  assuming	  that	  an	  antibody	  will	  be	  specific	  to	  its	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target	  protein	  only.	  	  By	  utilising	  techniques,	  like	  LC-­‐MS/MS,	  it	  is	  possible	  to	  have	  a	  more	   accurate	   identification	   of	   proteins	   like	   CTGF,	   thereby	   resulting	   in	   more	  accurate	  assay	  development.	  	  	  	  Conclusion:	  	  Other	   proteins,	   besides	   CTGF,	   were	   found	   to	   bind	   to	   the	   heparin	   column.	   	   The	  approach	  to	  making	  the	  anti-­‐CTGF	  peptide	  Sepharose	  4B	  column	  was	  also	  found	  to	  be	   not	   viable.	   	   Albumin	  was	   found	   to	   be	   present	   in	   the	   peritoneal	   dialysis	   fluid.	  	  This	   in	   turn	   affected	   the	   result	   of	   the	   LC-­‐MS/MS	   analysis.	   	   Albumin	   was	  successfully	  removed	  from	  the	  peritoneal	  dialysis	  fluid	  using	  a	  method	  modified	  by	  Chen	  et	  al	  (2005),	  and	  therefore	  used	  routinely	  in	  the	  subsequent	  chapter.	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Chapter	  7	  
Characterization	  of	  CTGF	  in	  diabetic	  urine	  
and	  peritoneal	  dialysis	  fluid	  using	  
immunoassays	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7.1	  Introduction	  	  In	  chapter	  6,	  various	  different	  methods	  of	  purifying	  CTGF	  from	  peritoneal	  dialysis	  fluid	   were	   introduced	   and	   carried	   out	   without	   much	   success.	   	   Sequencing	   of	  protein	   bands	   probed	   with	   the	   anti-­‐CTGF	   peptide-­‐biotin	   and	   commercial	   anti-­‐CTGF	  antibodies	  showed	  that	  albumin	  was	  found	  to	  be	  present	  in	  the	  samples.	  	  In	  order	  to	  circumvent	  this	  problem,	  an	  albumin-­‐depletion	  method	  was	  incorporated	  so	   that	   albumin	   was	   removed	   from	   to	   the	   peritoneal	   dialysis	   fluid	   and	   diabetic	  urine	  samples	  prior	  to	  any	  further	  study.	  	  	  	  The	  anti-­‐CTGF	  peptide-­‐biotin	  and	  commercial	  anti-­‐CTGF	  antibodies	  were	  used	   in	  chapter	  6.	  	  This	  chapter	  includes	  the	  additional	  NWA	  antibody	  (Protein	  G	  purified)	  for	   the	   identification	   of	   CTGF	   as	   well	   as	   the	   commercial	   anti-­‐CTGF	   antibody	  because	   the	  NWA	  antibody	  was	  also	  raised	  against	   the	  whole	   recombinant	  CTGF	  molecule.	  	  The	  patient	  samples	  were	  assessed	  by	  ELISA	  as	  well	  as	  by	  Western	  blot	  to	  determine	  their	  specificity	  and	  affinity.	  	  	  	  The	   results	   obtained	   using	   two-­‐dimensional	   electrophoresis	   on	   CTGF	   samples	   is	  reported	   in	   this	   chapter.	   	   This	   technique	   separates	   proteins	   according	   to	   their	  molecular	  weight	  as	  well	  as	  their	  isoelectric	  points.	  	  The	  isolelectric	  point	  of	  CTGF	  is	  predicted	  to	  be	  8.0	  (Mizutani	  et	  al.	  2010).	  	  Separation	  of	  the	  proteins	  in	  patient	  samples	  in	  this	  manner	  will	  define	  the	  characterization	  of	  CTGF	  more	  precisely.	  	  	  	  Aims:	  	  To	  obtain	  a	  high-­‐response	  sample	  each	  from	  peritoneal	  dialysis	  fluid	  and	  diabetic	  urine	  to	  be	  used	  in	  2D	  analysis.	  	  	  To	  assess	  peritoneal	  dialysis	  fluid	  and	  diabetic	  urine	  samples	  by	  ELISA	  using	  three	  antibodies.	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7.2	  Protein	  G	  purification	  of	  NWA	  antibody	  	  Protein	   G	   beads	   (Sigma	   Aldrich)	   were	   packed	   into	   a	   glass	   column	   and	   run	  according	   to	   the	   according	   to	   the	   manufacturer’s	   instructions.	   	   NWA	   antiserum	  was	  diluted	   in	  15	  ml	  50	  mM	  sodium	  phosphate,	  100	  mM	  sodium	  chloride	  pH	  7.4	  and	  loaded	  onto	  the	  protein	  G	  column.	  	  The	  NWA	  antibody	  was	  eluted	  using	  50	  mM	  glycine	  pH	  3.5	  and	  the	  fractions	  were	  neutralised	  with	  150	  µl	  of	  0.5	  M	  Tris.	   	  The	  purification	   steps	   were	   monitored	   at	   280	   nm	   using	   a	   spectrophotometer.	   	   The	  eluted	   NWA	   antibody	   fractions	   were	   pooled	   and	   the	   volume	   was	   reduced	   and	  equilibrated	  (against	  50	  mM	  sodium	  phosphate,	  100	  mM	  sodium	  chloride	  pH	  7.4)	  using	   an	   Amicon	   Ultra-­‐4	   Filter	   unit	   (Millipore).	   	   Equal	   volumes	   of	   saturated	  ammonium	  sulphate	  was	  added	  to	  the	  purified	  NWA	  sample	  and	  stored	  at	  4	  °C.	  	  	  	  
Assessment	  of	  protein	  G	  purified	  NWA	  by	  Western	  blot	  analysis	  	  The	  SDS-­‐PAGE	  and	  Western	  blotting	  protocol	  was	  carried	  out	  in	  the	  same	  manner	  as	  in	  6.2.2.	  	  One	  blot	  was	  then	  probed	  with	  the	  NWA	  and	  anti-­‐sheep	  IgG	  peroxidase	  antibodies	  and	  another	  blot	  was	  probed	  with	  the	  anti-­‐CTGF	  (Santa	  Cruz)	  and	  anti-­‐mouse	  IgG	  peroxidase	  antibodies.	  	  	  
Assessment	   of	   albumin-­‐depleted	   peritoneal	   dialysis	   fluid	   by	  
ELISA	   using	   anti-­‐peptide-­‐biotin,	   NWA	   and	   anti-­‐CTGF	   (Santa	  
Cruz)	  antibodies	  	  Peritoneal	   dialysis	   fluid	   (50	   µl)	   was	   added	   to	   the	   top	   row	   (A1	   –	   A12)	   of	   a	  microtitre	  plate	  containing	  100	  µl	  of	  50	  mM	  sodium	  phosphate,	  100	  mM	  sodium	  chloride	  pH	  7.4.	  	  The	  peritoneal	  dialysis	  fluid	  was	  then	  serially	  diluted	  downwards	  	  (1:3).	   	   The	   microtitre	   was	   then	   allowed	   to	   incubate	   overnight	   at	   4	   °C.	   	   The	  microtitre	  plate	  was	   then	  washed	   three	   times	  with	  plate	  washing	  buffer	   (100	  µl	  per	  well).	  	  The	  plate	  was	  blocked	  with	  1	  %	  skimmed	  milk	  powder	  in	  TBST	  for	  1	  h.	  	  Anti-­‐peptide-­‐biotin	   antibody,	   anti-­‐CTGF	   (Santa	   Cruz)	   antibody	   and	   protein	   G-­‐purified	  NWA	  antibody	  (all	  at	  a	  dilution	  factor	  of	  1:1500)	  were	  added	  to	  the	  wells	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of	   the	   microtitre	   plate	   (50	   µl	   per	   well)	   as	   shown	   in	   figure	   6.8	   and	   allowed	   to	  incubate	   37	   °C	   for	   1	   h.	   	   The	  microtitre	   plate	  was	   then	  washed	   three	   times	  with	  plate	  washing	  buffer	  (100	  µl	  per	  well).	  	  The	  respective	  second	  antibodies	  (1:1500)	  were	   added	   to	   the	  wells	   of	   the	  microtitre	   plate	   (50	  µl	   per	  well)	   and	   allowed	   to	  incubate	  37	   °C	   for	  1	  h.	   	   The	  microtitre	  plate	  was	  washed	   three	   times	  with	  plate	  washing	  buffer	   (100	  µl	  per	  well)	  and	  developed	  using	   the	  ABTS	   liquid	  substrate.	  	  The	  plate	  was	  then	  subsequently	  read	  at	  405	  nm	  using	  an	  ELISA	  plate	  reader.	  	  	  	  
	  
Figure 7.1 Serial dilution of peritoneal dialysis fluid on a microtitre plate.  The peritoneal dialysis 
fluid samples were assayed in duplicate.  
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7.3	   Results	   of	   the	   purification	   of	   NWA	   antibody	   by	  
Protein	  G	  	  
Assessment	   of	   the	   purified	   NWA	   antibody	   by	   Western	   blot	  
analysis	  	  It	  was	   demonstrated	   in	   chapter	   3	   that	   the	  NWA	   antibody	  was	   not	   as	   specific	   as	  required	  in	  the	  present	  study.	  	  One	  of	  the	  ways	  to	  overcome	  this	  issue	  was	  to	  pass	  the	  antibody	  through	  a	  protein	  G	  column,	  to	  purify	  the	  immunoglobulin	  fractions	  from	  the	  serum.	  	  The	  protein	  G-­‐purified	  NWA	  antibody	  was	  then	  used	  to	  probe	  for	  CTGF	   in	   the	  Western	   blot	   analysis	   of	   concentrated	   albumin-­‐depleted	   peritoneal	  dialysis	  fluid	  seen	  in	  7.2	  a	  compared	  with	  the	  anti-­‐CTGF	  (Santa	  Cruz)	  shown	  in	  7.2	  
b.	  	  Lanes	  1	  and	  2	  of	  both	  blots	  show	  the	  concentrated	  albumin-­‐depleted	  peritoneal	  dialysis	  fluid.	   	  Both	  antibodies	  detect	  similar	  protein	  bands	  (A,	  B,	  C	  and	  D)	  in	  the	  samples.	   	   The	   intensity	   of	   the	   bands	   is	   greater	   when	   probed	   with	   the	   NWA	  antibody	  compared	  to	  the	  anti-­‐CTGF	  (Santa	  Cruz)	  antibody.	  	  Both	  antibodies	  were	  raised	   against	   recombinant	   CTGF	   of	   human	   origin,	   albeit	   that	   NWA	   was	   a	  polyclonal	  antibody	  that	  was	  raised	  in	  sheep	  and	  the	  anti-­‐CTGF	  (Santa	  Cruz)	  was	  a	  monoclonal	  mouse	  antibody.	  	  It	  is	  encouraging	  that	  the	  NWA	  antibody	  indentified	  similar,	  if	  not	  the	  same	  bands,	  as	  the	  commercial	  anti-­‐CTGF	  (Santa	  Cruz)	  antibody.	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Figure 7.2 Western blots of concentrated albumin depleted peritoneal dialysis fluid. (a): Blot 
developed with NWA and anti-sheep IgG peroxidase.  (b): Blot developed with anti-CTGF 
(Santa Cruz) and anti-mouse IgG peroxidase.  Lanes 1 and 2 are the pellets obtained from the 
precipitation and centrifugation of the concentrated peritoneal dialysis fluid.  Bands A (140 kDa), 
B (95 kDa) C (60 kDa) and D (30 kDa) corresponds to the bands that have been identified on 
both blots. 	  
Assessment	   of	   albumin-­‐depleted	   peritoneal	   dialysis	   fluid	   by	  
ELISA	   using	   anti-­‐peptide-­‐biotin,	   NWA	   and	   anti-­‐CTGF	   (Santa	  
Cruz)	  antibodies	  	  An	  ELISA	  assay	  was	  carried	  out	  to	  compare	  the	  binding	  properties	  of	  the	  anti-­‐CTGF	  (Santa	   Cruz),	   NWA	   and	   anti-­‐peptide-­‐biotin	   antibodies.	   	   Concentrated	   albumin-­‐depleted	   peritoneal	   dialysis	   fluid	   was	   coated	   onto	   the	   microtitre	   plate	   and	   the	  three	   antibodies	   along	   with	   their	   corresponding	   secondary	   antibodies	   were	  applied	  to	   the	  microtitre	  plate.	   	  Figure	  7.3	  shows	  the	  dilution	  response	  curves	  of	  the	   albumin-­‐depleted	   peritoneal	   dialysis	   fluid.	   	   The	   response	   from	   the	   NWA	  antibody	  is	  shown	  to	  increase	  as	  the	  dilution	  factor	  of	  the	  peritoneal	  dialysis	  fluid	  increases,	  but	  decreases	  at	  about	  dilution	  factor	  1:200.	  	  The	  anti-­‐CTGF	  (Santa	  Cruz)	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produced	   a	   very	   weak	   response,	   and	   the	   anti-­‐peptide-­‐biotin	   antibody	   showing	  little	  or	  no	  response.	  	  The	  reason	  for	  the	  raised	  response	  from	  the	  NWA	  antibody	  could	  be	  due	  to	  the	  fact	  that	  anti-­‐sheep	  IgG	  peroxidase	  was	  used	  as	  the	  secondary	  antibody.	  	  This	  will	  result	  in	  the	  detection	  of	  other	  proteins	  such	  as	  human	  IgG	  that	  are	  present	  in	  the	  peritoneal	  dialysis	  fluid,	  which	  was	  discussed	  in	  chapter	  3.	  	  The	  reason	  for	  the	  weak	  responses	  coming	  from	  the	  anti-­‐CTGF	  (Santa	  Cruz)	  and	  anti-­‐peptide-­‐biotin	  could	  be	  due	  to	  the	  fact	  that	  there	  was	  simply	  very	  little	  or	  no	  CTGF	  present	   in	  the	  peritoneal	  dialysis	   fluid.	   	   It	  should	  be	  noted	  that	  up	  until	  now,	   the	  peritoneal	  dialysis	  fluid	  studied	  was	  obtained	  from	  only	  one	  diabetic	  patient,	  and	  that	  more	  patient	  samples	  should	  be	  assayed	  to	  obtain	  a	  more	  accurate	  insight	  of	  the	  CTGF	  present	  in	  the	  peritoneal	  dialysis	  fluid.	  	  	  	  
	  
Figure. 7.3 Dilution response curves of the albumin-depleted peritoneal dialysis fluid probed 
with the anti-CTGF (Santa Cruz), NWA and anti-peptide-biotin antibodies.  Error bars represent 
standard error and each sample was assayed three times. 
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7.4	   SDS-­‐PAGE	   and	   Western	   blot	   of	   two	   diabetic	   urine	  
samples	  (R23	  and	  R38)	  under	  reducing	  and	  non-­‐reducing	  
conditions	  	  The	  SDS-­‐PAGE	  and	  Western	  blotting	  protocol	  was	  carried	  out	  in	  the	  same	  manner	  as	   in	  6.2.2,	  with	   the	  exception	   that	  β-­‐mercaptoethanol	  was	  omitted	   to	  one	   set	  of	  gels.	  	  The	  Western	  blots	  were	  probed	  with	  the	  NWA	  and	  anti-­‐sheep	  IgG	  peroxidase	  antibodies	   and	   developed	   onto	   photosensitive	   film	   using	   enhanced	  chemiluminecence	  (ECL).	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Figure 7.4 Western blots of R23 and R38 under non-reduced (a and c) and reduced (b and d) conditions.  Blots a and b are sample R38.  Blots c and d are 
sample R23.  Lanes A, B C and D represent the serial dilution of the urine sample where A is undiluted and D has the highest dilution factor.  In blot d, lane A, 
the band at 50 kDa has been circled.  
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 Comparison	  of	  the	  non-­‐reduced	  (a	  and	  c)	  and	  reduced	  (b	  and	  d)	  blots	  of	  R38	  and	  R23	   respectively;	   show	   that	  R23	   contain	  higher	  protein	   content	   than	  R38.	   	  Both	  urine	   samples	   were	   serially	   diluted	   before	   addition	   to	   the	   SDS-­‐PAGE	   gel.	   	   The	  serial	   dilution	   can	   be	   seen	   clearly	   in	   blots	   a,	   c,	   and	   d,	   meaning	   that	   the	   bands	  decrease	   in	   intensity	   as	   the	   dilution	   factor	   increases.	   	   When	   the	   urine	   samples	  were	  run	   in	  non-­‐reduced	  conditions,	  high	  molecular	  weight	  proteins	  (~200	  kDa)	  were	   detected.	   	   When	   the	   urine	   samples	   were	   run	   in	   reduced	   conditions,	   five	  distinct	  bands	  (blot	  b)	  were	  observed.	   	  The	   four	  bands	  had	  molecular	  weights	  of	  approximately	  25	  kDa,	  40	  kDa,	  50	  kDa,	  72	  kDa	  and	  80	  kDa.	   	  The	   total	  molecular	  weights	  of	  these	  protein	  bands	  is	  ~267	  kDa.	   	  The	  25	  kDa	  and	  50	  kDa	  bands	  may	  correspond	   to	   the	   light	   and	   heavy	   chains	   of	   human	   IgG,	   as	   the	   blots	   were	  developed	  using	   the	   commercial	   anti-­‐sheep	   IgG	  peroxidase	   antibody.	   	   There	   is	   a	  probability	  that	  the	  72	  kDa	  band	  is	  albumin,	  and	  the	  identity	  of	  the	  40	  kDa	  and	  80	  kDa	  band	  is	  unknown.	  	  There	  is	  a	  possibility	  that	  the	  40	  kDa	  and	  80	  kDa	  bands	  are	  the	   CTGF	  molecule	   and	   its	   dimer.	   	   Further	   confirmation	   studies	   are	   required	   to	  assess	   the	   identities	   of	   these	   two	   bands.	   	   From	   these	   Western	   blots,	   it	   can	   be	  concluded	  that	  CTGF	  probably	  binds	  to	  different	  proteins	  in	  vivo.	  	  This	  is	  probably	  achieved	   through	   the	   cysteine	   residues	   found	   throughout	   the	   molecule.	   	   This	  makes	   it	   difficult	   to	   identify	  CTGF	  using	  LC-­‐MS/MS	  due	   to	   the	  presence	  of	   these	  proteins.	  	  	  	  
7.5	  Assessment	  of	   five	  peritoneal	  dialysis	   fluid	   samples	  
and	  five	  diabetic	  urine	  samples	  by	  ELISA	  	  Peritoneal	   dialysis	   fluid	   and	   diabetic	   urine	   samples	  were	   assessed	   by	   the	   ELISA	  procedure	  described	  in	  7.2.	  	  	  	  
Results	  of	  the	  ELISA	  of	  five	  peritoneal	  dialysis	  fluid	  samples	  and	  
five	  diabetic	  urine	  samples	  	  	  Patient	   urine	   and	   peritoneal	   dialysis	   samples	   were	   assessed	   by	   ELISA.	   	   The	  samples	  were	  serially	  diluted	  and	  anti-­‐CTGF	  (Santa	  Cruz),	  anti-­‐peptide-­‐biotin	  and	  NWA	   antibodies,	   and	   their	   corresponding	   secondary	   antibodies,	   were	   used	   to	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detect	  the	  presence	  of	  CTGF.	  	  Figures	  7.5	  and	  7.6	  show	  an	  example	  of	  the	  dilution	  response	   curves	   of	   diabetic	   urine	   and	   peritoneal	   dialysis	   fluid	   by	   ELISA.	   	   It	   is	  observed	   in	   figure	   7.5	   that	   the	   response	   from	  anti-­‐peptide-­‐biotin	   to	   the	   diabetic	  urine	   is	   the	  highest	  while	  exhibiting	  typical	  characteristics	  of	  a	  dilution	  response	  curve,	   where	   absorbance	   value	   decreases	   as	   dilution	   factor	   increases.	   	   Both	   the	  anti-­‐CTGF	  (Santa	  Cruz)	  and	  NWA	  antibodies	  produced	  very	  weak	  responses	  to	  the	  urine	  sample.	  	  While	  all	  three	  antibodies	  are	  targeted	  to	  CTGF,	  their	  responses	  are	  very	  different.	  	  It	  very	  clearly	  shows	  that	  when	  these	  antibodies	  are	  used	  to	  assay	  CTGF	   in	  urine,	   the	  anti-­‐peptide-­‐biotin	  antibody	  produced,	  by	   far,	   the	  best	   results	  compared	   to	   the	   anti-­‐CTGF	   (Santa	   Cruz)	   and	  NWA	   antibodies.	   	   Surprisingly,	   the	  anti-­‐CTGF	   (Santa	   Cruz)	   produced	   the	   weakest	   response,	   even	   though	   it	   is	   a	  commercially	  purchased	  antibody.	  	  	  	  
	  
Figure. 7.5 Dilution response curves of the ELISA of diabetic urine from patient R87 developed 
using the three antibodies.  The anti-peptide-biotin antibody showed the greatest response to 
the diabetic urine compared to the anti-CTGF (Santa Cruz) and the NWA antibodies.  Error bars 
represent standard error and each sample was assayed three times. 	  When	  the	  same	  three	  antibodies	  were	  used	  to	  assay	  the	  peritoneal	  dialysis	  fluid,	  a	  very	  different	  response	  is	  observed	  compared	  to	  figure	  7.5.	  	  The	  peritoneal	  dialysis	  fluid	   (figure	   7.6)	   elicited	   very	  weak	   responses	   from	   anti-­‐CTGF	   (Santa	   Cruz)	   and	  anti-­‐peptide-­‐biotin	   antibodies.	   	   The	   response	   from	   NWA,	   on	   the	   other	   hand,	  increases	   as	   the	   dilution	   factor	   increases.	   	   This	  may	   be	   due	   to	   the	   ‘hook	   effect’,	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where	   an	   antibody	   binding	   sites	   may	   be	   blocked,	   thereby	   producing	   lower	  absorbance	  values	  at	  low	  dilution	  factors.	  	  Even	  so,	  the	  dilution	  response	  curve	  for	  the	  NWA	  antibody	  peaked	  at	  1.0	   absorbance	  units,	  which	   is	   relatively	   low	  when	  comparing	  the	  peak	  of	  2.8	  absorbance	  units	  from	  the	  anti-­‐peptide-­‐biotin	  antibody	  in	  urine	  in	  figure	  7.5.	  	  There	  was	  no	  response	  produced	  from	  the	  anti-­‐CTGF	  (Santa	  Cruz)	   and	   anti-­‐peptide-­‐biotin	   antibodies	   against	   the	  peritoneal	   dialysis	   fluid.	   	   As	  mentioned	   earlier,	   the	   anti-­‐CTGF	   (Santa	   Cruz)	   was	   purchased	   commercially;	  therefore	  it	  was	  expected	  to	  produce	  a	  response	  when	  assayed	  with	  diabetic	  urine	  and	  peritoneal	  dialysis	  samples.	  	  	  	  
	  
Figure. 7.6 Dilution response curves of the ELISA of peritoneal dialysis fluid from patient PD98 
developed using the three antibodies.  The response from the NWA antibody increased as the 
dilution factor of the peritoneal dialysis fluid increased.  There was no response from the anti-
peptide-biotin and the anti-CTGF (Santa Cruz) antibodies.  Error bars represent standard error 
and each sample was assayed three times. 	  Figures	  7.7	  and	  7.8	  show	  the	  range	  of	  absorbance	  values	  from	  all	  the	  diabetic	  urine	  and	   peritoneal	   dialysis	   samples,	   respectively,	   when	   assayed	   with	   all	   three	  antibodies.	   	   When	   the	   diabetic	   urine	   samples	   were	   assayed	   by	   the	   antibodies	  (figure	  7.7),	  the	  anti-­‐peptide-­‐biotin	  antibody	  produced	  the	  highest	  response	  in	  all	  the	   samples	   except	  R74	  when	   compared	   to	   the	  other	   two	  antibodies.	   	   The	  urine	  samples	  assayed	  by	  the	  NWA	  antibody	  gave	  a	  higher	  response	  than	  the	  anti-­‐CTGF	  (Santa	  Cruz)	   antibody.	   	   There	  was	   very	   low	   to	  no	   response	  when	   the	  peritoneal	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dialysis	  fluid	  samples	  were	  assayed	  by	  all	  three	  antibodies	  (figure	  7.8).	  	  One	  of	  the	  reasons	  why	  this	   is	  the	  case	  could	  be	  because	  the	  CTGF	  present	  in	  the	  peritoneal	  dialysis	   fluid	   samples	   is	   very	   dilute,	   and	   therefore	   difficult	   to	   detect.	   	   It	   was	  demonstrated	   in	   previous	   chapters	   that	   the	   anti-­‐sheep	   IgG	   peroxidase	   antibody,	  used	  as	  a	  secondary	  antibody	  to	  the	  NWA	  antibody,	  detected	  proteins	  that	  may	  be	  the	   immunogloulin	   heavy	   chain.	   	   If	   this	   is	   the	   case,	   then	   it	  will	   explain	  why	   the	  response	   from	   the	  NWA	  antibody	   is	   generally	   slightly	  higher	   than	   the	   anti-­‐CTGF	  (Santa	  Cruz)	  antibody.	  	  	  	  
	  
Figure 7.7 Absorbance readings at 405 nm from the five diabetic urine samples when undiluted.  
An indirect ELISA was performed using the anti-CTGF (Santa Cruz), anti-peptide and NWA 
antibodies.  Each bar represents a single antibody dilution factor.   	  
	   147	  
	  
Figure. 7.8 Absorbance readings at 405 nm from the five peritoneal dialysis fluid samples when 
undiluted.  An indirect ELISA was performed using the anti-CTGF (Santa Cruz), anti-peptide 
and NWA antibodies.  Each bar represents a single antibody dilution factor.   
 
7.6	   Two	   dimensional	   electrophoresis	   of	   one	   peritoneal	  
dialysis	  fluid	  and	  one	  diabetic	  urine	  sample	  	  
Depletion	   of	   albumin	   from	   concentrated	   peritoneal	   dialysis	  
fluid	  and	  diabetic	  urine	  samples	  	  The	  depletion	  of	  albumin	  from	  concentrated	  peritoneal	  dialysis	  fluid	  and	  diabetic	  urine	  samples	  were	  carried	  out	  using	  the	  same	  procedure	  as	  described	  in	  chapter	  6.6.	  	  	  	  
Determination	   of	   protein	   content	   in	   concentrated	   albumin-­‐
depleted	   peritoneal	   dialysis	   fluid	   and	   diabetic	   urine	   samples	  
using	  the	  2-­‐D	  Quant	  Kit	  	  	  The	  protein	  contents	  of	  the	  albumin-­‐depleted	  peritoneal	  dialysis	  fluid	  and	  diabetic	  urine	  samples	  were	  determined	  using	  the	  2-­‐D	  Quant	  Kit	  (G	  E	  Healthcare).	  	  Bovine	  serum	   albumin	   standards	   ranging	   from	   0	   –	   50	   µg	   were	   used	   to	   construct	   a	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standard	  curve.	   	  The	  procedure	   for	   the	  quantification	  of	   the	  protein	  content	  was	  carried	  out	  according	  to	  the	  manufacturer’s	  protocol.	  	  	  	  
Isoelectric	   focusing	   of	   albumin-­‐depleted	   peritoneal	   dialysis	  
fluid	  and	  diabetic	  urine	  samples	  	  The	   protocol	   for	   the	   isoelectric	   focusing	   of	   the	   peritoneal	   dialysis	   and	   diabetic	  urine	  samples	  was	  adapted	  from	  2-­‐D	  Electrophoresis	  Principles	  and	  Methods	  (GE	  Healthcare).	   	   Immobiline	   DryStrip	   gels	   (7	   cm,	   pH	   6	   –	   11,	   G	   E	   Healthcare)	   were	  rehydrated	  using	  DeStreak	  Rehydration	  solution	  (G	  E	  Healthcare)	   (containing	  60	  
µl	  IPG	  buffer	  per	  3	  ml	  of	  rehydration	  solution)	  overnight.	  	  The	  DryStrip	  gels	  were	  then	  loaded	  onto	  the	  manifold	  of	  the	  Ettan	  IPGPhor	  3	  Isoelectric	  Focusing	  System	  (G	  E	  Healthcare).	  	  The	  peritoneal	  dialysis	  and	  diabetic	  urine	  samples	  were	  loaded	  onto	   the	   DryStrip	   gels	   by	   cup	   loading.	   	   The	   samples	   were	   run	   using	   a	   protocol	  specific	  for	  7	  cm	  pH	  6	  –	  11	  Immobiline	  DryStrip	  gels.	  	  After	  isoelectric	  focusing,	  the	  DryStrip	  gels	  were	  stored	  at	  –	  60	  °C	  for	  use	  later	  in	  the	  second	  dimension.	  	  	  	  
Equilibration	   of	   Immobiline	   DryStrip	   gels	   for	   the	   second	  
dimension	  	  The	   Immobiline	   DryStrip	   gels	   were	   equilibrated	   in	   1.5	   M	   Tris,	   pH	   8.8	   (10	   ml)	  containing	  6	  M	  urea,	  30	  %	  glycerol,	  2	  %	  SDS,	  0.2	  mg	  L-­‐1	   	   bromophonol	  blue	  and	  DTT	  (100	  mg	  per	  10	  ml)	  on	  a	  shaker	  for	  15	  min.	  	  The	  strips	  were	  then	  equilibrated	  for	  15	  min	  in	  1.5	  M	  Tris,	  pH	  8.8	  (10	  ml)	  containing	  6	  M	  urea,	  30	  %	  glycerol,	  2	  %	  SDS,	   1	  %	   bromophonol	   blue	   (from	   a	   stock	   of	   0.002	  %	  w/v)	   and	   iodoacetamide	  (250	  mg	  per	  10	  ml)	  on	  a	  shaker	  for	  15	  min.	  	  The	  strips	  were	  equilibrated	  one	  last	  time	  in	  for	  15	  min	  10	  ml	  of	  NuPAGE®	  MOPS	  SDS	  Running	  Buffer	  1X	  (Invitrogen).	  	  
Second	   dimension	   SDS-­‐PAGE	   and	  Western	   blot	   of	   isoelectric-­‐
focused	  	  	  The	  DryStrip	  gels	  were	  loaded	  onto	  NuPAGE®	  Novex	  4-­‐12	  %	  Bis-­‐Tris	  ZOOM®	  Gels,	  IPG	  Well	  1.0	  mm	  (Invitrogen).	  	  The	  gels	  were	  run	  in	  an	  XCell	  SureLock™	  Mini-­‐Cell	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(Invitrogen)	  according	  to	  the	  manufacturer’s	  instructions.	  	  The	  separated	  proteins	  on	   the	   gel	  were	   transferred	  onto	   a	  nitrocellulose	  membrane	  using	   a	  TE	  77	  PWR	  Semi-­‐Dry	   Transfer	   Unit	   (G	   E	   Healthcare)	   according	   to	   the	   manufacturer’s	  instructions.	  	  	  	  The	   Western	   blots	   were	   then	   developed	   using	   the	   SNAP	   i.d.	   Protein	   Detection	  System	  (Millipore)	  in	  accordance	  to	  the	  manufacturer’s	  instructions.	  	  The	  blot	  was	  blocked	  with	  0.5	  %	  skimmed	  milk	  powder	  in	  TBST	  (20	  mm	  Tris,	  100	  mM	  sodium	  chloride,	  pH	  7.6,	  0.1	  %	  Tween	  20)	  15	  min.	  	  The	  blot	  was	  then	  probed	  with	  the	  anti-­‐peptide-­‐biotin	   and	  anti-­‐biotin-­‐HRP	  antibodies	   respectively	   for	  1	  h	   each.	   	   TMB	  1-­‐Component	  Membrane	  Peroxidase	  Substrate	  (KPL)	  was	  used	  as	  a	  substrate	  for	  the	  colorimetric	  development	  of	  the	  blot.	  	  	  	  
7.5	   Results	   from	   the	   two	   dimensional	   analysis	   of	   the	  
peritoneal	  dialysis	  fluid	  and	  diabetic	  urine	  sample	  	  
Protein	   content	   in	   the	   albumin-­‐depleted	   peritoneal	   and	  
diabetic	  urine	  samples	  	  The	  protein	  content	  of	  the	  concentrated	  albumin-­‐depleted	  peritoneal	  dialysis	  and	  diabetic	  urine	  samples	  were	  determined	  using	  the	  2D-­‐Quant	  Kit.	  	  This	  is	  to	  ensure	  that	  a	  known	  amount	  of	  protein	  is	  loaded	  onto	  the	  Immobiline	  strips.	  	  Figure	  6.15	  shows	  a	  standard	  curve	  obtained	  from	  bovine	  serum	  albumin	  standards.	  	  From	  the	  assay	  performed,	  diabetic	  urine	  sample	  R87	  was	   found	   to	  contain	  400	  µg	  ml-­‐1	  of	  protein	  and	  peritoneal	  dialysis	  fluid	  PD97	  contains	  3	  mg	  ml-­‐1	  of	  protein.	  	  The	  large	  difference	   in	   protein	   concentration	   between	   the	   diabetic	   urine	   and	   peritoneal	  dialysis	  fluid	  is	  because	  the	  peritoneal	  dialysis	  fluid	  had	  been	  concentrated	  prior	  to	  performing	   the	   assay.	   	   From	   this	   assay,	   60	   µg	   of	   protein	   was	   loaded	   onto	   the	  Immobiline	  strips	  for	  isolelectric	  focussing.	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Figure 7.9 A standard curve derived of bovine serum albumin standards ranging from 0-50 µg.  
R87 and PD98 are diabetic urine and peritoneal dialysis fluid samples respectively.  From the 
figure, R87 contains 9 µg of protein in 20 µl of solution, and PD98 contains 30 µg of protein in 
10 µl of fluid.   
 
2-­‐D	  electrophoresis	  and	  Western	  blot	  analysis	  of	   the	  albumin-­‐
depleted	  peritoneal	  fluid	  and	  diabetic	  urine	  samples	  	  2-­‐D	   electrophoresis	   was	   applied	   to	   the	   albumin-­‐depleted	   peritoneal	   fluid	   and	  diabetic	  urine	  samples	  because	  analyses	  of	  these	  samples	  by	  ELISA,	  Western	  blot	  did	   produce	   any	   conclusive	   result	   by	   LC-­‐MS/MS.	   	   The	   application	   of	   2-­‐D	  electrophoresis	  was	   to	   separate	   the	  proteins	   in	   the	  patient	   samples	  according	   to	  their	   molecular	   weight	   as	   well	   as	   isoelectric	   point,	   thereby	   isolating	   and	  identifying	   CTGF.	   	   The	   reported	   isoelectric	   point	   of	   CTGF	   is	   8.0	   (Mizutani	   et	   al.	  2010).	   	   Up	   to	   date,	   there	   have	   been	   no	   data	   published	  with	   regards	   to	   the	   2D-­‐electrophoresis	   of	   CTGF	   from	   human	   fluid	   samples.	   	   Figure	   7.10	   shows	   the	  Western	   blot	   of	   the	   2-­‐D	   electrophoresis	   of	   the	   proteins	   from	   albumin-­‐depleted	  peritoneal	  dialysis	  sample.	  	  There	  are	  four	  identified	  protein	  streaks,	  A,	  B,	  C	  and	  D	  at	  170	  kDa,	  55	  kDa,	  34	  kDa	  and	  26	  kDa	  respectively	  at	  pI	  8.0	  on	  the	  Western	  blot.	  	  The	   blot	   was	   probed	  with	   the	   anti-­‐peptide-­‐biotin	   antibody	  with	   the	   anti-­‐biotin-­‐HRP	  antibody	  as	  the	  secondary	  antibody.	  	  Besides	  the	  widely	  reported	  36-­‐38	  kDa	  molecular	   weight	   of	   CTGF,	   other	   molecular	   weights	   of	   22	   kDa	   and	   25-­‐28	   kDa	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peptides	   and	   55	   kDa	   form	   have	   been	   previously	   reported	   (Mizutani	   et	   al.	   2010;	  Wahab	   et	   al.	   2001b).	   	   These	   molecular	   weights	   correspond	   to	   those	   present	   in	  figure	  7.10	  at	  the	  predicted	  pI	  of	  ~	  8.0.	  	  Therefore,	  there	  is	  a	  possibility	  that	  CTGF	  or	  its	  fragments	  have	  been	  identified	  in	  the	  peritoneal	  dialysis	  fluid.	  	  	  	  Another	  blot	  containing	  the	  diabetic	  urine	  sample	  was	  not	  shown	  because	  no	  spots	  were	   observed.	   	   This	  may	   be	   due	   to	   the	   fact	   that	   a	   larger	   amount	   of	   peritoneal	  dialysis	  fluid	  was	  initially	  concentrated	  before	  albumin	  depletion.	  	  Therefore,	  there	  would	  be	  a	   larger	  amount	  of	  CTGF	  being	  enriched	   in	   the	  peritoneal	  dialysis	   fluid	  than	  in	  the	  diabetic	  urine.	  	  	  	  
	  
Figure 7.10.  Western blot of peritoneal dialysis fluid from PD97 after two dimensional 
electrophoresis.  The blot was developed with anti-peptide-biotin and anti-biotin-HRP 
antibodies.  Immunoreactive proteins are identified at 170 kDa, 55 kDa, 34 kDa and 26 kDa 
respectively, at around pI 8.0.  A cluster of immunoreactive proteins are shown at about 170 
kDa.   
	   152	  
	  
Discussion	  	  Comparison	   of	   the	  NWA	  and	   anti-­‐CTGF	   (Santa	   Cruz)	   antibodies	   by	  Western	  blot	  showed	  that	  both	  antibodies	  bound	  to	  the	  same	  proteins	  present	   in	  the	  albumin-­‐depleted	  peritoneal	  dialysis	  fluid	  samples.	  	  The	  NWA	  antibody	  produced	  a	  stronger	  response	   to	   the	   commercial	   CTGF	   antibody.	   	   As	   mentioned	   previously,	   both	  antibodies	   were	   raised	   against	   the	   full-­‐length	   recombinant	   CTGF	   molecule.	   	   In	  chapter	  3,	  it	  was	  concluded	  that	  the	  NWA	  antibody	  was	  not	  as	  specific	  as	  desired.	  	  Through	   the	   results	   from	   figure	   7.2,	   it	   can	   now	   be	   ascertained	   that	   the	   NWA	  antibody	  is	  as	  good,	  if	  not	  better	  than	  the	  commercially	  available	  CTGF	  antibody.	  	  	  	  Assessment	  of	  two	  diabetic	  urine	  samples	  were	  carried	  out	  by	  Western	  blot	  under	  non-­‐reduced	   and	   reduced	   conditions.	   	   High	   molecular	   weight	   proteins	   were	  detected	   in	   the	   non-­‐reduced	   blots.	   	  When	   the	   samples	  were	   run	   under	   reduced	  conditions,	   four	   distinct	   bands	   were	   observed.	   	   The	   total	   molecular	   weights	   of	  these	  bands	  correspond	  to	  the	  molecular	  weight	  of	  the	  band	  detected	  in	  the	  non-­‐reduced	   blots.	   	   This	   shows	   very	   clearly	   that	   CTGF	   binds	   to	   other	   proteins,	   or	  perhaps	  form	  dimers.	  	  This	  may	  be	  due	  to	  the	  high	  content	  of	  cysteine	  residues	  in	  the	   CTGF	  molecule	   forming	   disulphide	   bonds	  with	   other	   proteins.	   	   If	   this	   is	   the	  case,	   then	   it	   explains	   the	   presence	   of	   the	   four	   bands	   in	   the	   samples	   run	   under	  reduced	  conditions,	  where	  β-­‐mercaptoethanol	  was	  used	  to	  treat	  the	  urine	  samples.	  	  
β-­‐mercaptoethanol	  would	   reduce	   the	  disulphide	  bonds	   that	  are	  present	  between	  CTGF	  and	  the	  other	  proteins.	  	  	  	  The	   five	   peritoneal	   dialysis	   and	   five	   diabetic	   urine	   samples	   obtained	   from	  Hammersmith	  Hospital	  were	  assessed.	  	  In	  general,	  the	  responses	  from	  the	  ELISA	  of	  the	   urine	   samples	  were	   better	   than	   that	   of	   the	   peritoneal	   dialysis	   fluid	   samples.	  	  This	   may	   be	   due	   to	   the	   concentration	   of	   the	   excretory	   products	   by	   the	   kidney.	  	  Variation	  in	  the	  responses	  of	  the	  diabetic	  urine	  samples	  to	  the	  different	  antibodies	  is	  due	  to	  the	  possibility	  that	  the	  kidneys	  of	  these	  patients	  have	  different	  degrees	  of	  fibrosis,	  leading	  to	  the	  differing	  amounts	  of	  CTGF	  present.	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Overall,	   the	   anti-­‐peptide-­‐biotin	   antibody	   produced	   the	   greatest	   response	   in	   the	  diabetic	   urine	   sample	   compared	   to	   the	   anti-­‐CTGF	   (Santa	   Cruz)	   and	   NWA	  antibodies.	   	   This	   shows	   that	   the	   anti-­‐peptide-­‐biotin	   antibody	   has	   the	   greatest	  affinity	  and	  specificity	  to	  CTGF	  present	  in	  the	  diabetic	  urine	  samples.	  	  This	  further	  confirms	   that	   the	   chemistry	   involved	   in	   the	   preparation	   of	   the	   peptide	   and	  immunogen	   (chapter	   4)	   was	   successful.	   	   This	   is	   highly	   encouraging	   as	   the	   anti-­‐peptide-­‐biotin/anti-­‐biotin-­‐HRP	  system	  can	  be	  used	  to	  develop	  a	  cheap	  and	  reliable	  immunoassay	  to	  detect	  and	  purify	  CTGF	  from	  diabetic	  urine.	  	  Following	  the	  ELISA	  of	  the	  peritoneal	  dialysis	  fluid	  and	  diabetic	  urine	  samples,	  one	  of	   each	   sample	   was	   assessed	   by	   2D-­‐electrophoresis	   and	   Western	   blot.	   	   As	  mentioned	  previously,	  there	  have	  been	  no	  publications	  to	  date	  containing	  the	  2D-­‐electrophoresis	   of	   CTGF,	   be	   it	   in	   its	   native	   form	   or	   a	   recombinant	   protein.	   	   The	  presence	  of	  protein	  streaks	  at	  approximately	  pI	  8.0	  on	  the	  Western	  blot	  from	  the	  anti-­‐peptide-­‐biotin	   antibody	   is	   of	   great	   interest	   as	   CTGF	   has	   been	   predicted	   to	  have	  an	  isolelectric	  point	  of	  8.0.	  	  	  	  Conclusion:	  	  Using	  an	  ELISA,	  it	  was	  demonstrated	  that	  the	  anti-­‐peptide-­‐biotin	  antibody	  showed	  the	  highest	  response	  to	  CTGF	  in	  clinical	  samples	  compared	  with	  anti-­‐CTGF	  (Santa	  Cruz)	  and	  NWA	  antibodies.	  	  The	  data	  obtained	  indicated	  that	  urine	  is	  a	  much	  richer	  source	  of	  immunoreactive	  CTGF	  than	  peritoneal	  dialysis	  fluid.	  	  	  Two-­‐dimensional	   electrophoresis	   analysis	   of	   peritoneal	   dialysis	   fluid	   showed	  immunoreactive	   species	   at	   approximately	   pH	   8	   at	   170,	   55,	   34	   and	   26	   kDa.	   	   The	  occurrence	   of	   immunoreactive	   CTGF	  with	  multiple	   apparent	   sizes	   indicates	   that	  the	   CTGF	  molecule	   may	   be	   bound	   to	   other	   proteins,	   multimerised,	   glycosylated	  and	  present	  as	  proteolytically	  cleaved	  fragments.	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Chapter	  8	  
Discussion	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  It	   is	   the	   aim	  of	   this	   study	  was	   to	   detect	   and	  purify	   CTGF	   from	  human	  biological	  fluids.	   	   In	   the	   process	   of	   achieving	   this,	   lessons	   have	   been	   learnt	   and	   new	  discoveries	  made.	   	   As	   such,	   it	   is	   not	   as	   straightforward	   as	   previously	   thought	   to	  isolate	  and	  detect	  naturally	  occurring	  CTGF.	  	  	  	  
Structure	  of	  the	  CTGF	  molecule	  	  	  CTGF	  has	  been	   shown	   in	   chapter	  7	   to	  bind	   to	  other	  proteins	   such	  as	  albumin	  as	  well	  as	  possibly	  dimerize.	  	  CTGF	  contains	  thirty-­‐eight	  cysteine	  residues	  distributed	  throughout	  the	  whole	  molecule	  (figure	  8.1).	  	  These	  cysteine	  residues	  contain	  thiol	  groups	   (figure	   8.2)	   that	   are	   susceptible	   to	   oxidation.	   	   This	   in	   turn	   leads	   to	   the	  formation	  of	  disulphide	  bonds.	  	  
	  
(MTAASMGPVR VAFVV)LLALC SRPAVGQNCS GPCRYPDEPA PRCPAGVSLV 50 
LDGCGCCRVC AKQLGELCTE RDPCDPHKGL FCDFGSPANR KIGVCTAKDG  100 
APCIFGGTVY RSGESFQSSC KYQCTCLDGA VGCMPLCSMD VRLPSPDCPF  150 
PRRVKLPGKC CEEWVCDEPK DQTVVGPALA AYRLEDTFGP DPTMIRANCL  200 
VQTTEWSACS KTCGMGISTR VTNDNASCRL EKQSRLCMVR PCEADLEENI  250 
KKGKKCIRTP KISKPIKFEL SGCTSMKTYR AKFCGVCTDG RCCTPHRTTT  300 
LPVEFKCPDG EVMKKNMMFI KTCACHYNCP GDNDI(FESLY YRKMYGDMA) 349 
 
Figure 8.1 The sequence of CTGF demonstrating the high amounts of cysteine residues, which 
are highlighted in red.  The peptide sequence in red brackets was synthesised in chapter 4 and 
the peptide sequence in green brackets should be synthesised to raise further antibodies. 
 The	  complete	  three-­‐dimensional	  structure	  of	  CTGF	  is	  still	  not	  known.	  	  It	  has	  been	  predicted	  that	  many	  of	  the	  cysteine	  residues	  of	  CTGF	  are	  apparently	  not	  involved	  in	  maintaining	   its	   own	   three-­‐dimensional	   structure	   (Gupta	   et	   al.	   2000,	  Brigstock	  1999).	   	   This	   would	   add	   considerable	   weight	   to	   the	   thought	   that	   what	   has	   been	  characterized	  through	  testing	  is	  very	  different	  to	  the	  theoretical	  structure	  of	  CTGF.	  	  Unfortunately,	   whether	   CTGF	   forms	   disulfide	   bonds	   with	   other	   biological	  molecules,	   or	   even	   itself	   has	   not	   been	   proven	   elsewhere.	   	   CTGF	   has	   also	   been	  hypothesised	  to	  form	  dimers	  via	  the	  cysteine	  knot	  domain	  of	  the	  molecule	  (Abreu	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et	   al.	   2002;	   Bork	   1993;	   Brigstock	   et	   al.	   1997;	   Shi-­‐Wen	   et	   al.	   2008;	   Tikellis	   et	   al.	  2004;	  Wahab	  et	  al.	  2001;	  Gojniczek	  et	  al.	  2010).	  	  	  	  	  	  
	  	  
Figure 8.2 Structure of a cysteine molecule.  The thiol group is highlighted in red.   	  The	  Western	  blot	  of	  two	  diabetic	  urine	  samples	  in	  chapter	  7,	  figure	  7.4	  (blot	  a	  and	  
c)	  show	  the	  presence	  of	  a	  large	  molecular	  weight	  band	  when	  they	  were	  run	  under	  non-­‐reduced	  conditions.	  	  This	  large	  molecular	  weight	  band	  is	  similar	  to	  that	  shown	  by	  Riser	  et.	  al	  (2003)	  when	  diabetic	  urine	  also	  was	  assessed	  by	  Western	  blot.	  	  The	  group	  reported	  that	  while	  the	  identity	  of	  this	  large	  molecule	  is	  unknown,	  there	  is	  a	  possibility	  that	  it	  represents	  CTGF	  complexed	  to	  a	  second	  urinary	  protein.	  	  It	  was	  not	  mentioned	   in	   the	   publication	   as	   to	  whether	   the	   immunoblot	  was	   run	   under	  reducing	  or	  non-­‐reducing	  conditions.	   	  By	  comparing	   it	   to	   the	   immunoblot	   run	   in	  this	  study,	  it	  can	  be	  concluded	  that	  the	  published	  immunoblot	  was	  run	  under	  non-­‐reducing	   conditions.	   	   The	   corresponding	   blots	   (blot	   b	   and	   d)	   show	   five	  immunoreactive	  protein	  bands	  when	  run	  under	  reducing	  conditions.	   	  This	  shows	  very	  clearly	  that	  the	  presence	  of	  these	  five	  bands	  is	  the	  result	  of	  the	  reduction	  of	  the	  high	  molecular	  weight	  band.	  	  Albumin	  was	  found	  to	  be	  an	  interfering	  presence	  in	  6.5.3,	  and	  this	  was	  observed	  again.	  	  There	  is	  a	  possibility	  that	  the	  40	  kDa	  protein	  is	   CTGF	   (at	   38	   kDa)	   and	   the	   80	   kDa	   protein,	   its	   dimer.	   	   This	  would	   confirm	   the	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theory	  proposed	  by	  Gupta	  et	  al.	  and	  Brigstock	  that	  the	  cysteine	  residues	  of	  CTGF	  are	  not	  involved	  in	  maintaining	  its	  own	  three-­‐dimensional	  structure.	  	  Rather,	  these	  cysteine	   residues	   are	   involved	   in	   binding	   to	   other	   proteins	   such	   as	   albumin,	   or	  forming	  dimers	  on	  itself.	  	  The	  commercial	  anti-­‐sheep	  IgG	  peroxidase	  antibody	  was	  used	  as	  a	  second	  antibody,	  and	  the	  bands	  that	  are	  present	  at	  50	  kDa	  and	  25	  kDa	  would	   be	   indicative	   of	   the	   heavy	   and	   light	   chains	   of	   the	   IgG	   molecule.	   	   These	  proteins	  need	  to	  be	  assessed	  further,	  as	  CTGF	  has	  also	  been	  reported	  at	  55	  kDa	  and	  its	  fragment	  at	  25	  kDa	  (Wahab	  et	  al.	  2001;	  Zarrinkalam	  et	  al.	  2003).	  	  	  	  The	  differences	   in	   intensity	   of	   the	  protein	  bands	   from	  both	   sets	   of	   immunoblots	  show	  the	  differing	  amounts	  of	  CTGF	  present	  in	  the	  urine.	  	  This	  is	  further	  confirmed	  by	  from	  the	  ELISA	  results	  shown	  in	  chapter	  3	  as	  well	  as	  chapter	  7.	  	  	  	  More	  importantly,	  the	  two	  blots	  from	  figure	  7.4	  (blot	  a	  and	  c)	  show	  a	  band	  at	  36	  kDa.	   	   A	   doublet	   of	   36-­‐38	   kDa	   can	   be	   seen	  more	   clearly	   in	   blot	   a.	   	   This	   doublet	  would	  no	  doubt	  be	  CTGF	  present	  in	  the	  urine.	  	  To	  date,	  no	  other	  group	  other	  than	  Riser	  et.	   al	   (2003)	  have	  shown	   the	  presence	  of	  urinary	  CTGF	  on	  an	   immunoblot.	  	  This	  can	  be	  attributed	  to	  several	  different	  factors.	  	  One	  of	  these	  would	  be	  the	  lack	  of	   clarity	  by	  which	  CTGF	  was	   treated	  before	   assessment	  by	  Western	  blot.	   	   From	  previous	   experience,	   it	  was	   very	  difficult	   to	   reproduce	   the	   result	   that	  Riser	   et	   al	  achieved	   because	   the	   exact	   details	   of	   their	   experimental	   protocol	   were	   not	  published.	   	   Even	   as	   the	  Western	   blotting	   method	   was	   referenced	   to	   a	   previous	  article	   (Riser	  et	  al.	  2000),	  no	  details	  as	   to	  whether	   the	  urine	  sample	  was	   treated	  with	  a	  reducing	  agent	  to	  obtain	  the	  immunoblot.	  	  Another	  factor	  would	  be	  the	  fact	  that	  cysteine	  residues	  consist	  of	  10	  %	  of	  the	  CTGF	  molecule.	   	  Therefore,	  handling	  of	  the	  urine	  sample	  prior	  to	  assessment	  is	  very	  important	  to	  prevent	  oxidation	  of	  the	  thiol	  groups.	   	  As	  mentioned	  above	  that	  CTGF	  may	  form	  complexes	  with	  other	  urinary	  proteins,	  it	  is	  not	  known	  whether	  these	  complexes	  were	  formed	  in	  vivo	  or	  after	   the	   urine	   has	   been	   passed	   from	   the	   body.	   	   These	   issues	   have	   yet	   to	   be	  addressed	  properly.	  	  Even	  if	  the	  samples	  have	  been	  handled	  with	  the	  utmost	  care,	  oxidation	   cannot	   be	   completely	   prevented,	   especially	   when	   collecting	   urine	  samples.	  	  The	  addition	  of	  a	  reducing	  agent	  such	  as	  sodium	  bohohydride	  may	  help	  to	  prevent	  the	  oxidation	  process.	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LC-­‐MS/MS,	  used	  in	  chapter	  6	  to	  identify	  proteins	  from	  Western	  blots,	  proved	  to	  be	  a	  very	  useful	  tool.	  	  By	  characterizing	  the	  immunoreactive	  proteins,	  the	  identities	  of	  each	  protein	  can	  be	  confirmed.	   	  Two-­‐dimensional	  electrophoresis	  was	  performed	  on	   an	   albumin-­‐depleted	   concentrated	   peritoneal	   dialysis	   fluid	   sample	   under	  reducing	   conditions,	   and	   Western	   blot	   analysis	   was	   used	   to	   identify	   the	  immunoreactive	  proteins.	   	  Several	  proteins	  were	  identified	  (figure	  7.10)	  between	  the	  predicted	  pI	  of	  8.0	  and	  9.0,	  and	   the	  characterization	  of	   these	  proteins	  by	  LC-­‐MS/MS	   is	   required	   to	   confirm	   their	   identities.	   	   The	   absence	   of	   albumin	   is	  significant.	   	  This	   is	  because	   it	  was	  a	   constantly	   recurring	  protein	   in	   the	  Western	  blot	   analyses	   of	   chapter	   6,	   which	   was	   then	   found	   to	   bind	   to	   CTGF.	   	   There	   is	   a	  possibility	  that	  the	  removal	  of	  albumin	  prior	  to	  the	  addition	  of	  the	  reducing	  agent	  may	  have	  also	  removed	  the	  CTGF	  that	  has	  been	  bound	  to	  the	  molecule.	  	  Whilst	  it	  is	  important	  to	  incorporate	  albumin	  in	  any	  two-­‐dimensional	  or	  LC-­‐MS/MS	  analyses,	  this	  protein	  greatly	  affects	  the	  outcome	  of	  the	  results	  obtained.	  	  This	  is	  because	  the	  presence	   of	   albumin	   in	   two-­‐dimensional	   electrophoresis	   causes	   streaking	   of	   the	  proteins	  on	  the	  gel.	  	  In	  LC-­‐MS/MS,	  it	  masks	  any	  other	  protein	  that	  may	  be	  present	  due	  to	  its	  sheer	  amount.	  	  A	  method	  can	  be	  developed	  to	  remove	  the	  albumin	  from	  the	   peritoneal	   dialysis	   fluid	   after	   the	   addition	   of	   the	   reducing	   agent.	   	   Both	   the	  albumin	  that	  has	  been	  removed	  and	  the	  albumin-­‐depleted	  sample	  would	  have	   to	  be	   assessed	   for	   CTGF	   to	   further	   confirm	   that	   albumin	   binds	   to	   CTGF.	   	   Diabetic	  urine	   samples	   should	  also	  be	   assessed	  by	   two-­‐dimensional	   electrophoresis	   since	  urine	  was	   found	   to	  be	  a	   richer	   source	  of	  CTGF	   (figure	  7.7),	   thereby	  omitting	   the	  need	  to	  concentrate	  the	  sample	  prior.	  	  	  	  
Compariseon	  of	  ELISA	  procedures	  using	  the	  anti-­‐
peptide,	  NWA	  antibodies	  with	  those	  used	  in	  published	  
methods	  	  Because	  CTGF	  exists	  in	  so	  many	  different	  fragments,	  detection	  and	  isolation	  of	  this	  molecule	   by	   immunochemical	   methods	   can	   prove	   to	   be	   difficult.	   The	   CTGF	  molecule	   consists	   of	   four	   modular	   domains;	   insulin-­‐like	   growth	   factor	   (IGFBP)-­‐binding	   domain,	   von	   Willebrand	   factor	   (VWF)	   type	   C	   repeat	   domain,	  thrombospondin	  (TSP)	  type	  1	  repeat	  domain	  and	  the	  cysteine	  knot	  domain	  (figure	  8.3).	  	  The	  IGFPB	  and	  VWF	  domains	  are	  separated	  from	  the	  TSP	  and	  cysteine	  knot	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domains	  by	  a	  hinge	  region.	  	  This	  hinge	  region	  is	  susceptible	  to	  proteolytic	  cleavage,	  leading	  to	  the	  N-­‐terminal	  and	  C-­‐terminal	  halves	  (Phanish	  et	  al.	  2010).	  	  A	  10-­‐12	  kDa	  heparin	  binding	  fragment	  has	  also	  been	  reported	  (Brigstock	  et	  al.	  1997).	  	  	  	  
	  	  
Figure 8.3 The modular structure of CTGF with the insulin-like growth factor (IGF)-binding 
domain, a von Willebrand factor (VWF) type C repeat domain, a thrombospondin (TSP) type 1 
repeat domain and the C-terminal (CT) domain.  The hinge region that separates the N and C-
terminals is susceptible to proteolytic attack, rendering the N and C-terminal fragments.  Also 
shown is the heparin-binding fragment.   	  	  The	  use	  of	  an	  antibody	  against	  the	  native	  CTGF	  molecule	  or	  its	  fragment	  would	  be	  more	  useful	  than	  using	  the	  antibody	  against	  the	  recombinant	  CTGF	  molecule.	  	  This	  can	  be	  seen	  clearly	  in	  chapter	  7	  (figure	  7.7),	  where	  the	  antibody	  against	  the	  CTGF	  peptide	   fragment	  showed	  the	  best	  response	   in	  an	  ELISA	  of	   five	  different	  diabetic	  urine	  samples	  when	  compared	  with	  the	  NWA	  antibody	  (raised	  against	   the	  whole	  recombinant	  CTGF	  molecule)	  and	  the	  commercial	  CTGF	  antibody	  from	  Santa	  Cruz	  Biotechnology	   (also	   raised	   against	   the	   whole	   recombinant	   CTGF	   molecule).	  	  Through	   the	   ELISA	   of	   the	   diabetic	   urine	   samples,	   it	   can	   also	   be	   concluded	   that	  diabetic	  urine	  is	  a	  richer	  source	  of	  CTGF	  compared	  to	  peritoneal	  dialysis	  fluid.	  	  	  	  Most	   reported	   studies	   use	   an	   antibody	   against	   the	   recombinant	   human	   CTGF,	  where	  the	  CTGF	  gene	  was	   inserted	   into	  a	  host	  plasmid	  (either	  bacterial	  or	  viral),	  causing	  it	  to	  produce	  the	  CTGF	  protein.	  	  This	  recombinant	  protein	  can	  then	  be	  used	  to	   raise	   polyclonal	   antibodies,	   in	   this	   case	   NWA	   (full-­‐length	   CTGF)	   and	   NWB	  (partial	  length	  CTGF)	  for	  the	  detection	  of	  CTGF.	  	  Commercially	  available	  antibodies	  to	  CTGF	  are	  always	  prepared	  against	  the	  recombinant	  human	  CTGF,	  as	  in	  the	  case	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of	   the	   anti-­‐CTGF	   (Santa	   Cruz)	   antibody,	   which	   is	   against	   the	   full-­‐length	  recombinant	  CTGF.	  	  	  	  Various	   studies	   have	   shown	   the	   quantification	   of	   urinary	   CTGF	   by	   ELISA	   using	  anti-­‐CTGF	  antibodies	  (Nguyen	  et	  al.	  2006;	  Kovalenko	  et	  al.	  2009).	   	  In	  these	  cases,	  the	  competitor	  used	  is	  recombinant	  human	  CTGF.	  	  Because	  the	  competitor	  used	  is	  not	   the	   naturally	   occurring	   CTGF	   (in	   this	   case	   urinary	   CTGF),	   how	   can	   it	   be	  confirmed	  that	  the	  native	  CTGF	  is	  actually	  being	  quantified?	  	  Whilst	  there	  are	  many	  advantages	  using	  recombinant	  CTGF	  in	  immunoassays,	  an	  assay	  for	  CTGF	  can	  only	  be	  deemed	  true	  if	  both	  antibodies	  and	  competitor	  are	  from	  native	  human	  CTGF,	  or	  if	   the	   recombinant	   CTGF	   antibody	   has	   been	   proven	   to	   detect	   native	   CTGF.	   	   The	  glycosylation	  pattern	  of	  CTGF	  is	  unknown,	  and	  while	  expressing	  proteins	  using	  a	  baculoviral	  system	  will	  result	  in	  the	  protein	  itself,	  the	  glycosylation	  of	  the	  protein	  may	   not	   be	   identical	  when	   the	   protein	   is	   produced	   in	   vivo	   as	   glycosylation	   is	   in	  effect	   a	   post-­‐translational	   modification.	   	   Even	   if	   CTGF	   undergoes	   glycosylation	  after	   being	   expressed,	   bacterial	   and	   viral	   enzymes	   and	   glycans	   will	   be	   very	  different	  compared	  to	  humans.	  	  As	  mentioned	  previously,	  CTGF	  fragments	  are	  also	  present	   in	   human	   biological	   fluids.	   	   This	   explains	   the	   use	   of	   N-­‐terminal	   or	   C-­‐terminal	  peptide	  antibodies	  in	  the	  immunoassays	  reported	  (Dendooven,	  2011).	  	  	  	  The	   initial	   studies	   utilised	   the	  NWA	  and	  NWB	  antibodies	   to	   develop	   a	   sandwich	  ELISA	   for	   CTGF.	   	   The	   efficacy	   and	   specificity	   of	   these	   antibodies	   were	   used	   to	  detect	   CTGF	   in	   diabetic	   urine	   samples,	   where	   these	   antibodies	   were	   coupled	   to	  horseradish	  peroxidase	  (HRP).	   	  The	  results	   from	  the	  ELISA	  showed	  that	  both	  the	  HRP-­‐coupled	  antibodies	  detected	  an	  antigen	  in	  the	  patients’	  diabetic	  urine,	  which	  could	  be	  CTGF.	  	  The	  response	  from	  the	  NWA-­‐HRP	  antibody	  was	  always	  higher	  than	  that	   of	   NWB-­‐HRP.	   	   This	   suggests	   that	   there	   is	   more	   of	   the	   full-­‐length	   CTGF	  molecule	  present	  in	  the	  diabetic	  urine	  samples.	  	  A	  different	  picture	  is	  painted	  when	  the	  NWA	  and	  NWB	  are	  used	  in	  the	  Western	  blots	  of	  the	  diabetic	  urine.	  	  This	  time,	  the	   antibodies	  were	   not	   coupled	   to	   HRP,	   and	   the	   immunoblots	   showed	   that	   the	  NWA	  antibody	  was	  not	  as	  specific	  as	  desired.	  	  Not	  only	  did	  it	  detect	  proteins	  in	  the	  diabetic	   urine,	   it	   also	   detected	   carbonic	   anhydrase	   and	   human	   serum	   albumin.	  	  The	  NWB	  antibody	  detected	  a	  protein	  at	  about	  50	  kDa.	  	  A	  similar	  binding	  pattern	  was	   observed	  when	   this	   immunoblot	   was	   compared	   to	   another	   developed	  with	  
	   161	  
only	   anti-­‐sheep	   IgG	  peroxidase.	   	   This	   suggests	   that	   the	  NWB	  antibody	  might	  not	  even	  be	  detecting	  any	  CTGF	  in	  the	  diabetic	  urine.	  Furthermore,	  the	  anti-­‐sheep	  IgG	  peroxidase	   that	  was	  used	   as	   the	   secondary	   antibody	   also	  detected	  protein	   at	   50	  kDa.	  	  It	  was	  concluded	  that	  to	  continue	  with	  the	  study,	  it	  was	  not	  feasible	  to	  use	  the	  anti-­‐sheep	  IgG	  peroxidase	  as	  a	  secondary	  antibody.	  	  There	  was	  also	  an	  issue	  with	  specificity	  of	  the	  NWA	  and	  NWB	  antibodies;	  therefore	  an	  alternative	  strategy	  had	  to	  be	  developed.	  	  	  	  As	  mentioned	  previously,	  to	  date,	  only	  one	  group	  has	  detected	  urinary	  CTGF	  on	  an	  immunoblot	   (Riser	   et	   al.	   2003).	   	   They	  were	   able	   to	   detect	   CTGF	   in	   the	   urine	   of	  healthy	  volunteers	  and	  diabetic	  patients	  by	  using	  heparin	  to	  extract	  CTGF	  before	  resolving	  and	  transferring	  onto	  a	  nitrocellulose	  membrane,	  then	  probing	  for	  CTGF	  using	   an	   antibody	   that	   was	   raised	   against	   the	   full-­‐length	   CTGF	   molecule.	   	   This	  group	  also	  raised	  another	  antibody	  to	  CTGF,	  but	  this	  time	  it	  was	  against	  a	  unique	  sequence	  of	  the	  C-­‐terminal	  of	  the	  protein	  similar	  in	  amino	  acid	  sequence	  to	  the	  one	  that	  was	  raised	  in	  this	  study	  (Riser	  et	  al.	  2000).	  	  	  	  The	  study	  by	  Riser	  et	  al	  in	  2000	  led	  to	  the	  synthesis	  of	  a	  peptide	  whose	  amino	  acid	  sequence	  was	  unique	  to	  CTGF,	  and	  the	  generation	  of	  an	  antibody	  to	  this	  sequence.	  	  By	   using	   several	   novel	   methods	   of	   linking	   the	   peptide	   to	   gelatine	   via	   different	  linker	  arms,	  the	  specificity	  of	  the	  anti-­‐peptide	  antibody	  was	  ascertained.	  	  This	  led	  to	   the	   biotinylation	   of	   the	   anti-­‐peptide	   antibody,	   and	   the	   purification	   and	  conjugation	   of	   the	   anti-­‐biotin	   antibody	   to	   HRP.	   	   This	   was	   then	   used	   as	   an	  alternative	   secondary	   antibody	   to	   the	   anti-­‐sheep	   IgG	   peroxidase.	   	   In	   doing	   so,	   a	  system	  was	  set	  up	  to	  detect	  CTGF	  from	  diabetic	  urine	  as	  well	  as	  peritoneal	  dialysis	  fluid.	  	  This	  system	  was	  shown	  to	  have	  greater	  amplification,	  and	  is	  more	  sensitive	  than	  using	  the	  commercial	  anti-­‐IgG	  peroxidase	  as	  the	  second	  antibody	  (chapter	  5,	  figure	  5.9).	  	  The	  method	  of	  the	  biotinylating	  the	  CTGF	  peptide	  can	  be	  adapted	  to	  be	  used	  on	  other	  peptides	  or	  even	  the	  whole	  CTGF	  molecule.	  	  Commercially	  available	  avidin-­‐peroxidase	  should	  be	  assessed	  together	  with	  the	  anti-­‐biotin-­‐HRP	  molecule.	  	  This	  will	  then	  further	  confirm	  the	  specificity	  and	  affinity	  of	  the	  anti-­‐biotin	  antibody	  to	   the	   biotin	  molecule.	   	   This	   is	   because	   avidin	   bind	   to	   biotin	  with	   a	   dissociation	  constant	   of	   1	   ×	   10	   -­‐15,	   which	   is	   one	   of	   the	   strongest	   known	   protein-­‐ligand	  interactions,	  approaching	  the	  covalent	  bond	  in	  strength	  (Wilchek	  &	  Bayer	  1988).	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  The	   present	   study	   investigated	   at	   three	   different	   methods	   of	   detecting	   CTGF;	  ELISA,	  Western	  blot	  and	  tandem	  mass	  spectrometry.	  	  	  	  Although	  a	  competitive	  ELISA	  system	  for	  the	  detection	  of	  CTGF	  is	  widely	  reported,	  this	  can	  be	  adapted	  for	  the	  modification	  of	  future	  studies.	  	  Chapter	  4	  describes	  the	  synthesis	  of	  the	  CTGF	  fragment	  from	  the	  C-­‐terminal	  of	  CTGF,	  with	  the	  addition	  of	  a	  cysteine	  residue	  shown	  in	  figure	  8.4.	  	  	  	  Phe-­‐Glu-­‐Ser-­‐Leu-­‐Tyr-­‐Tyr-­‐Arg-­‐Lys-­‐Met-­‐Tyr-­‐Gly-­‐Asp-­‐Met-­‐Ala-­‐Cys	  
 
Figure 8.4 Peptide sequence synthesised in this study, with the addition of a cysteine molecule 
for conjugation to a carrier protein in red.  	  Another	  peptide	  should	  be	  synthesised	  where	   the	  cysteine	  molecule	   is	  on	   the	  N-­‐terminal	  (figure	  8.5).	   	   In	  doing	  so,	  when	  the	  peptide	  is	  coupled	  to	  keyhole	   limpet	  haemocyanin	  for	  the	  generation	  of	  antibodies,	  the	  peptide	  will	  be	  presented	  to	  the	  B-­‐cells	  differently	  to	  that	  shown	  in	  figure	  8.4.	   	  This	  may	  result	   in	  antibodies	  with	  different	  affinities	  and	  specificities	  to	  CTGF,	  and	  the	  better	  antibody	  can	  used	  for	  the	  detection	  of	  CTGF.	  	  	  	  	  Cys-­‐Phe-­‐Glu-­‐Ser-­‐Leu-­‐Tyr-­‐Tyr-­‐Arg-­‐Lys-­‐Met-­‐Tyr-­‐Gly-­‐Asp-­‐Met-­‐Ala	  	  
Figure 8.5 Peptide sequence for future synthesis, with the addition of a cysteine molecule for 
conjugation to a carrier protein in red.  	  A	   peptide	   sequence	   from	   the	   N-­‐terminal	   of	   the	   CTGF	   molecule	   should	   also	   be	  synthesised	  in	  the	  same	  way	  and	  an	  antibody	  raised	  to	  it.	  	  This	  antibody	  can	  then	  the	  compared	  to	  that	  of	  the	  C-­‐terminal	  and	  used	  in	  conjunction	  with	  the	  C-­‐terminal	  peptide	   antibody	   to	   develop	   a	   sandwich	   ELISA	   for	   CTGF	   shown	   in	   figure	   8.6.	  	  Theoretically,	   a	   more	   sensitive	   assay	   would	   be	   to	   couple	   biotin	   to	   one	   of	   the	  terminal	  antibodies	  (figure	  8.7)	  and	  use	  the	  anti-­‐biotin-­‐peroxidase	  antibody	  (made	  in	   chapter	   5)	   as	   the	   developing	   antibody.	   	   This	   would	   amplify	   the	   signal	   of	   the	  assay,	  which	  can	  be	  compared	  to	  the	  assay	  shown	  in	  figure	  8.6.	  	  Through	  this,	  the	  best	  assay	  for	  detecting	  CTGF	  can	  be	  chosen	  for	  further	  development.	  	  Should	  this	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system	   prove	   effective,	   native	   urinary	   CTGF	   and	   its	   fragments	   can	   be	   isolated	  through	  the	  use	  of	  a	  Sepharose	  4B	  column	  where	  a	  mixture	  of	  the	  N	  and	  C-­‐terminal	  CTGF	  peptide	  antibodies	  are	  coupled	  to	  the	  beads.	  	  Preparative	  amounts	  of	  native	  CTGF	   can	   be	   eluted	   from	   the	   Sepharose	   4B	   column	   and	   used	   as	   a	   competitor	   in	  competitive	   immunoassays	   for	   CTGF.	   	   Isolated	   native	   CTGF	   can	   also	   be	   used	   to	  raise	  monoclonal	  antibodies	  mice	  to	  further	  improve	  the	  sensitivity	  of	  the	  assay.	  	  	  	  
	  	  
Figure 8.6 A proposed schematic of a sandwich ELISA for the detection of CTGF using N and 
C-terminal CTGF peptide antibodies, which can be interchangeable.  One of the antibodies will 
be coupled to horseradish peroxidase.  	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Figure 8.6 A proposed schematic of a sandwich ELISA for the detection of CTGF using N and 
C-terminal CTGF peptide antibodies, which can be interchangeable.  One of the antibodies will 
be coupled to biotin, whilst the anti-biotin-peroxidase antibody made in chapter 5 will be used as 
the developing antibody.  	  CTGF	  has	  been	  reported	  to	  bind	  to	  heparin,	  with	  the	  possibility	  of	  purifying	  CTGF	  from	  it	  (Ball	  et	  al.	  2003;	  Riser	  et	  al.	  2000).	  	  The	  isolation	  of	  CTGF	  from	  peritoneal	  dialysis	   fluid	   was	   attempted	   using	   a	   Heparin	   HiTrap	   column.	   	   Through	   tandem	  mass	   spectrometry	   analysis	   and	   by	   analysing	   the	   results	   using	   the	   DAVID	  Functional	   Annotation	   Bioinformatics	  Microarray	   Analysis	  website,	   it	   was	   found	  that	  apolipoprotein	  B	  and	  coagulation	   factor	  XI	  present	   in	   the	  peritoneal	  dialysis	  fluid	  also	  bound	   to	  heparin.	   	  Extraction	  of	  CTGF	  by	  heparin	  was	   first	   carried	  out	  from	  cell	  culture	  supernatants	  (Riser	  et	  al.	  2000).	  	  The	  conditions	  in	  which	  cells	  are	  induced	   to	   secrete	   CTGF	   are	   very	   tightly	   controlled.	   	   Therefore,	   the	   presence	   of	  heparin-­‐binding	  proteins	  will	  be	  kept	  to	  a	  minimum.	  	  While	  this	  may	  be	  true,	  Riser	  et	   al	   also	   reported	   to	   extract	   CTGF	  by	  heparin	   affinity	   purification	   from	  diabetic	  urine.	   	  His	  group	  showed	  immunobots	  of	  urinary	  CTGF	  from	  healthy	  and	  diabetic	  urine.	  	  Out	  of	  four	  diabetic	  patients	  and	  three	  healthy	  volunteers,	  CTGF	  at	  38	  kDa	  was	  identified	  in	  two	  diabetic	  patient’s	  urine	  and	  one	  healthy	  volunteer’s	  urine.	  	  An	  immunoreactive	  species	  at	  200	  kDa	  was	  also	  reported.	  	  This	  species	  was	  present	  in	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all	  the	  diabetic	  urine	  and	  in	  one	  healthy	  volunteer.	  	  They	  reported	  that	  the	  identity	  of	   this	   entity	   is	   currently	   unknown,	   but	   there	   is	   a	   possibility	   that	   CTGF	   has	  complexed	   to	   another	   urinary	   protein.	   	   Again,	   only	   this	   group	   has	   shown	   the	  extraction	   of	   CTGF	   from	   urine	   by	   heparin.	   	   Heparin	   binds	   to	   a	   variety	   other	  proteins	   that	   may	   be	   present	   in	   diabetic	   urine,	   and	   this	   will	   greatly	   affect	   the	  outcome	  of	   using	   it	   to	   extract	   CTGF	   from	  human	   fluid.	   	   It	   can	  be	   concluded	   that	  although	  CTGF	  binds	  to	  heparin,	  because	  of	  it	  non-­‐specificity,	  it	  cannot	  be	  used	  as	  an	  efficient	  and	  accurate	  method	  of	  purifying	  CTGF	  from	  urine.	  	  	  	  The	  isoelectric	  point	  of	  CTGF	  has	  been	  predicted	  to	  be	  8.0	  (Mizutani	  et	  al.	  2010).	  	  Western	  blot	  analysis	  of	  the	  2-­‐D	  electrophoresis	  of	  peritoneal	  dialysis	  fluid	  showed	  immunoreactive	  species	   to	   the	  anti-­‐peptide-­‐biotin	  antibody	  with	  an	  approximate	  pI	   of	   8.0.	   	   	   This	  has	  not	  been	   shown	  experimentally	  before.	   	   2-­‐D	   electrophoresis	  separates	  proteins	  according	  its	  charge	  as	  well	  as	  molecular	  weight	  and	  it	  is	  very	  unlikely	   that	   two	   proteins	   will	   share	   the	   same	   isoelectric	   point	   and	   molecular	  weight.	   	   Sequencing	   of	   these	   proteins	   from	   the	   immunoblot	   by	   tandem	   mass	  spectrometry	   will	   prove	   to	   be	   very	   interesting.	   	   By	   using	   this	   technique	   to	  sequence	  proteins,	  the	  identity	  of	  the	  proteins	  of	  interest	  that	  have	  been	  detected	  by	   immunoblots	  can	  be	  confirmed.	   	  To	  date,	  none	  of	   the	  published	  works	  on	   the	  identification	   of	   CTGF	   by	   immunoblotting	   have	   confirmed	   the	   presence	   of	   this	  protein	   through	   tandem	   mass	   spectrometry,	   and	   this	   is	   the	   first	   report	   to	   my	  knowledge.	   	   Identification	   of	   CTGF	   is	   solely	   relied	   upon	   by	   antibodies	   that	   are	  raised	  against	  recombinant	  CTGF	  or	  a	  unique	  peptide	  sequence	  in	  CTGF.	  	  There	  is	  no	   concrete	   proof	   is	   that	   the	   antibody	   is	   against	   CTGF,	   or	   that	   the	   indentified	  protein	   is	   indeed	   CTGF.	   	   It	   is	   only	   by	   using	   techniques	   such	   as	   tandem	   mass	  spectrometry	  can	  the	  protein	  identity	  be	  confirmed.	  	  CTGF	  has	  not	  been	  purified	  and	  characterized	  from	  human	  biological	  fluids.	  	  It	  has	  also	  not	  been	  crystallized;	  therefore	  the	  three-­‐dimensional	  structure	  of	  CTGF	  has	  not	   been	   elucidated.	   	   There	   are	  many	   unknowns	   in	   the	   characteristics	   of	   CTGF,	  which	  is	  why	  the	  purification	  of	  the	  native	  form	  of	  this	  protein	  is	  of	  great	  priority,	  as	  it	  will	  lead	  to	  the	  generation	  of	  antibodies	  and	  development	  of	  imuunoassays	  to	  the	  natural	  form	  of	  CTGF.	  	  In	  turn,	  this	  system	  can	  be	  used	  as	  a	  comparison	  to	  the	  other	  CTGF	  ELISA	  kits	  that	  are	  widely	  available.	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CTGF	  as	  a	  potential	  biomarker	  for	  fibrosis	  	  Throughout	  this	  study,	  the	  isolation	  and	  detection	  of	  CTGF	  was	  looked	  at	  in	  detail.	  	  In	   the	   bigger	   picture,	   CTGF	   is	   involved	   in	   several	   different	   pathways	   leading	   to	  fibrosis.	   	   CTGF	   upregulation	   is	   controlled	   by	   TGF-­‐β,	   which	   in	   turn	   enhances	   the	  profibrotic	   activity	   of	   TGF-­‐β/Smad	   pathway	   (figure	   8.7)	   by	   blocking	   Smad	   7	  (Wahab	   et	   al.	   2005).	   	   TGF-­‐β	   is	   one	   of	   the	   most	   potent	   profibrotic	   stimuli	   to	  fibroblasts.	   	   It	   is	   a	   25	   kDa	   homodimeric	   polypeptide	   and	   is	   involved	   in	   normal	  development,	  wound	  repair	  and	  pathological	  processes	  (Attisano	  &	  Wrana	  1996).	  	  TGF-­‐β	  is	  also	  an	  inducer	  of	  ECM	  protein	  synthesis	  and	  has	  been	  implicated	  as	  the	  key	  mediator	  of	  fibrogenesis	  in	  various	  tissues	  (Border	  &	  Noble	  1994).	  	  Smad	  7	  is	  a	  TGF-­‐β	   type	  1	  receptor	  antagonist.	   	   It	  blocks	  TGF-­‐β-­‐1	  and	  activin	  associating	  with	  the	  receptor,	   thereby	  blocking	  access	   to	  Smad	  2.	   	  By	  blocking	  Smad	  2,	   it	   thereby	  inhibits	  the	  TGF-­‐β	  pathway	  (Wahab	  et	  al.	  2005).	  	  CTGF	  is	  also	  an	  inhibitor	  of	  BMP-­‐7,	  which	  is	  an	  antifibrotic	  and	  proregenerative	  factor	  (Nguyen	  et	  al.	  2008).	  	  These	  key	   features	   of	   CTGF	   make	   it	   a	   potential	   biomarker	   for	   the	   detection	   and	  prevention	  of	  fibrosis.	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Figure 8.7 Cell signalling pathways effected by CTGF.  CTGF is shown to be upregulated by 
TGF-β, which in turn enhances the profibrotic effects of TGF-β by positive feedback.  BMP-7 
has an anti-fibrotic and pro-regenerative effect but CTGF upregulation inhibits the effect of 
BMP-7.   	  Fibrosis	   is	   the	   formation	  of	   excess	   connective	   tissue	  and	  collagen	   in	  an	  organ	  or	  tissue	  as	  a	  reparative	  or	  reactive	  process.	  	  Fibrosis	  is	  involved	  in	  the	  pathogenesis	  of	   various	   diseases	   such	   as	   pulmonary	   fibrosis,	   cirrhosis	   as	   well	   as	   diabetic	  nephropathy.	  	  TGF-­‐β	  increases	  the	  gene	  expression	  of	  COL1A1	  and	  COL1A2,	  which	  are	   the	  genes	  encoding	   collagen	   type	   I	  α1	  and	  collagen	   type	   I	  α2.	   	  Through	   this,	  type	   I	   collagen	   synthesis	   is	   increased,	   which	   leads	   to	   the	   deposition	   of	   type	   I	  collagen,	  leading	  to	  fibrosis	  (Verrecchia	  &	  Mauviel	  2007)	  as	  shown	  in	  figure	  8.8.	  	  	  	  Detecting	   an	   increase	   in	   CTGF	   would	   directly	   relate	   to	   an	   increase	   in	   fibrosis.	  	  Because	  CTGF	  occur	  much	  further	  downstream	  of	  the	  TGF-­‐β	  pathway,	  using	  it	  as	  a	  biomarker	  for	  fibrosis	  would	  prove	  to	  be	  more	  useful	  than	  TGF-­‐β.	  	  This	  is	  because	  TGF-­‐β	   is	   involved	   in	   normal	   tissue	   repair,	   and	   an	   increase	   in	   TGF-­‐β	   does	   not	  directly	  relate	  to	  the	  onset	  on	  fibrosis	  in	  tissues.	  	  Normal	  levels	  of	  CTGF	  present	  in	  human	  fluids	  have	  to	  be	  ascertained	  before	  an	  accurate	  measurement	  can	  be	  taken	  and	  the	  threshold	  of	  CTGF	  determined.	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  By	  using	  CTGF	  as	   a	  biomarker	   for	   fibrosis,	   fibrotic	  diseases	   can	  be	   treated	   at	   an	  earlier	  stage	  through	  the	  close	  monitoring	  of	  patients	  with	  increased	  CTGF	  levels.	  	  CTGF	   is	   also	  an	   ideal	  biomarker	  and	  has	  been	   reported	   to	  be	  detected	   in	   serum,	  plasma	   and	   urine	   for	   a	   whole	   range	   of	   diseases	   such	   as	   diabetic	   nephropathy,	  systemic	  sclerosis,	  chronic	  liver	  disease	  and	  chronic	  heart	  failure.	  	  	  	  
	  	  
Figure 8.8 A schematic showing the involvement of TGF-β in collagen gene expression and 
synthesis, leading to tissue fibrosis.   	  Currently,	  a	  fully	  human	  monoclonal	  anti-­‐CTGF	  (FG-­‐3019)	  has	  been	  developed	  by	  FibroGen,	  Inc	  (San	  Francisco,	  CA)	  to	  block	  the	  pathological	  activity	  of	  CTGF	  for	  the	  treatment	   of	   chronic	   kidney	   disease,	   fibrotic	   diseases	   and	   certain	   metastatic	  cancers.	   	  This	  company	  claims	  that	  by	  directly	  blocking	  CTGF	  activity,	  the	  decline	  of	  kidney	  function	   in	  chronic	  kidney	  disease	  can	  be	  slowed	  down,	  cardiovascular	  risk	   and	   progression	   to	   chronic	   heart	   failure	   can	   be	   reduced,	   organ	   function	   in	  fibrotic	  diseases	   can	  be	  preserved	  and	   tumour	  growth	  and	  metastases	   in	   certain	  cancers	  can	  be	  reduced.	  	  In	  theory,	  this	  form	  of	  therapy	  can	  be	  highly	  effective.	  	  But	  using	  an	  antibody	  to	  target	  CTGF	  can	  also	  pose	  certain	  problems.	  	  Firstly,	  blocking	  CTGF	  activity	  may	  also	   retard	   the	  process	  of	  wound	  healing.	   	   Secondly,	   the	  anti-­‐
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CTGF	  antibody	   is	  not	   tissue	  specific,	   and	  will	  also	   target	  CTGF	   in	  healthy	  organs.	  	  Thirdly,	   how	   this	   antibody	   reacts	   in	   vivo	   will	   differ	   between	   patients.	   	   Further	  independent	  studies	  are	  required	  for	  the	  characterization	  of	  this	  antibody	  for	  the	  use	  as	  a	  therapy	  to	  fibrotic	  diseases	  and	  cancer.	  	  
Future	  work	  	  Future	   developments	   of	   this	   study	   should	   include	   the	   further	   enhancement	   of	   a	  specific	  assay	  to	  detect	  and	  isolate	  CTGF.	  	  	  	  Urine	  was	   found	   to	   be	   a	   rich	   source	   of	   CTGF,	   therefore,	  more	   diabetic	   and	   non-­‐diabetic	  patient	  urine	  samples	  should	  be	  assessed	  by	  ELISA	  and	  Western	  blot.	  	  This	  could	   be	   performed	   using	   the	   three	   antibodies	   described	   in	   this	   study.	  	  Alternatively,	   the	   assay	   produced	   could	   be	   used	   to	   monitor	   the	   progression	   or	  early	  detection	  of	  renal	  fibrosis.	   	   In	  order	  to	  do	  this,	  Western	  blot	  analysis	  would	  be	  carried	  out	  on	  non-­‐reduced	  urine	  samples	  to	  identify	  CTGF.	  	  	  	  
	  	  
Figure 8.9 A schematic for the future development and enhancement of a specific assay to 
detect and isolate CTGF. 	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Two-­‐dimensional	  electrophoresis	  followed	  by	  Western	  blot	  analysis	  could	  also	  be	  carried	   out	   on	   reduced	   and	   non-­‐reduced	   urine	   samples	   together	   with	   albumin	  extracted	  from	  the	  urine	  and	  the	  albumin-­‐depleted	  urine	  samples.	  	  	  	  More	   detailed	  molecular	   studies	   could	   be	   carried	   out	   using	   LC-­‐MS/MS	  on	   bands	  that	  have	  been	  detected	  by	  the	  CTGF	  antibodies	  to	  ascertain	  the	  presence	  of	  CTGF	  in	  these	  samples.	  	  	  	  In	   addition,	   because	   of	   the	   presence	   of	   N-­‐terminal	   fragments	   present	   in	   urine,	  peptides	   to	   the	   N-­‐terminal	   of	   the	   CTGF	   sequence	   will	   be	   synthesised	   and	   new	  polyclonal	  antibodies	  raised	  to	  it.	  	  These	  antibodies	  can	  then	  be	  used	  to	  couple	  to	  Sepharose	  4B	  beads	  to	  extract	  quantitative	  amounts	  of	  CTGF	  from	  urine,	  as	  urine	  from	   renal	   patients	   might	   provide	   an	   excellent	   source	   for	   the	   isolation	   of	   the	  natural	  molecule.	  	  The	   glycosylation	   pattern	   of	   CTGF	   can	   then	   be	   assessed	   by	   nuclear	   magnetic	  resonance	   (NMR)	   analysis,	   mass	   spectrometry	   and	   biochemical	   procedures.	  	  Monoclonal	  antibodies	  can	  be	  raised	  against	  the	  native	  CTGF	  molecule	  would	  have	  the	  advantage	  of	  greater	  specificity	  than	  polyclonal	  antibodies.	  	  The	  availability	  of	  native	   CTGF,	   in	   addition	   to	   the	  monoclonal	   and	   polyclonal	   CTGF	   antibodies	   can	  then	  be	  used	  to	  develop	  a	  robust	  assay	  (sandwich	  ELISA)	  for	  the	  detection	  of	  CTGF,	  and	  possibly	  treatment	  to	  fibrotic	  diseases.	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Appendix	  
Protein name Protein MW (Da) % sequence coverage
Tenascin-X OS=Homo sapiens GN=TNXB PE=1 SV=2 464,420.20 0.72%
Serotransferrin OS=Homo sapiens GN=TF PE=1 SV=2 77,032.20 5.59%
Fibronectin OS=Homo sapiens GN=FN1 PE=1 SV=3 262,581.00 4.44%
Serum albumin OS=Homo sapiens GN=ALB PE=1 SV=2 69,348.90 17.40%
Rap1 GTPase-GDP dissociation stimulator 1 OS=Homo sapiens GN=RAP1GDS1 PE=1 SV=3 66,300.10 7.58%
Complement factor H OS=Homo sapiens GN=CFH PE=1 SV=4 139,078.20 3.49%
Apolipoprotein B-100 OS=Homo sapiens GN=APOB PE=1 SV=1 515,554.20 5.26%
Inter-alpha-trypsin inhibitor heavy chain H1 OS=Homo sapiens GN=ITIH1 PE=1 SV=3 101,371.80 8.34%
Antithrombin-III OS=Homo sapiens GN=SERPINC1 PE=1 SV=1 52,586.00 17.20%
Hemoglobin subunit beta OS=Homo sapiens GN=HBB PE=1 SV=2 15,980.00 21.10%
Keratin, type I cytoskeletal 10 OS=Homo sapiens GN=KRT10 PE=1 SV=6 58,810.80 5.82%
Inter-alpha-trypsin inhibitor heavy chain H2 OS=Homo sapiens GN=ITIH2 PE=1 SV=2 106,447.50 4.86%
Serum albumin OS=Homo sapiens GN=ALB PE=1 SV=2 69,348.90 33.30%
Haptoglobin OS=Homo sapiens GN=HP PE=1 SV=1 45,186.90 9.11%
Complement factor H OS=Homo sapiens GN=CFH PE=1 SV=4 139,078.20 12.10%
Keratin, type II cytoskeletal 1 OS=Homo sapiens GN=KRT1 PE=1 SV=6 66,022.30 12.90%
Fibrillin-1 OS=Homo sapiens GN=FBN1 PE=1 SV=2 312,268.10 2.75%
Tenascin-X OS=Homo sapiens GN=TNXB PE=1 SV=2 464,420.20 1.87%
Serotransferrin OS=Homo sapiens GN=TF PE=1 SV=2 77,032.20 5.44%
Fibronectin OS=Homo sapiens GN=FN1 PE=1 SV=3 262,581.00 18.10%
Protein AMBP OS=Homo sapiens GN=AMBP PE=1 SV=1 38,981.50 9.66%
Target of Nesh-SH3 OS=Homo sapiens GN=ABI3BP PE=1 SV=1 118,626.20 3.07%
Hemoglobin subunit alpha OS=Homo sapiens GN=HBA1 PE=1 SV=2 15,239.60 25.40%
Complement C3 OS=Homo sapiens GN=C3 PE=1 SV=2 187,131.10 1.68%
Keratin, type I cytoskeletal 9 OS=Homo sapiens GN=KRT9 PE=1 SV=3 62,047.80 3.05%
Apolipoprotein B-100 OS=Homo sapiens GN=APOB PE=1 SV=1 515,554.20 16.30%
Keratin, type II cytoskeletal 2 epidermal OS=Homo sapiens GN=KRT2 PE=1 SV=2 65,415.90 6.26%
Antithrombin-III OS=Homo sapiens GN=SERPINC1 PE=1 SV=1 52,586.00 6.03%
Hemoglobin subunit beta OS=Homo sapiens GN=HBB PE=1 SV=2 15,980.00 31.30%
Adipocyte enhancer-binding protein 1 OS=Homo sapiens GN=AEBP1 PE=1 SV=1 130,912.90 3.54%
Keratin, type I cytoskeletal 10 OS=Homo sapiens GN=KRT10 PE=1 SV=6 58,810.80 8.56%
Serum albumin OS=Homo sapiens GN=ALB PE=1 SV=2 69,348.90 25.60%
Ig mu chain C region OS=Homo sapiens GN=IGHM PE=1 SV=3 49,287.70 8.63%
Complement factor H OS=Homo sapiens GN=CFH PE=1 SV=4 139,078.20 13.60%
Keratin, type II cytoskeletal 1 OS=Homo sapiens GN=KRT1 PE=1 SV=6 66,022.30 9.16%
Tenascin-X OS=Homo sapiens GN=TNXB PE=1 SV=2 464,420.20 1.56%
Serotransferrin OS=Homo sapiens GN=TF PE=1 SV=2 77,032.20 13.60%
Fibronectin OS=Homo sapiens GN=FN1 PE=1 SV=3 262,581.00 5.62%
Collagen alpha-1(XII) chain OS=Homo sapiens GN=COL12A1 PE=1 SV=2 333,127.30 1.24%
Hemoglobin subunit alpha OS=Homo sapiens GN=HBA1 PE=1 SV=2 15,239.60 25.40%
Keratin, type I cytoskeletal 9 OS=Homo sapiens GN=KRT9 PE=1 SV=3 62,047.80 8.19%
Apolipoprotein B-100 OS=Homo sapiens GN=APOB PE=1 SV=1 515,554.20 5.90%
Adipocyte enhancer-binding protein 1 OS=Homo sapiens GN=AEBP1 PE=1 SV=1 130,912.90 3.28%
Serum albumin OS=Homo sapiens GN=ALB PE=1 SV=2 69,348.90 26.80%
Complement factor H OS=Homo sapiens GN=CFH PE=1 SV=4 139,078.20 21.00%
Keratin, type II cytoskeletal 1 OS=Homo sapiens GN=KRT1 PE=1 SV=6 66,022.30 8.85%
Complement component C8 alpha chain OS=Homo sapiens GN=C8A PE=1 SV=2 65,145.80 6.16%
Tenascin-X OS=Homo sapiens GN=TNXB PE=1 SV=2 464,420.20 1.05%
Serotransferrin OS=Homo sapiens GN=TF PE=1 SV=2 77,032.20 5.87%
Fibronectin OS=Homo sapiens GN=FN1 PE=1 SV=3 262,581.00 5.11%
Collagen alpha-1(XII) chain OS=Homo sapiens GN=COL12A1 PE=1 SV=2 333,127.30 2.06%
Keratin, type I cytoskeletal 14 OS=Homo sapiens GN=KRT14 PE=1 SV=4 51,544.50 6.36%
Keratin, type I cytoskeletal 9 OS=Homo sapiens GN=KRT9 PE=1 SV=3 62,047.80 7.06%
Apolipoprotein B-100 OS=Homo sapiens GN=APOB PE=1 SV=1 515,554.20 5.83%
Collagen alpha-1(XIV) chain OS=Homo sapiens GN=COL14A1 PE=1 SV=3 193,498.10 1.89%
Inter-alpha-trypsin inhibitor heavy chain H1 OS=Homo sapiens GN=ITIH1 PE=1 SV=3 101,371.80 3.84%
Antithrombin-III OS=Homo sapiens GN=SERPINC1 PE=1 SV=1 52,586.00 16.40%
Keratin, type I cytoskeletal 10 OS=Homo sapiens GN=KRT10 PE=1 SV=6 58,810.80 11.10%
Serum albumin OS=Homo sapiens GN=ALB PE=1 SV=2 69,348.90 21.00%
Lactotransferrin OS=Homo sapiens GN=LTF PE=1 SV=6 78,164.30 19.00%
Kininogen-1 OS=Homo sapiens GN=KNG1 PE=1 SV=2 71,939.60 12.60%
Complement C1r subcomponent OS=Homo sapiens GN=C1R PE=1 SV=2 80,101.60 4.82%
Coagulation factor IX OS=Homo sapiens GN=F9 PE=1 SV=2 51,759.60 10.60%
Inter-alpha-trypsin inhibitor heavy chain H5 OS=Homo sapiens GN=ITIH5 PE=2 SV=2 104,561.20 4.35%
Periostin OS=Homo sapiens GN=POSTN PE=1 SV=2 93,300.00 9.21%
Cartilage intermediate layer protein 1 OS=Homo sapiens GN=CILP PE=1 SV=3 132,606.20 3.21%
Ezrin OS=Homo sapiens GN=EZR PE=1 SV=4 69,396.60 5.97%
Coagulation factor XIII A chain OS=Homo sapiens GN=F13A1 PE=1 SV=4 83,249.30 14.60%
Inter-alpha-trypsin inhibitor heavy chain H4 OS=Homo sapiens GN=ITIH4 PE=1 SV=4 103,340.40 3.12%
Ig mu chain C region OS=Homo sapiens GN=IGHM PE=1 SV=3 49,287.70 17.50%
Hepatocyte growth factor-like protein OS=Homo sapiens GN=MST1 PE=1 SV=2 80,299.80 18.80%
Phospholipid transfer protein OS=Homo sapiens GN=PLTP PE=1 SV=1 54,723.10 6.49%
Complement factor H OS=Homo sapiens GN=CFH PE=1 SV=4 139,078.20 14.00%
Keratin, type II cytoskeletal 1 OS=Homo sapiens GN=KRT1 PE=1 SV=6 66,022.30 20.80%
Podocan OS=Homo sapiens GN=PODN PE=1 SV=2 68,961.10 13.90%
Apolipoprotein A-I OS=Homo sapiens GN=APOA1 PE=1 SV=1 30,760.50 14.60%
Complement component C8 alpha chain OS=Homo sapiens GN=C8A PE=1 SV=2 65,145.80 6.16%
Tenascin-X OS=Homo sapiens GN=TNXB PE=1 SV=2 464,420.20 1.05%
Serotransferrin OS=Homo sapiens GN=TF PE=1 SV=2 77,032.20 28.10%
Plasma serine protease inhibitor OS=Homo sapiens GN=SERPINA5 PE=1 SV=2 45,684.80 9.36%
Fibronectin OS=Homo sapiens GN=FN1 PE=1 SV=3 262,581.00 10.30%
Gelsolin OS=Homo sapiens GN=GSN PE=1 SV=1 85,679.80 9.08%
Keratin, type I cytoskeletal 14 OS=Homo sapiens GN=KRT14 PE=1 SV=4 51,544.50 8.26%
Sulfhydryl oxidase 1 OS=Homo sapiens GN=QSOX1 PE=1 SV=3 82,560.70 9.91%
Complement C3 OS=Homo sapiens GN=C3 PE=1 SV=2 187,131.10 3.13%
Keratin, type I cytoskeletal 9 OS=Homo sapiens GN=KRT9 PE=1 SV=3 62,047.80 7.54%
Histidine-rich glycoprotein OS=Homo sapiens GN=HRG PE=1 SV=1 59,558.60 6.29%
Complement factor D OS=Homo sapiens GN=CFD PE=1 SV=5 27,014.40 18.60%
Collagen alpha-3(VI) chain OS=Homo sapiens GN=COL6A3 PE=1 SV=4 343,645.40 5.13%
Coagulation factor XI OS=Homo sapiens GN=F11 PE=1 SV=1 70,091.20 13.60%
Extracellular matrix protein 1 OS=Homo sapiens GN=ECM1 PE=1 SV=2 60,655.40 23.90%
Apolipoprotein B-100 OS=Homo sapiens GN=APOB PE=1 SV=1 515,554.20 7.32%
Prothrombin OS=Homo sapiens GN=F2 PE=1 SV=2 70,018.80 5.47%
Fibrinogen gamma chain OS=Homo sapiens GN=FGG PE=1 SV=3 51,495.30 9.49%
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In this report, we describe a two-step protocol for labeling of an affinity-purified antibody to biotin with horseradish peroxidase
(HRP) using cyanuric chloride (CC) as a bridge. The enzyme was first modified with CC, and following chromatography on a PD-10
column, the activated HRP was incubated with the antibody to effect coupling of the two proteins. Assessment of the conjugate
product was carried out using ELISA and SDS-PAGE electrophoresis where evidence for high antibody activity, high specific activity of
the conjugate preparation, coupling of nearly all the antibody and over 90% of the enzyme was shown. The titer of the conjugate
exceeded 1/100,000. High molecular weight complexes were observed in the SDS-PAGE results, indicating an efficient conjugation
procedure. The presence of high molecular weight complexes indicated an efficient conjugation procedure. The protocol is simple, and
the conjugation steps can be completed in 27 h once the preparatory phase has been carried out; the method is entirely generic and
may be applied to labeling of any antibody.
INTRODUCTION
The development of sensitive immunological methods has been
made possible by the use of enzymes as tracers to quantify concen-
trations of antibody–antigen complexes as end products1–3. Enzymes
are valuable as catalytic tracers, as their turnover of substrates results
in the amplification of detectable products, especially as there is a
wide range of synthetic chromogenic and fluorescent substrates
commercially available. However, owing to a number of factors,
including structural features, sourcing and stability, only a few of
these enzymes have proven to be of practical use as tracers in applied
immunochemical techniques. These are HRP, alkaline phosphatase
and b-D-galactosidase4–8. HRP is probably the most commonly used
labeling agent due to its high stability, low cost, nature of it being a
plant protein (and hence less likely to have potentially interfering
autoantibodies in biological samples9–14) and the availability of a
great number of oxidizable dyes. The action of HRP on H2O2 enables
a wide choice of dyes and soluble and insoluble end products to be
designed for both chromogenic and fluorigenic substances15–21. To
incorporate a selected enzyme into an immunochemical method
such as an enzyme-linked immunosorbent assay, the enzyme has to
be covalently coupled to a signal-developing secondary antibody, the
primary antibody or to an antigen or hapten. Recently, this labora-
tory described a new method for coupling HRP to IgG based on
cyanuric chloride (CC)22, which takes advantages of the structural
features of HRP and enables the efficient conjugation of several
antibodies (prepared in sheep and hence share nearly identical
structures) under relatively mild conditions. The described conjuga-
tion method is a universal protocol for labeling antibodies, protein
antigens as well as amine-bearing ligands (haptens) with HRP. The
chemical-linking principle of using CC as a bifunctional bridging
molecule allows the modification (activation) of HRP in a step that is
entirely independent of the nature of antibodies or protein antigens
except that they must bear free amino groups. All antibodies and
protein antigens meet this simple requirement irrespective of the
functional specificities and hence the protocol is generic.
Coupling to HRP is a critical step in the development of
immunochemical techniques, as it defines the efficiency and quality
of the signal-developing reagent and it affects the stability of
the labeled reagent. A wide range of methods for coupling HRP to
antibodies and antigens have been described, including the periodate
oxidation23–27 glutaraldehyde reagent28, dihydrazide methods29–31
and bifunctional reagent procedures32–35. When coupling to HRP,
its paucity of free amino groups10 and large carbohydrate content
(22%) require consideration9,11. Lack of sufficient free amino groups
in most of the commercially available HRP preparations limits the
choice of efficient conjugation methods. Although the commonly
used periodate method makes use of the presence of carbohydrate
moieties and a lack of free amino groups on the HRP molecule, it has
proven to be technically challenging, particularly in research labora-
tories (unpublished results). Evidence for this is seen in the multiple
publications that describe improved periodate oxidation procedures
for the conjugation of HRP to proteins.
The CC method described in this protocol (Fig. 1) shares some









































































Figure 1 | Conjugation steps according to the CC protocol. The figure shows
the steps used in this protocol for the activation of HRP (I) with CC (II) to
generate HRP–CC complexes (III) and subsequent coupling with antibodies
(IV) through free amine groups.
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availability and low cost of the activation reagents, nonproprietary
position and targeting the carbohydrate moiety in the HRP
molecule, as the linkage site and both methods are two-step
conjugation procedures. However, the difficulties inherent in the
control of the periodate oxidation step, particularly when using
small amounts of HRP, which is often the case in research
laboratories, has been a major disadvantage23–27. In addition, the
periodate method requires that conjugates are treated with sodium
borohydride or the equivalent to stabilize the bonds made by the
aldehyde functions and the amine groups. This not only presents an
additional step but exposes the products to relatively harsh redu-
cing conditions that may cause chemical alterations to certain
reagents23–27. This step is not required for the CC method;
therefore, it should provide a more reliable procedure for users
across many areas of applied immunochemistry.
Procedures that are based on the use of conventional bifunctional
coupling reagents, such as maleimide compounds32–34, are funda-
mentally different from the CC protocol, as they rely on the
availability of free amino groups in the HRP molecule, whereas
the CC method is able to effect links with both amine groups and
hydroxyl groups on the carbohydrate moieties of the HRP mole-
cule. One of the distinctive structural features of commercially
available HRP is the absence of free amino groups, so the use of
conventional bifunctional reagent methods are of limited value.
The protocol described in this report is based on the same
chemical coupling principles as our previous report but incorpo-
rates additional procedural improvements that have rendered the
method easier to carry out in less time and enhanced the quality of
the product in terms of obtaining higher conjugate titers. The
method is simple both in concept and in application; it is also
ideally suited for linking HRP to amine-bearing reagents due to its
unique structural features. The paucity (or absence) of free amino
groups prevents the self-coupling of HRP during the activation step
and reduces the likelihood of self-coupling during the second phase
of the procedure in the presence of the second molecule (with
excess amino groups). When compared with the previous meth-
od35, the improvements obtained by this protocol can be explained
by three factors. The antibody used in this investigation has a
different specificity and affinity, even though it was generated in the
same host animal species and a PD-10 column was used to rapidly
remove excess CC as opposed to the more traditional method of
dialysis used in the previous procedure. Finally, the use of the
commercially available Amicon Ultra-4 Centrifugal Filter Device
that is specifically designed for use with small volumes, such as
those used in this procedure, facilitates rapid and efficient con-
centration of the conjugation mixture.
This report describes the details of a CC conjugation protocol
incorporating the technical improvements in key steps that have
been introduced since the original report.
Experimental design
The labeling of antibodies with HRP using the CC method is
carried out using a two-step protocol outlined in the flow chart in
Figure 3.
In the activation step, excess CC is reacted with HRP at low
temperature (on ice) but at a relatively high pH (9.4) to ensure
reaction with amine groups as well as the unreactive hydroxyl
groups of the carbohydrate moieties. The low-temperature condi-
tion is chosen to increase the stability of the CC during the
activation step. The CC is presented as a dry residue to avoid the
use of organic solvents and to further increase the stability of the
reagent. The commercially available CC is less pure than desired
and hence there is a need to crystallize CC from organic solvents.
This may be of concern to some users; however, once crystallized,
the material may be stored dry in the cold for several years. Higher





























































Figure 2 | Conjugation steps according to the sodium periodate methods. In
the oxidation step, sugars in carbohydrate moiety of the enzyme (I) are
oxidized to generate aldehyde functions (II). In the coupling step, amine
groups in the antibody molecule (III) attack the aldehyde functions to form
Schiff’s bases (IV). Reduction with sodium borohydride or equivalent is
normally used to reduce Schiff’s bases to amines. Note that the periodate
oxidation steps leads to opening of the sugar molecules.
Step 1
Activate 6 mg of HRP
with 3.2 mg of CC in 1












(fractions 4 and 5,
brown color).
Step 9
Add 0.5 ml of glycerol to the
antibody–HRP conjugate,
recover and store in 50 µl
aliquots at –80 °C.
Step 4
Dialyze antibody sample against pH 9.4
buffer ~10 mg ml–1. This step should be
carried out before activation of HRP.
Step 5
Transfer the activated HRP (2 ml) and
dialysed antibody (6 mg in 0.6 ml) to the
Amicon Ultra filter unit. Add 1 ml of pH
9.4 buffer and concentrate by
centrifugation to 0.3 ml.
Step 6
Add 1 ml of pH 9.4 buffer and
concentrate by centrifugation to
a final volume of 0.3 ml.
Step 7
Incubate the reaction mixture in
a 37 °C water bath for 16 h.
Step 8
Add 1 ml of pH 5.5
buffer and concentrate the
conjugate to 0.5 ml.
Repeat step.
Figure 3 | A flowchart of the conjugation procedure. The flowchart shows the
main steps involved in the labeling of antibodies with HRP using the CC as a
bridging agent.
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expected product of this step is HRP–CC or HRP–(dichloro-
triazine)n complexes and unreacted excess reagent. The excess
reagent must be removed before the next step (Fig. 3, Step 1).
(1) Removal of excess reagent is carried out by rapid gel filtration
chromatography on PD-10 Sephadex columns. The columns
are equilibrated with cold, low pH buffer (5.5) to limit the loss
of the reactive chloride functions in the HRP–CC complex
during the chromatography step. The chromatographed HRP–
CC is collected in a relatively large volume (2 ml) and at low
pH. Both of these factors are incompatible with the next step
and therefore need to be corrected. (Fig. 3, Step 2).
(2) The required amount of antibody, previously equilibrated to
pH 9.4 (approximately 0.25 molar ratio with respect to HRP),
is mixed with the chromatographed HRP–CC directly in the
commercially available ultrafiltration centrifugation unit, and
the volume is reduced and flushed with a high pH buffer
(pH 9.4) using repeated centrifugation steps. The use of the
centrifugation microfiltration unit enables changing of buffers
quickly under controlled conditions. It is important to control
temperature and pH conditions in the key steps, which involve
rapidly switching to higher pH at particular points. The aim is
to have the reaction mixture in a small volume (0.3 ml) at pH
9.4 (Fig. 3, Steps 3–6).
(3) Without transfer of the reaction mixture, the coupling step is
allowed to continue in the ultrafiltration unit in a 37 1C water
bath for 16 h (Fig. 3, Step 7).
(4) The conjugation mixture is equilibrated with a storage buffer
(phosphate, pH 5.5) by flushing the mixture with the required
buffer as mentioned above (Fig. 3, Step 8).
(5) Finally, the conjugate (B0.5 ml) is collected and mixed with an
equal volume of glycerol. Aliquots of 50 ml are stored at80 1C
until required (Fig. 3, Step 9).
MATERIALS
REAGENTS
.Acetone (Sigma-Aldrich, cat. no. 179124)
.2,2¢-Azino-bis(3-ethylbenz-thiazoline-6-sulfonic acid (ABTS; Sigma-Aldrich,
cat. no. A1888)
.Acrylamide/bis-acrylamide, 30% (wt/vol) solution (Sigma-Aldrich, cat. no.
A3449)
.Activated charcoal (Sigma-Aldrich, cat. no. C4386)
.Ammonium persulfate (Sigma-Aldrich, cat. no. A3678)
.Benzene (Sigma-Aldrich, cat. no. 270709) ! CAUTION Toxic and
carcinogenic. Store and handle according to appropriate health and safety
requirements.
.Bio-Safe Coomassie stain (Bio-Rad Laboratories, cat. no. 161-0786)
.Boric acid (Sigma-Aldrich, cat. no. B6768)
.Citric acid (Sigma-Aldrich, cat. no. C1857)
.Concentrated hydrochloric acid (Sigma-Aldrich, cat. no. H-1758)
! CAUTION Hazardous and highly corrosive. Store and handle according to
appropriate health and safety requirements.
.Cyanuric chloride (Sigma-Aldrich, cat. no. C95501)
.D-biotin (Sigma, cat. no. B4501)
.Gelatin from porcine skin (Sigma-Aldrich, cat. no. G8150)
.Glycerol (Sigma-Aldrich, cat. no. G5516)
.Isobutyl chloroformate (Aldrich, cat. no. 177989) ! CAUTION Harmful and
toxic. Store and handle according to appropriate health and safety
requirements.
.Laemmli sample buffer (Bio-Rad Laboratories, cat. no. 161-0737)
.Methanol (Sigma-Aldrich, cat. no.179957)
.N,N,N ¢,N ¢-Tetramethylethylenediamine (TEMED; Sigma-Aldrich,
cat. no. T9281) ! CAUTION Extremely flammable and highly
corrosive. Store and handle according to appropriate health and safety
requirements.
.N,N-Dimethylformamide (Fluka, cat. no. 40240) ! CAUTION Toxic. Store
and handle according to appropriate health and safety requirements.
.Page ruler unstained protein ladder (Fermentas, cat. no. SM0661)
.Potassium dihydrogen orthophosphate (Sigma-Aldrich,
cat. no. P0662)
.Pyridine anhydrous (Sigma-Aldrich, cat. no. 270970) ! CAUTION
Carcinogenic and highly flammable. Store and handle according to
appropriate health and safety requirements.
.Silica (Sigma-Aldrich, cat. no. 381276)
.Sodium azide (Sigma-Aldrich, cat. no. S8032)
.Sodium bicarbonate (Sigma-Aldrich, cat. no. S5761)
.Sodium carbonate anhydrous (Sigma-Aldrich, cat. no. 204420)
.Sodium chloride (Sigma-Aldrich, cat. no. S7653)
.Sodium phosphate dibasic (Sigma-Aldrich, cat. no. S7907)
.Sodium tetraborate decahydrate (Sigma-Aldrich, cat. no. S9640)
.Thimerosal (Sigma-Aldrich, cat. no. T5125)
.Tributylamine (Sigma-Aldrich, cat. no. 471313) ! CAUTION Hazardous and
highly flammable. Store and handle according to appropriate health and
safety requirements.
.Tween-20 (Sigma-Aldrich, cat. no. P1379)
.30% (vol/vol) Hydrogen peroxide (Sigma-Aldrich, cat. no. H1009)
! CAUTION Harmful and toxic. Store and handle according to
appropriate health and safety requirements.
.10 Tris/glycine/SDS (Bio-Rad Laboratories, cat. no. 161-0732)
.1-Butanol (Sigma-Aldrich, cat. no. B7906)
EQUIPMENT
.96-Well microtiter plate (Griener Bio One GmbH, cat. no. 655101)
.96-Well microtiter plate lids (Greiner Bio One GmbH, cat. no. 656170)
.ELISA plate reader (Dynex MRX II)
.Multichannel pipette (mLine from Biohit, cat. no. 725140)
.PD-10 Sephadex G-25 columns (GE Healthcare, cat. no. 17-0851-01)
.Spectrophotometer (Cecil Instruments Ltd, cat. no. CE1011)
.Amicon Ultra-4 centrifugal filter devices (Millipore, cat. no. UFC810008
http://www.millipore.com/catalogue/module/c7719)
.RT6000B refrigerated centrifuge (Sorvall)
.Mini-PROTEAN Tetra electrophoresis system (Bio-Rad Laboratories,
cat. no. 165-8025)
REAGENT SETUP
Gelatin solution Dissolve 100 mg of porcine gelatin (Bloom 300) in
50 ml of NaHCO3–Na2CO3 (pH 8.6) with 20% (vol/vol) N,N-dimethylforma-
mide. Heat the solution to 50 1C to ensure that gelatin has completely
dissolved. The gelatin solution can be prepared before use and stored at 4 1C for
up to 1 month.
Plate-coating buffer Add 19 g (50 mM) of sodium tetraborate
decahydrate to 1 liter of deionized water and adjust the pH to 9.0 by
adding boric acid or concentrated hydrochloric acid. Add sodium azide
(1 g liter1). Once prepared, the plate-coating buffer can be stored at
4 1C for up to 1 month.
Blocking buffer Add 7.1 g (50 mM) of sodium phosphate dibasic
and 1.2 g (20 mM) of sodium chloride to 1 liter of deionized water.
Adjust the pH to 7.6 by adding potassium dihydrogen orthophosphate.
Add porcine gelatin (Bloom 300, 2.5 g liter1) and thimerosal (0.1 g liter1).
Place the buffer in a hot water bath at 37 1C and mix occasionally until
all of the gelatin has dissolved. Once prepared, the plate-blocking buffer
can be stored at 4 1C for 2 weeks.
Antibody buffer Add 14.2 g (100 mM) of sodium phosphate dibasic
and 5.8 g (100 mM) of sodium chloride to 1 liter of deionized water.
Adjust the pH to 7.4 by adding potassium dihydrogen orthophosphate.
Add porcine gelatin (Bloom 300, 2 g liter1) and thimerosal
(0.1 g liter1). Place buffer in warm water bath until all of the gelatin has
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Substrate buffer Add 4.1 g (50 mM) of sodium acetate to 1 liter of deionized
water. Adjust the pH to 4.1 by adding citric acid. Once prepared, the plate
substrate buffer can be stored at 4 1C for 2 weeks.
Enzyme–substrate solution Add 10 mg of ABTS in 20 ml of substrate
buffer as described in the table below. m CRITICAL H2O2 should be added just
before use. The enzyme–substrate solution is prepared in the proportions
described in the table below:
Chemical Required quantity
ABTS 10 mg
Substrate buffer 20 ml
H2O2 8 ml
Plate washing buffer Add 42 g (100 mM) of sodium bicarbonate, 58.4 g
(100 mM) of sodium chloride and 5 ml of Tween-20 to 10 liters of deionized
water. The plate washing buffer can be prepared in advance and stored for
1 month at room temperature (B22 1C). m CRITICAL Tween-20 should be
mixed thoroughly in the solution before use.
Conjugation buffer Prepare a 50 mM sodium bicarbonate solution. Adjust the
pH to 9.4 by adding sodium carbonate. The conjugation buffer should be
prepared before use and kept on ice at all times.
PD-10 column equilibration buffer Prepare a 10 mM sodium phosphate
dibasic solution. Adjust the pH to 5.5 by adding citric acid. The PD-10 column
equilibration buffer should be prepared before use and kept on ice at all times.
Conjugate equilibration buffer Prepare a 50 mM sodium phosphate dibasic
solution. Adjust the pH to 5.5 by adding citric acid. The conjugate equilibration
buffer should be prepared before use and kept on ice at all times.
SDS-PAGE resolving gel To make two mini gels using 0.75-mm spacer plates,
see the table below:
Reagent Volume added to make a 7% gel
30% acrylamide 2.3 ml
Deionized water 5.2 ml
Gel buffer 2.5 ml
TEMED 18 ml
10% APS 34 ml
SDS-PAGE stacking gel (4% (vol/vol) acrylamide) To make two mini gels
using 0.75-mm spacer plates, see the table below:
Reagent Volume added to make a 4% gel
30% acrylamide 0.53 ml
Deionized water 2.47 ml
Gel buffer 1 ml
TEMED 20 ml
10% APS 12 ml
PROCEDURE
Preparation of gelatin biotin plate-coating antigen for the solid-phase ELISA  TIMING 20 h
1| Take 10 ml of the gelatin solution, as listed in REAGENT SETUP, and leave to stand for 5 min at room temperature.
2| To 10 mg of biotin, add (in order): 0.5 ml of N,N-dimethylformamide, 0.5 ml of pyridine, 75 ml of tributylamine and 30 ml
of isobutyl chloroformate in a glass test tube and mix.
! CAUTION The reaction should be carried out in the fume hood because the solvents such as isobutyl chloroformate, pyridine
and tributylamine are toxic, highly flammable and harmful by inhalation.
m CRITICAL STEP The reaction should be carried out on ice.
3| Incubate the reagents on ice forB7 min.
4| Add 10 ml of the gelatin solution prepared in Step 1 (B20 mg of gelatin) to a small conical flask.
5| While stirring rapidly, add 50 ml of the activated biotin prepared in Step 2 to the gelatin solution every 3 min, until a total
ofB150 ml has been added.
m CRITICAL STEP Stop the addition of activated biotin immediately if the gelatin solution begins to appear cloudy.
6| Incubate in the fume hood for 2 h.
7| Dialyze the plate-coating antigen (PCA) prepared in Step 6 in 2 liters of conjugation buffer (see REAGENT SETUP) with 5 g
of activated charcoal powder for 16 h at room temperature. Recover the biotin–gelatin conjugate and store in 1 ml aliquots
(B1.5 mg ml1) at 20 1C.
’ PAUSE POINT The biotin–gelatin conjugate can be stored at 20 1C for up to 1 year.
Preparation of CC  TIMING 20 h
8| Weigh 20 g of CC and dissolve inB70 ml of boiling benzene for 30 min until solution is completely saturated.
! CAUTION Recrystallization of CC using benzene should be carried out under a well-ventilated fume hood. Alternatively, this
step could also be carried out using acetonitrile.
9| Filter over dry silica in a Bu¨chner funnel while still hot and leave to crystallize at room temperature for 16 h.
10| Filter and wash the crystals withB20 ml of ice-cold benzene and allow to dry under vacuum.
’ PAUSE POINT Cyanuric chloride crystals can be stored dry at 4 1C until required, for up to 2 years.
Preparation of antibodies  TIMING 18 h
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m CRITICAL STEP Samples of the antibodies are stored under saturated ammonium sulfate, so care should be taken to ensure that
the antibodies and ammonium sulfate are mixed gently before use.
12| Place the sample into the centrifuge rotor and counterbalance with a similar container.
13| Centrifuge at 3,000g at 4 1C forB15 min.
14| Redissolve the pellet inB1 ml of conjugation buffer (see REAGENT SETUP).
15| Dialyze the sample in 2 liters of conjugation buffer for 16 h at 4 1C.
16| Recover by collecting the antibody solution into a Falcon tube, while on ice, and measure the absorbance at 280 nm.
17| Using the absorbance to estimate the protein concentration in the antibody sample (A280 of 1 mg ml
1 ¼ 1.35)
(see ref. 36), take a volume containingB6 mg of antibody for use in the experiment.
Activation of HRP  TIMING 5 h
18| Dissolve 20 mg of CC crystals in 1 ml of ice-cold acetone (20 mg ml1).
m CRITICAL STEP Anhydrous acetone solution should be cooled on ice before the addition of CC.
19| Transfer 160 ml (3.2 mg of CC) of the acetone solution to a glass vial and remove the solvent by a stream of nitrogen in the
fume hood.
20| Cool the conjugation buffer on ice before use. Weigh 6 mg of HRP powder and dissolve in 1 ml of the cooled conjugation
bufferB6 mg ml1.
21| Immediately add the HRP solution to the glass vial containing the dry CC (from Step 19), cover and leave on a stirring
plate to mix in the cold for 4 h.
m CRITICAL STEP HRP should not be exposed to light, so the steps should be carried out immediately.
Preparation of the PD-10 Sephadex G-25 column  TIMING 30 min
22| Flush the PD-10 column with 8 ml of deionized water; add 1 ml at a time.
m CRITICAL STEP The maximum running volume for the PD-10 column is 1 ml. All buffers passed through the column should be
cooled on ice before addition to the PD-10 column.
23| Equilibrate the column with 8  1 ml of ice-cold PD-10 column equilibration buffer, adding 1 ml at a time
(see REAGENT SETUP).
24| Collect the 1-ml fractions in glass tubes and store on ice.
Column chromatography of HRP-CC using PD-10 Sephadex G-25  TIMING 15 min
25| Transfer the HRP–CC reaction mixture prepared in Step 21 to the column and collect a 1-ml fraction.
26| Change to the next fraction tube.
27| Add 1 ml of PD-10 column equilibration buffer to the column and allow the buffer to travel into the gel, collect a 1-ml
fraction and continue to collect at least six more 1-ml fractions.
28| Measure the absorbance of the HRP–CC fractions (usually fractions 4 and 5).
29| Determine which two fractions have the highest optical density readings (i.e., the peak of the HRP–CC sample where the
fractions containing the conjugate appear brown, as the excess CC follows closely behind); use these two fractions only for
conjugation to the antibody.
Conjugation of HRP–CC to antibody  TIMING 21 h
30| Add 6 mg of the antibody prepared in Step 17 (B1 ml) to the HRP–CC in the Amicon Ultra Filter unit and mix.
31| Add 1 ml of conjugation buffer and mix well.
32| Place a capped filter device into the centrifuge rotor (cooled to 4–6 1C) and counterbalance with a similar device.
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34| The contents should be mixed well using a P200 Gilson pipette.
35| Add 1 ml of conjugation buffer to the Amicon Ultra filter unit, mix the contents and centrifuge at 4,000g at 4 1C forB30 min.
36| The sample should be concentrated by centrifugation as mentioned in Steps 34 and 35 to a final volume of 300 ml.
m CRITICAL STEP The centrifugation time may need to be increased to ensure that the reaction volume is reduced to 300 ml.
37| Discard the filtrate from the Amicon Ultra centrifuge tube and then addB7 ml of conjugation buffer (4 1C) to the unit.
This is carried out so that once the filter unit is placed back in the centrifuge tube, it is partially submerged.
m CRITICAL STEP The addition of buffer to the centrifuge tube ensures that the temperature of the sample in the
filter unit is 37 1C.
38| Incubate the filter device unit in a test tube holder for 16 h at 37 1C in a water bath. Discard the buffer from the Amicon
Ultra centrifuge tube before continuing with the subsequent step.
39| Add 1 ml of the conjugate equilibration buffer (see REAGENT SETUP) to the antibody–HRP conjugate in the filter unit and
centrifuge forB20 min at 4,000g.
40| Mix the contents using a pipette.
41| Repeat Steps 39 and 40 to ensure that the conjugate is fully equilibrated.
42| The conjugate should be reduced to a final volume ofB0.5 ml by further centrifugation and mixing; if necessary, repeat
Steps 39 and 40 for further concentration.
43| Add an equal volume of glycerol to the conjugate products, so that the final volume isB1 ml, and store in 50 ml volumes
at 80 1C. The final concentration of antibody in the stored samples (stock solutions) is estimated to be 6 mg ml1.
’ PAUSE POINT The samples can be stored at 80 1C for up to 2 years.
Coating of the ELISA plates  TIMING 17 h
44| Add 150 ml of plate-coating buffer into each well of a Greiner 96-well microtiter plate.
45| Dilute the biotin–gelatin conjugate (B1.5 mg ml1) prepared in Step 7 (PCA) 1:250 in plate-coating buffer.
46| Add 50 ml of the 1:250 biotin–gelatin conjugate to all the wells in column 1 of the microtiter plate.
47| Mix and transfer 50 ml of the solution across the columns from 1 to 6, discarding the final 50 ml. Mix by pipetting up and
down (consistently, typically 5).
48| Cover the plates with an ELISA plate cover and leave overnight at 4 1C.
49| Discard the coating reagent and wash each well four times with 250 ml of washing buffer. Pat the plates dry on an
absorbent towel.
50| Add 250 ml of blocking buffer to each well for 45 min.
51| Discard the blocking buffer and wash the microtiter plate as mentioned in Step 49.
Titration of antibody–CC–HRP conjugate  TIMING 1 h 30 min
52| Add 150 ml of primary antibody buffer into each well of the PCA-coated plate.
53| Take one of the 50-ml stock preparations of antibody–HRP, prepared in Step 43, bring to room temperature and prepare a
1:25 dilution by adding 1.2 ml of antibody buffer to the aliquot.
54| Add 50 ml of the 1:25 antibody–HRP conjugate to wells in rows A1–A6. Mix by pipetting up and down (consistently,
typically 5) and transfer 50 ml of the solution from row A downward (rows A–H) discarding the final 50 ml.
55| Incubate the plate for 1 h on a shaker at room temperature.
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Signal-development steps  TIMING 40 min
57| Add 150 ml of enzyme–substrate solution to each well and cover the plate.
m CRITICAL STEP Plates must be kept away from direct light at room temperature.
58| Read the absorbance at 405 nm after 15 and 30 min of incubation using an ELISA plate reader.
m CRITICAL STEP Gently rotate the plate to mix the contents to ensure accurate measurement of color development.
? TROUBLESHOOTING
Pouring of homogeneous SDS-PAGE gel  TIMING 2 h
59| Prepare the 7% resolving gel and stacking gel solutions (see REAGENT SETUP) without the addition of TEMED and
10% (wt/vol) ammonium persulfate (APS) solution.
60| Degas both solutions forB10 min by placing under negative pressure.
61| Clean the glass spacer and short plates with methanol. Assemble the apparatus according to the manufacturer’s manual to
ensure that there is no leakage of the gel solution.
62| Add the required volumes of TEMED and 10% APS solution (see REAGENT SETUP) to the resolving gel mixture. Using a 1-ml
pipette, add the resolving gel mixture in between the plates until it reachesB1 cm below the top of the short plate and allow
the gel to set for a minimum of 20 min. To remove any air bubbles that might form, immediately after pouring the resolving gel,
addB100 ml of butanol to the surface of gel.
63| Once the resolving gel has set, wash off the butanol by adding deionized water and carefully remove the excess water.
64| Add the TEMED and 10% APS solution to the stacking gel mixture.
65| Using a 1-ml pipette, add the stacking gel solution above the 7% resolving gel, then insert the comb into the solution and
allow the gel to set. Once the stacking gel has set, the comb can be carefully extracted and the gel is ready to be used.
Testing conjugates with SDS-PAGE gels  TIMING 2 h
66| Add 100 ml of Laemmli sample buffer to equal volumes of each of the samples (antibody Step 17, HRP–CC Step 21 and
antibody–HRP–CC conjugate Step 43).
67| Load 10 ml of the Page Ruler Unstained Protein Ladder and 5 ml of the samples onto the gel.
68| Run the gel at 70 V until the bromophenol blue front reaches the bottom of the stacking gel, and then increase the voltage
to 100 V.
69| Allow the bromophenol blue front to run off the gel for a further 10 min.




Steps 1–7, preparation of gelatin–biotin PCA for the solid-phase ELISA: 20 h
Steps 8–10, preparation of CC: 20 h
Steps 11–17, preparation of antibodies: 18 h
Steps 18–21, activation of HRP: 5 h
Steps 22–24, preparation of the PD-10 Sephadex G-25 column: 30 min
Steps 25–29, column chromatography of HRP–CC using PD-10 Sephadex G-25: 15 min
Steps 30–43, conjugation of HRP–CC to antibody: 21 h
Steps 44–51, coating of the ELISA plates: 17 h
Steps 52–56, titration of antibody–CC–HRP conjugate: 1 h 30 min
Steps 57–58, signal development: 40 min
Steps 59–65, pouring of homogeneous gels: 2 h
Steps 66–70, testing conjugates with SDS-PAGE gels: 2 h
? TROUBLESHOOTING
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ANTICIPATED RESULTS
Titration of the binding activity of the prepared antibody–HRP conjugate using ELISA (Steps 44–58) showed a titer in excess of
1/100,000 (Fig. 4). The titer value was calculated with respect to the conjugate dilution that showed a binding signal of 1.7
absorbance units. In the previous study, using different antibodies, the titer values of the prepared conjugates were in the
region of 1/40,000–1/70,000 (see ref. 22). The higher titer value seen in this protocol can be attributed to the inclusion of the
PD-10 column where excess CC is rapidly removed, thus reducing the likelihood of loss of reactive intermediates. In addition,
the effect of the step incorporating the Amicon Ultra-4 centrifugal filter device, instead of Sartorius colloidion bags, was a
substantial improvement of the key volume reduction step. Titration of the conjugate (6 mg of antibody and HRP) was carried
out using the recovered product in a final volume of 1 ml. The high antibody-binding activity in the conjugate (Fig. 4) is
evident from the dilution response curve of the conjugate. Expected titer values may range from 1/20,000 to 1/100,000 for any
primary antibody–enzyme conjugate of a typical haptenic analyte. In analogous studies carried out in this laboratory, the
following hapten antibodies were labeled with HRP using the described protocol: anti-cholic acid, anti-methadone and
anti L-thyroxine. The titers obtained by the conjugates were 1/60,000, 1/40,000 and 1/20,000, respectively. The titer values
reflect the quality of the conjugates and are also dependent upon the specific affinity of the different antibodies.
In this report, the conjugate dilution response graph (Fig. 4) (selected from the binding profile with 0.1 mg ml1 of
plate-coated antigen) suggests that at a 1/100,000 dilution of the antibody–enzyme, the amount of antibody
per well isB9 ng. This figure is calculated on the basis that
the stock solution of the conjugate contained 6 mg ml1,
and this was diluted to 1/100,000, of which 150 ml was added
to the assay wells. This shows the high purity of the antibody,
its high affinity for the coated hapten and the high molar

































TABLE 1 | Troubleshooting table.
Steps Problem Possible reason Solution
58 Low titer of conjugate Inactivation of HRP due to breakdown of CC Ensure that all solutions are ice cold to
prevent breakdown of CC before addition
of HRP
Failure to activate HRP due to CC not being
freshly prepared
CC should be prepared dry and used as
crystalline salts
Failure to couple antibody to HRP–CC due to
possible contamination of buffers with thiol or
amine reagents
Use freshly prepared buffers and ensure
that the pH of the buffers is correct
No color development seen on the
ELISA plate
ABTS or H2O2 has not been added to the sub-
strate solution
Prepare fresh substrate solution, ensuring
that all reagents have been added
Substrate solution is contaminated, e.g., by
sodium azide
Use freshly prepared buffer and ensure
that the pH is correct
Conjugation failed so there is no detectable HRP Repeat conjugation procedure
70 No protein is visualized on the gel Insufficient electrophoresis Prolong the run
Coomassie stain is not sensitive enough Gel can be rinsed and subsequently
silver-stained
Not enough sample loaded onto the gel, i.e., not
enough protein
For Coomassie blue-stained gels, each
protein band needs at least 0.5 mg of


















100 1,000 10,000 100,000 1,000,000 10,000,000
Antibody dilution factor
Figure 4 | Antibody–HRP conjugate dilution response graph. An example of
dilution–response curves obtained by the prepared anti-biotin–HRP
conjugate. The conjugate was prepared as described and the graph was
obtained from a titration experiment using direct solid-phase ELISA (Steps
44–58). The graph shows a conjugate binding profile with 0.1 mg ml1 plate-
coating antigen (biotin–gelatin conjugate). A high titer of 1/100,000 can be
observed (arrow), indicating both high antibody labeling efficiency and high
HRP/antibody molar ratio.
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Analysis of the conjugate and starting proteins by SDS-PAGE
under nonreducing conditions (Fig. 5) show, as expected, the
presence of a range of high molecular weight complexes in the
conjugate preparation (lane 4). In addition, the conjugate
lane should show only a minor proportion of unconjugated
enzyme and virtually no free antibody.
The figures presented provide examples of the anticipated
results when the described protocol is followed.
Published online at http://www.natureprotocols.com/
Reprints and permissions information is available online at http://npg.nature.com/
reprintsandpermissions/
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Figure 5 | An image of a Coomassie-stained nonreducing SDS-PAGE gel of a
conjugate sample. SDS-PAGE analysis of biotin antibody–HRP conjugate,
unconjugated antibody and enzyme using a nonreduced 7% homogenous gel
(Steps 59–65). Lane 1: marker; lane 2: antibody; lane 3: HRP–CC; and lane 4:
antibody–HRP–CC conjugate. Note that the conjugation products show very
high molecular weight complexes; all of the antibody added to the
conjugation reaction appears to have become linked to the enzyme (absence
of unconjugated material) and only a minor proportion of the enzyme
appears to remain uncoupled.
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